---
document_datetime: 2023-09-21 19:24:48
document_pages: 182
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/mektovi-epar-public-assessment-report_en.pdf
document_name: mektovi-epar-public-assessment-report_en.pdf
version: success
processing_time: 240.8128642
conversion_datetime: 2025-12-27 15:07:56.061412
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

26 July 2018 EMA/CHMP/554701/2018 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Mektovi

International non-proprietary name: binimetinib

Procedure No. EMEA/H/C/004579/0000

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

+44 (0)20 3660 6000

Facsimile

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                                | ..............................................8                                                          |
|---------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier......................................................................................8     |                                                                                                          |
| 1.2. Steps taken for the assessment of the product.........................................................9              |                                                                                                          |
| 2. Scientific discussion                                                                                                  | ..............................................................................10                         |
| 2.1. Problem statement                                                                                                    | .............................................................................................10          |
| 2.1.1. Disease or condition.........................................................................................10    |                                                                                                          |
| 2.1.2. Biologic features..............................................................................................10  |                                                                                                          |
| 2.1.3. Clinical presentation, diagnosis and stage/prognosis                                                               | ............................................10                                                           |
| 2.1.4. Management...................................................................................................11    |                                                                                                          |
| 2.2. Quality aspects                                                                                                      | ..................................................................................................14     |
| 2.2.1. Introduction....................................................................................................14 |                                                                                                          |
| 2.2.2. Active Substance.............................................................................................14    |                                                                                                          |
| 2.2.3. Finished Medicinal Product                                                                                         | ................................................................................16                       |
| 2.2.4. Discussion on chemical, pharmaceutical and biological aspects..............................17                      |                                                                                                          |
| 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects                                                 | ......................17                                                                                 |
| 2.2.6. Recommendation(s) for future quality development.............................................17                    |                                                                                                          |
| 2.3. Non-clinical aspects                                                                                                 | ............................................................................................18           |
| 2.3.1. Introduction....................................................................................................18 |                                                                                                          |
| 2.3.2. Pharmacology                                                                                                       | .................................................................................................18      |
| 2.3.3. Pharmacokinetics.............................................................................................24    |                                                                                                          |
| 2.3.4. Toxicology                                                                                                         | ......................................................................................................33 |
| 2.3.5. Ecotoxicity/environmental risk assessment                                                                          | .........................................................44                                              |
| 2.3.6. Discussion on non-clinical aspects......................................................................45         |                                                                                                          |
| 2.3.7. Conclusion on the non-clinical aspects................................................................47           |                                                                                                          |
| 2.4. Clinical aspects                                                                                                     | ..................................................................................................47     |
| 2.4.1. Introduction....................................................................................................47 |                                                                                                          |
| 2.4.2. Pharmacokinetics.............................................................................................50    |                                                                                                          |
| 2.4.3. Pharmacodynamics..........................................................................................60       |                                                                                                          |
| 2.4.4. Discussion on clinical pharmacology...................................................................62           |                                                                                                          |
| 2.4.5. Conclusions on clinical pharmacology.................................................................65            |                                                                                                          |
| 2.5. Clinical efficacy                                                                                                    | ..................................................................................................66     |
| 2.5.1. Dose response study(ies)                                                                                           | .................................................................................66                      |
| 2.5.2. Main study(ies)                                                                                                    | ...............................................................................................68        |
| 2.5.1. Discussion on clinical efficacy..........................................................................          | 117                                                                                                      |
| 2.5.2. Conclusions on the clinical efficacy...................................................................            | 121                                                                                                      |
| 2.6. Clinical safety                                                                                                      | .................................................................................................. 121   |
| 2.6.1. Discussion on clinical safety                                                                                      | ............................................................................ 156                         |
| 2.6.2. Conclusions on the clinical safety.....................................................................            | 168                                                                                                      |
| 2.7. Risk Management Plan......................................................................................           | 169                                                                                                      |
| 2.8. Pharmacovigilance............................................................................................        | 173                                                                                                      |
| 2.9. New Active Substance.......................................................................................          | 173                                                                                                      |

<div style=\"page-break-after: always\"></div>

2.10. Product information ........................................................................................  173

2.10.1. User consultation  .........................................................................................  173

2.10.2. Additional monitoring ...................................................................................  173

3. Benefit-Risk Balance............................................................................  173

3.1. Therapeutic Context .........................................................................................  173

3.1.1. Disease or condition  .......................................................................................  173

3.1.2. Available therapies and unmet medical need  ..................................................... 174

3.1.3. Main clinical studies .......................................................................................  174

3.2. Favourable effects ............................................................................................  174

3.3. Uncertainties and limitations about favourable effects  ........................................... 175

3.4. Unfavourable effects  .........................................................................................  176

3.5. Uncertainties and limitations about unfavourable effects ....................................... 178

3.6. Effects Table  ....................................................................................................  178

3.7. Benefit-risk assessment and discussion  ............................................................... 180

3.7.1. Importance of favourable and unfavourable effects  ............................................ 180

3.7.2. Balance of benefits and risks  ...........................................................................  180

3.7.3. Additional considerations on the benefit-risk balance ......................................... 180

3.8. Conclusions .....................................................................................................  181

4. Recommendations ...............................................................................  181

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| ADME       | Absorption, distribution metabolism and excretion                                     |
|------------|---------------------------------------------------------------------------------------|
| ADR        | Adverse drug reaction                                                                 |
| AE         | Adverse event                                                                         |
| AESI       | Adverse events of special interest                                                    |
| AJCC       | American Joint Committee on Cancer                                                    |
| ALT        | Alanine aminotransferase                                                              |
| AST        | Aspartate aminotransferase                                                            |
| ATP        | Adenosine triphosphate                                                                |
| AUC 0-12   | Area under the concentration-time curve from time 0 to 12 hours                       |
| AUC tau,ss | Area under the concentration-time curve from time 0 to the end of the dosing interval |
| BCRP       | Breast cancer resistance protein                                                      |
| BCS        | Biopharmaceutics Classification System                                                |
| BID        | Twice-daily                                                                           |
| BIRC       | Blinded independent review committee                                                  |
| BRAF       | V-raf murine sarcoma viral oncogene homolog B1                                        |
| CHMP       | Committee for Medicinal Products for Human Use                                        |
| CI         | Confidence intervals                                                                  |
| CK         | Creatine kinase                                                                       |
| CL/F       | Apparent total clearance following oral administration                                |
| Cmax       | Maximum observed plasma concentration                                                 |
| Cmax,ss    | Maximum observed plasma concentration at steady state                                 |
| Cmin,ss    | Minimum observed plasma concentration at steady state                                 |
| CrCL       | Calculated creatinine clearance                                                       |
| CSP        | Clinical study protocol                                                               |
| CSR        | Clinical study report                                                                 |
| CTCAE      | Common Terminology Criteria for Adverse Events                                        |
| CTLA-4     | Human cytotoxic T-lymphocyte antigen-4                                                |
| CYP        | Cytochrome P450                                                                       |
| DCR        | Disease control rate                                                                  |

<div style=\"page-break-after: always\"></div>

| DOR     | Duration of response                                                                 |
|---------|--------------------------------------------------------------------------------------|
| DRESS   | Drug reaction with eosinophilia and systemic symptoms                                |
| DSC     | Differential scanning calorimetry                                                    |
| ECG     | Electrocardiogram                                                                    |
| ECOG PS | Eastern Cooperative Oncology Group Performance Status                                |
| EMA     | European Medicines Agency                                                            |
| ESMO    | European Society for Medical Oncology                                                |
| EU      | European Union                                                                       |
| FAS     | Full Analysis Set                                                                    |
| GC      | Gas chromatography                                                                   |
| HPLC    | High performance liquid chromatography                                               |
| HR      | Hazard ratio                                                                         |
| ICH     | International Conference on Harmonisation of Technical Requirements for Registration |
|         | of Pharmaceuticals for Human Use                                                     |
| INR     | International Normalized Ratio                                                       |
| IPC     | In-process control                                                                   |
| IOP     | Intraocular pressure                                                                 |
| IR      | Infrared absorption spectrophotometry                                                |
| IRB     | Institutional Review Board                                                           |
| IRT     | Interactive Response Technology                                                      |
| ISE     | Integrated Summary of Effectiveness                                                  |
| ISS     | Integrated Summary of Safety                                                         |
| ITT     | Intention-to-Treat                                                                   |
| IV      | Intravenous(ly)                                                                      |
| KF      | Karl-Fisher titration                                                                |
| KM      | Kaplan-Meier                                                                         |
| KRAS    | Kirsten rat sarcoma viral oncogene homolog                                           |
| LDH     | Lactate dehydrogenase                                                                |
| LLN     | Lower limit of normal                                                                |
| LVEF    | Left ventricular ejection fraction                                                   |
| MAA     | Marketing Authorisation Application                                                  |
| MAP     | Mitogen-activated protein                                                            |

<div style=\"page-break-after: always\"></div>

| MedDRA    | Medical Dictionary for Regulatory Activities                             |
|-----------|--------------------------------------------------------------------------|
| MEK       | Mitogen-activated protein kinase                                         |
| MEK162    | Binimetinib                                                              |
| MEK162-4  | Methyl 2,4-diamino-3-fluoro-5-nitrobenzoate                              |
| MUGA      | Multi-gated acquisition                                                  |
| MS        | Mass spectrometry                                                        |
| NCI CTCAE | National Cancer Institute Common Terminology Criteria for Adverse Events |
| NE        | Not estimable                                                            |
| NLT       | Not less than                                                            |
| NMR       | Nuclear magnetic resonance                                               |
| NRAS      | Neuroblastoma RAS viral (v-ras) oncogene homolog                         |
| OCT       | Optical coherence tomography                                             |
| OR        | Odds ratio                                                               |
| ORR       | Objective response rate                                                  |
| OS        | Overall survival                                                         |
| PD        | Progressive disease                                                      |
| PD-1      | Programmed cell death protein 1                                          |
| pERK      | Phosphorylated extracellular signal-regulated kinase                     |
| PFS       | Progression-free survival                                                |
| P-gp      | Phosphorylated glycoprotein                                              |
| PIP       | Paediatric investigational plan                                          |
| PK        | Pharmacokinetics                                                         |
| PRO       | Patient-Reported Outcome                                                 |
| PT        | Preferred term                                                           |
| QTcF      | QT interval corrected for heart rate using Fridericia's formula          |
| RECIST    | Response Evaluation Criteria in Solid Tumours                            |
| RP2D      | Recommended Phase 2 dose                                                 |
| RPED      | Retinal pigment epithelium detachment                                    |
| RVO       | Retinal vein occlusion                                                   |
| SAE       | Serious adverse event                                                    |
| t1/2      | Apparent terminal half-life                                              |
| TLC       | Thin layer chromatography                                                |

<div style=\"page-break-after: always\"></div>

| Tmax   | Time to maximum observed plasma concentration   |
|--------|-------------------------------------------------|
| TNFα   | Tumours necrosis factor alpha                   |
| TTR    | Time to response                                |
| UGT    | Uridine glucuronosyltransferase                 |
| UHPLC  | Ultra-performance liquid chromatography         |
| ULN    | Upper limit of normal                           |
| UV     | Ultra violet spectroscopy                       |
| VTE    | Venous thromboembolism                          |
| Vz/F   | Volume of central distribution                  |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The applicant Pierre Fabre Medicament submitted on 28 July 2017 an application for marketing authorisation to the European Medicines Agency (EMA) for Mektovi, through the centralised procedure falling within the Article 3(1) and point 3 of Annex of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 21 July 2016.

The applicant applied for the following indication: Binimetinib in combination with encorafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation (see section 4.4).

## The legal basis for this application refers to:

Article 8.3 of Directive 2001/83/EC - complete and independent application

The application submitted is composed of administrative information, complete quality data, nonclinical and clinical data based on applicants' own tests and studies and/or bibliographic literature substituting/supporting certain test(s) or study(ies).

This application is submitted, in accordance with Article 82.1 of Regulation (EC) No 726/2004, as a multiple of Balimek (EMEA/H/C/004052), which at the time of filing of this application was under initial assessment.

Of note, the application for Balimek (EMEA/H/C/004052) was withdrawn by the applicant on 4 January 2018. As a consequence, the present application does not fall under Article 82.1 of Regulation (EC) No 726/2004 anymore.

## Information on Paediatric requirements

Pursuant to Article 7 of Regulation (EC) No 1901/2006, the application included an EMA Decision(s) P0051/2016 on the agreement of a paediatric investigation plan (PIP) and CW/1/2011 on the granting of a class waiver.

At the time of submission of the application, the PIP P0051/2016 was not yet completed as some measures were deferred.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Applicant's request(s) for consideration

## New active Substance status

The applicant requested the active substance binimetinib contained in the above medicinal product to be considered as a new active substance, as the applicant claims that it is not a constituent of a

<div style=\"page-break-after: always\"></div>

medicinal product previously authorised within the European Union.

## Scientific advice

The applicant did not seek Scientific advice at the CHMP.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur: Nithyanandan Nagercoil Co-Rapporteur:  Harald Enzmann

| The application was received by the EMA on                                                                                                                                              | 28 July 2017     |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| The procedure started on                                                                                                                                                                | 17 August 2017   |
| The Rapporteur's first Assessment Report was circulated to all CHMP members on                                                                                                          | 3 November 2017  |
| The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on                                                                                                       | 30 October 2017  |
| The PRAC Rapporteur's first Assessment Report was circulated to all PRAC members on                                                                                                     | 17 November 2017 |
| The CHMP agreed on the consolidated List of Questions to be sent to the applicant during the meeting on                                                                                 | 14 December 2017 |
| The applicant submitted the responses to the CHMP consolidated List of Questions on                                                                                                     | 28 March 2018    |
| The Rapporteurs circulated the Joint Assessment Report on the responses to the List of Questions to all CHMP members on                                                                 | 4 May 2018       |
| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                                                                                | 17 May 2018      |
| The CHMP agreed on a list of outstanding issues <in writing and/or in an oral explanation> to be sent to the applicant on                                                               | 31 May 2018      |
| The applicant submitted the responses to the CHMP List of Outstanding Issues on                                                                                                         | 25 June 2018     |
| The Rapporteurs circulated the Joint Assessment Report on the responses to the List of Outstanding Issues to all CHMP members on                                                        | 11 July 2018     |
| The Rapporteurs circulated the updated Joint Assessment Report on the responses to the List of Outstanding Issues to all CHMP members on                                                | 20 July 2018     |
| The CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a marketing authorisation to Mektovi on | 26 July 2018     |

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Problem statement

## 2.1.1. Disease or condition

Cutaneous melanoma, which arises from the oncogenic transformation of melanocytes that reside in the  epidermal  layer  of  the  skin,  is  the  most  lethal  form  of  skin  cancer,  due  to  its  propensity  to metastasise  to  vital  organs,  including  the  brain,  lungs,  liver  and  other  visceral  organs 1 .  Malignant melanoma is the 19th most common cancer worldwide, with around 232,000 new cases (2% of the total)  diagnosed  in  2012 2 , 3 .  Malignant  melanoma is the ninth most common cancer in Europe, with 123,135  new  cases  (3%  of  the  total)  diagnosed  in  2012.  The  European  incidence  of  malignant melanoma varies from 3 to 5/100 000/year in Mediterranean countries to 12-25 (and rising) in Nordic countries. The most common phenotypic risk factor for developing cutaneous melanoma is having fair skin that tends to burn in the sun. Genetic risk factors also include inheriting melanocortin-1 receptor variant  as  well  as  the  presence  of  high  numbers  of  common  naevi  and  those  with  large  congenital naevi, multiple and/or atypical naevi (dysplastic naevi) are at a greater risk to developing cutaneous melanoma. The most important external risk factor is prolonged exposure to UV irradiation, particularly intermittent sun exposure.

## 2.1.2. Biologic features

There  are  four  main  subtypes  of  cutaneous  melanomas:  superficial  spreading  melanoma,  nodular melanoma,  lentigo  maligna  melanoma,  acral  lentiginous  melanoma.  These  can  be  clinically  and histologically defined based on overall appearance, location and histologic features of the melanocytes. Approximately 50% of patients with metastatic melanoma have mutations in BRAF , and over 95% of these  are  in BRAF exon  15  at  V600.  The  most  common  V600  mutations  are  V600E  and  V600K accounting for 66-91% and 7-30% of all BRAF V600 mutations, respectively 4 , 5 , 6 , 7 , 8 . These mutations constitutively activate BRAF protein and downstream signal transduction in the RAF/MEK/ERK pathway (MAPK pathway), which signals for cancer cell proliferation and survival.

## 2.1.3. Clinical presentation, diagnosis and stage/prognosis

Over 90% of melanomas are diagnosed as primary tumours without any evidence of metastasis. The tumour-specific  10-year  survival  for  such  tumours  is  75%-85%,  with  10-20%  of  cases  becoming metastatic and eventually fatal 9 , . However, the survival rate of unresectable or metastatic melanoma decreases sharply; the 5-year survival rate is 17% and, if left untreated, the median survival is 6-9

1 Garbe C., Peris K., Hauschild A. et al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2016. Eur J Cancer. 2016 Aug; 63: 201-17

2 Ferlay J., Steliarova-Foucher E., Lortet-Tieulent J. et al Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013 Apr;49(6):1374-403.

3 Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM,  Forman D, Bray F. Cancer incidence and

mortality worldwide: sources, methods and  major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar 1;136(5):E359-86

4 Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002;417(6892):949-54.

5 Cheng S, Chu P, Hinshaw M et al. Frequency of mutations associated with targeted therapy in malignant melanoma patient. J Clin Oncol 2011; 29(suppl; abstr 8597)

6 Colombino M., Capone M., Lissia A. et al BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J. Clin. Oncol., 2012; 30(20): 2522-9

7 Jakob J.A., Bassett R.L. Jr., Ng CS et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 2012;118(16):4014-23

8 Greaves WO, Verma S, Patel KP et al. Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma. J Mol Diagn 2013;15(2): 220-6

9 Zbytek B, Carlson J.A., Granese J, Ross J, et al. Current concepts of metastasis in melanoma Expert review of dermatology. 2008;3(5):569-85

<div style=\"page-break-after: always\"></div>

months. The clinical  presentation  of  cutaneous  melanoma  varies  depending  on  the  subtype  but  the typical  features  relate  to  asymmetry  of  the  lesion,  irregular  borders,  colour  and  diameter  of  the lesions. The most important prognostic factors in metastatic melanoma are the site(s) of metastases (presence of visceral metastases) and the presence of elevated serum lactate dehydrogenase (LDH). Prognosis is particularly poor in patients with American Joint Committee on Cancer (AJCC) stage IV M1c melanoma, defined as disease that has metastasised to visceral organs (other than the lungs) and LDH is normal or with elevated LDH and any distant metastases, with an estimated 1-year survival rate of 33% 10 .

Table 1: AJCC staging of melanoma (7th edition)

<!-- image -->

| ANATOMICSTAGE/PROGNOSTICGROUPS   | ANATOMICSTAGE/PROGNOSTICGROUPS   | ANATOMICSTAGE/PROGNOSTICGROUPS   | ANATOMICSTAGE/PROGNOSTICGROUPS   | ANATOMICSTAGE/PROGNOSTICGROUPS   | ANATOMICSTAGE/PROGNOSTICGROUPS   | ANATOMICSTAGE/PROGNOSTICGROUPS   | ANATOMICSTAGE/PROGNOSTICGROUPS   |
|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|
| Clinical Staging                 | Clinical Staging                 | Clinical Staging                 | Clinical Staging                 | PathologicStaging                | PathologicStaging                | PathologicStaging                | PathologicStaging                |
| Stageo                           | Tis                              | NO                               | MO                               | 0                                | Tis                              | NO                               | MO                               |
| StageIA                          | Tla                              | NO                               | MO                               | IA                               | T1a                              | NO                               | MO                               |
| StageIB                          | T1b                              | NO                               | MO                               | IB                               | T1b                              | NO                               | MO                               |
|                                  | T2a                              | NO                               | MO                               |                                  | T2a                              | NO                               | MO                               |
| StagelIA                         | T2b                              | NO                               | MO                               | IIA                              | T2b                              | NO                               | MO                               |
|                                  | T3a                              | NO                               | MO                               |                                  | T3a                              | NO                               | MO                               |
| Stage IIB                        | T3b                              | NO                               | MO                               | IIB                              | T3b                              | NO                               | MO                               |
|                                  | T4a                              | NO                               | MO                               |                                  | T4a                              | NO                               | MO                               |
| StagelIc                         | T4b                              | NO                               | MO                               | IIC                              | T4b                              | NO                               | MO                               |
| Stage lll                        | AnyT                             | ≥N1                              | MO                               | IIIA                             | T1-4a                            | Nla                              | Mo                               |
|                                  |                                  |                                  |                                  |                                  | T1-4a                            | N2a                              | MO                               |
|                                  |                                  |                                  |                                  | IIIB                             | T1-4b                            | Nla                              | MO                               |
|                                  |                                  |                                  |                                  |                                  | T1-4b                            | N2a                              | MO                               |
|                                  |                                  |                                  |                                  |                                  | T1-4a                            | N1b                              | MO                               |
|                                  |                                  |                                  |                                  |                                  | T1-4a                            | N2b                              | MO                               |
|                                  |                                  |                                  |                                  |                                  | T1-4a                            | N2c                              | MO                               |
|                                  |                                  |                                  |                                  | IIIC                             | T1-4b                            | N1b                              | MO                               |
|                                  |                                  |                                  |                                  |                                  | T1-4b                            | N2b                              | MO                               |
|                                  |                                  |                                  |                                  |                                  | T1-4b                            | N2C                              | MO                               |
|                                  |                                  |                                  |                                  |                                  | AnyT                             | N3                               | MO                               |
| StageIV                          | AnyT                             | AnyN                             | M1                               | IV                               | AnyT                             | AnyN                             | M1                               |

## Notes

Micrometastasesarediagnosed aftersentinel lymphnodebiopsyand completion lymphadenectomy(ifperformed).

Macrometastasesaredfinedasclinicallydetectablenodalmetastasesconfrmedbytherapeuticymhadenectomyorwhennodalmetastasisexhibitsgrossextracapsularextension.

3Clinicalstagingincludesmicrostagingof theprimarymelanomaandclinical/radiologicevaluationformetastases.Byconvention,itshould

Pathologicstagingincludesmicrostagingoftheprimarymelanomaandpathologicinformationabouttheregionallymphnodesafterpartialorcomplete lymphadenectomy.PathologicStageOorStagelA patientsarethe exception;they donotrequire pathologicevaluation oftheir lymphnodes.

## 2.1.4. Management

The  current  treatment  options  for  metastatic  melanoma  include  2  classes  of  agents,  immune checkpoint  inhibitors  and  kinase  inhibitors  targeting  the  MAPK  pathway  in  patients  with BRAF mutations.  BRAF  and  its  downstream  target,  MEK,  are  kinases  in  the  MAPK  pathway,  and  play  an important  role  in  cell  proliferation 11 .  These  new  therapies  have  been  shown  to  prolong  survival  in

10  Dickson PV and Gershenwald JE. Staging and prognosis of cutaneous melanoma. Surg Oncol Clin N Am. 2011 Jan;20 (1):1-17

11  Peyssonnaux C, Eychène A. The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell. 2001;93(1-2):53-62

<div style=\"page-break-after: always\"></div>

recent Phase 3 clinical trials 12 , 13 , 14 , 15 , 16 , 17 , with the BRAF/MEK combinations vemurafenib/cobimetinib  and  dabrafenib/trametinib  increasing  the  median  progression-free  survival (PFS) to approximately 12 months and the median overall survival (OS) to 22-26 months in metastatic melanoma with a BRAF mutation,.

Vemurafenib  single-agent  was  the  first  BRAF  inhibitor  to  be  approved  for  patients  with  advanced unresectable or metastatic BRAF -mutant melanoma, followed by dabrafenib single-agent. In the pivotal Phase  3  studies,    the  median  PFS  was  5.3  months  with  vemurafenib  and  1.6  months  with dacarbazine 18   while median PFS was 5.1 months for dabrafenib and 2.7 months for dacarbazine 19 . The duration  of  response  (DOR)  for  single  agent  BRAF  inhibition  is  often  short  lived,  with  resistance developing  within  approximately  6  months, 20 , . To  delay  resistance  to  BRAF  inhibition,  the combination of BRAF- and a MEK1/2-inhibitors showed prolonged durationof the response in patients with advanced BRAF -mutant melanoma 21 , 22 , . In addition, the combination of a MEK inhibitor and a BRAF inhibitor appears to result in improved tolerability compared with either agent alone, , , , . Based on these data, the BRAF/MEK inhibitors have been the standard of care for patients with previously untreated  unresectable  or  metastatic BRAF V600E  or  V600K  mutation-positive  melanoma.  Recent European consensus-based interdisciplinary guidelines recommend the use of the BRAF/MEK inhibitor combinations  dabrafenib/trametinib  or  vemurafenib/cobimetinib  for  the  treatment  of BRAFmutated unresectable or metastatic melanoma  patients,  where targeted therapy is indicated and the combination  has  overtaken  BRAF  monotherapies  (e.g.  vemurafenib  monotherapy)  as  the  current standard of care.

## About the product

Binimetinib  is  an  ATP-uncompetitive,  reversible  inhibitor  of  the  kinase  activity  of  mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2. In cell free system, binimetinib inhibits MEK1 and MEK2 with the half maximal inhibitory concentration (IC50)'s in the 12-46 nM. MEK proteins are upstream regulators of the extracellular signal-related kinase (ERK) pathway, which promotes cellular proliferation.  In  melanoma  and  other  cancers,  this  pathway  is  often  activated  by  mutated  forms  of BRAF  which  activates  MEK.  Binimetinib  inhibits  activation  of  MEK  by  BRAF  and  inhibits  MEK  kinase

12 Chapman P.B., Hauschild A., Robert C. et al Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med., 2011; 364(26): 2507-16

13 Hodi F.S. O'Day S.J. McDermott D.F. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010 Aug 19;363(8):711-23

14 Larkin J., Ascierto P.A., Dréno B. et al Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N. Engl. J. Med., 2014; 371(20): 1867-76

15 Robert C., Karaszewska B, Schachter J et al Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib. N. Engl. J. Med., 2015a; 372: 30-9

16 Robert C., Long G.V., Brady B. et al. Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study

comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as firstline therapy in patients

(pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma. Eur J Cancer 2015b 51 sup3:

S-663

17 Ascierto P.A., McArthur G.A., Dréno B. et al. Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016 ;17(9):1248-60

18 Chapman P.B., Hauschild A., Robert C. et al Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med., 2011; 364(26): 2507-16

19 Hauschild A., Grob J.J., Demidov L.V. et al Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet, 2012(9839); 380: 358-65

20  McArthur GA, Chapman PB, Robert C et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014;15(3):323-32

21 Flaherty K.T., Robert C., Hersey P. et al Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med., 2012; 367(2):107-14

22 Long GV, Stroyakovskiy D, Gogas H et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 2014; 371(20):1877-88

<div style=\"page-break-after: always\"></div>

activity. Binimetinib inhibits growth of BRAF V600 mutant melanoma cell lines and demonstrates antitumour effects in BRAF V600 mutant melanoma animal models.

## Combination with encorafenib

Binimetinib and encorafenib (a BRAF inhibitor, see section 5.1 of encorafenib SmPC) both inhibit the MAPK pathway resulting in  higher anti-tumour activity.

Additionally,  the  combination  of  encorafenib  and  binimetinib  prevented  the  emergence  of  treatment resistance in BRAF V600E mutant human melanoma xenografts in vivo.

The applicant applied for the following indication:

'Binimetinib is indicated for use in combination with encorafenib for the treatment of adult patients with unresectable or metastatic melanoma, with BRAF V600 mutation.'

The agreed final indication is as follows:

'Binimetinib in combination with encorafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation (see sections 4.4 and 5.1).'

Binimetinib  will  be  supplied  as  15 mg  film-coated  tablets  for  oral  administration.  Each  film-coated tablet contains 15 mg  of  binimetinib. Each  film coated  tablet contains 133.5  mg  of  lactose monohydrate.

The recommended dose of binimetinib is 45 mg (three 15 mg tablets) twice daily, corresponding to a total daily dose of 90 mg approximately 12 hours apart.

Binimetinib treatment in combination with encorafenib should be initiated and supervised under the responsibility of a physician experienced in the use of anticancer medicinal products.

Method of administration

Mektovi is for oral use.

The tablets are to be swallowed whole with water. They may be taken with or without food. In case of vomiting after administration of binimetinib, the patient should not re-take the dose and should take the next scheduled dose.

## Duration of treatment

Treatment should continue until the patient no longer derives benefit or the development of unacceptable toxicity.

## Missed doses

If a dose of binimetinib is missed, it should not be taken if it is less than 6 hours until the next dose is due.

## Type of Application and aspects on development

Scientific advice was given by 2 national European (EU) Agencies (Medical Products Agency [MPA] and Medicines  Evaluation  Board  [MEB])  on  the  design  of  the  pivotal  Phase  3  study  CMEK162B2301, intended to establish the safety and efficacy of binimetinib 45 mg BID in combination with encorafenib 450 mg QD vs vemurafenib 960 mg BID and encorafenib 300 mg QD monotherapies in patients with unresectable or metastatic BRAF V600-mutant melanoma. The choice of PFS as primary endpoint for

<div style=\"page-break-after: always\"></div>

the study as well as the proposed central response assessment was agreed. However, the importance of presenting the overall survival data, was also highlighted. Hierarchical and event-driven statistical testing strategy was agreed in a follow-up advice meeting with the MPA.

## 2.2. Quality aspects

## 2.2.1. Introduction

The finished product is presented as a film-coated tablet containing 15 mg of binimetinib as active substance.

Other ingredients of the tablet core are: lactose monohydrate, cellulose microcrystalline (E460i), silica colloidal anhydrous (E551), croscarmellose sodium (E468) and magnesium stearate (E470b).

Other ingredients of film-coating of the tablet are: polyvinyl alcohol (E1203), macrogol 3350 (E1521), titanium dioxide (E171), talc (E533b), iron oxide yellow (E172), and iron oxide black (E172).

The product is available in PVC/PVDC/Alu blisters as described in section 6.5 of the SmPC.

## 2.2.2. Active Substance

## General information

The chemical name of binimetinib is 5-[(4-bromo-2-fluorophenyl)amino]-4-fluoroN -(2hydroxyethoxy)-1-methyl-1 H -benzimidazole-6-carboxamide corresponding to the molecular formula C17H15BrF2N4O3. It has a relative molecular mass of 441.23g/mol and the following structure:

Figure 1: active substance structure

<!-- image -->

The chemical structure of binimetinib was elucidated by a combination of infrared  absorption spectrophotometry (IR), ultraviolet spectroscopy (UV) in different media, proton and carbon nuclear magnetic resonance (NMR) spectroscopy, and mass spectrometry (MS).

Binimetinib is a white to slightly yellow powder. As discussed under the pharmaceutical development of the finished product, the particle size of the active substance is controlled. Binimetinib does not contain any chiral centres; hence, it is not chiral.

<div style=\"page-break-after: always\"></div>

## Manufacture, characterisation and process controls

Binimetinib is synthesised insteps using well defined starting materials with acceptable specifications. A synthesis scheme and a detailed, comprehensive synthesis description have been provided including standard quantities or molar equivalents of used raw materials, solvents and reagents as well as temperatures, pressure/vacuum conditions, pH values and times.

IPCs and critical process steps are indicated in the narrative description.

Adequate IPCs are applied during the synthesis. The specifications and control methods for intermediate products, starting materials and reagents have been presented.

The characterisation of the active substance and its impurities are in accordance with the EU guideline on chemistry of new active substances.

Potential and actual impurities were well discussed with regards to their origin and characterised. Mutagenic impurities are controlled in an intermediate in line with ICH M7 guidance.

The commercial manufacturing process for the active substance was developed in parallel with the clinical development program. Changes introduced in the manufacturing process have been presented in sufficient detail, justified and supported with bridging studies when needed.

The active substance is packaged in double polyethylene (PE) bags which comply with the EC directive 2002/72/EC and EC 10/2011 as amended. The bags are placed into 120 L metallic drums.

## Specification

The active substance specification includes tests for appearance, identification (IR), water content (by Karl-Fisher titration method (KF)), sulphated ash (Ph.Eur.), residual solvents (gas chromatography (GC)), particle size (laser diffraction), assay and related substances (ultra-performance liquid chromatography (UHPLC)) and microbiological examination (Ph. Eur.).

The analytical methods used have been adequately described and non-compendial methods appropriately validated in accordance with the ICH guidelines. Satisfactory information regarding the reference standards used for assay testing has been presented.

Batch analysis data (batches manufactured at commercial scale with the proposed commercial process) of the active substance were provided. The results were within the specifications and consistent from batch to batch.

## Stability

Stability data from commercial scale batches of active substance from the proposed manufacturer stored in a container closure system representative of that intended for the marketunder long term conditions and under accelerated conditionsaccording to the ICH guidelines was provided.

The following parameters were tested: appearance, polymorphic form, assay, related substances, water content and microbial purity . The analytical methods used were the same as for release and are stability indicating

All tested parameters were within the specifications and no significant trends were observed. Photostability testing following the ICH guideline Q1B was performed on one batch.

<div style=\"page-break-after: always\"></div>

## 2.2.3. Finished Medicinal Product

## Description of the product and Pharmaceutical development

Mektovi is an immediate release film-coated tablet for oral administration. The tablet is ovaloid biconvex (capsule shaped), yellow to dark yellow in colour, and debossed with a stylized 'A' on one side and '15' on the other. The length of the film-coated tablet is approximately 12 mm. The width of the film-coated tablet is approximately 5 mm.

Mektovi is an immediate release film-coated tablet for oral administration. The development of the formulation and manufacturing process were conducted following a traditional empirical pharmaceutical development approach that targeted an immediate release oral product with complete disintegration and rapid dissolution in the stomach that would achieve acceptable bioavailability and would allow for room temperature storage.

All excipients are well known pharmaceutical ingredients and their quality is compliant with Ph. Eur standards. There are no novel excipients used in the finished product formulation. The list of excipients is included in section 6.1 of the SmPC and in paragraph 2.1.1 of this report.

The dissolution specification has been set according the clinical batches used which dissolution profiles have been presented. No overages are used in the manufacture of the finished product.

The  primary  packaging  is  PVC/PVDC/Alu  blister.  The  materials  comply  with  Ph.  Eur.  and  EC requirements. The choice of the container closure system has been validated by stability data and is adequate for the intended use of the product.

## Manufacture of the product and process controls

The manufacturing process consists of blending, milling, compression, film-coating and packaging. The content of active substance exceeds 2% of the finished dosage form; hence, the process is considered to be a standard manufacturing process.

Formal process validation studies for batches manufactured at the proposed commercial scale have been presented. The bulk holding time is justified based on the stability data provided. It has been demonstrated that the manufacturing process is capable of producing the finished product of intended quality in a reproducible manner. The IPCs are adequate for this pharmaceutical form.

## Product specification

The finished product release specifications shown in include appropriate tests for this kind of dosage form:  appearance,  identification  (thin  layer  chromatography  (TLC)  and  High  performance  liquid chromatography  (HPLC))  assay  and  related  products  (UHPLC/UV),  uniformity  of  dosage  units  by content uniformity (HPLC), dissolution (HPLC), water content (KF) and microbiological examination.

The analytical methods used have been adequately described and appropriately validated in accordance with the ICH guidelines. Satisfactory information regarding the reference standard used for assay has been presented, as discussed in the active substance section.

Batch analysis results were provided for commercial scale batches confirming the consistency of the manufacturing process and its ability to manufacture to the intended product specification.

<div style=\"page-break-after: always\"></div>

## Stability of the product

Stability data from batches of finished productstored under long term conditions andunder accelerated conditions according to the ICH guidelines were provided. The batches of Mektovi are identical to those proposed for marketing and were packed in the primary packaging proposed for marketing.

Samples  were  tested  for  appearance,  assay  and  related  products,  dissolution,  water  content  and microbial enumeration. The analytical procedures used are stability indicating. No significant changes or trends were observed under any of the storage conditions.

In addition, one batch was exposed to light as defined in the ICH Guideline on Photostability Testing of New Drug Substances and Products. Data presented for tablet appearance, assay, individual and total unspecified degradation products and dissolution show no changes following exposure.

Data to demonstrate stability to temperature excursions which could be encountered during shipping or  storage,  i.e.  refrigerated,  frozen  and  exposed  to  cycles  of  freeze  /  thaw  conditions  were  also presented. The data indicate no adverse impact on product quality from such temperature excursions.

Based on available stability data, the proposed shelf-life of 36 months without special temperature storage conditions as stated in the SmPC (section 6.3) is acceptable.

## Adventitious agents

All constituent parts of the formulation are of non-biological/chemical origin, with the exception of lactose monohydrate for which a suitable TSE declaration has been provided.  It is confirmed that the lactose is produced from milk from healthy animals in the same condition as those used to collect milk for human consumption and that the lactose has been prepared without the use of ruminant material other than calf rennet according to the Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents Via Human and veterinary medicinal products.

## 2.2.4. Discussion on chemical, pharmaceutical and biological aspects

Information on development, manufacture and control of the active substance and finished product has been presented in a satisfactory manner. The results of tests carried out indicate consistency and uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance in clinical use.

## 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects

The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way. Data has been presented to give reassurance on viral/TSE safety.

## 2.2.6. Recommendation(s) for future quality development

Not applicable.

<div style=\"page-break-after: always\"></div>

## 2.3. Non-clinical aspects

## 2.3.1. Introduction

Pharmacology studies were performed for the binimetinib alone as well as the combination of encorafenib with binimetinib in both in vitro (isolated enzyme and cell culture) and in vivo (mouse xenograft) model systems. Pharmacokinetic studies were conducted in mice, rats and monkeys with binimetinib administered either orally or/and intravenously. No PK, ADME or toxicology studies have been performed with the combination. The safety pharmacology and toxicology studies were performed in accordance with GLP (unless otherwise indicated).

## 2.3.2. Pharmacology

## Primary pharmacodynamic studies

The activity of binimetinib against purified MEK1 has been evaluated using standard screening assays. Measurements of the IC50 for binimetinib at a concentration of ATP at/near its Km(app) (10 μM) yielded an average value of 12.1 ± 5.6 nM (n=4). Results of the enzymatic studies revealed that binimetinib is a weakly time-dependent, slowly reversible, allosteric inhibitor of MEK that displays uncompetitive inhibition versus ATP and non-competitive inhibition versus the substrate ERK2.

## Viability and p-ERK Inhibition by binimetinib in B-Raf-Mutant Human Melanoma Cell Lines

In viability assays, binimetinib was most potent in A375 and UACC-62 cell lines (Table 2) and less sensitive in cell lines IGR-39, MDA-MB435S and RPMI-7051, both by relatively high IC50 values and by low maximal inhibition of about 50%. IGR-1, WM-115 and Colo-800 lines showed medium sensitivity in this panel. Cell lines of variable sensitivity (UACC-62, WM- 115 and Colo-800) showed signs of cell death after treatment with MEK162.

Table 2: Effect of binimetinib Single Agent on p-ERK in B-Raf-Mutant Melanoma Cell Lines

| CellLines   | Concentrations Used (nM)   | p-ERK               | p-ERK               | p-ERK               |
|-------------|----------------------------|---------------------|---------------------|---------------------|
| CellLines   | Concentrations Used (nM)   | Relative ICso (nMI) | Absolute ICso (nMI) | Max. Inhibition (%) |
| A375        | 0.13 -10.000               | 17.1                | 27.4                | 87.4                |
| UACC-62     | 0.13 -10.000               | 13.1                | 14.4                | 76.1                |
| RPMI-7951   | 0.13 -10.000               | 57.9                | 125.8               | 73.0                |
| Colo-800    | 0.13 -10.000               | 5.3                 | 7.6                 | 97.3                |

B-Raf mutant melanoma cells were seeded at 15,000 cells per well in triplicate black 96-well plates and treated for 24 h with MEK162. A p-Erk in-cell Western assay was performed and maximal inhibition, relative and absolute IC50 values calculated using Excel Fit software.

## Nude Mouse, HT-29 Xenograft

The effects of binimetinib on ERK phosphorylation in HT-29 human colorectal carcinoma xenograft tumours were evaluated in nude mice (Study 060304-800). Mice were implanted with tumour cells (5 x 10 6 cells, subcutaneous [SC] and the tumours were allowed to grow to 300 mm 3 . Animals received a single dose of vehicle or binimetinib (3, 10 or 30 mg/kg, PO) and were sacrificed at 2, 4, 12 and 24 hours post-dose.

<div style=\"page-break-after: always\"></div>

Target inhibition of nearly 100% was achieved at all doses of binimetinib, and 50% inhibition was maintained at 24 hours following a single dose of either 10 or 30 mg/kg binimetinib, which supports BID dosing to achieve maximum target inhibition in the mouse tumour models.

Figure 2: Effects of binimetinib on ERK Phosphorylation in HT-29 Human Colorectal Carcinoma Tumours

<!-- image -->

N = 4 mice per treatment group T-ERK = total ERK Data are mean ± SEM

## Nude Mouse, A375 B-Raf-Mutant Melanoma Xenograft (High Dose Ranging)

The effects binimetinib on A375 human B-Raf-mutant melanoma tumour growth in nude mice were evaluated (Study RD-2010-00964). Mice were implanted with tumour fragments, and the tumours were allowed to grow to 100-150 mm 3 . Animals received vehicle or binimetinib (30 or100 mg/kg, PO, BID for 14 days; or 300 mg/kg, PO BID for 3 days, weekly x 2). At the end of the treatment period, tumour growth delay for each drug treated group was assessed in comparison to the vehicle treated control group. The current summary limits itself to a description of the efficacy and tolerability after 14 days of treatment.

Oral administration of MEK162 at 30 and 100 mg/kg, BID produced tumour regression (T/C% = - 11 and -20%, respectively). In contrast, MEK162 administered at 300 mg/kg BID intermittently only caused tumour growth delay which was not statistically different from the control group (Figure 3). MEK162 treatment at all doses was well tolerated with minimal body weight loss and no treatment related deaths.

<div style=\"page-break-after: always\"></div>

Figure 3: Effects of binimetinib on Tumour Growth in A375 Human B-Raf-Mutant Melanoma Xenografts in Nude Mice (Low Dose Ranging)

<!-- image -->

N = 12 mice per treatment group at study start

$ 300m/kg dose was administered 3 days on and 4 days off over 14 days.

*P&lt;0.05 ANOVA Kruskal-Wallis post hoc Dunn's versus vehicle control.

## Binimetinib and Encorafenib in combination

## Cell Culture

Binimetinib (ARRY-438162, MEK162) in combination with encorafenib (LGX818) with was assessed in melanoma and CRC-derived cancer cell. For each cell line, the LGX818 combination with MEK162 was compared to the combination of each agent with itself (self-crosses) as a control (Table 3).

<div style=\"page-break-after: always\"></div>

Table 3: Summary of Synergy Evaluations for MEK162 with LGX818

| Cell-line Name     | Cancer   | MEK162 IC50 (nM)   | LGX818 IC50 (nM)   |   Syngergy | Best LI (at 50% inhibition)   | Effect Description   | BRAF   | KRAS   | 3   | PIK3CA   | PTEN   |
|--------------------|----------|--------------------|--------------------|------------|-------------------------------|----------------------|--------|--------|-----|----------|--------|
| SW1417             | CRC      | 24.01              | 15.0               |       2.55 | 1.34                          | Additive/Synergy     | Mut    | wt     | wt  | wt       | wt     |
| COLO 205           | CRC      | 15.71              | 3.7                |       2.05 | 1.05                          | Additive/Synergy     | Mut    | wt     | wt  | wt       | wt     |
| LS411N             | CRC      | 19.42              | 3.6                |       2.01 | 0.89                          | Additive/Synergy     | Mut    | wt     | wt  | wt       | wt     |
| HT-29              | CRC      | 32.00              | 4.1                |       3.32 | 1.43                          | Additive/Synergy     | Mut    | wt     | wt  | Mut      | wt     |
| RKO                | CRC      | >2700              | 560.7              |       1.72 | 0.48                          | Synergy              | Mut    | wt     | wt  | Mut      | wt     |
| OUMS-23            | CRC      | >2700              | >2700              |       0.17 | nc                            | Additive             | Mut    | wt     | wt  | wt       | Muts   |
| HuTu 80            | CRC      | >2700              | >2700              |       1.75 | 0.64                          | Additive/Synergy     | wt     | wt     | wt  | wt       | wt     |
| CW-2               | CRC      | >2700              | >2700              |       0.14 | nc                            | Additive             | wt     | wt     | wt  | wt       | wt     |
| NCI-H716           | CRC      | >2700              | >2700              |       0.93 | nc                            | Additive             | wt     | wt     | wt  | wt       | wt     |
| C2BBe1             | CRC      | >2700              | >2700              |       0.5  | 0.63                          | Additive             | wt     | wt     | wt  | wt       | wt     |
| SNU-C1             | CRC      | 10.2               | >2700              |       0.35 | 2.23                          | Additive             | wt     | wt     | wt  | wt       | wt     |
| KM12               | CRC      | 231.6              | >2700              |       0.19 | 1.30                          | Additive             | wt     | wt     | wt  | wt       | wt     |
| A-375              | Melanoma | 20.0               | 5.8                |       1.2  | 0.87                          | Additive/Synergy     | Mut    | wt     | wt  | wt       | wt     |
| COLO741            | Melanoma | 1190.4             | 32.6               |       1.45 | 0.27                          | Additive/Synergy     | Mut    | wt     | wt  | wt       | wt     |
| COLO-800           | Melanoma | 50.5               | 7.9                |       2.67 | 0.84                          | Additive/Synergy     | Mut    | wt     | wt  | wt       | wt     |
| IGR-1              | Melanoma | 893.0              | 167.6              |       3.81 | 0.02                          | Synergy              | Mut    | wt     | wt  | wt       | wt     |
| IGR-37             | Melanoma | 82.8               | 17.6               |       1.03 | 0.70                          | Additive/Synergy     | Mut    | wt     | wt  | wt       | 1M     |
| K029AX             | Melanoma | 78.8               | 12.8               |       2.59 | 0.73                          | Additive/Synergy     | Mut    | wt     | wt  | wt       | wt     |
| LOXIMVI            | Melanoma | >2700              | >2700              |       5.99 | 0.28                          | Synergy              | Mut    | wt     | wt  | wt       | wt     |
| A2058              | Melanoma | 978.0              | 1486.1             |       2.07 | 0.34                          | Synergy              | Mut    | wt     | wt  | wt       | Mut    |
| IGR-39             | Melanoma | >2700              | >2700              |       0.7  | nc                            | Additive             | Mut    | wt     | wt  | wt       | Mut    |
| RPML-7951          | Melanoma | >2700              | >2700              |       1.02 | nc                            | Additive             | Mut    | wt     | wt  | wt       | Muts   |
| SK-MEL-24          | Melanoma | 892.2              | 776.0              |       1.87 | 0.66                          | Additive             | Mut    | wt     | wt  | wt       | Muts   |
| UACC-62            | Melanoma | 47.0               | 3.7                |       1.26 | 0.93                          | Additive/Synergy     | Mut    | wt     | wt  | wt       | Mut    |
| COLO792            | Melanoma | 182.5              | >2700              |       0.9  | 1.29                          | Additive             | wt     | wt     | wt  | wt       | wt     |
| HMCB               | Melanoma | >2700              | >2700              |       2.86 | 0.04                          | Synergy              | wt     | wt     | wt  | wt       | wt     |
| MeWo               | Melanoma | >2700              | >2700              |       2.6  | 0.25                          | Synergy              | wt     | wt     | wt  | wt       | wt     |
| SK-MEL-31 Melanoma |          | >2700              | 1032.0             |       0.93 | 0.80                          | Additive             | wt     | wt     | wt  | wt       | Mut    |

## Nude Mouse, HMEX1906 (BRAFV600E) Mutant Human Melanoma Primary Xenograft

This study was designed to evaluate whether combining binimetinib and encorafenib would prevent the emergence of resistance in the HMEX1906 (BRAFV600E) PDX model. MEK162 was evaluated at two doses that approximate the clinically-relevant doses, and LGX818 was evaluated at a dose that was anticipated to result in resistance within 1 to 2 months. There were 6 treatment groups: vehicle (1% CMC/0.5 % Tween 80 in water), binimetinib (MEK162; 3 or 10 mg/kg, PO, BID), encorafenib (LGX818; 3 mg/kg, PO, BID) and 2 combination treatment groups with binimetinib (MEK162, 3 or 10 mg/kg, PO, BID) plus encorafenib (LGX818; 3 mg/kg, PO, BID).

<div style=\"page-break-after: always\"></div>

Figure 4: Efficacy of Encorafenib and Binimetinib as Single Agents and in Combination in the HMEX1906 (BRAFV600E) PDX Model

<!-- image -->

N = 8 mice per treatment group at study start

Tumour growth curves end when 2 or more mice have been removed from the study due to tumour burden.

Figure 5: Survival Analysis of Binimetinib and Encorafenib as Single Agents and in Combination in the HMEX1906 (BRAFV600E) Melanoma PDX Model

<!-- image -->

Median survival for the Vehicle control, 3 mg/kg binimetinib and 10 mg/kg binimetinib groups was 42 days, 92 days and 117 days, respectively. Median survival was not reached for the 3 mg/kg encorafenib and both combination groups. There was also a significant increase in survival for the 10 mg/kg binimetinib + 3 mg/kg encorafenib combination group compared to each single agent treatment group, however there was no significant difference between the 3 mg/kg binimetinib + 3 mg/kg encorafenib and single-agent encorafenib treatment groups.

<div style=\"page-break-after: always\"></div>

## Secondary pharmacodynamic studies

Binimetinib was tested against a panel of 219 kinases. Other than MEK1, 1 μM binimetinib did not inhibit any of the other kinases by more than 30%. With 10 μM binimetinib, only calcium/calmodulin kinase IV (31%), Fer (fps/fes related) tyrosine kinase (phosphoprotein NCP94) (38%) and MEK1 (92%) were inhibited by more than 30%.

Table 4: Kinase Activity and Receptor Screening Assay and Off-target activity

| Species/ Strain                | Method of Admin.   | OrganSystemsEvaluated                      | Doses and Duration         | Gender and No. per Group   | Noteworthy Findings                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|--------------------------------|--------------------|--------------------------------------------|----------------------------|----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Selectivity Enzymatic activity | In vitro           | 219 kinases Selectivity                    | 1 or 10 μM                 | NA                         | *1 μM binimetinib did not inhibit any of the other 219 kinases by more than 30%. *Binimetinib is selective                                                                                                                                                                                                                                                                                                                                          |
| Off target activity            | In vitro           | Enzymes, receptors, transporters, channels | Range of 12 concentrations | NA                         | Binimetinib did not show an activity of greater than 50% inhibition or activation at 10μM in any ofthe targets tested. The only activity found was in the bile salt export pump (BSEP) vesicular uptake assay (ICso = 87 μM). Even though the ICso for BSEP is quite high, this could still become relevant in a therapeuticsituationif thelocal free concentration of the compound in the liver is high. None of the suicidality targets were hit. |

## Safety pharmacology programme

Safety pharmacology studies performed with binimetinib as a single agent are shown in Table 5.

Table 5: Overview of the safety pharmacology studies

| Organ Systems Study Number        | Species /Strain      | Method of Admini stration   | Doses a (mg/kg)b                             | Number of Animals per Group (M/F)   | Noteworthy Findings                                                                       |
|-----------------------------------|----------------------|-----------------------------|----------------------------------------------|-------------------------------------|-------------------------------------------------------------------------------------------|
| Neurobehavioral Function 1140-012 | Rat, Sprague- Dawley | PO                          | 0, 10, 30 or 100                             | 15/15                               | • No significant effect up to 100 mg/kg • NOEL > 100 mg/kg                                |
| hERG Channel 050726.BCP           | HEK293 cells         | In vitro                    | Up to 30 μM                                  | NA                                  | hERG channel inhibition was 30% at 30μM                                                   |
| hERG Channel pcs-1414541          | HEK293 cells         | In vitro                    | Up to 100 μM, AR00426032 (active metabolite) | NA                                  | hERG channel inhibition was 11% at 100μM for AR00426032                                   |
| Cardiovascular Function JAY00033  | Monkey, Cynomol gus  | PO                          | 0, 1, 3 or 10                                | 6/0                                 | No significant effects noted in MABP, HR or ECG waveform QT or QTc data • NOEL = 10 mg/kg |

<div style=\"page-break-after: always\"></div>

| Respiratory Function 1140-011   | Rat, Sprague- Dawley                             | PO   | 0, 10, 30 or 100                                                                                                      | 12/0   | • No significant effect up to 100 mg/kg • NOEL =100 mg/kg                                                                                                                                                                                           |
|---------------------------------|--------------------------------------------------|------|-----------------------------------------------------------------------------------------------------------------------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Gastric Secretion AA30228       | Rat, Sprague- Dawley                             | PO   | 0, 10, 30 or 100                                                                                                      | 10/0   | Slight, dose-related decreases in gastric acid secretion and gastric volume at 10 and 30 mg/kg • No significant effects at 100 mg/kg • NOEL = 100 mg/kg                                                                                             |
| Gastric Motility 1140-013       | Rat, Sprague- Dawley                             | PO   | 0, 10, 30 or 100                                                                                                      | 10/10  | No significant effect up to 100 mg/kg • NOEL = 100 mg/kg                                                                                                                                                                                            |
| Renal Function 1140-010         | Rat, Sprague- Dawley                             | PO   | 0, 10, 30 or 100                                                                                                      | 0/10   | • No significant effect up to 100 mg/kg • NOEL = 100 mg/kg                                                                                                                                                                                          |
| Immune Modulation PT#1105452    | Mouse/C D-1; Mouse/ C57/Bl6 (LPS challenge only) | PO   | LPS Challenge: 0, 3, 10 or 30 (QD for 3 days) • S. aureus or C. albicans Challenge: 0, 10 , 30 or 100 (QD for 7 days) | 8/0    | • LPS Challenge: Non-significant protective effect on survival at 10 and 30 mg/kg • S. aureus or C. albicans Challenge: Significant protective effect on survival at 10 and 30 mg/kg in the S.aureus study and at 30 mg/kg in the C. albicans study |
| Wound Healing PT#1077057        | Mouse/C D-1                                      | PO   | 0, 3, 10 or 30 (BID for 10 days)                                                                                      | 12/0   | No effects on wound healing                                                                                                                                                                                                                         |

a Single dose unless specified otherwise b All studies were conducted using ARRY-438162 and all dose levels refer to active compound. All doses are in units of mg/kg unless otherwise specified.

NA = Not Applicable

## Pharmacodynamic drug interactions

Pharmacodynamic drug interactions were not submitted (see non-clinical discussion).

## 2.3.3. Pharmacokinetics

## Absorption

The table below shows a summary of the PK data in various animal models.

<div style=\"page-break-after: always\"></div>

Table 6: PK data in mice, rats and monkeys following oral of IV administration of binimetinib

| Study ID   | Type of Study                            | Species N/Gender   | Route, Dose                                                      | Results                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|------------|------------------------------------------|--------------------|------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| DM05- 049  | Single dose BV of free base              | Rats 3M            | Oral 10; 30; 100 mg/kg BW IV 1 mg/kg BW                          | Following a single IV dose to male rats, the mean AUC inf value was 10.0 ± 0.9 μg- hr/mL. The mean plasma clearance (CL inf ), t 1/2 and steady-state volume of distribution values were 1.67 mL/min/kg, 2.37 hr, and 189 mL/kg, respectively. The mean AUC inf , t1/2 and mean residence time (MRT) were 10.0 μg-hr/mL, 2.37 hours and 1.89 hours, respectively. Following a single PO dose the mean C max values were 5.38, 11.9 and 20.2 μg/mL for doses of 10, 30, and 100 mg/kg, respectively. The mean oral bioavailability values were 76.4%, 53.1%, and 45.5%, respectively.                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| DM05- 050  | Single and repeated dose BV of free base | Monkeys 3M         | IV 3 mg/kg BW (single) Oral 1; 3; 10 mg/kg BW (single or 5 Days) | Following single IV dose the mean AUC inf , plasma clearance, steady-state volume of distribution (Vss), and t1/2 were 6.60 ± 1.82 μghr/ mL, 8.05 ± 2.60 mL/min/kg, 1.04 ± 0.58 L/kg, and 5.48 ± 2.11 hr, respectively. Following single po doses the mean plasma AUC 0-t values were 0.564 ± 0.030, 2.50 ± 0.701, and 7.87 ± 1.39 μg-hr/mL for the 1-, 3-, and 10-mg/kg doses, respectively. The mean plasma C max values were 0.049 ± 0.012, 0.330 ± 0.239, and 0.898 ± 0.483 μg/mL while the mean plasma T max values were 2.83, 2.33, and 2.17 hours for the 1-, 3-, and 10-mg/kg doses, respectively. The t 1/2 was 8.48 ± 0.72 hr, 7.7 ± 0.95 hr, and 7.93 ± 0.27 hr for the 1-, 3-, and 10-mg/kg doses, respectively. The oral bioavailability (F) values were 26.7 ± 1.4%, 39.4 ± 11.1% and 37.2 ± 6.6%, respectively. Following oral dosing for 5 days the plasma AUC 0-t values on Day-1 were 0.417, 1.28 and 4.38 μg-hr/mL. The AUC 0-t values on Day-5 were nearly the same at the 1 and 3 mg/kg doses, but show a slight trend for |

<div style=\"page-break-after: always\"></div>

| Study ID   | Type of Study                                                                      | Species N/Gender            | Route, Dose                                         | Results                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|------------|------------------------------------------------------------------------------------|-----------------------------|-----------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| DM09- 001  | BV of oral Binimetinib Capsules or Tablets                                         | Monkeys 6 M Parallel design | Oral 1mg/kg BW                                      | in oral bioavailability (to 12.7%) when determined with respect to the mean dose- normalized IV AUC 0-t . Capsules exhibited a mean C max of 291 ± 332 ng/mL, a mean apparent T max of 1.67 ± 1.21 hr and a mean AUC 0-inf of 1,110 ± 514 ng-hr/mL. Tablets: the resulting mean dose normalized C max value was 428 ± 231 ng/mL, the mean apparent T max was 1.17 ± 0.68 hr and the mean dose normalized AUC 0-inf was 1,710 ± 784 ng-hr/mL. In comparison to the capsule formulation, the mean dose normalized values of C max and exposure (AUC 0-inf ) are greater for the tablet formulation but the differences were not statistically significant due to intersubject variability. |
| DM09- 043  | Single dose PK of free base and two metabolites (N-desmethyl and amide metabolite) | Nude Mice 30 F              | IV 1 mg/kg BW Oral 3; 10; 30 mg/kg BW Or 100 or 300 | IV : AUC inf 2,916 ng-hr/mL, CL 5.72 mL/min/kg, Vss 0.29 L/kg, t 1/2 4.80 hr, and MRT 0.85 hr. Oral: The absolute oral bioavailability in athymic female nu/nu NCr mice at 3, 10, 30, 100, or 300 mg/kg was approximately 43, 47, 54, 42, and 29%, respectively. The mean C max and AUC indicated that oral exposure was approximately dose proportional from 3 to 100 mg/kg. For AUC values ref. to text. Considerable concentrations of the N - desmethyl (AR00426032) or amide (AR00426618) metabolites were found in the plasma of each group of animals at each dose level. Plasma exposure of                                                                                      |

<div style=\"page-break-after: always\"></div>

| Study ID      | Type of Study                                                                                                                                           | Species N/Gender     | Route, Dose                  | Results                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|---------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|               |                                                                                                                                                         |                      |                              | AR00426032 (M3) increased with increasing dose and accounted for approximately 25, 21, 17, 11, and 7% of the plasma exposure of ARRY-438162. Plasma exposure of AR00426618 increased with increasing dose and accounted for approximately 52, 30, 56, 27, and 14% of the plasma exposure of ARRY-438162.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| DM09- 044     | Two doses PK of free base and two metabolites (N-desmethyl and amide metabolite) After antibiotic treatment for 5 days in order to deplete gut bacteria | Nude Mice 3 F /group | Oral 30 mg/kg twice on day 6 | Plasma concentrations of ARRY-438162 and AR00426032 were comparable between the animals in this study and those in study DM09-043. However, plasma concentrations of AR00426618 (amide metabolite) were significantly lower in the present study than in study DM09-043. The plasma concentrations of AR00426618, together with the decreased bacterial content in feces, indicate that the formation of AR00426618 in the nude mouse is most likely due to gut bacteria. (see section 3.4. metabolism).                                                                                                                                                                                                                                                                                                                                                                                                               |
| Dmpk- 1100228 | Single dose PK of 14 C-MEK162                                                                                                                           | Rats 3 M             | IV 1mg/kgBW Oral 4mg/kgBW    | IV: The blood radioactivity concentrations decreased rapidly to ~19% at 1 h and <1% at 24 h, as compared to the mean total radioactivity concentrations (4550 ngEq/mL) at 5 min. The plasma and blood profiles of radioactivity were bi-phasic. Radioactivity concentrations in blood were slightly lower than that in plasma, indicating the plasma had a higher affinity for the radioactivity. This is consistent with the in vitro higher distribution to plasma in rats .The concentration of MEK162 in plasma appeared to be biphasic. The mean terminal half-life of was 6.6 hours. The mean C max and AUC inf were 6990 ng/mL and 5920 ng ⋅ h/mL respectively. The mean volume of distribution at steady state (Vss) was low (0.618 L/kg). The systemic plasma clearance of the compound (CL) was low with a mean value of 0.173 L/h/kg comparing to rat hepatic blood flow. Oral: T max in plasma was 0.33 h, |

<div style=\"page-break-after: always\"></div>

| Study ID      | Type of Study                 | Species N/Gender        | Route, Dose                 | Results                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|---------------|-------------------------------|-------------------------|-----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|               |                               |                         |                             | suggesting a fast absorption. Based on the dose normalized plasma radioactivity AUC inf and total radioactivity recovery in urine after i.v. and oral dose, the percentage of absorption of MEK162 was estimated to be ~50%. The bioavailability for MEK162 was calculated to be 47.1%, indicating minor first pass effect.                                                                                                                                                               |
| Dmpk- 1100796 | Single dose PK of 14 C-MEK162 | Monkeys 3 M oral 2M IV. | IV 1 mg/kgBW Oral 3 mg/kgBW | IV: ref to study amendment 1: Radioactivity in blood: C max 3510 ngEq/ml AUC last (ngEq•h/mL ) 4420 Radioactivity in plasma: C max 6790 AUC last 8170 MEK162 in plasma: C max 5240 AUC last 8170 Oral: Following a 3 mg/kg MEK162 was rapidly absorbed with a T max at 0.67 h. The overall oral absorption was estimated to be 50% ~ complete, based on plasma radioactivity concentration and urine recovery after IV and oral dose, while the bioavailability was calculated to be 48%. |

## Distribution

## Tissue distribution

## Whole body autoradiography

A tissue distribution study was performed for drug-derived carbon-14 material using quantitative whole body autoradiography (DM07-001) following a single oral dose of [14C]binimetinib (30 mg/kg) to fasted male albino (Sprague-Dawley) and pigmented (Long- Evans) rats. Drug-derived radioactivity was absorbed and widely distributed to tissues of albino and pigmented rats, with maximum concentrations in most tissues observed 1 to 2 hours post-dose.

<div style=\"page-break-after: always\"></div>

Table 7: Quantitative Tissue Distribution of Drug-Related Material Using Whole-Body Autoradiography Following A Single Oral Dose of [14C]ARRY- 438162 (30 mg/kg) to Male Long-Evans and SpragueDawley Rats and Human Radiation Dosimetry Prediction

| Species                       | Species                       |                                                                        |                                                                        |                                                                        |                                                                        |                                                                        |                                                                        |                                                                       |                                                                       |                                                                       |                                                                       |
|-------------------------------|-------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------|
| Gender (MF) Number of animals | Gender (MF) Number of animals | M n=6 (1/timepoint)                                                    | M n=6 (1/timepoint)                                                    | M n=6 (1/timepoint)                                                    | M n=6 (1/timepoint)                                                    | M n=6 (1/timepoint)                                                    | M n=6 (1/timepoint)                                                    | M n=4 (1/timepoint)                                                   | M n=4 (1/timepoint)                                                   | M n=4 (1/timepoint)                                                   | M n=4 (1/timepoint)                                                   |
| Feeding Condition             | Feeding Condition             | Fasted ovemight (12 h prior to dose and 4 h post-dose administration). | Fasted ovemight (12 h prior to dose and 4 h post-dose administration). | Fasted ovemight (12 h prior to dose and 4 h post-dose administration). | Fasted ovemight (12 h prior to dose and 4 h post-dose administration). | Fasted ovemight (12 h prior to dose and 4 h post-dose administration). | Fasted ovemight (12 h prior to dose and 4 h post-dose administration). | Fasted ovemight (12 h prior to dose and 4 h post-dose administration) | Fasted ovemight (12 h prior to dose and 4 h post-dose administration) | Fasted ovemight (12 h prior to dose and 4 h post-dose administration) | Fasted ovemight (12 h prior to dose and 4 h post-dose administration) |
| Vehicle/Formulation           | Vehicle/Formulation           | 1% CMC and 0.5% Tween 80                                               | 1% CMC and 0.5% Tween 80                                               | 1% CMC and 0.5% Tween 80                                               | 1% CMC and 0.5% Tween 80                                               | 1% CMC and 0.5% Tween 80                                               | 1% CMC and 0.5% Tween 80                                               | 1% CMC and 0.5% Tween 80                                              | 1% CMC and 0.5% Tween 80                                              | 1% CMC and 0.5% Tween 80                                              | 1% CMC and 0.5% Tween 80                                              |
| Method of Administration      | Method of Administration      | PO/single dose                                                         | PO/single dose                                                         | PO/single dose                                                         | PO/single dose                                                         | PO/single dose                                                         | PO/single dose                                                         | PO/single dose                                                        | PO/single dose                                                        | PO/single dose                                                        | PO/single dose                                                        |
| Dose (mg/kg)                  | Dose (mg/kg)                  | 30                                                                     | 30                                                                     | 30                                                                     | 30                                                                     | 30                                                                     | 30                                                                     | 30                                                                    | 30                                                                    | 30                                                                    | 30                                                                    |
| Radionuclide                  | Radionuclide                  | ['C]ARRY-438162                                                        | ['C]ARRY-438162                                                        | ['C]ARRY-438162                                                        | ['C]ARRY-438162                                                        | ['C]ARRY-438162                                                        | ['C]ARRY-438162                                                        | [\"C]ARRY-438162                                                       | [\"C]ARRY-438162                                                       | [\"C]ARRY-438162                                                       | [\"C]ARRY-438162                                                       |
| Specific Activity             | Specific Activity             | 42.3 mCi/mmol                                                          | 42.3 mCi/mmol                                                          | 42.3 mCi/mmol                                                          | 42.3 mCi/mmol                                                          | 42.3 mCi/mmol                                                          | 42.3 mCi/mmol                                                          | 42.3 mCi/mmol                                                         | 42.3 mCi/mmol                                                         | 42.3 mCi/mmol                                                         | 42.3 mCi/mmol                                                         |
| Sampling time                 | Sampling time                 | 1,2,4, 8,24, 168 h                                                     | 1,2,4, 8,24, 168 h                                                     | 1,2,4, 8,24, 168 h                                                     | 1,2,4, 8,24, 168 h                                                     | 1,2,4, 8,24, 168 h                                                     | 1,2,4, 8,24, 168 h                                                     | 2,8, 24, 168 h                                                        | 2,8, 24, 168 h                                                        | 2,8, 24, 168 h                                                        | 2,8, 24, 168 h                                                        |
|                               |                               | Concentration (ugEq/g tissue)                                          | Concentration (ugEq/g tissue)                                          | Concentration (ugEq/g tissue)                                          | Concentration (ugEq/g tissue)                                          | Concentration (ugEq/g tissue)                                          | Concentration (ugEq/g tissue)                                          | Concentration (ugEq/g tissue)                                         | Concentration (ugEq/g tissue)                                         | Concentration (ugEq/g tissue)                                         | Concentration (ugEq/g tissue)                                         |
|                               |                               | Albino Rat                                                             | Albino Rat                                                             | Albino Rat                                                             | Albino Rat                                                             | Albino Rat                                                             | Albino Rat                                                             | Pigmented Rat                                                         | Pigmented Rat                                                         | Pigmented Rat                                                         | Pigmented Rat                                                         |
| Tissues type                  | Tissue                        | 1h                                                                     | 2h                                                                     | 4h                                                                     | 8h                                                                     | Itt                                                                    | 168 h                                                                  | 2h                                                                    | 18                                                                    | 24h                                                                   | 168 h                                                                 |
| Vascular/ Lymphatic           | Blood (cardiac)               | 14.7                                                                   | 6.68                                                                   | 2.58                                                                   | 1.87                                                                   | 0.536                                                                  | BQL                                                                    | 13.6                                                                  | 6.32                                                                  | 0.430                                                                 | BQL                                                                   |
| Vascular/ Lymphatic           | Bone Marow                    | 4.54                                                                   | 2.08                                                                   | 1.58                                                                   | 0.926                                                                  | 0.480                                                                  | BQL                                                                    | 5.08                                                                  | 2.49                                                                  | 0.569                                                                 | BQL                                                                   |
| Excretory! Metabolic          | Bile (in duct)                | 283                                                                    | 86.5                                                                   | 80.8                                                                   | 48.3                                                                   | 4.76                                                                   | BQL                                                                    | 123                                                                   | 110                                                                   | 13.5                                                                  | BQL                                                                   |
| Excretory! Metabolic          | Renal Cortex                  | t81                                                                    | 13.5                                                                   | 12.8                                                                   | 2.54                                                                   | 1.26                                                                   | BQL                                                                    | 18.7                                                                  | 7.83                                                                  |                                                                       | BQL                                                                   |
| Excretory! Metabolic          | Renal Medulla                 | 25.0                                                                   | 8.41                                                                   | 14.0                                                                   | 2.16                                                                   | 0.920                                                                  | BQL                                                                    | 21.1                                                                  | 7.52                                                                  | 1.47                                                                  | BQL                                                                   |
| Excretory! Metabolic          | Liver                         | 11.0                                                                   | 7.50                                                                   | 6.74                                                                   | 3.21                                                                   | 1.94                                                                   | BQL                                                                    | 13.9                                                                  | 9.09                                                                  | 3.27                                                                  | 0.348                                                                 |
| Excretory! Metabolic          | Urinary Bladder               | 6.88                                                                   | 19.5                                                                   | 3.32                                                                   | 0.718                                                                  | 1.16                                                                   | BQL                                                                    | 16.3                                                                  | 3.77                                                                  | 0.975                                                                 | BQL                                                                   |

LLOQ = 0.00084264 μCi/g /0.002506 μCi/μg = 0.336 μg equivalent/g issue UL0Q = 8.177 uCilg / 0.002506 μuCi/ig = 3262.969 μg equivalent/g tisse

M: male; F: Female; IV: intravenous; PO: per os; CMC: carboxymethylcellulose; LLOQ: Lower Limit of Quantification; ULOQ : Upper Limit of Quantification; BQL: Below Limit of Quantification i.e below the LLOQ or could not be visualized on autoradioluminograph due to BQL radioactivity; Eq: equivalent; NA: not applicable

An in vitro study subsequently confirmed that MEK162 and the active N-desmethyl (M3) metabolite both have low affinity to melanin (Report DMPK R1100541). There was no evidence of CNS penetration (i.e., all measurements in this compartment were below the limits of quantification). There was no accumulation of radioactivity in various glands (testes, thyroid, pituitary gland, pancreas, harderian gland and adrenal gland). The blood-to-plasma concentration ratios ranged from 0.652 to 0.994 across species (0.718 in humans).

## Protein binding and distribution in blood cells

The distribution of [14C]binimetinib was determined in blood and plasma across multiple preclinical species and humans (DMPK R1100217). The plasma protein binding of binimetinib was high (&gt; 96%) in all species tested except in the dog where the plasma protein binding was moderate (84%).

## Metabolism

## In vitro metabolism

Binimetinib was shown to be both chemically and metabolically stable in the plasma from rats, monkeys and human at 37°C (DM05-027). The metabolic stability of binimetinib in hepatocytes from CD-1 mice, Sprague-Dawley rats, beagle dogs, cynomolgus monkeys and humans was characterized as low to moderate with hepatic extraction ratios (ER) &lt; 30% predicted for all species.

<div style=\"page-break-after: always\"></div>

The in vitro metabolism of binimetinib was studied in the presence of hepatic microsomes and hepatocytes from CD-1 mice, Sprague-Dawley rats, beagle dogs, cynomolgus monkeys, and humans (DM05-038). The most abundant metabolites produced from human hepatocyte incubations were products of direct glucuronidation of binimetinib.

In incubations of [14C]binimetinib with human hepatocytes the relative contributions of glucuronidation (M10.2 and M10.9), hydrolysis (M15.9), formation of M10.5, and the oxidative Ndesmethylation (M3), to the overall metabolism of [14C]binimetinib were 45.1%, 5.1%, 5.9%, and 2.4%, respectively. The primary oxidative metabolite in human hepatocyte incubations was Ndesmethyl binimetinib (M3). Finally, no metabolites were observed in incubations of [14C]binimetinib with human liver cytosol fractions, and no additional metabolites were observed in incubations with S9 fractions of human liver supplemented with NAPDH.

## CYP Studies

Experiments to determine which CYP enzymes were responsible for the oxidative metabolism of [14C]binimetinib were performed using insect cell membrane preparations containing individual recombinant CYP and flavin monooxygenases (FMO) enzymes. [14C]binimetinib metabolism above control levels was detectable in incubations with CYP1A1, CYP1A2, CYP2C19 and CYP3A4. The oxidative metabolite M3, found in HLM, was found to be formed by CYP1A1, CYP1A2 and CYP2C19. A of binimetinib oxidative metabolites (P8.5, M18.2, M23.0 and M24.5) were observed in CYP3A4 incubations that were not detected following human hepatocytes or microsomal incubations.

An in vitro study using recombinant human CYP enzymes showed that the enzymes capable of metabolizing binimetinib were CYP1A1, CYP1A2, CYP2C19, and CYP3A4 (DMPK R1100166). CYP1A2 and CYP2C19 catalyzed the formation of the active metabolite, AR00426032 (M3). Further studies were conducted to determine the contribution of CYPs to the oxidative metabolism of binimetinib (DMPK R1100166). The inhibitor of CYP1A2, furafylline, decreased [14C]binimetinib oxidative metabolism in HLM (i.e., formation of M3) by ~62% with an approximate IC50 of 2.4 μM. The maximal percent inhibition observed with ticlopidine (CYP2B6/CYP2C19 inhibitor) was ~41%. In contrast, the inhibitors ketoconazole (CYP3A4), azamulin (CYP3A), quinidine (CYP2D6), montelukast (CYP2C8), and sulfaphenazole (CYP2C9) had little effect on total [14C]binimetinib metabolism; with maximal observed percent inhibitions of 0.3-9%. The percent contribution of both CYP1A2 and CYP2C19 to total hepatic oxidative microsomal metabolism of binimetinib was estimated to be equivalent (~50%).

## CYP Inhibition

Binimetinib was assessed as a potential inhibitor of cytochrome P450s. Binimetinib was a weak inhibitor (IC50 ~ 50 μM) of CYP1A2 and CYP2C9 activity. Very little or no inhibition of CYP2A6, CYP2C8, CYP2C19, CYP2D6, CYP2E1 and CYP3A4/5 was observed at binimetinib concentrations up to 100 μM. Binimetinib showed no apparent time dependent inhibition of CYP1A2, CYP2C9, CYP2D6 or CYP3A4/5 at binimetinib concentrations up to 50 μM. Binimetinib showed relatively potent inhibitory activity for CYP2B6 (IC50 of 6 μM and a Ki of ~1.73 μM; and was similar when adjusted for microsomal protein binding, Ki,u of 1.67 μM).

## CYP Induction

Binimetinib was investigated as an in vitro inducer of cytochrome P450 enzymes in human hepatocytes in several studies. Significant induction of CYP3A4 activity was not observed in a human DDI study, where multi-day administration of binimetinib (30 mg, BID) did not significantly affect the exposure of the CYP3A4 probe midazolam.

<div style=\"page-break-after: always\"></div>

## UGT enzymes

Experiments to determine which UGT enzymes were predicted to catalyze the conjugative biotransformation of binimetinib to the direct glucuronides, M10.2 and M10.9, were performed with a panel of recombinant UGT enzymes.  By this approach, UGT1A1, UGT1A3, UGT1A7, UGT1A8, UGT1A9, UGT1A10, UGT2B4 and UGT2B7 were capable of generating both the binimetinib -glucuronide conjugates, M10.2 and M10.9.

UGT1A1 was shown to be the major contributor (90%) to the formation of the direct glucuronide M10.9 from binimetinib in HLMs. UGT1A3 and UGT1A9 contributed 3% and 7%, respectively, to the glucuronidation activity.

## UGT Inhibition

Binimetinib was found to be a weak inhibitor of human liver microsomal UGT1A-mediated SN- 38 conjugation, with an IC50 value greater than 25 μM (DM09-035).

Table 8: Summary table of binimetinib metabolites in rat, monkey and humans

| Study No      | CMEK162A2102, DMPK R1100796, DMPK 1100228 DMPK R1200065                                                               | CMEK162A2102, DMPK R1100796, DMPK 1100228 DMPK R1200065                                                               | CMEK162A2102, DMPK R1100796, DMPK 1100228 DMPK R1200065                                                               | CMEK162A2102, DMPK R1100796, DMPK 1100228 DMPK R1200065                                                               | CMEK162A2102, DMPK R1100796, DMPK 1100228 DMPK R1200065                                                               | CMEK162A2102, DMPK R1100796, DMPK 1100228 DMPK R1200065                                                               | CMEK162A2102, DMPK R1100796, DMPK 1100228 DMPK R1200065                                                               | CMEK162A2102, DMPK R1100796, DMPK 1100228 DMPK R1200065                                                               | CMEK162A2102, DMPK R1100796, DMPK 1100228 DMPK R1200065                                                               | CMEK162A2102, DMPK R1100796, DMPK 1100228 DMPK R1200065                                                               | CMEK162A2102, DMPK R1100796, DMPK 1100228 DMPK R1200065                                                               | CMEK162A2102, DMPK R1100796, DMPK 1100228 DMPK R1200065                                                               |
|---------------|-----------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|
| Study System  | See referencedreports                                                                                                 | See referencedreports                                                                                                 | See referencedreports                                                                                                 | See referencedreports                                                                                                 | See referencedreports                                                                                                 | See referencedreports                                                                                                 | See referencedreports                                                                                                 | See referencedreports                                                                                                 | See referencedreports                                                                                                 | See referencedreports                                                                                                 | See referencedreports                                                                                                 | See referencedreports                                                                                                 |
| Objective     | Metabolite Identification of[14CMEK162 Metabolsm m the Plasma, Urne and Feces From Rats Cynomolgus Monkeys and Humans | Metabolite Identification of[14CMEK162 Metabolsm m the Plasma, Urne and Feces From Rats Cynomolgus Monkeys and Humans | Metabolite Identification of[14CMEK162 Metabolsm m the Plasma, Urne and Feces From Rats Cynomolgus Monkeys and Humans | Metabolite Identification of[14CMEK162 Metabolsm m the Plasma, Urne and Feces From Rats Cynomolgus Monkeys and Humans | Metabolite Identification of[14CMEK162 Metabolsm m the Plasma, Urne and Feces From Rats Cynomolgus Monkeys and Humans | Metabolite Identification of[14CMEK162 Metabolsm m the Plasma, Urne and Feces From Rats Cynomolgus Monkeys and Humans | Metabolite Identification of[14CMEK162 Metabolsm m the Plasma, Urne and Feces From Rats Cynomolgus Monkeys and Humans | Metabolite Identification of[14CMEK162 Metabolsm m the Plasma, Urne and Feces From Rats Cynomolgus Monkeys and Humans | Metabolite Identification of[14CMEK162 Metabolsm m the Plasma, Urne and Feces From Rats Cynomolgus Monkeys and Humans | Metabolite Identification of[14CMEK162 Metabolsm m the Plasma, Urne and Feces From Rats Cynomolgus Monkeys and Humans | Metabolite Identification of[14CMEK162 Metabolsm m the Plasma, Urne and Feces From Rats Cynomolgus Monkeys and Humans | Metabolite Identification of[14CMEK162 Metabolsm m the Plasma, Urne and Feces From Rats Cynomolgus Monkeys and Humans |
| Metabolite    | Putative Structural Description                                                                                       | +HN m/                                                                                                                | Plasma                                                                                                                | Plasma                                                                                                                | Plasma                                                                                                                | Urine                                                                                                                 | Urine                                                                                                                 | Urine                                                                                                                 | Feres                                                                                                                 | Feres                                                                                                                 | Feres                                                                                                                 | Bile                                                                                                                  |
| Metabolite    | Putative Structural Description                                                                                       | +HN m/                                                                                                                | Rat                                                                                                                   | Monkey                                                                                                                | Huma                                                                                                                  | Rat                                                                                                                   | Monkey                                                                                                                | Human                                                                                                                 | Rat                                                                                                                   | Moukey                                                                                                                | Human                                                                                                                 | Rat                                                                                                                   |
| M8.0          | Indiet ghewonide ofM4                                                                                                 | 3                                                                                                                     |                                                                                                                       | +                                                                                                                     | +                                                                                                                     |                                                                                                                       | +                                                                                                                     | +                                                                                                                     | +                                                                                                                     |                                                                                                                       |                                                                                                                       | +                                                                                                                     |
| M10.2         | Direct ghucwonide                                                                                                     | 617                                                                                                                   |                                                                                                                       | #                                                                                                                     | +                                                                                                                     | +                                                                                                                     | +                                                                                                                     | +                                                                                                                     |                                                                                                                       |                                                                                                                       |                                                                                                                       | +                                                                                                                     |
| M10.5         | Indirect ghucuwonde ofM4                                                                                              | 555                                                                                                                   | +                                                                                                                     | +                                                                                                                     | +                                                                                                                     | +                                                                                                                     | +                                                                                                                     | +                                                                                                                     |                                                                                                                       |                                                                                                                       |                                                                                                                       | +                                                                                                                     |
| M10.9         | Direct glucwonide                                                                                                     | 617                                                                                                                   | +                                                                                                                     | +                                                                                                                     | +                                                                                                                     | +                                                                                                                     | +                                                                                                                     | +                                                                                                                     |                                                                                                                       |                                                                                                                       |                                                                                                                       | +                                                                                                                     |
| MI11.0        | Glucwonide ofM170                                                                                                     | 545                                                                                                                   |                                                                                                                       | +                                                                                                                     |                                                                                                                       |                                                                                                                       | +                                                                                                                     |                                                                                                                       |                                                                                                                       |                                                                                                                       |                                                                                                                       |                                                                                                                       |
| MIl1          | Oridation                                                                                                             | 457                                                                                                                   | +                                                                                                                     |                                                                                                                       |                                                                                                                       | +                                                                                                                     |                                                                                                                       |                                                                                                                       | +                                                                                                                     |                                                                                                                       |                                                                                                                       |                                                                                                                       |
| M3.2          | O-ghucwroide conjugateo M4                                                                                            | 575                                                                                                                   |                                                                                                                       |                                                                                                                       |                                                                                                                       |                                                                                                                       | +                                                                                                                     |                                                                                                                       |                                                                                                                       |                                                                                                                       |                                                                                                                       |                                                                                                                       |
| MI4           | Duect glhcoe conjugate                                                                                                | 605                                                                                                                   |                                                                                                                       |                                                                                                                       |                                                                                                                       | +                                                                                                                     |                                                                                                                       |                                                                                                                       | +                                                                                                                     |                                                                                                                       |                                                                                                                       |                                                                                                                       |
| M4.6          | Glucuonide of M3                                                                                                      | 603                                                                                                                   |                                                                                                                       |                                                                                                                       | +                                                                                                                     | (BDC)                                                                                                                 |                                                                                                                       | +                                                                                                                     |                                                                                                                       |                                                                                                                       |                                                                                                                       | +                                                                                                                     |
| M15.1         | Glucuonide ofM17.0                                                                                                    | 541                                                                                                                   |                                                                                                                       |                                                                                                                       | +                                                                                                                     | +(BDC)                                                                                                                |                                                                                                                       | +                                                                                                                     |                                                                                                                       |                                                                                                                       |                                                                                                                       | +                                                                                                                     |
| MB:AR00426032 | N-desmethyl                                                                                                           | 427                                                                                                                   | +                                                                                                                     | +                                                                                                                     | +                                                                                                                     | +                                                                                                                     | +                                                                                                                     | +                                                                                                                     | +                                                                                                                     | +                                                                                                                     | +                                                                                                                     |                                                                                                                       |
| MI5.7         | Gluwonide                                                                                                             | 617                                                                                                                   |                                                                                                                       |                                                                                                                       | +                                                                                                                     | (BDC)                                                                                                                 |                                                                                                                       |                                                                                                                       |                                                                                                                       |                                                                                                                       |                                                                                                                       | +                                                                                                                     |
| M15.9         | Carboxylie acid                                                                                                       | 382                                                                                                                   | +                                                                                                                     | +                                                                                                                     | +                                                                                                                     | +                                                                                                                     | +                                                                                                                     | +                                                                                                                     | +                                                                                                                     | +                                                                                                                     | +                                                                                                                     |                                                                                                                       |
| M16.0         | Glucuonide ofMB                                                                                                       | 603                                                                                                                   |                                                                                                                       |                                                                                                                       | +                                                                                                                     | (BDC)                                                                                                                 |                                                                                                                       | +                                                                                                                     |                                                                                                                       |                                                                                                                       |                                                                                                                       | +                                                                                                                     |
| MEK162        | Parent dnug                                                                                                           | 41                                                                                                                    | +                                                                                                                     | #                                                                                                                     | #                                                                                                                     | +                                                                                                                     | +                                                                                                                     | +                                                                                                                     | +                                                                                                                     | +                                                                                                                     | +                                                                                                                     | +                                                                                                                     |
| M17.0         | N-demethylaion of M4                                                                                                  | 367                                                                                                                   | +                                                                                                                     | #                                                                                                                     | +                                                                                                                     | +                                                                                                                     | +                                                                                                                     | +                                                                                                                     | +                                                                                                                     | +                                                                                                                     | +                                                                                                                     |                                                                                                                       |
| M18.2         | Dehydhogenated M4                                                                                                     | 381                                                                                                                   |                                                                                                                       | +                                                                                                                     |                                                                                                                       | +                                                                                                                     | +                                                                                                                     |                                                                                                                       | +                                                                                                                     | +                                                                                                                     |                                                                                                                       |                                                                                                                       |
| MI8.9         | Indirect glucuonide of M15.9                                                                                          | 54                                                                                                                    |                                                                                                                       |                                                                                                                       | +                                                                                                                     |                                                                                                                       |                                                                                                                       | +                                                                                                                     |                                                                                                                       |                                                                                                                       |                                                                                                                       |                                                                                                                       |
|               | Anmide(ethane-diol cleavage pochet)                                                                                   | 381                                                                                                                   |                                                                                                                       |                                                                                                                       |                                                                                                                       | 中                                                                                                                     |                                                                                                                       |                                                                                                                       |                                                                                                                       | 中                                                                                                                     |                                                                                                                       |                                                                                                                       |
| M19.5         | Glucwonide ofM15.9                                                                                                    | 558                                                                                                                   |                                                                                                                       |                                                                                                                       | +                                                                                                                     |                                                                                                                       |                                                                                                                       | +                                                                                                                     |                                                                                                                       |                                                                                                                       |                                                                                                                       | +                                                                                                                     |
| M24.1         | Monoxygenated M3                                                                                                      | 443                                                                                                                   |                                                                                                                       |                                                                                                                       | +                                                                                                                     |                                                                                                                       |                                                                                                                       | +                                                                                                                     |                                                                                                                       |                                                                                                                       | +                                                                                                                     |                                                                                                                       |
| M24.5         | Los of NHg fom MEK162                                                                                                 | 428                                                                                                                   |                                                                                                                       |                                                                                                                       |                                                                                                                       |                                                                                                                       |                                                                                                                       |                                                                                                                       |                                                                                                                       | +                                                                                                                     |                                                                                                                       |                                                                                                                       |

<div style=\"page-break-after: always\"></div>

Figure 6: In vivo putative metabolic pathways of MEK162

<!-- image -->

p:plasma   u:urine   f:faeces/bile   b:bile from BDC rats only

## Excretion

## Routes and extent of excretion

Following IV dosing of [14C]-binimetinib in the rat, faecal and urinary excretion accounted for 45% and 46% of total radioactivity, respectively. Approximately 15% of binimetinib was excreted unchanged in the urine and 16% in the faeces of rats. Total radioactivity in the excreta of monkey was 99% and 85% following PO and IV dosing, respectively, with an equal contribution for urinary and faecal excretory routes. The most abundant drug-related components in monkey urine included binimetinib and two direct glucuronides (M10.2 and M10.9). In monkey faeces, binimetinib and the amide metabolite (M4; ethane-diol hydrolysis product) were the most abundant entities.

Biliary excretion of binimetinib and its metabolites was investigated in bile-duct cannulated rats (n=3) (DMPK R1400168). Following either intravenous (1mg/kg) or oral dosing (4mg/kg) of [14C]binimetinib, 50% and 39.5% of the administered radioactivity was recovered in the bile, respectively. Biliary levels of M10.9 accounted for up to 90% of the radioactivity recovered in bile.

<div style=\"page-break-after: always\"></div>

Unchanged levels of binimetinib in bile were less than 2% of the [14C]binimetinib dose administered by oral or IV routes.

## 2.3.4. Toxicology

## Single dose toxicity

Table 9: Tabular summary of single dose toxicity

| Species/Strain       | Method of Administration (Vehicle / Formulation)        | Doses (mg/kg)   | Gender and No. per Group                                                    |   Observed Maximum Nonlethal Dose (mg/kg) | Approximate Lethal Dose (mg/kg)   | Noteworthy Findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|----------------------|---------------------------------------------------------|-----------------|-----------------------------------------------------------------------------|-------------------------------------------|-----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Rat, Sprague- Dawley | Gavage (1.0% CMC and 0.5% Tween80 in water/ suspension) | 0,30, 100,300   | 10M/10F per toxicology group; 6M/6F per toxicokinetic group (64M/64F total) |                                       300 | >300                              | 30 mg/kg: o M: None o F: mineralization of ovaries 100 mg/kg: 0 M : slight decreases in bw, significant decreases in food consumption; mild, but reversible increases in neutrophils (2 fold) 0 M+F: Mineralization of glandular stomach o F: mineralization of ovaries 300 mg/kg: 0 M : slight decreases in bw, significant decreases in food consumption; 0M+F: Mineralization of glandular stomach mild, but reversible increases in neutrophils (2-3 fold) oF: Sparse hair on abdomen not dose-related, mineralization of ovaries · NOAEL in M: 30 mg/kg. · NOAEL in F: not determined. · Higher exposure in F (Cmax = 13.8, 26.6, and 35.5 μg/mL versus dose) than in M (Cmx = 10.0, 12.7, and 24.2 μg/mL)  Mean AUCunf value for F was 2.2-fold higher than for M. Mean Tmax increased from 1.5 to 4.0 hours with increasing dose; no sex-related differences in Tmax. |

## Repeat dose toxicity

A  28-day  and  a  6-month  repeat-dose  toxicity  study  (including  a  13  weeks  subset  analysis)  were performed  in  rats.  In  both  studies  different  serum  and  haematology  parameters  were  evaluated including toxicokinetics in satellite animals. A recovery phase was also implemented.

Table 10 shows the design and the major findings of the 28-day toxicity study. Most of the findings were reversible after 4 weeks of recovery; irreversible findings (irrev.) are marked accordingly.

## Table 10: 28-day oral gavage repeat-dose toxicity and toxicokinetic study with binimetinib in rats

| Study Type   | Species;   | Dose   | Major findings   |
|--------------|------------|--------|------------------|

<div style=\"page-break-after: always\"></div>

| (Study ID) GLP                                                                | Number/Dose Group                                                                            | (mg/kg/day) p.o.                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|-------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 28 day repeat dose toxicity + 4 week recovery (1140-007) GLP + toxicokinetics | SD rat; 10/sex/dose recovery: +5/sex/dose toxicokinetics: +6/sex/dose (treated animals only) | 0 (vehicle) 30*/10 100*/30 300*/100 *protocol error: for first 3 days dosed with higher dose | mortality: 1 ♀ control, 1 ♂ MD, 1 ♂ 1 ♀ HD hair loss ( ♀ MD,HD) ↑ neutrophils, ↑ monocytes ( ♂ HD ♀ MD,HD) ↓ lymphocytes ( ♂ MD,HD ♀ LD-HD) ↓ eosinophils ( ♂ LD-HD) ↓ reticulocytes ( ♂♀ HD) irrev. ↑ prothrombin time ( ♂ HD) irrev. ↑↓ prothrombin time ( ♀ LD-HD) ↓ Ca ( ♂ HD ♀ MD,HD) ↑ PO 4 ( ♂ MD,HD ♀ LD-HD) ↑ AST ( ♂♀ LD-HD) ↑ ALT ( ♂ MD,HD ♀ LD-HD) ↑ BUN ( ♂ LD-HD ♀ MD-HD) ↓ albumin ( ♂♀ MD-HD) ↑ globulin ( ♀ LD-HD) ↓ albumin/globulin ( ♂ MD,HD ♀ LD-HD) ↓ glucose ( ♀ MD-HD) skin: scab formation, abrasion alopecia ( ♂ HD ♀ MD,HD) erosion, ulcer, hemorrhage ( ♂ HD ♀ LD-HD) femur: ↑ thickness of growth plate, osteopenia, fibro-osseous proliferation ( ♂ HD) femoral bone marrow: focal necrosis ( ♂♀ HD) organ weights: ↓ abs. + rel. heart ( ♂ MD,HD ♀ HD) ↑ abs. + rel. adrenal ( ♂ HD ♀ MD,HD) ↓ abs. + rel. pituitary gland ( ♂♀ HD ♀ MD) ↑ rel. lung ( ♂ HD) ↑ rel. kidney ( ♀ HD) ↓ abs. + rel. spleen ( ♀ MD,HD) ↓ abs. liver ( ♂ HD) ↓ abs. + rel. thymus ( ♀ HD) irrev. (tissue and/or vascular) mineralisation of glandular stomach ( ♂♀ LD-HD), tongue ( ♂ LD- HD ♀ MD,HD), pituitary gland ( ♂♀ MD,HD), ovaries ( ♀ LD-HD), aorta ( ♀ HD), kidney ( ♀ LD-HD), heart ( ♂♀ HD) rev. (tissue and/or vascular) mineralisation of: duodenum ( ♂ ♀ HD), colon ( ♂ HD), kidney ( ♂ MD,HD), lung ( ♂ HD), pancreas ( ♂ ♀ HD), Harderian glands ( ♂ MD,HD), brain ( ♀ HD), mandibular salivary gland ( ♂♀ HD), prostate gland ( ♂ MD) |
| NOAEL = Ø                                                                     |                                                                                              |                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

abs.: absolute, ALT: alanine amino transferase, AST: aspartate amino transferase, BUN: blood urea nitrogen, HD: high dose, irrev: irreversible, MD: mid dose, LD: low dose, rel.: relative, vehicle: 1% CMC/0.5 % Tween ® 80 in sterile water

<div style=\"page-break-after: always\"></div>

A 6-month repeated-dose toxicity study was subsequently performed. Table 11 shows the study design and the major findings.

Table 11: 6-month oral gavage repeat-dose toxicity and toxicokinetic study with binimetinib in rats

| Study Type (Study ID) GLP                                                                                                                              | Species; Number/Dose Group                                                                                                                       | Dose (mg/kg/day) p.o.   | Major findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 6 month repeat-dose toxicity study + 4 week recovery (= week 31) 13 week interim analysis + 4 week recovery (= week 18) (1140-029) GLP + toxicokinetic | SD rats 10/sex/dose for 6 month and interim analysis, each recovery: 5/sex/dose for 6 month and interim analysis, each toxicokinetics 3/sex/dose | 0 (vehicle) 1 3 10      | mortality: 2 ♀ control, 1 ♀ HD interim, 1 ♂ HD terminal, 1 ♂ HD toxicokinetic skin: scabbing ( ♂ HD, ♀ MD, irrev. ♀ HD) ↓ erythrocytes ( ♂ HD) ↓ hemoglobin, ↓ platelets, ↓ eosinophils, ↓ large stained cells, ↓ APTT ( ♂ HD) ↑ leukocytes, ↑ platelets, ↑ monocytes ( ♀ HD) ↑ neutrophils ( ♀ MD,HD) ↓ Na + ( ♂ HD), ↑ PO 4 - ( ♂♀ HD) ↓ total protein, albumin, cholesterol ( ♂ HD), ↑ BUN ( ♂♀ HD) ↑ AP, ↑ AST ( ♀ HD) ↑ albumin, ↑ globulin, ↓ albumin/globulin ( ♀ HD) parathyroid hormone: ↓ week 27 and week 31 ( ♂ ♀ MD,HD) vitamin D: ↓ week 31 ( ♂ MD,HD); =/ ↑ week 27 ( ♂ MD,HD), ↑ /=week 31 ( ♀ MD,HD), ↓ week 27 ( ♀ MD,HD) organ weights: interim: ↓ abs. + rel. spleen ( ♂ MD,HD) terminal: ↑ bw ( ♂ HD): ↓ relative organ weights of brain, epididymis, heart, liver, pituitary gland, salivary gland, spleen microscopic findings at interim: ↑ adipocytes in bone marrow of femur (irrev. ♂ MD,HD) and sternum ( ♂ MD,HD) ↑ adipocytes in bone marrow of femur ( ♀ LD-HD) glandular stomach: mineralisation (irrev. ♂ HD) kidneys: tubular mineralisation ( ♀ LD-HD) dilatation of uterus ( ♀ LD-HD) skin: alopecia, erosion/ulcer,epidermal hyperplasia, inflammation ( ♂ LD-HD, ♀ HD; partial recovery of findings) microscopic findings at terminal: ↑ adipocytes in bone marrow of femur ( ♂ ♀ LD- HD) kidney: tubular mineralisation ( ♂ LD-HD, ♀ MD- HD) lung: alveolar histiocytosis ( ♀ LD-HD) skin: alopecia, bacterial colonies, erosion/ulcer, exudate on epidermal surface , inflammation ( ♂ LD, ♀ MD,HD recovery, but 1 ♀ HD) |

NOAEL ♂ rats= 3 mg/kg/day (Cmax= 2.93 µg/mL, AUC0-24hr= 15.2 µg.hr/mL); NOAEL ♀ rats= 1 mg/kg/day (Cmax= 2.0 µg/mL, AUC0-24hr= 11.0 µg.hr/mL)

<div style=\"page-break-after: always\"></div>

abs.: absolute, ALP: alkaline phosphatase, APPT: activated partial thromboplastin time, AST: aspartate amino transferase, BUN: blood urea nitrogen, HD: high dose, irrev: irreversible, MD: mid dose, LD: low dose, rel.: relative, vehicle: 1% CMC/0.5 % Tween ® 80 in sterile water

A  6-month  repeated-dose  toxicity  study  was  subsequently  performed.    Table  12  shows  the  study design and the major findings.

Table 12: 6-month oral gavage repeat-dose toxicity and toxicokinetic study with binimetinib in rats

| Study Type (Study ID) GLP                                                                                                                              | Species; Number/Dose Group                                                                                                                       | Dose (mg/kg/day) p.o.   | Major findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|--------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 6 month repeat-dose toxicity study + 4 week recovery (= week 31) 13 week interim analysis + 4 week recovery (= week 18) (1140-029) GLP + toxicokinetic | SD rats 10/sex/dose for 6 month and interim analysis, each recovery: 5/sex/dose for 6 month and interim analysis, each toxicokinetics 3/sex/dose | 0 (vehicle) 1 3 10      | mortality: 2 ♀ control, 1 ♀ HD interim, 1 ♂ HD terminal, 1 ♂ HD toxicokinetic skin: scabbing ( ♂ HD, ♀ MD, irrev. ♀ HD) ↓ erythrocytes ( ♂ HD) ↓ hemoglobin, ↓ platelets, ↓ eosinophils, ↓ large stained cells, ↓ APTT ( ♂ HD) ↑ leukocytes, ↑ platelets, ↑ monocytes ( ♀ HD) ↑ neutrophils ( ♀ MD,HD) ↓ Na + ( ♂ HD), ↑ PO 4 - ( ♂♀ HD) ↓ total protein, albumin, cholesterol ( ♂ HD), ↑ BUN ( ♂♀ HD) ↑ AP, ↑ AST ( ♀ HD) ↑ albumin, ↑ globulin, ↓ albumin/globulin ( ♀ HD) parathyroid hormone: ↓ week 27 and week 31 ( ♂ ♀ MD,HD) vitamin D: ↓ week 31 ( ♂ MD,HD); =/ ↑ week 27 ( ♂ MD,HD), ↑ /=week 31 ( ♀ MD,HD), ↓ week 27 ( ♀ MD,HD) organ weights: interim: ↓ abs. + rel. spleen ( ♂ MD,HD) terminal: ↑ bw ( ♂ HD): ↓ relative organ weights of brain, epididymis, heart, liver, pituitary gland, salivary gland, spleen microscopic findings at interim: ↑ adipocytes in bone marrow of femur (irrev. ♂ MD,HD) and sternum ( ♂ MD,HD) ↑ adipocytes in bone marrow of femur ( ♀ LD-HD) glandular stomach: mineralisation (irrev. ♂ HD) kidneys: tubular mineralisation ( ♀ LD-HD) dilatation of uterus ( ♀ LD-HD) skin: alopecia, erosion/ulcer,epidermal hyperplasia, inflammation ( ♂ LD-HD, ♀ HD; partial recovery of findings) microscopic findings at terminal: ↑ adipocytes in bone marrow of femur ( ♂ ♀ LD- HD) kidney: tubular mineralisation ( ♂ LD-HD, ♀ MD- HD) lung: alveolar histiocytosis ( ♀ LD-HD) skin: alopecia, bacterial colonies, erosion/ulcer, |

<div style=\"page-break-after: always\"></div>

exudate on epidermal surface , inflammation ( ♂ LD, ♀ MD,HD recovery, but 1 ♀ HD)

NOAEL ♂ rats= 3 mg/kg/day (Cmax= 2.93 µg/mL, AUC0-24hr= 15.2 µg.hr/mL); NOAEL ♀ rats= 1 mg/kg/day (Cmax= 2.0 µg/mL, AUC0-24hr= 11.0 µg.hr/mL)

abs.: absolute, ALP: alkaline phosphatase, APPT: activated partial thromboplastin time, AST: aspartate amino transferase, BUN: blood urea nitrogen, HD: high dose, irrev: irreversible, MD: mid dose, LD: low dose, rel.: relative, vehicle: 1% CMC/0.5 % Tween80 in sterile water

A  28-day  and  a  9-month  repeat-dose  toxicity  study  were  performed  in  Cynomolgous  monkeys  with nasogastric  intubation  of  binimetinib.  A  recovery  group  and  toxicokinetic  measurements  were implemented in each study. Table 13 and Table 14 show the study design applied and major findings noticed during these studies.

Table 13: 28-day repeated-dose toxicity and toxicokinetic study in Cynomolgous monkeys with nasogastric administration of binimetinib

| Study Type (Study ID) GLP                                                                           | Species; Number/Dose Group                          | Dose (mg/kg/day) p.o.   | Major findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-----------------------------------------------------------------------------------------------------|-----------------------------------------------------|-------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 28-day repeat-dose toxicity study +4-week recovery (JAY00028) GLP + toxicokinetic and PBMC analysis | Cynomolgous monkeys 3/sex/dose recovery: 2/sex/dose | 0 (vehicle) 1 3 10      | mortality: 1 ♀ HD sacrificed on Day 14, 1 ♂ HD sacrificed on Day 28 (lethargy, hypothermia, severe diarrhea, dehydration, positive hemocult, intestinal inflammation, bone marrow hypercellularity) clinical signs: watery stool, lethargy, hunched posture ( ♂♀ HD) haematology: ↓ RBC, ↓ hemoglobin, ↓ haematocrit, ↑ reticulocytes, ↑ neutrophils, ↑ platelets, ↑ WBC ( ♂♀ HD) ↓ MCHC ( ♂♀ MD) serum chemistry: ↓ albumin, ↑ AST ( ♂♀ HD) ↑ globulin, ↓ albumin/globin, ↑ ALT, ↑ BUN ( ♂♀ MD,HD) organ weights: ↓ rel. heart weight ( ♂♀ HD) macroscopic findings: abnormal intestinal content/gas distention of colon and cecum ( ♂♀ HD) microscopic findings: degeneration of absorptive mucosal epithelium, mucosal mixed cell inflammation in the cecum, colon and/or rectum ( ♂ ♀ HD), erythroid hypercellularity of bone marrow ( ♂♀ HD) (for statistical analysis data from males and females were pooled) |

NOAEL for ♂ and ♀ =3 mg/kg/day (Cmax= 0.29 µg/mL, AUC0-12hr= 1.48 µg.hr/mL)* *mean values

<div style=\"page-break-after: always\"></div>

BUN: blood urea nitrogen, bw: body weight, HD: high dose, LD: low dose, MCHC: mean corpuscular hemoglobin concentration, MD: mid dose, RBC: red blood cell count, WBC: white blood cell count, vehicle: 1% CMC/0.5 % Tween ® 80 in sterile water

Table 14: 9-month repeat-dose toxicity and toxicokinetic study in Cynomolgous monkeys with nasogastric administration of binimetinib

| Study Type (Study ID) GLP                                                                                                                      | Species; Number/Dose Group                                                                                | Dose (mg/kg/day) p.o.                            | Major findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|--------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 9-month repeat-dose toxicity study + 3-month recovery + Day 92 and Day 120 interim sacrifice (JAY00117) GLP + toxicokinetics and PBMC analysis | Cynomolgous monkeys 3/sex/dose for Day 92 interim and terminal 2/sex/dose for Day120 interim and recovery | 0 (vehicle) 0.2 2 (only terminal and recovery) 5 | mortality: 1 ♂ control found dead on Day 12, 1 ♀ HD sacrificed on Day 155 (hunched appearance, decreased activity, dehydration, inflammation and epithelial degeneration in the large intestine) clinical signs: abnormal, watery feces ( ♂ ♀ HD), periorbital swelling ( ♂ LD,HD), skin alterations ( ♂ HD, ♀ MD.HD) haematology: ↓ RBC ( ♂ HD), ↓ hemoglobin ( ♂♀ HD), ↓ haematocrit ( ♂ HD), ↓ MCHC ( ♂ HD), ↑ reticulocytes ( ♂ HD), ↑ neutrophils ( ♂ HD ♀ MD), ↑ platelets ( ♀ HD), ↓ prothrombin time ( ♀ HD), ↑ fibrinogen ( ♂♀ HD) serum chemistry: ↓ albumin ( ♂ ♀ HD), ↑ globulin ( ♂ MD,HD), ↓ albumin/globulin ( ♂ MD, ♂ ♀ HD), ↑ triglycerides ( ♀ HD), ↑ AST ( ♂ MD, ♂♀ HD), ↑ ALT ( ♀ HD), ↓ ALP ( ♂ HD), ↑ creatinine ( ♂ LD-HD ♀ LD,HD), ↑ PO 4 - ( ♂ ♀ HD), ↓ calcium ( ♀ LD,HD), ↑ Na ( ♀ LD,MD) organ weights: ↓ rel. spleen ( ♂ HD), ↑ rel. liver ( ♂ HD), ↓ abs. + rel. thymus ( ♂ HD), ↓ rel. heart ( ♂ MD,HD) microscopic findings: large intestine: degeneration of luminal epithelium, increased mononuclear or mixed cell infiltrates, mucosal hyperplasia in the cecum, colon, and/or rectum ( ♂ ♀ MD,HD), liver: mixed cell infiltrates ( ♂ ♀ LD,HD), bone marrow : erythroid hypercellularity ( ♂ ♀ LD,HD only at Day 92 interim) |

## Genotoxicity

Binimetinib  was  tested  in  a  standard  battery  of  in  vitro  and  in  vivo  assays  for  genotoxicity.  Tests performed are summarized in Table 15. All tests were negative.

<div style=\"page-break-after: always\"></div>

| Table 15:                                                                                                                                                          | Overview of genotoxicity studies with binimetinib                                                                                  | Overview of genotoxicity studies with binimetinib                                                                                                                                                      | Overview of genotoxicity studies with binimetinib                                                                                                                                                                                                                                                                                  |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Type of test/study ID/GLP                                                                                                                                          | Test system                                                                                                                        | Concentrations/ Concentration range/ Metabolising system                                                                                                                                               | Results Positive/negative/equivocal                                                                                                                                                                                                                                                                                                |
| Gene mutations in bacteria / AB14DW.503.BTL / GLP Gene mutations in mammalian cells / AB14DW.704.BTL / GLP chromosomal aberrations in vivo / AB14DW.123M.BTL / GLP | Salmonella strains TA98, 100, 1535, 1537, E. coli WP2 uvrA L5178Y TK+/- mouse lymphoma cells ICR mouse, micronuclei in bone marrow | +/- S9 first study: 0.015 - 5000 µg/plate second study: 15 - 5000 µg/plate 4 h exposure: +/- S9 75 - 300 µg/ml 24 h exposure: +/- S9 75 - 250 µg/ml 0, 500, 1000, 2000 mg/kg, single dose, oral gavage | precipitation at ≥ 1500 µg/plate no relevant increase in revertant colonies precipitation ≥ 250 µg/ml, cytotoxicity around 50% at highest dose no relevant increase in mutant colonies or mutant frequency no relevant increase in micronuclei in PCEs no measurement of exposure, piloerection observed in high dose male animals |

## Carcinogenicity

The applicant did not submit carcinogenicity studies (see non-clinical discussion).

## Reproduction Toxicity

Reproductive  toxicity  testing  was  limited  to  embryofetal  development  studies  in  pregnant  rats  and rabbits, respectively. All pivotal studies were performed in accordance with GLP regulations and comply with ICH S9 Nonclinical evaluation for anticancer pharmaceuticals.

Table 16: Overview on the study design of and the main findings in the reproductive toxicity studies in rats and rabbits

| Study type/ Study ID / Species / Number Female/ group   | Route / dose (mg/kg/d) / vehicle / dosing period / caesarean section                                          | Major findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | NOAEL AUC Safety margin                                                                                                     |
|---------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|
| Embryofetal development #1140-026 Rats Crl:CD(SD) 25    | oral / gavage 0 - 10 - 30 - 100 1% carboxy methylcellulose + 0.5% Tween 80 in ultrapure water gd 6 - 17 gd 20 | F 0 : mortality : 1 MD due to gavage error bw :  in HD bw change :  in all treated groups, but in LD only during gd 6 - 9 fc :  in all treated groups necropsy : no findings uterine parameters : no effects F 1 : uterine parameters : no effects mean fetal bw :  in MD + HD total no. of foetuses with malformation(s) / no. of litters with malformed fetuses: 0/0 - 3/2 (1 with fused cervical vertebrae neural arches + absent ribs and 1 with fused exoccipital bone, misshapen humerus, fused cervical neural arches, absent thoracal vertebrae neural arches, absent ribs, bent scapula + spine of scapula and 1 with absent thyroid) - 2/2 (1 | F 0 : < 10 mg/kg/d F 1 : 10 mg/kg/d 10 mg/kg/d  AUC 0-24 : 57 µg*h/ml  safety margin 13.6 (based on human AUC 0-12 of 2.1 |

<div style=\"page-break-after: always\"></div>

|                                                                                                      |                                                                                                                   | with retroesophageal + right sided aortic arch; 1 with misshapen kidney) - 0/0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | µg*h/ml)                                                                                                                                                                                      |
|------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Embryofetal development Dose range finding (DRF) # 1140-022 Rabbits Hra:(NZW)SPF Main study: 5 TK: 4 | oral / gavage 0 - 3 - 10 - 30 - 100 1% carboxy methylcellulose + 0.5% Tween 80 in ultrapure water gd 6 - 18 gd 29 | F 0 : mortality : main study: 100 mg/kg/d  all does 30 mg/kg/d: 2/5 does TK component: 100 mg/kg/d  3/4 does clinical signs: 100 mg/kg/d  activity  , thin, soft/few/absent faeces; 30, 10 + 3 mg/kg/d  soft/few/absent faeces bw : 100 mg/kg/d   30 mg/kg/d   gd 16 - 21 10 mg/kg/d   gd 0 - 6; gd 25 - 29 fc : 30 + 10 mg/kg/d   , except gd 0 - 6 for 10 mg/kg/d group, when fc was  necropsy : no findings abortions : 30 mg/kg/d  2 does; 10 mg/kg/d  1 doe F 1 : postimplantation loss (%) : 100% at 30 mg/kg/d, no data for 100 mg/kg/d external malformation: 1 fetus at 10 mg/kg/d with rachischisis, encephalocele, malrotated hind limb, cleft palate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | F 0 : 3 mg/kg/d F 1 : 3 mg/kg/d 3 mg/kg/d  AUC 0-12 : 5.9 µg*h/ml  safety margin 2.8 (based on human AUC 0-12 of 2.1 µg*h/ml)                                                               |
| Embryofetal development # 1140-023 Rabbits Hra:(NZW)SPF 23                                           | oral / gavage 0 - 2 - 10 - 20 1% carboxy methylcellulose + 0.5% Tween 80 in ultrapure water gd 6 - 18 gd 29       | F 0 : mortality : HD: 2/23 found dead (gd 16 + 18); 4/21 euthanized in extremis (gd 20 - 22) MD: 3/23 found dead (gd 11, 13 , 15) gavage error suspected, proven for 2 rabbits with perforation pf oesophagus clinical signs: HD + MD: activity  , thin, soft/few/absent faeces (soft/few/absent faeces: 4 Co - 11 LD - 22 MD - 23 HD); red material in bedding  some related to abortions, thin (4 HD + 3 MD) bw : HD + MD:  fc : HD + MD  ; LD  on 3 occasions, not considered to be treatment related as body weights were not affected necropsy : no findings abortions : 1 HD + 1 MD early delivery : 1 HD no. of does pregnant at C-section : 23/23 - 23/23 - 19/23 - 14/23 F 1 : postimplantation loss : HD + MD  mean no. of live fetuses/doe : HD + MD  mean fetal bw : HD + MD  external malformation (no. of fetuses affected / total no. of fetuses) : 0 - 0 - 1/150 with ectrodactyly, rachischisis, abnormal flexure of entire forelimb, acephaly, omphalocele - 1/91 with syndactyly visceral malformation (no. of fetuses affected / no. of litters with affected fetuses / total no. of fetuses) : Control: 2/2/217 (1/1 with absent thyroid + 1/1 with dilated aortic arch, microphthalmia, absent | F 0 : 2 mg/kg/d F 1: 2 mg/kg/d no TK values for 2 mg/kg/d available  TK from DRF study  3 mg/kg/d  AUC 0-12 : 5.90 µg*h/ml  safety margin: ≤ 2.8 (based on human AUC 0-12 of 2.1 µg*h/ml) |

<div style=\"page-break-after: always\"></div>

| gallbladder, septum) LD: 1/1/199 MD: 4/4/150 kidney; interventricular arch, absent heart, pulmonary absent HD: 13/8/91 constricted interventricular 2/1 arteriosus, septum; septum ureter; ductus septum, malpositioned ureter; septum) skeletal affected total Control: 5/5/217 and fused ribs; jugal thoracic LD: 3/3/199 fused MD: 5/3/150 fused misshapen + HD: 6/6/91 accessory ribs;   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

gd = gestation day; Co = control; LD = low dose group; MD = mid dose group; HD = high dose group; m = male; f = female; bw = body weight(s); fc = food consumption;  = significant decrease(d);  = significant increase(d)

## Toxicokinetic data

For the 28-day toxicity study in the rat, no NOAEL could be identified. Exposure multiples at the LOAEL were about 8 to 14. The exposure multiple for the 6-month repeat-dose toxicity study in the rat is approximately 3 for males and females. Similar exposure multiples but different NOAELs for males and females are due to the generally higher exposure of female rats compared to males.

<div style=\"page-break-after: always\"></div>

Table 17: Animal to human exposure multiples at the NOAEL, respectively LOAEL of the different pivotal toxicity studies performed for binimetinib in rats, monkeys and rabbits

| Study                                         | NOAEL or LOAEL (mg/kg/day   |   Animal to Human Exposure Multiples |
|-----------------------------------------------|-----------------------------|--------------------------------------|
| Single dose toxicity rat (1140-006)           | NOAEL ♂ = 30                |                                  7.1 |
| Single dose toxicity rat (1140-006)           | LOAEL ♀ = 30                |                                 41.9 |
| 28-day repeat-dose toxicity rat (1140-007)    | LOAEL ♂ = 10                |                                  7.6 |
| 28-day repeat-dose toxicity rat (1140-007)    | LOAEL ♀ = 10                |                                 13.6 |
| 6-month repeat-dose toxicity rat (1140-029)   | NOAEL ♂ = 3                 |                                  3.6 |
| 6-month repeat-dose toxicity rat (1140-029)   | NOAEL ♀ = 1                 |                                  2.6 |
| 28-day repeat-dose toxicity monkey (JAY00028) | NOAEL ♂ = 3                 |                                  0.5 |
| 28-day repeat-dose toxicity monkey (JAY00028) | NOAEL ♀ = 3                 |                                  0.9 |
| 9-month repeat-dose monkey (JAY00117)         | NOAEL ♂ = 2                 |                                  0.4 |
| 9-month repeat-dose monkey (JAY00117)         | NOAEL ♀ = 2                 |                                  0.4 |
| Embryo-fetal development rat (1140-026)       | NOAEL ♀ = 10                |                                 13.6 |
| Embryo-fetal development rabbit (1140-22)     | NOAEL ♀ = 2                 |                                  2.8 |

Phase I animals were treated from postnatal day (PND) 10 to PND 16, while Phase II animals received binimetinib  orally  from  PND  10  to  PND  40.  The  following  table  provides  an  overview  on  the  study design and the main findings of the juvenile toxicity study.

Table 18: Main findings of the juvenile toxicity study in rats

| Study type/ Study ID / Species / Number rats/sex/ group                                                                                                                                                                                                                 | Route / dose (mg/kg/d) / vehicle / dosing period                                                                                                                         | Major findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Juvenile toxicity study #9000303 Rats Crl:CD(SD) Phase I: main study:6 TK (PND 10 + 16): 2f+2f / 2m+2m for control and 10f+10f / 10m+10m for LD, MD and HD Phase II: main study: 12 TK (PND 25 + 40): 2f+2f / 2m+2m for control and 10f+10f / 10m+10m for LD, MD and HD | oral / gavage Phase I: 0 - 3 - 10 - 30 Phase II: 0 - 1 - 3 - 10 1% carboxy methylcellulose + 0.5% Tween 80 in ultrapure water Phase I: PND 10 - 16 Phase II: PND 10 - 40 | Mortality: Phase I: HD (30 mg/kg/d): 2 m + 1 f found dead between PND 14 and 15, 1 m euthanized in poor condition on PND 14. In addition 7 pups from HD TK group due to high mortality + clinical signs in HD group  surviving HD animals euthanized on PND 16 Phase II: HD (10 mg/kg/d): 1 m euthanized in poor condition on PND 18, 1 f found dead on PND 15 due to early mortality + clinical signs in HD group  dosing discontinued except for 10 HD TK rats / sex with last dose on PND 18 to allow blood collection for TK analysis Clinical signs: Phase I: HD: PND 13 onwards 5/6 m + 4/6 f with tremors, thin, cold to touch,  activity, suspected dehydration, suspected empty stomach Phase II: PND 16, 17 and/or 18: abnormal gait, uncoordinated and/or locomotor stereotypy, tremors, limited usage of limbs, prostration, and/or  activity Body weights (bw): Phase I: |

<div style=\"page-break-after: always\"></div>

| HD: -25% on PND 14 MD: -9 to -10% Phase II: HD: -12 to -18% on PND 17 MD: m: -6 to -10% from PND 14 to 41; f: -29% between PND 12 and 17 only, bw remains comparable to controls throughout postweaning period Clinical pathology ( Phase II rats only ): Haematology: MD (3 mg/kg/d) lymphocyte count  10% in m + f; MD (3 mg/kg/d) + LD (1 mg/kg/d) females only:  MCHC +  platelets MD (3 mg/kg/d) females only:  reticulocytes Clinical chemistry: MD (3 mg/kg/d): aspartate aminotransferase  (m + f), alanine aminotransferase (  m +  f), alkaline phosphatase (m + f), total bilirubin  f, phosphorus (  m + f), cholesterin (  f ), calcium + potassium (  f) compared to controls.  phosphorus considered related to pharmacology of the compound LD (1 mg/kg/d) females only:  cholesterin + calcium + phosphorus Histopathology ( Phase II rats only ): 3 mg/kg/d: In sections of heart of 2 males, mild or moderate mineralization in tunica media of proximal aorta near its origin (aortic root), characterized by multifocal dystrophic mineralization of medial smooth muscle cells; in the glandular stomachs of 6 males, minimal or mild mineralization multifocally within mucosa, characterized by oval to irregular, amphophilic deposits in upper to mid-level mucosa 10 mg/kg/d: In 3 males euthanized on day 16 PND, minimal to mild decreased cellularity (haematopoietic) in bone marrow (femur); relationship to test item administration considered equivocal due to low incidence + severity, + fact that maximum tolerated dose was exceeded, + absence of age matched control group   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

Co = control; LD = low dose group; MD = mid dose group; HD = high dose group; m = male; f = female; bw = body weight(s); fc = food consumption;  = decrease(d);  = significant decrease(d);  = increase(d);  = significant increase(d)

## Local Tolerance

## Gastric irritation in rats (Study AA30230)

The gastric irritation potential of binimetinib (10, 30, and 100 mg/kg, PO, single dose) in 1% CMC/ 0.5% Tween 80 in water was evaluated in male SD rats (N = 10 per group). No significant effects of binimetinib administration were observed at 10 and 30 mg/kg. At 100 mg/kg, binimetinib induced an increased incidence of superficial mucosal lesions (10/10 animals) and of hemorrhagic ulcers (9/10 animals) compared to vehicle-treated animals.

## Skin irritation in rabbit (Study pcs-r502321)

The possible irritation or corrosion potential of a single dose of the test substance was assessed when administered to the intact skin of rabbits.  Three rabbits were exposed to 0.5 grams of binimetinib, moistened with 0.4 mL water by application onto clipped skin for 4 hours using a semi-occlusive dressing. Skin reactions were assessed 1, 24, 48 and 72 hours after exposure. No skin irritation, corrosion or discoloration was caused by binimetinib.

<div style=\"page-break-after: always\"></div>

## Other toxicity studies

A study was conducted to evaluate the photosensitising potential of binimetinib after oral administration to female BALB/c mice. The study design and the major findings are outlined in Table 19.

Table 19: Local lymph node assay with exposure to UVA to evaluate the photosensitising potential of binimetinib

| Study Type (Study ID) GLP                                                      | Species; Number/Dose/ Treatment Group                                                                                                                                                    | Dose (mg/kg/day) p.o.                                                                                                  | Major findings*                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|--------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Local lymph node assay (pcs-1170390) GLP (Ø skin bioanalysis) + toxicokinetics | Mouse Balb/c 6 females/dose / treatment group toxicokinetics: 9 females / dose group (+ toxicokinetic samples before sacrifice from all binimetinib treated animals and vehicle control) | 0 (vehicle) - UVA 10 +/- UVA 30 +/- UVA 100 +/- UVA positive control: 100 mg/kg sparfloxacin +/- UVA dosing for 3 days | transient erythema of the tail and ear (MD,HD+UVA) significant increase in ear weight in binimetinib treated groups (MD +UVA, HD +/-UVA) increase in lymph node weight and cell count in irradiated group (HD +UVA) transient erythema or auricular lymph node hyperplasia in individual binimetinib treated mice plus irradiation positive control + UVA: statistically significant differences in ear weight, lymph node weight, lymph node cell count |

## NOAEL= 10 mg/kg/day (Cmax= 4.4 µg/mL, AUC0-24hr= 16.0 µg.hr/mL)

(*exposure at the NOAEL approximately 3.6-times the human clinical exposure)

+ UVA: exposure to at least 10 J/cm 2  UVA light; *human exposure: AUC0-12hr= 2.1 µg.hr/mL (Study CMEK162X2201; patients with 45 mg BID)

## 2.3.5. Ecotoxicity/environmental risk assessment

Table 20: Summary of main study results

| Substance (INN/Invented Name):binimetinib   | Substance (INN/Invented Name):binimetinib       | Substance (INN/Invented Name):binimetinib       | Substance (INN/Invented Name):binimetinib       |
|---------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| CAS-number (if available): 606143-89-9      | CAS-number (if available): 606143-89-9          | CAS-number (if available): 606143-89-9          | CAS-number (if available): 606143-89-9          |
| PBT screening                               |                                                 | Result                                          | Conclusion                                      |
| Bioaccumulation potential- log K ow         | OECD107                                         | 1.5 (pH 4 and 7) 2.1 (pH 9)                     | Potential PBT (N)                               |
| PBT-assessment                              | PBT-assessment                                  | PBT-assessment                                  | PBT-assessment                                  |
| Parameter                                   | Result relevant for conclusion                  |                                                 | Conclusion                                      |
| Bioaccumulation                             | log K ow                                        | 1.5 - 2.1                                       | not B                                           |
| Persistence                                 | DT50 (12°C) of main transformation product M-1  | 294.5 /106.5                                    | vP                                              |
| Toxicity                                    | NOEC                                            |                                                 | not T                                           |
| PBT-statement :                             | The compound is not considered as PBT nor vPvB. | The compound is not considered as PBT nor vPvB. | The compound is not considered as PBT nor vPvB. |
| Phase I                                     | Phase I                                         | Phase I                                         | Phase I                                         |

<div style=\"page-break-after: always\"></div>

| Calculation                                                      | Value                                          | Unit                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Unit                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Unit                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Conclusion                                                                                                             |
|------------------------------------------------------------------|------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------|
| PEC surfacewater , default                                       | 0.45                                           | µ g/L                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | µ g/L                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | µ g/L                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | > 0.01 threshold (Y)                                                                                                   |
| Phase II Physical-chemical properties and fate                   | Phase II Physical-chemical properties and fate | Phase II Physical-chemical properties and fate                                                                                                                                                                                                                                                                                                                                                                                                                              | Phase II Physical-chemical properties and fate                                                                                                                                                                                                                                                                                                                                                                                                                              | Phase II Physical-chemical properties and fate                                                                                                                                                                                                                                                                                                                                                                                                                              | Phase II Physical-chemical properties and fate                                                                         |
| Study type                                                       | Test protocol                                  | Results                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Results                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Results                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Remarks                                                                                                                |
| Adsorption-Desorption                                            | OECD 106                                       | K oc = 122.7 / 162.3 l kg -1 (sludge) K OC = 709.3 / 1280.7 /                                                                                                                                                                                                                                                                                                                                                                                                               | K oc = 122.7 / 162.3 l kg -1 (sludge) K OC = 709.3 / 1280.7 /                                                                                                                                                                                                                                                                                                                                                                                                               | K oc = 122.7 / 162.3 l kg -1 (sludge) K OC = 709.3 / 1280.7 /                                                                                                                                                                                                                                                                                                                                                                                                               | No soil assessment required                                                                                            |
| Ready Biodegradability Test                                      | OECD 301                                       | Not readily biodegradable                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Not readily biodegradable                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Not readily biodegradable                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Not readily biodegradable                                                                                              |
| Aerobic and Anaerobic Transformation in Aquatic Sediment systems | OECD 308                                       | System 1 Parent: DT 50, water 20 °C = 6.2 d DT 50, sediment = n.d. DT 50, whole system 20 °C = 7.1 d M-1: DT 50,whole system, 20 °C =138 d %shifting to sediment = 11.1 (day 14) NER = 52.8% (test end) TP >10%: M-1 max. 64% at d14 System 2 Parent: DT 50, water 20 °C = 5.2 d DT 50, sediment = n.d. DT 50, whole system 20 °C = 5.6 d M-1: DT 50,whole system, 20 °C = 49.9 d %shifting to sediment = 10.5 (day 14) NER = 66.1 %(test end) TP >10%: M-1 max. 75% at d28 | System 1 Parent: DT 50, water 20 °C = 6.2 d DT 50, sediment = n.d. DT 50, whole system 20 °C = 7.1 d M-1: DT 50,whole system, 20 °C =138 d %shifting to sediment = 11.1 (day 14) NER = 52.8% (test end) TP >10%: M-1 max. 64% at d14 System 2 Parent: DT 50, water 20 °C = 5.2 d DT 50, sediment = n.d. DT 50, whole system 20 °C = 5.6 d M-1: DT 50,whole system, 20 °C = 49.9 d %shifting to sediment = 10.5 (day 14) NER = 66.1 %(test end) TP >10%: M-1 max. 75% at d28 | System 1 Parent: DT 50, water 20 °C = 6.2 d DT 50, sediment = n.d. DT 50, whole system 20 °C = 7.1 d M-1: DT 50,whole system, 20 °C =138 d %shifting to sediment = 11.1 (day 14) NER = 52.8% (test end) TP >10%: M-1 max. 64% at d14 System 2 Parent: DT 50, water 20 °C = 5.2 d DT 50, sediment = n.d. DT 50, whole system 20 °C = 5.6 d M-1: DT 50,whole system, 20 °C = 49.9 d %shifting to sediment = 10.5 (day 14) NER = 66.1 %(test end) TP >10%: M-1 max. 75% at d28 | Binimetinib is classified as very persistent (persistent transformation product M-1 DT 50 = 295 d, normalized to 12°C) |
| Phase IIa Effect studies                                         | Phase IIa Effect studies                       | Phase IIa Effect studies                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Phase IIa Effect studies                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Phase IIa Effect studies                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Phase IIa Effect studies                                                                                               |
| Study type                                                       | Test protocol                                  | Endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | value                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Unit                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Remarks                                                                                                                |
| Algae, Growth Inhibition Test/ Pseudokirchneriella subcapitata   | OECD 201                                       | NOEC                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 8400                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | µg/L                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Pseudokirchneriell a subcapitata                                                                                       |
| Daphnia magna . Reproduction Test                                | OECD 211                                       | NOEC                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 650                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | µg/L                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Daphnia magna                                                                                                          |
| Fish, Early Life Stage Toxicity Test/ Pimephales promelas        | OECD 210                                       | NOEC                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 2200                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | µg/L                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Pimephales promelas                                                                                                    |
| Activated Sludge, Respiration Inhibition Test                    | OECD 209                                       | NOEC                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 1000 000                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | µg/L                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                        |
| Phase IIb Studies                                                | Phase IIb Studies                              | Phase IIb Studies                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Phase IIb Studies                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Phase IIb Studies                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Phase IIb Studies                                                                                                      |
| Sediment dwelling organism, Chironomus riparius                  | OECD 218                                       | NOEC                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 20                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | mg/ kg                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Chironomus riparius                                                                                                    |

## 2.3.6. Discussion on non-clinical aspects

In biochemical studies, binimetinib has been shown to be a potent and selective inhibitor of MEK1/2 with an enzyme IC50 of 12.1 nM.

In  cellular  studies  in  vitro,  binimetinib  potently  inhibited  MEK-dependent  phosphorylation  of  ERK  as well as B-Raf-mutant melanoma cell lines. In vivo, binimetinib significantly inhibited A375 xenograft tumours in nude mice as well as HMEX1906 a patient-derived xenografts a dose- and time-dependent

<div style=\"page-break-after: always\"></div>

manner.  Tumour  inhibition  was  best  achieved  with  the  combination  of  either  10  or  30  mg/kg binimetinib and encorafenib.

In  safety  pharmacology  studies,  binimetinib  did  not  have  any  adverse  effects  on  cardiovascular (monkey  telemetry),  gastrointestinal  motility  and  secretion  (in  rats),  neurobehavioral  (Irwin  rats), renal (rats) or respiratory function (rats) up to the highest single dose tested (100 mg/kg in rats and 10  mg/kg  in  monkeys).  These  doses  are  above  the  MTDs  determined  in  the  repeat  dose  toxicity studies  in  rats  and  monkeys.  In  rats,  no  adverse  effect  on  the  main  physiological  functions  were observed up to approximately 65-fold the human exposure at the therapeutic dose level. In monkeys, no cardiovascular effects were noted at about 1.2 to 1.6-fold the human exposure at the therapeutic dose, based on AUC.

The plasma protein binding has been measured at a range of physiologically relevant concentrations of 97.2%.

In  vitro,  binimetinib  and  its  active  metabolite  (AR00426032)  have  no  appreciable  activity  on  hERG channel current (IC50 &gt; 30 μM and &gt; 100 μM, respectively).

Repeated oral administration of binimetinib in rats for up to 6 months was associated with soft tissue mineralisation, gastric mucosal lesions and reversible minimal to mild clinical pathology changes at 7 to  12.5 times  human  therapeutic  exposures.    Specifically,  repeated  administration  of  binimetinib  to rats was associated with abrasion, alopecia and scabbing of the skin, and minimal to mild increases in neutrophils and monocytes, ALT, AST, urea and phosphorus, and decreases in calcium and albumin. Treatment  related  histopathological  changes  included  cutaneous  erosion/ulceration  and  multi-centric vascular  and  tissue  mineralization,  which  only  partially  reversed  after  a  treatment  free  period.  Skin lesions were  dose  related  in  both  severity  and  incidence  and  were  only  partially  reversible. Dermatological reactions to the administration of binimetinib are a known clinical finding. The finding of mineralisation of soft tissues in the rat may be species specific and has been seen with another MAP kinase  (MEK)  inhibitor.  The  published  literature  confirms  that  MEK  inhibition  caused  soft  tissue mineralisation  in  the  rat  secondary  to  serum  inorganic  phosphorus  increase,  but  nevertheless  the molecular mechanisms remain unknown. In a gastric irritation study in rats, an increased incidence of superficial mucosal lesions and of hemorrhagic ulcers were observed.  The observations were observed with greater frequency and at lower dose level in females than in males. In cynomolgus monkeys, oral administration  of  binimetinib  was  associated  with  gastro-intestinal  intolerance,  moderate  clinical pathology changes, bone marrow  hypercellularity and microscopic findings of gastrointestinal inflammation, reversible at the lowest doses which were below human therapeutic exposures.

Administration of binimetinib was also associated with weight loss, soft stools, decrease in red blood cell mass, increased platelet, monocyte and neutrophil counts, serum globulin, and decreases in serum albumin, and albumin/globulin ratio. All these changes were reversible after a treatment free period. Treatment-related  histological  findings  included  slight  degeneration  of  the  luminal  epithelium  and mixed cell infiltrates in the large intestine, mucosal hyperplasia in the cecum, colon and/or rectum.

Binimetinib was not genotoxic. The lack of studies on pharmacodynamics drug interactions, single dose toxicity, carcinogencity and reproduction toxicity are acceptable as per the ICH S9 guideline. (SmPC section 5.3).

Embryo-foetal development studies conducted in rats and rabbits showed evidence of embryotoxicity (increased post-implantation loss and resorptions) and teratogenicity in rabbits only (ventricular septal defects and pulmonary trunk alterations) (SmPC section 5.3). In rats, lower gestational body weight gain and fetal body weights and a decreased number of ossified fetal sternebrae were noted. No effects were noted at 14-times the human therapeutic exposure. In rabbits, mortality, maternal physical signs of toxicity, lower gestational body weight and abortion were noted. The number of viable foetuses and foetal  body  weights  were  reduced  and  post-implantation  loss  and  resorptions  were  increased.  An

<div style=\"page-break-after: always\"></div>

increased litter incidence of foetal ventricular septal defects and pulmonary trunk alterations was noted at  the  highest  doses.  No  effects  were  observed  at  3times  the  human  therapeutic  exposure.    No teratogenic effects were noted in rats and rabbits up to about 30- and 3-fold, respectively, the human exposure  at  the  therapeutic  dose,  based  on  AUC.  Therefore,  studies  in  animals  have  shown reproductive  toxicity  (see  section  5.3).  There  are  no  data  from  the  use  of  binimetinb  in  pregnant women. Recommendations have been included in section 4.6 of the SmPC concerning pregnancy and that  if  binimetinib  is  used  during  pregnancy,  or  if  the  patient  becomes  pregnant  while  taking binimetinib,  the  patient  should  be  informed  of  the  potential  hazard  to  the  foetus.  Women  of childbearing  potential  must  use  effective  contraception  during  treatment  with  binimetinib  and  for  at least 1 month following the last dose.

Fertility studies were not conducted with binimetinib. In repeat-dose toxicity studies, no concern in terms of fertility was raised from pathological examination of reproductive organs in rats and monkeys. There are no data on the effect on fertility in humans for binimetinib.

Binimetinib has phototoxic potential in vitro .

A minimal risk for photosensitisation was shown in vivo at an oral dose providing 3.8-fold higher exposure than that achieved with the recommended dose in humans. These data indicate that there is minimal risk for phototoxicity with binimetinib at therapeutic doses in patients.

Binimetinib is neither expected to bio-accumulate, nor to show any significant transfer to sludge and soil. The environmental risk assessment indicates the proposed therapeutic use of binimetinib is not expected to pose a significant risk to the environment. Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

## 2.3.7. Conclusion on the non-clinical aspects

The non-clinical studies (pharmacology, pharmacokinetics and toxicology), submitted for the marketing authorisation application for binimetinib, were considered adequate and acceptable for the assessment of non-clinical aspects. The lack of carcinogenicity, fertility and pre-and post-natal development studies were well justified. Relevant information on the non-clinical aspects of binimetinib has been included in section 4.6 and 5.3 of the product information. Binimetinib is not expected to pose a significant risk to the environment.

## 2.4. Clinical aspects

## 2.4.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the applicant.

The applicant has provided a statement to the effect that clinical trials conducted outside the Community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

<div style=\"page-break-after: always\"></div>

Table 21: Clinical pharmacology studies - Healthy volunteers

| Study Code    | Short Title                                                                                                              | Design                                                 | Formulation                  | PK sampling   |
|---------------|--------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|------------------------------|---------------|
|               |                                                                                                                          | Number of subjects (m)                                 | Number of subjects (m)       |               |
| ARRY-162-0601 | Single ascending dose shudy to assess the safety, tolerability, PK and PD                                                | Double-blind. placebo-controlled, dose-escalation (20) | Aqueous oral suspension      | Rich          |
| ARRY-162-0602 | Multiple ascending dose study to assess the safety, tolerability. PK and PD                                              | Double-blind, placebo-controlled, dose-escalation (38) | Aqueous oral suspension, PIC | Rich          |
| CMEK162A2102  | Single oral dose of 45 mg[*C]-MEK162 study to investigate the absorption, distribution, metabolism, and excretion (ADME) | Open 1abel, single dose (6)                            | Radio-labelled PIC           | Rich          |

MEK162: binimetinib, PIC: powder-in-capsule.

1 For detailed descriptions of clinical formulations and drug product please refer to Module 3.2.P.2.2;

Pharmaceutical Development.

<div style=\"page-break-after: always\"></div>

Table 22: Study overview of single agent binimetinib clinical pharmacology studies in cancer patients

| Study Code                                                                                                                                         | Study Title                                                                                                                                                                                                                                              | Number of subjects (n)                                                                                                                             | Formulation                                                                                                                                        | PK sampling'                                                                                                                                       |
|----------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|
| ARRAY-162-111                                                                                                                                      | A Phase l dose- escalation study of oral ARRAY-438162 im patients with advanced solid tumors followed by expansion cohorts in patients with advanced or metastatie biliary cancer or metastatic colorectal cancer                                        | 93                                                                                                                                                 | Tablet (ACSF, EPT, QS-CSF)                                                                                                                         | Rich/Sparse                                                                                                                                        |
| CMEK162X1101                                                                                                                                       | A Phase l study of oral binimetinib in Japanese patients with advanced solid tumors (enrolment complete)                                                                                                                                                 | 21                                                                                                                                                 | Tablet (P3-MI, ACSF)                                                                                                                               | Rich                                                                                                                                               |
| CMEK162X2201                                                                                                                                       | A Phase 2 open-label shudy of single-agent binimetinib in adult patients with advanced cutaneous malignant melanoma, harboring BRAF V600 or NRLAS mutations (enrolment complete)                                                                         | 183                                                                                                                                                | Tablet (ACSF)                                                                                                                                      | Rich                                                                                                                                               |
| CMEK162A2301                                                                                                                                       | The NEMO tial (NRAS melanoma and MEK inhibitor): A randomized Phase 3, open-label, multicenter, 2-arm shudy comparingthe efficacy of binimetinib versus dacarbazine in patients with advanced umresectable or metastatic NRAS mutation-positive melanoma | 402                                                                                                                                                | Tablet (P3-MI)                                                                                                                                     | Sparse                                                                                                                                             |
| ACSF: Aray clinical service formulation, EPT: early prototype tablet, QS-CSF: QS Pharma clinical service formulation, P3-Ml: Phase 3-market image. | ACSF: Aray clinical service formulation, EPT: early prototype tablet, QS-CSF: QS Pharma clinical service formulation, P3-Ml: Phase 3-market image.                                                                                                       | ACSF: Aray clinical service formulation, EPT: early prototype tablet, QS-CSF: QS Pharma clinical service formulation, P3-Ml: Phase 3-market image. | ACSF: Aray clinical service formulation, EPT: early prototype tablet, QS-CSF: QS Pharma clinical service formulation, P3-Ml: Phase 3-market image. | ACSF: Aray clinical service formulation, EPT: early prototype tablet, QS-CSF: QS Pharma clinical service formulation, P3-Ml: Phase 3-market image. |

<div style=\"page-break-after: always\"></div>

Table 23: Studies of binimetinib in combination with encorafenib in cancer patients

| Study Code                 | Study Title                                                                                                                                                                                                                                                                           | Number of subjects   | Binimetinib Formulation   | PK sampling     |
|----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|---------------------------|-----------------|
| CMEK162X2110               | A phase Ib/II, multicenter, open-label, dose escalation study ofLGX818 in combinationwith MEK162 in adult patients with BR4F V600-dependent advanced solid tumors                                                                                                                     | 126                  | Tablet (P3-MI)            | Rich            |
| CLGX818X2109 (Part 1 only) | The LOGIC 2 trial A phase II, multi-center, open-label study of sequentialLGX818/MEK162 combination followed by a rational combination with targeted agents after progression, to overcome resistance in adult patients with locally advanced or metastatic BR4F V600 melanoma        | 158 (Part 1)         | Tablet (P3-MI)            | Sparse (Part 1) |
| CMEK162B2301 (Part 1 only) | COLUMBUS -Combined LGX818 used with MEK162 in BR4Fmutant umresectable Skin cancer. A 2-part phase III randomized, open label, multicenter study of LGX8i8 plus MEK162 versus vemurafenib and LGX818 monotherapy in patients with umresectable or metastatic BR4F V600 mutant melanoma | 577                  | Tablet (P3-MI)            | Sparse          |

P3-MI: Phase 3-market image.

## 2.4.2. Pharmacokinetics

Binimetinib has been studied in a number of clinical studies to determine the PK in healthy volunteers and patients.  A population PK analysis was also performed to determine important covariates on the PK and to support an analysis of exposure versus efficacy and safety.

## Absorption

Study MEK162A2103 : A randomized, single-centre, open-label, three-period, cross-over study to investigate the effect of food on the pharmacokinetics of oral MEK162 in healthy subjects

Study MEKA62A2103 investigated the effect of food on the bioavailability of binimetinib. The study was an open-label, randomized, 3-treatment, 3-period, six-sequence, crossover study evaluating the effect of  food  on  the  bioavailability  of  binimetinib  tablets  (P3-MI)  in  healthy  subjects.  Subjects  were randomized to 1 of 6 treatment sequences. Subjects received the following treatments in a crossover manner at the same time of the day in each period of the study.

Treatment 1 consisted of single oral 45 mg dose (3 x 15 mg tablets) of binimetinib with a high-calorie HFM (Test 1). Treatment 2 consisted of single oral 45 mg dose (3 x 15 mg tablets) of binimetinib with a low-calorie LFM (Test 2). Treatment 3 consisted of single oral 45 mg dose (3 x 15 mg tablets) of binimetinib in FS (reference), where subjects fasted for at least 10 hours prior to dosing and 4 hours after dosing.

Meal composition for a representative LFM consisted of approximately 334 kcal, of which approximately 23% of the caloric content was attributed to fat.

<div style=\"page-break-after: always\"></div>

A summary of the key PK parameters from study MEK162A2103 is presented in Table 24.

Table 24: Summary of the Pharmacokinetic Parameters of binimetinib in plasma following administration of Binimetinib (P3-MI) to health subjects under fasted conditions and with high and low-fat meal

<!-- image -->

Key: AUCmr: area umder the cuurve to infinity, maximumobservedplasmaconcentration,（ CSR: clinical study report, Geo-CV: geometmic coeficient of variation, Geo-mean: geometric mean, Max: maximumobservedvalue,Min:Minimumobservedvalue,n:mumberofsubjectswithnon-missingvalues, P3-Ml: phase 3-market image, T.x: time tomaximum observed plasma concentration. ~P3-MI was administered as a single oral 45 mg dose ofbinimetinib (3 x 15 mg tablets).

Source: [StudyMEK162A2103CSR,Table11-3]

## Distribution

Plasma binimetinib concentrations exhibit biphasic elimination with a median terminal half-life of 4-13 hours across all healthy subject and patient studies. The apparent oral clearance was 28.2 L/h and apparent volume of distribution based on the human ADME study was about 384 L.

## Elimination

CMEK162A2102: A Phase I, Single Centre, Open-Label Study to Investigate the Absorption, Distribution, Metabolism, and Excretion (ADME) Of MEK162 Following a Single Oral Dose of 45 mg [ 14 C] MEK162 in Healthy Male Subjects

The clinical study CMEK162A2102 was conducted in healthy subjects with an objective to determine the rates and routes of excretion of binimetinib and its metabolites, including mass balance of total drug related radioactivity in urine and faeces, following the administration of a single 45 mg dose of [ 14 C] binimetinib.

After the oral administration of binimetinib to humans, an average of 62.3% of the administered radioactive dose was excreted in the faeces and included a total of six identified metabolites and binimetinib. Binimetinib was the most abundant radioactive component and accounted for 21.1% to 45.7% of the administered radioactive dose, with an average value of 29.8%. The most abundant metabolites were M4, an ethane-diol cleavage product, and M15.9, carboxylic acid formed from amide hydrolysis, accounting for 17.2% and 6.7% of the dose, respectively. All other metabolites were present at ≤ 2.7% of the dose.

Overall, a mean of 31.4% of the radioactivity dose was eliminated in the urine. A total of 14 metabolites and binimetinib were identified. Binimetinib was the most abundant radioactive component

<div style=\"page-break-after: always\"></div>

and accounted for 5.3% to 8.1% of the administered radioactive dose, with an average value of 6.5%. The most abundant metabolites were M10.9 (direct glucuronide of binimetinib), M3 (AR00426032, Ndemethylated binimetinib), and M10.2 (another direct glucuronide of binimetinib), accounting for 6.2%, 5.1% and 4.2% of the dose, respectively. All other metabolites were present at ≤ 3.2% of the dose. The mean cumulative excretion of radioactivity in urine and faeces is shown in Figure 3.

The estimated mean CLR value of 1.78 L/hr accounted for 6.3% of the total mean CL/F value of 28.2 L/hr.

Table 25: Amounts of Binimetinib and its metabolites in faeces following a single oral dose of 45 mg of 14C-Binimetinib

| MetabolitelSubject   |   5010- 00006 |   5010- 00020 |   5010- 00028 |   5010- 00034 |   5010- 00037 |   5010- 00039 |   Mean |   SD |
|----------------------|---------------|---------------|---------------|---------------|---------------|---------------|--------|------|
| P22.9                |           1.5 |           1.2 |           1.6 |           2.1 |           1.6 |           2.3 |    1.7 |  0.4 |
| M24.1                |           2.5 |           0.7 |           1.5 |           3.6 |           0.4 |           0.5 |    1.6 |  1.3 |
| M3 (AR00426032)      |           5.9 |           2.1 |           4.9 |           1.7 |           0.5 |           0.6 |    2.6 |  2.3 |
| M15.9                |           5.9 |           5   |           5.5 |           9   |           6.7 |           8.1 |    6.7 |  1.6 |
| binimetinib          |          35.7 |          21.1 |          45.7 |          31   |          23.8 |          21.2 |   29.8 |  9.7 |
| M17.0                |           1.5 |           5.2 |           0.8 |           3.2 |           3.8 |           1.9 |    2.7 |  1.6 |
| M4                   |           4.5 |          27.8 |           4.8 |          18.6 |          24.4 |          23.2 |   17.2 | 10.2 |

Note: Amounts expressed as % of dose

In the human ADME study (CMEK162A2102), approximately 60% of the plasma radioactivity AUC was attributable to binimetinib.

An in vitro study using human hepatocytes was conducted to assess the relative contributions of CYP and UGT enzymes to binimetinib metabolism. The metabolic clearance of binimetinib is likely to be dominated by the glucuronidation pathway. The relative contributions of the glucuronidation, hydrolysis, or the oxidative pathways (AR00426032 or M3) to overall binimetinib metabolism in human hepatocytes were 45.1%, 5.1% and 2.4%, respectively. In this study, unchanged binimetinib accounted for 17.3% of total radioactivity after 24 hours.

The primary metabolic pathways include glucuronidation (up to 61.2% via UGT1A1 per in vitro data) and N-dealkylation, amide hydrolysis (up to 17.8% via CYP1A1 and CYP2C19 based on in vitro data), respectively. The estimated mean CLR value of 1.78 L/hours was 6.3% of the total mean CL/F value of 28.2 L/hr.

## Dose proportionality and time dependencies

ARRY-162-0601:  Phase  I,  Randomized,  Placebo-Controlled,  Double-Blind  Study  to  Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of ARRY-438162 in Healthy Volunteers

In study ARRY-162-0601, healthy subjects received single, escalating doses of 5, 10, 20, 30 and 40 mg binimetinib as an oral suspension. The geometric mean of binimetinib exposure parameters (Cmax and Area Under the Concentration Time curve [AUC]) generally increased with increasing dose and inter-subject variability [intra-cohort % Coefficient of Variation (CV)] ranged from 9.95% to 53.5%. The median Apparent Terminal Half-Life (t1/2) of binimetinib across doses was 5.98 hours, and the median Time to Maximum Observed Plasma Concentration (Tmax) was 1 hour post-dose. The overall Geometric Mean Ratio (GMR) of AR00426032 to binimetinib exposure, metabolic ratio of parent drug

<div style=\"page-break-after: always\"></div>

AUC and metabolite AUC (Mean Ratio of Exposure [MRAUC]) was 12.8%. The overall mean percent of the dose excreted into urine over a 24-hour period as unchanged binimetinib and AR00426032 was 2.5% and 4.4%, respectively.

The PK of binimetinib and AR00426032 after repeat doses are studied in four clinical studies (ARRY162-0602, ARRAY-162-111, CMEK162X2201 and CMEK162X1101) and are summarized in Table 26 and Table 27 respectively.

Table 26: Pharmacokinetics of Binimetinib following Multiple Doses

<!-- image -->

<!-- image -->

Key: AuC area under the coneentmliom time curve, BID: twico dnily, CL/F: appurent totd cleamuce Tollowing oml adminisialion,C..! maximum obacmed plsma concenlallon, o: Number, NC: oot calulhble, Np: aol delemned, LFAuc: lefl ventdeulr uen wnder the cuwe, QD: once daby, Rm: oceumultion mlio, Te.: time lo maximnm observed plsmn concenlrlion, VaF: temmal volume of distnbulilon.

*Melian (minimum-maximum),

ARRAY-162-111 =AUC.a, CMEK162X1101 amd CMEK162X2201= AUCa1n

<div style=\"page-break-after: always\"></div>

## Table 27: Pharmacokinetics of AR004260322 Following Multiple doses

<!-- image -->

timelomaximumobscrvcdplasmaconccnlmlion,Va/F:temminadvolumeofdistnbatiom coneenlration, n: number, NC: not calealable, ND: not deermined, QD: once daily,R

Gcomctriemcan(CoelmcientofVaniation)

ARRAY-162-111-AUC.,CMEK162X1101and CMEK162X2201=AUC.12

Medinn(minimum-maximum)

Pharmacokinetics in target population sceumulalion mtio,T..

<div style=\"page-break-after: always\"></div>

Table 28: Binimetinib Pharmacokinetic Parameters on Cycle 1 Day 15

| Study Code, Dose and Regimen (n)                                                  | Cmax,ss (ng/mL)                                                                   | Tmax (E)                                                                          | AUCtau,ss (ng.h/mL)                                                               | RAUC                                                                              | CL/F (L/h)                                                                        | V/F (E)                                                                           |
|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| StudyARRAY-l62-ll1BinimetinibSingleAgent                                          | StudyARRAY-l62-ll1BinimetinibSingleAgent                                          | StudyARRAY-l62-ll1BinimetinibSingleAgent                                          | StudyARRAY-l62-ll1BinimetinibSingleAgent                                          | StudyARRAY-l62-ll1BinimetinibSingleAgent                                          | StudyARRAY-l62-ll1BinimetinibSingleAgent                                          | StudyARRAY-l62-ll1BinimetinibSingleAgent                                          |
| 45 mg Binimetinib BID (N=4)                                                       | 273 (64.7)                                                                        | 2.00 (1.07,2.87)                                                                  | ND                                                                                | 1.50 (NC)                                                                         | NC                                                                                | NC                                                                                |
| StudyCMEKl62X2201BinimetinibSingleAgent                                           | StudyCMEKl62X2201BinimetinibSingleAgent                                           | StudyCMEKl62X2201BinimetinibSingleAgent                                           | StudyCMEKl62X2201BinimetinibSingleAgent                                           | StudyCMEKl62X2201BinimetinibSingleAgent                                           | StudyCMEKl62X2201BinimetinibSingleAgent                                           | StudyCMEKl62X2201BinimetinibSingleAgent                                           |
| 45 mg Binimetinib BID (N=22)                                                      | 438.5 (53.9)                                                                      | 1.48 (0.42,8.00)                                                                  | 2103 (38.4)                                                                       | 1.31 (NC)                                                                         | 20.2 (24.1)                                                                       | NC                                                                                |
| StudyCMEK162X211045mgBinimetinibBIDinCombinationwithEscalatingDosesof Encorafenib | StudyCMEK162X211045mgBinimetinibBIDinCombinationwithEscalatingDosesof Encorafenib | StudyCMEK162X211045mgBinimetinibBIDinCombinationwithEscalatingDosesof Encorafenib | StudyCMEK162X211045mgBinimetinibBIDinCombinationwithEscalatingDosesof Encorafenib | StudyCMEK162X211045mgBinimetinibBIDinCombinationwithEscalatingDosesof Encorafenib | StudyCMEK162X211045mgBinimetinibBIDinCombinationwithEscalatingDosesof Encorafenib | StudyCMEK162X211045mgBinimetinibBIDinCombinationwithEscalatingDosesof Encorafenib |
| 50 mg Encorafenib QD (N=6)                                                        | 648 (40.9)                                                                        | 1.50 (0.500, 2.50)                                                                | 2690 (50.0)                                                                       | 1.50 (16.8)                                                                       | 16.8 (50.1)                                                                       | 111 (119.0)                                                                       |
| 100 mg Encorafenib QD (N=S)                                                       | 526 (48.9)                                                                        | 1.50 (0.500, 1.62)                                                                | 2480 (37.7)                                                                       | 1.25 (12.3)                                                                       | 17.8 (33.4)                                                                       | 126 (70.5)                                                                        |
| 200 mg Encorafenib QD (N=4)                                                       | 532 (92.0)                                                                        | 2.01 (1.52,2.50)                                                                  | 2300 (92.2)                                                                       | 1.06 (13.4)                                                                       | 19.6 (91.8)                                                                       | 53.5 (NC)                                                                         |
| 400 mg Encorafenib QD (N=5)                                                       | 464 (84.9)                                                                        | 1.50 (1.48, 1.67)                                                                 | 1880 (59.0)                                                                       | 0.938 (40.1)                                                                      | 23.9 (59.0)                                                                       | 138 (63.6)                                                                        |
| 450 mg Encorafenib QD (N=13)                                                      | 595 (39.0)                                                                        | 1.57 (0.483, 2.57)                                                                | 2420 (33.9)                                                                       | 0.987 (32.0)                                                                      | 18.5 (33.2)                                                                       | 91.8 (45.0)                                                                       |
| 600 mg Encorafenib QD (N=8)                                                       | 651 (52.1)                                                                        | 1.48 (0.500, 2.68)                                                                | 2210 (67.9)                                                                       | 0.928 (34.4)                                                                      | 25.2 (37.7)                                                                       | NC (NC)                                                                           |
| 800 mg Encorafenib QD (N=6)                                                       | 705 (27.5)                                                                        | 2.13 (0.533, 2.50)                                                                | 2500 (20.2)                                                                       | 1.13 (36.7)                                                                       | 18.0 (25.6)                                                                       | 68.8 (25.2)                                                                       |

Geometric mean (CV% geometric mean) values were reported for the parameters, except for Tmax for which median （min,max)were shown.

RAuc=AUCo-sh in ARRAY-162-111 and AUCo-12h in CMEK162X2201.

NC: not calculated; ND: not determined.

## Special populations

## Impaired renal function

ARRY-162-106: A Phase 1, Open-Label, Multicentre, Single-Dose Study to Evaluate the Pharmacokinetics of Binimetinib in Healthy Subjects with Normal Renal Function and Subjects with Impaired Renal Function

The impact of renal impairment (as determined using the modification of diet in renal disease formula) on 45 mg single dose binimetinib as monotherapy was assessed in a clinical study with an abbreviated design (Study ARRAY-162-106). Results from the severe impairment cohort (i.e. subjects with eGFR ≤29 mL/min/1.73 m2, N=6) indicated an approximate 29% and 21% increase in binimetinib exposure (AUCinf) and in Cmax, respectively, compared with matching healthy subjects (N=6). This increase in exposure was within the variability observed in both cohorts (25.6% and 38.2% for AUC and 42.5% and 48.7% for Cmax). Compared with the healthy subjects, the severe renal impairment cohort exhibited a 22% lower clearance and a slightly longer t1/2 (11.2 vs 9.16 hours).

<div style=\"page-break-after: always\"></div>

In the binimetinib and encorafenib combination model, moderate and severe renal impairment was assessed as a categorical covariate using eGFR for assessment. A 5% increase in CL/F was observed in the moderate/severe group (grouped because of limited number of severe patients). In addition, a 2% increase in CL/F was observed in the mild impairment group.

## Impaired hepatic function

CMEK162A2104: A Phase 1, Multicentre, Open-Label, Single-Dose Study to Assess the Pharmacokinetics of MEK162  in Subjects with Mild, Moderate and Severe Hepatic Impairment

Study CMEK162A2104 was a dedicated clinical study investigating the binimetinib PK as monotherapy in subjects with hepatic impairment, as defined by the NCI Organ Dysfunction Working Group versus healthy subjects. Healthy subjects were enrolled based on matched age, gender and body weight to subjects with hepatic impairment and could have matched more than one subject. Six subjects with mild hepatic impairment, 6 subjects with moderate impairment, 5 subjects with severe hepatic impairment and 7 matching healthy subjects have been dosed.

For the mild impairment versus healthy subject comparison, GMR (90% CI) for AUC0-inf and Cmax were 1.10 (0.86, 1.40) and 1.11 (0.79, 1.57), respectively. For the moderate impairment (i.e. total bilirubin levels &gt;1.5 and ≤3.0 × ULN and any AST value) versus healthy subject comparison, GMR (90% CI) for AUC0-inf and Cmax were 1.94 (1.53, 2.47) and 1.38 (0.98, 1.95), respectively. Due to the 2-fold increase in exposure observed in the moderate impairment cohort, the dose was reduced to 15 mg in the severe impairment cohort. For the severe impairment (i.e. total bilirubin levels &gt;3.0 × ULN and any AST value) versus healthy subject comparison, GMR (90% CI) for AUC0-inf and Cmax were 2.11 (1.62, 2.74) and 1.57 (1.12, 2.20), respectively.

## Population Pharmacokinetic and Exposure Response Analysis of Binimetinib

The study CP16-001 was conducted with the objective to develop a PopPK model for binimetinib and active metabolite AR00426032, to predict binimetinib and active metabolite exposures.

Final population PK models were used to derive rich concentration-time profiles and exposure parameters were derived according to the randomized dose in patients enrolled in all studies. Simulations were derived based on steady-state conditions. Exposure parameters of binimetinib following concomitant administration with encorafenib in patients enrolled in the COLUMBUS Part 1 study are presented in Table 29.

Table 29: Exposure parameters of Binimetinib Administered in combination with Encorafenib (COLUMBUS Study, Part 1)

|               | Combo(Binimetinib at 45mgandEncorafenibat450mg)(n=192)   | Combo(Binimetinib at 45mgandEncorafenibat450mg)(n=192)   | Combo(Binimetinib at 45mgandEncorafenibat450mg)(n=192)   | Combo(Binimetinib at 45mgandEncorafenibat450mg)(n=192)   | Combo(Binimetinib at 45mgandEncorafenibat450mg)(n=192)   |
|---------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|
| Statisties    | AUCss (=gl/mL)                                           | Cminss (mg/mL)                                           | Cmaxss (mg/mL)                                           | Tmar (E)                                                 | t1/28 (E)                                                |
| Mean (CV%)    | 2.28 (23.8%)                                             | 38.3 (33.1%)                                             | 692 (32.1%)                                              | 1.22 (69.0%)                                             | 17.8 (11.6%)                                             |
| [Min, Q25]    | [1.15, 1.90]                                             | [13.1, 28.6]                                             | [191, 541]                                               | [0.509,0.809]                                            | [4.81, 16.7]                                             |
| [Q25, Median] | [1.90, 2.23]                                             | [28.6, 36.0]                                             | [541, 677]                                               | [0.809, 1.01]                                            | [16.7, 17.7]                                             |
| [Median, Q75] | [2.23, 2.54]                                             | [36.0, 44.2]                                             | [677, 813]                                               | [1.01, 1.31]                                             | [17.7, 19.1]                                             |
| [Q75, Max]    | [2.54, 4.18]                                             | [44.2.9, 89.5]                                           | [813, 1610]                                              | [1.31, 6.31]                                             | [19.1, 23.5]                                             |

AuCss=Area-undertheciuveuudersteady-stateoverthedosinginterval;Cmsx=Maximumconcentrationatsteady-state: Cmin=Minimumconcentrationatsteady-state:CV=Coefficientofvaniation:Max=Maximum;Min=Mimimum;n=Numberof subjects; Q25=25percentile; Q75=75percentile;Tmax=Time to reach maximum concentration; tinp=Tenminal elimination half-life

<div style=\"page-break-after: always\"></div>

## Gender

In the binimetinib monotherapy analysis, female subjects (N=387) were found in a greater proportion in the population PK analysis dataset than males (N=214). A similar trend was observed for binimetinib in the binimetinib and encorafenib combination population model including 166 females and 256 males, with females exhibiting a 13% lower CL/F and 14% lower V/F relative to males.

## Race

Japanese patients have shown 1.5 to 2-fold higher binimetinib exposures (Cmin,ss, Cmax, AUC0-12h) than non-Japanese patients after administration as monotherapy. In Study CMEK162X1101, Japanese patients (N=9) were shown to have higher steady-state binimetinib exposures compared to all patients in Study CMEK162X2201 (N=22) following administration of 45 mg binimetinib. The mean Cmax and AUC0-12h values were 771 ng/mL versus 439 ng/mL and 3550 ng.h/mL versus 2103 ng.h/mL, respectively. In Study CMEK162A2301, plasma concentrations of binimetinib and AR00426032 were analysed in Japanese versus non-Japanese patients. Six Japanese patients were identified in the binimetinib arm for comparison to non-Japanese patients. At steady-state condition (i.e. pre-dose Week 4), Japanese patients showed higher mean binimetinib concentrations than non-Japanese patients (305 ng/mL versus 127 ng/mL pre-dose, respectively).

## Weight

For an individual in the 95th percentile of weight (i.e. 110 kg), the population PK analysis suggested a 26% change in V/F compared to the typical individual of 78 kg, and a 23% change for an individual in the 5th percentile of weight (53kg). A similar trend between body weight and binimetinib V/F was observed in the binimetinib and encorafenib combination model with 34% increase at the 95th percentile (i.e. 112 kg) and 26% decrease at the 5th percentile (i.e. 54 kg).

## Elderly

Bayesian PK parameters for binimetinib were derived and summarised according to the proposed age categories and descriptive statistics are provided in each age group in the tables below.

Table 30: Bayesian PK Parameters by age categories

## 65-74 years

| STUDY   |   Ka (1/h) |   VF (L) |   V2/F (L) |   CI/F (L/h) |   C12/F (L/h) |   Tlag (b) |   AGE ( |
|---------|------------|----------|------------|--------------|---------------|------------|---------|
| Mean    |      2.86  |      9.1 |      215   |        18.5  |         14.3  |      0.164 |   69.2  |
| SD      |      1.99  |     24.5 |      172   |         7    |          1.63 |      0     |    2.83 |
| CV9     |     69.5   |     24.7 |       80   |        37.9  |         11.4  |      0     |    4.09 |
| Mi      |      0.151 |     46.9 |       57.1 |         7.19 |         10.1  |      0.164 |   65    |
| Max     |      9.31  |    190   |     1782   |        64.4  |         19.8  |      0.164 |   74    |
| Medisn  |      2.51  |     98.9 |      186   |        17.5  |         14.2  |      0.164 |   69    |
| N       |    146     |    146   |      146   |       146    |        146    |    146     |  146    |

CIF: apparent clearance:Cl2/F:apparent inter-compartuental clearance:Ka:first order absorption rate constant:Tlag:lag time;V/F:apparent central vohumeof distnbution:V2/F:apparent peripheral volume of distnbution

Source:CP16-001reportappendix8.1.7

<div style=\"page-break-after: always\"></div>

75- 84 years

| STUDY   |   Ka (1/h) | VF (L)   | V2/F (L)   | CI/F (L/h)   |   C12/F (L/h) | Tlag (b)   | AGE (   |
|---------|------------|----------|------------|--------------|---------------|------------|---------|
| Mean    |     3      | 86.3     | 198        | 15.3         |         14.1  | 0.164      | 78.8    |
| SD      |     2.32   | 19.7     | 97.8       | 5.87         |          1.71 | 0.00       | 2.56    |
| CV%     |    77.5    | 22.8     | 49.4       | +'8E         |         12.2  | 00'0       | 3.25    |
| Mi      |     0.0626 | 46.3     | 65.9       | 6.86         |         10    | 0.164      | 75.0    |
| Max     |    14.1    | 139      | 799        | 41.9         |         18.6  | 0.164      |         |
| Median  |     2.74   | 84.5     | 184        | 14.5         |         14.1  | 0.164      | 79.0    |
| N       |    64      | t9       | t9         | 64           |         64    | 64         | t9      |

ClF:apparent clearance: CI2/F:apparentinter-compartmental clearance;Ka:first order absorpdonrate constant;Tlag:lag time:V/F:apparent cental volume of disunbution:V2/F:apparent peripheral vohume of distnibution

Source:CP16-001reportappendix8.1.7

85 years and over

| STUDY   |   Patient ID |   Ka V/F (1/h) (L) | V2/F (L)   |   CI/F (L/h) |   C12/F (L/h) |   Tlag (b) | AGE ()   |
|---------|--------------|--------------------|------------|--------------|---------------|------------|----------|
| Mean    |        2.77  |               95.4 | 183 14.5   |        13.3  |         0.164 |     87     |          |
| SD      |        1.31  |               18.4 | 11.9       |         2.03 |         1.24  |      0     | 2.08     |
| CV9     |       47.2   |               19.3 | 6.53       |        14    |         9.35  |      0     | 2.39     |
| Min     |        0.919 |               70.3 | 163        |        11.4  |        12     |      0.164 | 85.0     |
| Max     |        4.39  |              120   | 196        |        16.5  |        15.2   |      0.164 | 90.0     |
| Median  |        2.98  |               93.3 | 180        |        15.3  |        12.9   |      0.164 | 87.0     |
| N       |        7     |                7   | 7          |         7    |         7     |      7     | 7        |

CVF:apparent clearance;Cl/F:apparent inter-compartmental clearance;Ka:first orderabsorptionrate constant.Tlaglag time:V/F:apparentcentralvohume of distnbutionV2/F:apparentperipheral volume ofdistmbution

Source:CP16-001reportappendix8.1.7

Table 31: Number of elderly subjects for PK studies

|           | Age 65-74 (Older subjects number /total number)   | Age 75-84 (Older subjects number /total number)   | Age 85+ (Older subjects number /total number)   |
|-----------|---------------------------------------------------|---------------------------------------------------|-------------------------------------------------|
| PK Trials | 201/749                                           | 70/749                                            | n/a                                             |

## Pharmacokinetic interaction studies

Binimetinib showed weak inhibition (IC50 ~ 50 μM) of CYP1A2 and CYP2C9. Very little or no inhibition of CYP2A6, CYP2C8, CYP2C19, CYP2D6, CYP2E1 and CYP3A4/5 was observed at binimetinib concentrations of up to 100 μM. Binimetinib showed no apparent time-dependent inhibition of CYP1A2, CYP2C9, CYP2D6 or CYP3A4/5 at binimetinib concentrations of up to 50 μM.

Binimetinib showed inhibition of CYP2B6 with an IC50 value of ~6 μM and a Ki value of 1.7 μM. A basic model for reversible inhibition was used to calculate the R value of inhibition of CYP2B6 with binimetinib using the parameters obtained in the in vitro studies. Since the R value was 1.61, the static mechanistic model was used to calculate the AUCR to determine if an in vivo study was warranted (if AUCR &gt; 1.25). The AUCR was calculated to be 1.03, therefore it was concluded that binimetinib was not likely to be an inhibitor of CYP2B6 and an in vivo study not needed to assess the interaction potential.

<div style=\"page-break-after: always\"></div>

Binimetinib showed a 1.88 to 2.24-fold induction for CYP2C9 mRNA with 20 μM of binimetinib, relative to the vehicle control in primary human hepatocytes. The induction at lower concentrations (0.1, 1, and 10 μM) was less than 2-fold. Treatment of hepatocytes with binimetinib caused no induction of CYP2C9 activity, as shown by less than 2-fold metabolism of diclofenac. In the second experiment, binimetinib concentrations ranged from 0.01 to 30 μM, and a 2.68-fold induction was observed only in one of the two hepatocyte donors at 30 μM.

CYP3A4 induction was observed at all concentration ranges tested. At 0.1 μM binimetinib the induction ranged from 1.88 to 3.00-fold, and at 20 μM binimetinib, the induction ranged from 23.7 to 37.2-fold.

Binimetinib was a weak inhibitor of UGT1A-mediated glucuronidation of SN-38 with an IC50 value of greater than 25 μM. The average percent of inhibition at 25 μM was 20.3%. The effect of binimetinib on UGT1A enzyme activities is presented in Table 32.

Table 32: Effect of Binimetinib on UGT1A Enzyme Activities

| UGT Isoform   | Substrate   | Average binimetinib ICgo (mI)   |   %Inhibitionof binimetinib at 25 μMI |   Saquinavir (Control Compound) ICso (μMI) |
|---------------|-------------|---------------------------------|---------------------------------------|--------------------------------------------|
| UGT1A         | SN-38       | >25                             |                                  20.3 |                                       5.84 |

Binimetinib was not found to be an in vitro inhibitor of BCRP or P-gp. BCRP and P-gp efflux activity were largely unaffected by concentrations of binimetinib up to 50 μM.

Study ARRAY-162-105 was a study in 15 healthy subjects investigating the PK of binimetinib in the presence of the proton-pump inhibitor rabeprazole. The GMR for Area Under the Concentration-Time Curve from Time 0 Extrapolated to Infinity (AUCinf) increased 4% (GMR = 1.04) following coadministration with rabeprazole. The treatment groups were bioequivalent as indicated by the 90% CI of the GMR (0.930 - 1.17). Likewise, there was no effect on Tmax. In contrast, Cmax was decreased after administration with rabeprazole by 17% (GMR = 0.826) and this change was determined to be statistically significant as indicated by the 90% CI of the GMR (0.692 - 0.984). However, the magnitude of change (17%) was less than the reported variability in the study for Cmax across both treatment periods (30.9 % to 41.7%).

## Pharmacokinetics using human biomaterials

In humans, the mean plasma protein binding of binimetinib was 97.4% when evaluated by the rapid equilibrium dialysis method (DMPK R1300621\\_DMPK R1300621a). The blood-to-plasma concentration ratios of binimetinib ranged from 0.65 to 0.99 in the species tested, and appeared to be independent of concentration. In humans, the blood-to-plasma ratio was 0.72 over the concentration range evaluated (50 to 10,000 ng/mL).

## Characterization of Binimetinib as a Substrate of Xenobiotic Transporters

In Caco-2 cells, MEK162 was confirmed as an efflux substrate (BA/AB &gt;2.0), since, in the presence of verapamil, a specific P-gp inhibitor, the transwell permeability and efflux of binimetinib were increased and reduced, respectively. Binimetinib was confirmed as a substrate of both P-gp and BCRP in MDR1expressing LLC-PK1 cells and BCRP expressing MDCK cells, respectively.

<div style=\"page-break-after: always\"></div>

The potential involvement of several uptake transporter families (OCT1, OATP1B1, OATP1B3, and OATP2B1) in binimetinib plasma clearance was investigated using a representative cocktail of transporter inhibitors in human hepatocyte assays (DMPK R1100398). The data suggested that hepatic uptake transporters are not involved in binimetinb plasma clearance and distribution into human hepatocytes. Additionally, binimetinib does not display significant active renal secretion as only 6.5% of the dose was excreted in urine as binimetinib in humans (Study CMEK162A2102); as such it was not evaluated as a substrate of OAT1/3 and OCT2.

## Transporter Inhibition

Binimetinib was not found to be an inhibitor of BCRP or P-gp. BCRP and P-gp efflux activity were largely unaffected by concentrations of binimetinib up to 50 μM (DMPK R 1100165). MEK162 did not affect the P-gp mediated transport of digoxin in Caco-2 or MDR1 transfected LLC-PK1 cell monolayers (DM05-042-A1\\_DM05-042-A2).

Binimetinib was shown to reduce [3H] estradiol 17ß-glucuronide ([3H]E217ßG) accumulation into OATP1B1 and OATP1B3-expressing cells in a dose-dependent manner, however, the estimated IC50 values for inhibition of OATP1B1 or OATP1B3-mediated ([3H]E217ßG) uptake by binimetinib were 23.6 ± 9.6 μM and ~29 μM, respectively. Binimetinib did not inhibit the transport activity of OCT1 (1 to 100 μM) but was a weak inhibitor of the transport activity of OCT2 (IC50 18.1 ± 1.3 μM) in vitro). The IC50 values for binimetinib inhibition of OAT1 and OAT3 activities were approximately 27 μM and 1.9 ± 0.17 μM, respectively. Additionally, binimetinib was assessed as an inhibitor of BSEP-mediated taurocholic acid transport in inside-out membrane vesicles containing expressed BSEP from 0.1 to 25 μM. Binimetinib did not cause a dose-dependent inhibition of BSEP activity (~20% maximal inhibition). Likewise, binimetinib is not predicted to affect transport of substrates of the renal MATE1 or MATE2-K transporters. Binimetinib was not a potent inhibitor of metformin uptake by MATE1 (IC50 &gt;50 μM) and did not inhibit MATE2-K when tested up to 50 μM in recombinant HEK cell lines expressing each transporter (DMPK R 1100433; DMPK R 1200819; DMPK R 1200760; DMPK R 1400791; DMPK R 1400790).

## 2.4.3. Pharmacodynamics

## Mechanism of action

See non-clinical pharmacology.

## Primary and Secondary pharmacology

In Study ARRAY-162-111, post-dose decreases in tumour necrosis factor alpha (TNFα) levels were observed in serum samples, as well as post-dose decreases in Ki67 and phosphorylated ERK (pERK) levels in skin punch biopsies for patients in the 30 to 60 mg BID dose cohorts.

In Study CMEK162X1101, skin expression of pERK was evaluated as potential surrogate PD marker of binimetinib inhibition, pre-dose at baseline and post-dose on Day 15 of Cycle 1. Tumour tissue was not evaluated as no paired tumour sample was available. A total of 11 out of 17 patients with matched skin samples demonstrated a decrease in pERK H-score from baseline (4 of 6 patients in the 30 mg BID and 7 of 11 patients in the 45 mg BID dose level cohorts). The median (range) percentage change from baseline to Day 15 of Cycle 1 was -34.6% (-95.3% to 108.3%), indicating inhibition of the target at both evaluated dose levels.

<div style=\"page-break-after: always\"></div>

## Exposure-Safety

Exposure-safety analyses were conducted using a logistic regression model across multiple oncology studies with binimetinib in combination with encorafenib (Studies CMEK162B2301 [Part 1], CMEK162X2109, CMEK162X2110 and CLGX818X2101). The relationships between model-predicted binimetinib and encorafenib exposure (AUCss) and the expected incidence of increased ALT, PPE, pyrexia and diarrhoea were assessed. Exposure-response relationships for binimetinib and encorafenib in combination were similar in most instances due to the confounding effect of the combination therapy.

When anchored for encorafenib monotherapy, high AUCss of binimetinib were associated with slightly higher probabilities of increased ALT (all grades), pyrexia (grade ≥2) and diarrhoea (grade ≥2), though none were statistically significant.

Binimetinib appeared to mitigate the effect of encorafenib on PPE (grade ≥2) by reducing the probability from 32.4% to 42.6% across quartiles of encorafenib exposure to 1.0% to 2.0%.

Logistic regression evaluation of grade 2 or greater LVEF reduction and exposure found no significant relationships for increased incidence and increased exposure for model predicted exposure metrics (Cmin,ss, AUCtau,ss, Cmax,ss [p &gt; 0.05]). Additional ER analyses were conducted on CHMP request including the ADRs skin rash (grade ≥ 2), skin infections (grade ≥ 2), skin neoplasms (grade ≥ 2), retinal events (grade ≥ 2), high levels of AST (all grades), high levels of gGT (all grades), CK elevations (all grades) and arthralgia (grade ≥ 2) and included patients from COLUMBUS parts 1 and 2.

Results from the updated logistic models with positive relationship (i.e. harmful effect [p&lt;0.05]) between the exposure and the probability of adverse events showed that all higher exposure parameters levels of binimetinib (Cmin,ss, Cmax,ss, AUCtau,ss) were associated with increased probabilities of retinal events (grade ≥ 2), high levels of AST (all grades) and high levels of CK (all grades).

For the probability of high CK levels, the probability estimated with the absence of binimetinib (i.e., encorafenib monotherapy) was 3.84% and then this probability increased to 11.73%, 15.95%, 20.03% and 30.08% for patients with AUCss binimetinib in the 1st, 2nd, 3rd and 4th quartiles, respectively.

Logistic regression models with negative relationship (i.e., beneficial effect [p&lt;0.05]) between drug exposure and the probability of adverse events showed that higher exposure of binimetinib was associated with a decrease in the probability of skin infection, rash events and of arthralgia events. Secondary pharmacology with regard to cardiac safety was assessed by popPK modelling. No relevant change of QTcF from baseline was found, and this supported also results from the pivotal study.

Regarding pharmacodynamic drug interactions the applicant argued that in the pivotal study no potential interacting drugs were used. As currently only few drug substances have the potential to inhibit MEK the potential for such PD interactions is generally low. Potential off-target activity of binimetinib (and encorafenib) to inhibit other kinases is low at the proposed recommended doses.

Regarding genetic differences in PD response of binimetinib UGT1A1 genotype analysis of binimetinib exposure performed in the pivotal study did not establish meaningful changes of predose concentrations between genotypes. Presumably, for a similar concentration safety and efficacy effects could be expected comparable.

<div style=\"page-break-after: always\"></div>

## 2.4.4. Discussion on clinical pharmacology

The pharmacokinetics of binimetinib were studied in healthy subjects and patients with solid tumours and advanced and unresectable or metastatic cutaneous melanoma. After repeat twice-daily dosing concomitantly with encorafenib, steady-state conditions for binimetinib were reached within 15 days with no major accumulation. The mean (CV %) Cmax,ss was 654 ng/mL (34.7 %) and mean AUCss was 2.35 ug.h/mL (28.0 %) in combination with encorafenib as estimated by population PK modelling. Binimetinib pharmacokinetics have been shown to be approximately dose-linear.

After oral administration, binimetinib is rapidly absorbed with a median Tmax of 1.5 hours. Following a single oral dose of 45 mg [ 14 C] binimetinib in healthy subjects, at least 50 % of the binimetinib dose was  absorbed.  Binimetinib  showed  low  solubility  at  physiological  pH  but  higher  at  acidic  pH. Administration of a single 45 mg dose of binimetinib with a high-fat, high-calorie meal decreased the maximum  binimetinib  concentration  (Cmax)  by  17 %,  while  the  area  under  the  concentration-time curve (AUC) was unchanged. A drug interaction study in healthy subjects indicated that the extent of binimetinib exposure is not altered in the presence of a gastric pH-altering agent (rabeprazole).

Administration of the commercial formulation of binimetinib with food (HFM) resulted in no significant change in total exposure. Cmax increased with a LFM (29%) but decreased with a HFM (17%). Both a high fat and low-fat meal have only a small effect on Cmax, therefore it can be agreed the drug can be taken without regard for food.

The plasma protein binding has been measured at a range of physiologically relevant concentrations and is 97.2 % bound to human plasma proteins in vitro . Binimetinib is more distributed in plasma than blood.  In  humans,  the  blood-to-plasma  ratio  is  0.718.  Following  a  single  oral  dose  of  45 mg  [ 14 C] binimetinib in healthy subjects, the apparent volume of distribution (Vz/F) of binimetinib is 374 L.

Following a single oral dose of 45 mg [ 14 C] binimetinib in healthy subjects, the primary biotransformation pathways of binimetinib observed in humans include glucuronidation, N-dealkylation, amide  hydrolysis,  and  loss  of  ethane-diol  from  the  side  chain.  The  maximum  contribution  of  direct glucuronidation to the clearance of binimetinib was estimated to have been 61.2 %. Following a single oral  dose  of  45 mg  [ 14 C]  binimetinib  in  healthy  subjects,  approximately  60 %  of  the  circulating radioactivity AUC in plasma was attributable to binimetinib. In vitro , CYP1A2 and CYP2C19 catalyse the formation  of  the  active  metabolite,  which  represents  less  than  20 %  of  the  binimetinib  exposure clinically.

Following a single oral dose of 45 mg [ 14 C] binimetinib in healthy subjects, a mean of 62.3 % of the radioactivity was eliminated in the feces while 31.4 % was eliminated in the urine. In urine, 6.5 % of the  radioactivity  was  excreted  as  binimetinib.  The  mean  (CV %)  apparent  clearance  (CL/F)  of binimetinib was 28.2 L/h (17.5 %). The median (range) binimetinib terminal half-life (T1/2) was 8.66 h (8.10 to 13.6 h). In faeces binimetinib was the most abundant radioactive component and accounted for  an  average  value  of  29.8%  of  dose.  The  most  abundant  metabolites  were  M4,  an  ethane-diol cleavage product, and M15.9, a carboxylic acid formed from amide hydrolysis, accounting for 17.2% and 6.7% of the dose, respectively. All other metabolites were present at ≤ 2.7% of the dose. In urine binimetinib  was  the  most  abundant  radioactive  component  and  accounted  for  5.3%  to  8.1%  of  the administered radioactive dose, with an average value of 6.5%. The most abundant metabolites were M10.9 (direct glucuronide of binimetinib), M3 (AR00426032, N-demethylated binimetinib), and M10.2 (another  direct  glucuronide  of  binimetinib),  accounting  for  6.2%,  5.1%  and  4.2%  of  the  dose, respectively. All other metabolites were present at ≤ 3.2% of the dose.

<div style=\"page-break-after: always\"></div>

Given  the  31.7%  unchanged  in  faeces,  biliary  elimination  of  binimetinib  cannot  be  discounted.  The elimination appears mainly hepatic. The major route of elimination appears to be due to metabolism by UGT1A1 but the quantitative contribution is uncertain.  Binimetinib is primarily metabolised through UGT1A1  mediated  glucuronidation.  In  clinical  study  sub-analysis,  however,  there  was  no  apparent relationship  observed  between  binimetinib  exposure  and  UGT1A1 mutation  status.  In  addition, simulations  to  investigate  the  effect  of  400 mg  atazanavir  (UGT1A1  inhibitor)  on  the  exposure  of 45 mg  binimetinib  predicted  similar  binimetinib  Cmax  in  the  presence  or  absence  of  atazanavir. Therefore,  the  extent  of  drug  interactions  mediated  by  UGT1A1  is  minimal,  and  unlikely  clinically relevant;  however,  as  this  has  not  been  evaluated  in  a  formal  clinical  study,  UGT1A1  inducers  or inhibitors  should  be  administered  with  caution    (see  Section  4.5  and  5.2  of  the  SmPC).  UGT1A1 inducers (such as rifampicin and phenobarbital) and inhibitors (such as indinavir, atazanavir, sorafenib) should be co administered with caution.Binimetinib is not an inhibitor of UGT1A1. While encorafenib is a  relatively  potent  reversible  inhibitor  of  UGT1A1,  no  differences  in  binimetinib  exposure  have  been observed clinically when binimetinib is co-administered with encorafenib (see section 5.2 ) .

Cytochrome P450 enzymes appear to account for less than 25% of the elimination. Binimetinib does not inhibit CYPs except for CYP 2B6 which had a Ki of 1.7 µM, however the mechanistic static model was used to rule out an interaction. Binimetinib shows induction of CYP 3A4 in vitro and this was investigated in a clinical study. Induction of mRNA for CYP 1A2 and 2B6 is greater than 2-fold (16.5 and 2.6-fold respectively). In vitro , CYP1A2 and CYP2C19 catalyse the formation of the active metabolite, AR00426032 (M3) by oxidative N-desmethylation. Binimetinib is a potential inducer of CYP1A2, and caution should be taken when it is used with sensitive substrates (such as duloxetine or theophylline). Binimetinib is a weak reversible inhibitor of CYP1A2 and CYP2C9. Inducers of CYP1A2 enzymes (such as carbamazepine and rifampicin) and inducers of Pgp transport (such as Saint John's wort or phenytoin) may decrease binimetinib exposure, which could result in a decrease of efficacy.

Binimetinib is a weak inhibitor of OAT3, and caution should be taken when it is used with sensitive substrates (such as pravastatin or ciprofloxacin) and no clinicallly significant drug-drug interactions caused by binimetinib on other transporters is expected.

Binimetinib is not an inhibitor of Pgp, BCRP, OAT1, OCT1, OCT2, MATE-1, MATE-2k or BSEP.  It is a weak inhibitor of OATP1B1 and 1B3, but it can be agreed this does not appear to be clinically relevant concentrations. In addition, as 30% is eliminated unchanged in faeces, therefore biliary excretion, possibly by Pgp, cannot be discounted. In vitro experiments indicate that binimetinib is a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). Inhibition of P-gp or BCRP is unlikely to result in a clinically important increase in binimetinib concentrations as binimetinib exhibits moderate to high passive permeability. In vitro studies also demonstrated that binimetinib is a P-gp and BCRP substrate, but the effects of inhibitors of these substrates on the PK of binimetinib in vivo has not been investigated.

Binimetinib is metabolised by UGTs and CYP1A2 is a substrate for Pgp..  Specific inducers of these enzymes have not been studied and may result in a loss of efficacy.

There do not appear to be any major metabolites of binimetinib. M3 is stated to be equipotent and attributes  less  than  20% of  binimetinib  exposure. The  plasma  protein  binding  of  metabolite  M3  has been determined in all relevant species and is 95.26% in man.

Binimetinib appears essentially linear over the dose range of 20 to 100 mg, however there may be some  less  than  proportional  increase  at  steady  state  in  patients  at  does  above  30  mg  but  data  is limited.

<div style=\"page-break-after: always\"></div>

Modest accumulation is seen following multiple dosing, ~1.3 fold in patients following 45 mg.  This is consistent with the calculated half-life. The data is based on a comparison of Day 1 to Day 15. Data from the midazolam study shows that steady state is achieved by Day 8 which is slightly longer than may be expected based on the half-life.

The exposure appears to be slightly higher in patients compared to healthy volunteers.  In the POPPK analysis clearance is determined to be 32% greater in healthy volunteers.

Exposure to binimetinib 45 mg BID in Study CMEK162X2110 was within the ranges of values observed in  the  single-agent  studies  (Studies  ARRAY-162-111 and CMEK162X2201), regardless of encorafenib dose level.

Binimetinib undergoes minimal renal elimination. Results from a dedicated clinical study showed that patients with severe renal impairment (eGFR ≤ 29 mL/min/1.73 m 2 ), had a 29 % increase in exposure (AUCinf),  a  21 %  increase  in  Cmax,  and  a  22 %  decrease  in  CL/F  compared  to  matching  healthy subjects. These differences were within the variability observed for these parameters in both cohorts of this study (25 % - 49 %) and the variability previously observed in patient clinical studies, hence these differences are unlikely to be clinically relevant. It is agreed that based on these PK results no dose adjustment is recommended for patients with renal impairment (see section 5.2).

The effects of renal impairment on the pharmacokinetics of binimetinib in combination with encorafenib have not been evaluated clinically.

As binimetinib is primarily metabolised and eliminated via the liver, patients with moderate to severe hepatic  impairment  may  have  increased  exposure.  Results  from  a  dedicated  clinical  study  with binimetinib only indicate similar exposures in patients with mild impairment (Child-Pugh Class A) and subjects with normal liver function. While an increase in dose-normalised (total) binimetinib exposure was  only  small  with  mild  impairment,  a  two-fold  increase  in  total  binimetinib  exposure  (AUC)  was observed  in  patients  with  moderate  (Child-Pugh Class B)  and  severe  (Child-Pugh Class C)  hepatic impairment (see section 4.2)    and  clearance  reduced  to  about  50%.  In  contrast  to  binimetinib,  the plasma concentration  of  the  metabolite  AR00426032  decreased  with  increasing  hepatic  impairment. This increase expends to three fold in both moderate and severe hepatic impairment when considering unbound binimetinib exposure (see section 4.2).

No dose adjustment is required in patients with mild hepatic impairment (Child Pugh A).

As encorafenib is not recommended in patients with moderate (Child Pugh B) or severe hepatic impairment (Child-Pugh C), administration of binimetinib is not recommended in these patients. (see section 4.2 of encorafenib SmPC).

Binimetinib has not been evaluated in patients with Gilbert's disease. The main route of hepatic transformation of binimetinib being glucoronidation, the  decision for treatement should be made by the treating physician taking into account the individual benefit-risk.

Based on a population pharmacokinetic analysis, age or body weight do not have a clinically important effect on the systemic exposure of binimetinib. Based on a population pharmacokinetic (PK) analysis, the PK of binimetinib were similar in males as compared with females. There are insufficient data to evaluate potential differences in the exposure of binimetinib by race or ethnicity.

An analysis performed with the POPPK model does not show a significant effect for a 79-year-old compared to a 59 or 75-year-old. Data has been provided for different age categories based on Bayesian PK parameters.  There is evidence of a slight decrease in clearance in older patients however

<div style=\"page-break-after: always\"></div>

this does not seem to be large enough to require a dose adjustment. No dose adjustment is required for patients aged 65 years and older (see section 5.2).

It is unknown whether binimetinib or its active metabolite are excreted in human. A risk to the newborns/infants cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue binimetinib therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the mother.

## Exposure - Response Relationship: Binimetinib in Combination with Encorafenib

When analysing ORR, a relationship between binimetinib AUCss and the probability of ORR shows no positive or negative trend. This was observed for part 1 with Combo450 and for part 2 in Combo300. Overall, results derived with Cox proportional hazard models are consistent with those derived for ORR and exposure-response observations from Kaplan-Meier plots, whereby baseline LDH was the strongest prognostic  factor  of  death  or  progression.  The  results  of  these  analyses  indicated  that  higher binimetinib exposure was associated with longer PFS than lower exposure (updated analyses Combo 450 Part 1: 16.6 and 12.7 months, respectively), whereas high and low encorafenib exposure showed an  inverse  relationship  with  PFS  (updated  analyses  Combo  450  Part  1:  9.36  and  16.5  months, respectively). All groups showed longer PFS than the vemurafenib control arm (7.33 months).

With  the  responses,  the  applicant  submitted  corresponding  analyses  for  OS.  These  showed  a comparable pattern: with higher than median binimetinib AUCss OS of 39.5 months, with lower AUCss 29.6 months; and for encorafenib inversely a longer OS with lower AUCss (36.8. vs. 23.1 months).

For part 2, with Combo300, the new analyses for PFS were comparable for binimetinib: higher than median AUCss 13.4 months, lower AUCss 11.1 months. Here, no effect of encorafenib exposure as in part 1 was observed.

## 2.4.5. Conclusions on clinical pharmacology

The pharmacokinetics and pharmacodynamic aspects of binimetinib are generally well presented and considered sufficiently well characterised.  The relevant information has been included in section 4.5 and 5.3 of the SmPC.

The CHMP requests the following measures to address the issues related to pharmacology:

- -DDI cocktail study: OATP and BCRP will be explored in the ongoing DDI study with rosuvastatin (study ARRAY-818-103)
- -Overall survival results stratified by LDH level for Combo 300 and Enco 300 (Part 2).
- -To collect PK samples from BRAF melanoma patients with moderate and severe hepatic impairment after repeated dosing of encorafenib in combination with binimetinib to determine the plasma concentrations in relation to administered dose and AEs observed to guide dosing recommendations in these patient populations.

The CHMP recommends the applicant to submit the following measures to address the issues related to pharmacology:

- -The applicant should commit to submit the results of the planned biomarker analyses for Study B2301 (from all 3 treatment arms) for evaluation as soon as available, to support the synergistic pharmacodynamic activity of encorafenib in combination with binimetinib. Genomic analysis of baseline samples remaining after centralized BRAF testing. As indicated in the protocol, genomic alterations in BRAF, HRAS, KRAS, NRAS, PTEN, cKIT, PIK3CA, MAP2K1,

<div style=\"page-break-after: always\"></div>

MAP2K2, ARAF, c-MET, CRAF, EGFR and CCND1 may be explored to find a potential association between baseline mutations and efficacy outcomes.

- -The relationship between baseline mutations and efficacy outcomes should be performed, and a date provided to submit the results.

## 2.5. Clinical efficacy

## 2.5.1. Dose response study(ies)

The dose recommended for binimetinib and the administration schedule for use in combination with encorafenib in patients with BRAF V600 mutation-positive melanoma is 45 mg BID. This corresponds to 0.35 μg/mL and 2.1 μg.hr/mL in terms of Cmax and AUC0-12h at steady state in humans.

Clinical studies relevant in the determination of binimetinib dose selection are presented in the Table 33 below.

Table 33: Clinical Studies Relevant in Determination of Binimetinib Dose Selection

| Study No.      | Study Objective, Population                                          | No. of Patients Receiving Binimetinib                                                       | Binimetinib Dose                                         | Efficacy Endpoint       |
|----------------|----------------------------------------------------------------------|---------------------------------------------------------------------------------------------|----------------------------------------------------------|-------------------------|
| ARRY-162- 0601 | Single ascending dose in healthy subjects                            | Planned: 20 Actual: 20                                                                      | 5, 10,20,30 and 40 mg                                    | None                    |
| ARRY-162- 0602 | Multiple ascending dose in healthy subjects                          | Planned: 46 Actual: 38                                                                      | 5,10,20,40 and 60 mg QD, 20 mg BID and 80 mg single dose | None                    |
| ARRAY- 162-111 | MTD/RP2D- finding study in patients with advanced solid tumors       | Planned: 95 (30 dose escalation, 65 expansion) Actual:93 (19 dose escalation, 74 expansion) | 30,45, 60, 80 mg BID                                     | Objective response rate |
| CMEK162X 2201  | Efficacy/safety in BRAF or NRAS mutation-positive cutaneous melanoma | Planned: 156 (100 NRAS, 56 BRAF) Actual: 183 (117 NRAS, 66 BRAF)                            | 45, 60 mg BID                                            | Objective response rate |

Sources: Synopses of Individual Studies, Tabular Listing of All Clinical Studies

Key: BID: twice daily, BRAF: b-raf proto-oncogene serine/threonine-protein kinase, MTD: maximum tolerated dose, No.: number, NRAS: neuroblastoma ras viral oncogene homolog, QD: once daily, RP2D: recommended phase 2 dose.

In study ARRY-162-0601 , healthy subjects received single, escalating doses of 5, 10, 20, 30 and 40 mg binimetinib or matching placebo. Twenty subjects (4 subjects per dose level) received treatment with  binimetinib  and  1  subject  per  dose  level  received  placebo.  Headache  was  the  most  common adverse  in  this study. Clinical laboratory results, vital signs,  electrocardiograms  and  physical examinations indicated no safety concern of a single dose of binimetinib ranging from 5 mg to 40 mg.

In study ARRY-162-0602 , healthy subjects received escalating doses of 5, 10, or 20 mg Once Daily (QD) binimetinib, 20 mg BID binimetinib, 40 or 60 mg QD binimetinib for 14 days, a single dose of 80 mg binimetinib or matching placebo. A total of 50 subjects were enrolled and 44 completed the study. The most commonly reported adverse events were diarrhoea, headache, rash and acne. There was no evidence that diarrhoea or headache was dose-related and none of these events led to discontinuation

<div style=\"page-break-after: always\"></div>

of  study  drug.  Adverse  events  in  the  Skin  and  Subcutaneous  Tissue  Disorders  system  organ  class occurred with the greatest incidence in the 20 mg BID, 40 mg QD, and 60 mg QD binimetinib groups.

The  recommended  Phase  2  dose  (RP2D)  of  binimetinib  monotherapy  was  determined  in Study ARRAY-162-111 ,  a  Phase 1 dose-escalation study in patients with advanced cancer to determine a maximum  tolerated  dose  (MTD)  following  30,  45,  60,  and  80  mg  BID  binimetinib.  The  primary objectives were to determine the Maximum Tolerated Dose (MTD) and to characterize the safety and PK  of  binimetinib.  Nineteen  patients  with  advanced  solid  tumours  received  binimetinib  in  the  Doseescalation Phase. Four dose levels were evaluated: 30 mg BID, 45 mg BID, 60 mg BID and 80 mg BID. Two of 4 patients receiving 80 mg BID experienced Dose Limiting Toxicities (DLTs), thus the 80 mg BID dose was declared non-tolerable. Seven patients were enrolled at 60 mg BID and no DLTs were observed; therefore, 60 mg BID was declared the MTD. Following completion of the Dose-escalation Phase, 74 patients were enrolled in the Expansion Phase, including 28 patients in the biliary cancer cohort at 60 mg BID dose, 31 patients in KRASmutant CRC cohort with 6 patients at 60 mg BID and 25  at  45  mg  BID  dose,  and  15  patients  in  the  BRAF-mutant  CRC  cohort  at  45  mg  BID  dose.  The incidence of adverse events resulting in reduction of binimetinib dose were reported at a 3-fold higher incidence in patients in the 60 mg BID dose group compared with the 45 mg BID dose group, and resulted in the decision to discontinue evaluation of the 60 mg BID dose in this study, thus 45 mg BID was determined to be the RP2D.

The safety and efficacy of binimetinib monotherapy was assessed in the Phase 2 study,

CMEK162X2201 , conducted in patients with advanced and unresectable or metastatic cutaneous melanoma harbouring a BRAF V600E or NRAS mutation. Patients received a dose of either 45 or 60 mg BID binimetinib, which demonstrated preliminary signs of antitumour activity. Twenty-five patients initially received 60 mg BID binimetinib but subsequently had their dose reduced to 45 mg BID due to the occurrence of 2 serious AEs with suspected relationship to the study drug. The results confirmed 45 mg BID to be a generally well-tolerated dose with an acceptable safety profile in patients with BRAF V600E mutation-positive advanced cutaneous melanoma.

<div style=\"page-break-after: always\"></div>

## 2.5.2. Main study(ies)

COLUMBUS: A 2-part phase III randomized, open label, multicenter study of LGX818 plus MEK162 versus vemurafenib and LGX818 monotherapy in patients with unresectable or metastatic BRAF V600 mutant melanoma

## Methods

Figure1:StudyCMEK162B2301RandomisationScheme

<!-- image -->

BID:twicedaily;Combo300:encorafenib300mgQDincombinationwithbinimetinib45mgBID;Combo450:binimetinib 45mgBIDincombinationwithencorafenib450mgQD;LGx818:encorafenib300mgmonotherapy;QD:oncedaily;Rando: randomised.

## PART 1

## Study Participants

## Inclusion Criteria

1. Signed written informed consent;
2. Male or female patient, age &gt; 18 years;
3. Histologically confirmed diagnosis of locally advanced, unresectable or metastatic cutaneous melanoma or unknown primary melanoma AJCC Stage IIIB, IIIC or IV;
4. Presence of BRAF V600E and/or V600K mutation in tumor tissue prior to enrollment, as determined by a Sponsor designated central laboratory(ies);
5. Naive untreated patients or patients who have progressed on or after prior first-line immunotherapy for unresectable locally advanced or metastatic melanoma;

Note : Prior adjuvant therapy is permitted (e.g. IFN, IL-2 therapy, any other immunotherapy, radiotherapy or chemotherapy), except the administration of BRAF or MEK inhibitors.

6. Evidence of at least one measurable lesion as detected by radiological or photographic methods according to guidelines based on RECIST version 1.1 (Appendix 2);

Note : A previously irradiated lesion is eligible to be considered as a measurable lesion provided that there is objective evidence of progression of the lesion since discontinuation of therapy and prior to starting study drug.

7. ECOG performance status of 0 or 1;
8. Adequate bone marrow, organ function and laboratory parameters:

<div style=\"page-break-after: always\"></div>

- Absolute neutrophil count (ANC) &gt; 1.5 x 10 9 /L,
- Hemoglobin (Hgb) &gt; 9 g/dL without transfusions,
- Platelets (PLT) &gt; 100 x 109/L without transfusions,
- AST and/or ALT &lt; 2.5 × upper limit of normal (ULN); patient with liver metastases &lt; 5 ×ULN,
- Total bilirubin &lt; 2 × ULN,
- Creatinine &lt; 1.5 mg/dL, or calculated creatinine clearance (determined as per Cockcroft-Gault) &gt; 50mL/min;
9. Adequate cardiac function:
- left ventricular ejection fraction (LVEF) &gt; 50% as determined by a multigated acquisition (MUGA) scan or echocardiogram,
- triplicate average baseline QTc interval &lt; 480 ms;
10. Able to take oral medications;
11. Patient is deemed by the Investigator to have the initiative and means to be compliant with the protocol (treatment and follow-up);
12. Negative serum β-HCG test (female patient of childbearing potential only) performed within 72 hours prior to first dose.

## Exclusion criteria

1. Any untreated central nervous system (CNS) lesion. However, patients are eligible if: a) all known CNS lesions have been treated with radiotherapy or surgery and b) patient remained without evidence of CNS disease progression &gt; 4 weeks and c) patients must be off corticosteroid therapy for &gt; 3 weeks.
2. Uveal and mucosal melanoma;
3. History of leptomeningeal metastases;
4. History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO (e.g. uncontrolled glaucoma or ocular hypertension, history of hyperviscosity or hypercoagulability syndromes);
5. History of allogeneic bone marrow transplantation or organ transplantation;
6. History of Gilbert ' s syndrome;
7. Previous or concurrent malignancy with the following exceptions:
- adequately treated basal cell or squamous cell carcinoma of the skin (adequate wound healing is required prior to study entry),
- in situ carcinoma of the cervix, treated curatively and without evidence of recurrence for at least 3 years prior to the study,
- or other solid tumor treated curatively, and without evidence of recurrence for at least 3 years prior to study entry; (note: based on mechanism of action, BRAF inhibitors may cause progression of cancers associated with RAS mutations. Thus, benefits and risks should be

<div style=\"page-break-after: always\"></div>

carefully considered before administering a BRAF inhibitor to patients with a prior cancer associated with RAS mutation).

8. Prior therapy with a BRAF inhibitor (including but not limited to vemurafenib, dabrafenib, LGX818, and XL281/BMS-908662) and/or a MEK inhibitor (including but not limited to trametinib, AZD6244, MEK162, GDC-0973 and RDEA119);
9. Any previous systemic chemotherapy treatment, extensive radiotherapy or investigational agent other than immunotherapy, or patients who have received more than one line of immunotherapy for locally advanced unresectable or metastatic melanoma; Note: Ipilimumab or other immunotherapy treatment must have ended at least 6 weeks prior to randomization. Chemotherapy given as part of isolated limb perfusion, regional or intralesional treatment will not be considered systemic treatment.
10. Impaired cardiovascular function or clinically significant cardiovascular diseases, including any of the following:
- History of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty, or stenting) &lt;6 months prior to screening,
- Symptomatic chronic heart failure, history or current evidence of clinically significant cardiac arrhythmia and/or conduction abnormality &lt;6 months prior to screening except atrial fibrillation and paroxysmal supraventricular tachycardia;
11. Uncontrolled arterial hypertension despite medical treatment;
12. Known positive serology for HIV(Human immunodeficiency virus), active hepatitis B, and/or active hepatitis C infection;
13. Patients who have neuromuscular disorders that are associated with elevated CK (e.g., inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy);
14. Patients who are planning on embarking on a new strenuous exercise regimen after first dose of study treatment.
15. Impairment of gastrointestinal function (e.g., active ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome);
16. Any other condition that would, in the Investigator ' s judgment, contraindicate the patient ' s participation in the clinical study due to safety concerns or compliance with clinical study procedures, e.g., infection/inflammation, intestinal obstruction, unable to swallow medication, social/ psychological issues, etc.;
17. Patients who have undergone major surgery or radiotherapy &lt; 3 weeks prior to starting study drug or who have not recovered from side effects of such procedure;
18. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test;
19. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception throughout the study and for 8 weeks (6 months for women of child-bearing potential randomized to vemurafenib) after study drug discontinuation.

<div style=\"page-break-after: always\"></div>

20. Medical, psychiatric, cognitive or other conditions that may compromise the patient's ability to understand the patient information, give informed consent, comply with the study protocol or complete the study.
21. Patients taking non-topical medication known to be a strong inhibitor of CYP3A4.

## Treatments

Encorafenib was supplied as 50mg and 100mg capsules (the MAA is for 50mg and 75mg capsules). Patients were not to have eaten anything for 2 hours before and 1 hour after the morning dose of study drug.

Patients received study treatment until progressive disease (PD) per RECIST v1.1 as determined by the blinded independent review committee (BIRC), unacceptable toxicity, withdrawal of consent, death, physician decision or early termination of the study.

The permitted dose reduction levels for encorafenib were 300 mg, 200 mg, 100 mg and 50 mg QD with specific recommendations regarding eye disorders, CK elevation, decreased LVEF, QTc prolongation, skin, gastrointestinal and liver-related AEs. Dose re-escalation was permitted if toxicity improved to ≤ Grade 1, except for QT prolongation (QTcF &gt;500msec). A patient in the Combo 450 arm who permanently discontinued binimetinib could continue encorafenib monotherapy but, if encorafenib was permanently discontinued, then binimetinib had to be discontinued due to its limited efficacy in monotherapy.  Patients requiring treatment interruption &gt;28 days were to be permanently discontinued.

## Objectives

The primary objective was to determine whether treatment with Combo 450 prolongs progression-free survival  (PFS)  compared  with  vemurafenib  in  patients  with BRAF V600  mutant  locally  advanced unresectable or metastatic melanoma. This was addressed by Part 1 of the study.

The key secondary objectives were to determine the contribution of binimetinib to the combination by comparing the PFS of Combo 450 vs. encorafenib (Part 1) and to further quantify the contribution of binimetinib to the combination by comparing the PFS of Combo 300 vs. encorafenib (Part 2).

Other secondary objectives included:

Part  1  only  -  to  compare  the  treatment  effect  of  Combo  450  vs.  vemurafenib  in  terms  of  overall survival  (OS);  to  estimate  the  treatment  effect  of  combo  450  vs.  encorafenib  in  terms  of  OS;  to determine the safety and tolerability of Combo 450 and encorafenib in this patient population

Part  2  only-  to  estimate  the  safety  and  tolerability  of  combo  300  vs.  encorafenib  in  this  patient population;  to  estimate  the  safety  and  tolerability  of  Combo  300  vs.  Combo  450  in  this  patient population; to estimate the treatment effect of Combo 300 vs. encorafenib in terms of OS; to estimate the treatment effect of Combo 300 vs. vemurafenib in terms of PFS and OS; to estimate the treatment effect of Combo 300 vs. Combo 450 in terms of PFS and OS.

Parts 1 &amp; 2- to estimate the treatment effect of encorafenib vs. vemurafenib in terms of PFS and OS; to assess objective response rate (ORR) by treatment arms; to describe time to response (TTR); to assess disease control rate (DCR); to evaluate duration of response (DOR); to compare the patientreported outcomes (PROs) and the ECOG PS between the treatment arms and to characterise the PK of encorafenib and binimetinib in this patient population.

<div style=\"page-break-after: always\"></div>

Exploratory objectives included:

Part 1- to assess whether the BRAF mutation status in circulating tumour DNA correlates with the BRAF mutation status in tumour tissue

Parts  1  &amp;  2-  to  explore  baseline  molecular  status  of  genes  relevant  to  RAF/MEK/ERK  and  PI3K/AKT signalling in tumour tissue and their potential correlation to efficacy outcomes and to explore potential markers of acquired resistance to encorafenib and encorafenib plus binimetinib

## Outcomes/endpoints

The primary  efficacy  endpoint of  the  study  was  PFS,  defined  as  the  time  from  the  date  of randomisation  to  the  date  of  the  first  documented  progression  based  on  tumour  assessment  read centrally by a BICR according to RECIST v1.1 criteria, or death due to any cause, whichever occurred first. If a patient did not have an event at the time of the analysis cut-off or at the start of any new antineoplastic therapy, PFS was censored at the date of the last adequate tumour assessment. If a patient discontinued treatment for 'disease progression', without documented evidence of progression based on RECIST v1.1, it was not to be considered as a PFS event.

The key secondary for Part 1 was PFS per BIRC on Combo 450 vs. Enco 300.

## Other secondary endpoints

Other secondary efficacy endpoints included:

- OS (time from the date of randomization to date of death due to any cause);
- ORR (proportion of patients with a best overall response of CR or PR, calculated for confirmed and unconfirmed responses separately);
- TTR (time from date of randomization until first documented CR or PR);
- DCR (proportion of patients with a best overall response of CR, PR or stable disease);
- DOR (time from the date of first documented CR or PR to the first documented progression or death due to underlying cancer) and
- the  PROs  i.e.  Functional  Assessment  of  Cancer  Therapy  Melanoma  [FACT-M]  v  4,  European Organization  for  Research  and  Treatment  of  Cancer  Quality  of  Life  Questionnaire  Core  30 [EORTC QLQ-C30] v 3.0 and EuroQoL-5D-5 Level (EQ-5D-5L] v 4.0. The main PRO endpoints were time to definitive 10% deterioration in the FACT-M melanoma subscale and global health status score of the EORTC QLQ-C30; change from baseline in the FACT-M melanoma subscale, EQ-5D-5L, and global health status score of the EORTC QLQ-C30; change from baseline in the other EORTC QLQ-C30 subscales.

Efficacy and PROs were assessed every 8 weeks until week 105 and every 12 weeks thereafter until progression or end of treatment. Patients were then followed every 12 weeks for survival and use of subsequent anticancer therapy. Safety was assessed every 4 weeks. Patients in the combination arms had an ophthalmic exam at the start of each treatment cycle and pre- and post-dose PK samples.

<div style=\"page-break-after: always\"></div>

## Sample size

For the vemurafenib arm, a median PFS of 7 months was assumed based on results from studies in previously untreated patients and patients who progressed after at least one prior systemic treatment were studied, respectively, where the median PFS values were 6.9 and 6.8 months, respectively.

Based on the dose-escalation results and the dose-expansion results of the Clinical Study CLGX818X2101, the observed median for patients treated with encorafenib was 7.1 months (95% CI 3.7, 14.7) and 7.4 months (95% CI 7.4, not estimable [NE]), respectively. In this less advanced patient population, the median PFS was therefore expected to be around 8 months.

Based on results from Clinical Study CMEK162X2110, Combo 450 was expected to result in a 42% reduction in hazard rate compared to vemurafenib (corresponding to an increase in median from 7 months to 12 months).

The observed benefit with Combo 300 was expected to be lower than with Combo 450. The median PFS was therefore anticipated to be around 11 months.

In study Part 1, patients were randomized in a 1:1:1 ratio to receive Combo 450, encorafenib or vemurafenib. The sample size driver for study Part 1 was the Combo 450 vs. encorafenib comparison. For the comparison of Combo 450 vs. encorafenib, 191 PFS events were required to detect a HR of 0.667 with an 80% power using a log-rank test at a one-sided 2.5% level of significance. For the Part 1 primary comparison, Combo 450 vs. vemurafenib, 145 PFS events were required to detect a HR of 0.58 with a 90% power using a log-rank test at a one-sided 2.5% level of significance.

A total of 576 patients (192 patients in each arm) were planned to be recruited in Part 1 over around 15 months, accounting for 15% loss to follow-up. The primary analysis was to be performed when a sufficient number of PFS events for both the primary and key secondary comparisons were available, which was expected to occur around 22 months after first treatment of the first patient.

In Part 2, the new Combo 300 arm was added. The data already collected in Part 1 for the encorafenib arm represented a considerable amount of information; therefore, the randomization ratio for Combo 300 to encorafenib in Part 2 was 3:1.

Considering a 3:1 randomization ratio in the second part of the study and aiming for a similar number of patients in the Combo 300 and the encorafenib arm (combining Part 1 and 2), 320 additional patients were to be randomized (80 in the encorafenib arm and 240 in the Combo 300 arm).

The Part 2 PFS Analysis was to be performed when approximately 340 PFS events had occurred in total in the encorafenib (both parts) and Combo 300 arms. Based on the differential follow-up and expected median PFS times, it was expected that approximately 330 of these events would contribute to the HR estimate and log-rank test, and would result in approximately 80% power to detect a HR of 0.727 (8/11) at a one-sided 2.5% level of significance. This was anticipated to occur approximatively 37 months after first treatment of the first patient.

## Randomisation

In Part 1, approximately 576 patients were to be randomised in a 1:1:1 ratio to one of the 3 treatment arms.

Randomisation was stratified by AJCC stage (IIIB + IIIC + IVM1a + IVM1b vs. IVM1c); ECOG PS (0 vs. 1), BRAF mutation status (V600E vs. V600K) and prior first-line immunotherapy for unresectable or metastatic disease (yes vs. no).

<div style=\"page-break-after: always\"></div>

Prior first line immunotherapy (yes vs. no) added with Protocol Amendment 2 (post enrolment of 2 patients), when inclusion of this patient group was allowed.

BRAF mutation status (V600E vs. V600K) was removed as a stratification factor with Protocol Amendment 2, as the V600K stratum was expected to be very small.

## Blinding (masking)

The study was open label. However, blinded tumour assessment data read centrally by a BIRC were used in the primary efficacy analysis.

## Statistical methods

The following analysis populations were defined:

The Full Analysis Set (FAS) was defined according to the Intention-to-Treat (ITT) principle, and consisted of all randomized patients. Following the ITT principle, patients were analyzed according to the treatment and stratification factors they were assigned to at randomization.

The Per-protocol Set (PPS) consisted of all patients from the FAS without any major protocol deviations and who received at least one dose of study medication.

The Safety Set included all patients who received at least one dose of the study medication and had at least one valid post-baseline safety evaluation. Patients were analyzed according to the study treatment they actually received.

The Pharmacokinetic Analysis Set (PAS) consisted of all patients who received at least one dose of encorafenib or binimetinib and had at least one evaluable post-baseline encorafenib or binimetinib concentration measurement. The same definition applied to the Japanese subgroup.

All efficacy analyses were performed using the FAS, unless otherwise specified.

The primary and key secondary efficacy comparisons were based on PFS, defined as the time from the date of randomization to the date of the first documented progression, or death due to any cause, whichever occurred first. Censoring rules to be applied to the PFS endpoint are described in the following table.

<div style=\"page-break-after: always\"></div>

Table 34: Censoring rules to be applied to the progression-free survival analysis

|    | Situation                                                                                                                                     | Erent Date                                                                                                                            | Outcome             |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------|---------------------|
| A\" | No baseline assessment                                                                                                                        | Date of randomization                                                                                                                 | Censored            |
| B  | Progression or death at or before next scheduled assessment                                                                                   | Date of progression (or death)                                                                                                        | Progressed          |
| C1 | Progression or death after exactly one missing assessment                                                                                     | Date of progression (or death)                                                                                                        | Progressed          |
| C2 | Progression or death after two or more missing assessments                                                                                    | Date of last adequate tumor assessment*                                                                                               | Censored            |
| D  | No progression                                                                                                                                | Date of last adequate tumor assessment*                                                                                               | Censored            |
| E  | Treatment discontinuation due to \"Disease progression\" without documented progression, i.e., clinical progression based on investigator claim | N/A (not considered as an event, patient without documented PD should be followed for progression after discontinuation of treatment) | Information ignored |
| F  | New anticancer therapy given                                                                                                                  | Date of last adequate tumor assessment*                                                                                               | Censored            |

Blinded tumor assessment data read centrally by a BIRC were used in the primary efficacy analysis. The local Investigator's assessments were used in a supportive analysis of PFS.

The primary analysis was the comparison of the distribution of PFS between Combo 450 and vemurafenib using a stratified log-rank test at a one-sided 2.5% cumulative level of significance.

The null and the alternative hypothesis were defined as follows:

where Svem(t) is the survival distribution function of PFS in the control arm (i.e. vemurafenib) and SC450(t) is the survival distribution function of PFS in the experimental arm (i.e. Combo 450). Ho: Sc45o(t) ≤ Svem(t) vs HA: Sc45o(t) &gt; Svem(t), t≥ 0

Progression-free survival was analyzed based on the data from the FAS according to the treatment arm and 2 of the stratification factors (cancer stage and ECOG PS) patients were randomized to. Due to the relatively low expected prevalence of patients with prior immunotherapy (around 15%), the 2 prior immunotherapy strata (yes and no) were combined at the time of the analysis to avoid small or empty strata. The same principle applied to all stratified tests and models in this study.

The distribution of PFS was described in tabular and graphical format by treatment arm using KaplanMeier methods, reporting estimated median (in months) with 95% confidence interval (CI), 25th and 75th percentiles and Kaplan-Meier estimated probabilities with corresponding 95% CIs at several time points (including at least 2, 4, 6, 8, 10, 12 and 14 months).

A Cox regression model stratified by randomization stratification factors was used to estimate the HR of PFS, along with 95% CI based on the Wald test.

To control type I error, a hierarchical testing procedure was used and the secondary endpoint of OS Combo 450 vs vemurafenib was to be tested only if the primary and key secondary PFS comparisons were statistically significant.

Data cut-off for Part 1 was to take place once the planned number of patients had been randomised to Part 1 (i.e. 576 patients) and sufficient PFS events were available for the final primary and Part 1 key secondary comparison (i.e.145 PFS events for Combo 450 vs. vemurafenib and 191 PFS events for

<div style=\"page-break-after: always\"></div>

Combo  450  vs.  encorafenib).  The  analysis  was  performed  at  204  PFS  events  for  Combo  450  vs. vemurafenib and 223 PFS events for Combo 450 vs. Enco 300.

Figure 7: Timing of Testing of Primary and Key Secondary Endpoints (hierarchical testing sequence)

<!-- image -->

C450= Combo 450; C300= Combo 300; L=LGX818 (encorafenib); V= vemurafenib

Overall survival was defined as the time from the date of randomization to the date of death due to any cause. If a death was not observed by the date of analysis cutoff, OS was to be censored at the date of last contact. Survival time for patients with no post-baseline survival information was to be censored on the date of randomization. For analysis of OS, a group sequential design with one interim analysis (at time of PFS analysis (Part 2)) was planned to be used. To maintain the overall type-I error rate for the trial, the type-1 error rate was based on a α-spending function using a Gamma function with  parameter  1.  At  the  time  of  the  Primary  PFS  Analysis  (Part  1),  no  formal  testing  of  OS  was performed in order to preserve Sponsor blinding to OS and maintain the integrity of the planned first interim analysis.

Secondary efficacy variables were analyzed in the FAS and were to include ORR, TTR, DCR, DOR and PROs.

The BIRC assessments were used for the main analyses of best overall response (BOR), ORR, TTR, DCR and DOR. ORR and DCR were presented by treatment arm along with exact 95% CI using the Clopper-Pearson method.

Time  to  response  and  duration  of  response  were  descriptively  analyzed  using  the  Kaplan-Meier method.

<div style=\"page-break-after: always\"></div>

The  change  in  tumor  size  was  to  be  depicted  using  waterfall  plots  presenting  the  best  percentage change from baseline in the sum of the diameter of all target lesions. These plots were to display the best percentage change from baseline in the sum of the diameter of all target lesions for each patient.

Health-related QoL data were collected via PROs. The FACT-M, EQ-5D-5L and EORTC QLQ-C30 patient questionnaires  were  used  in  this  study.  Health-related  QoL  data  were  analyzed  using  the  FAS.  The FACT-M melanoma subscale, index score of EQ-5D-5L and the global health status/QoL score of the EORTC  QLQ-C30  were  identified  as  the  primary  PRO  variables  of  interest.  Physical  functioning, emotional functioning and social functioning scale scores of the EORTC QLQ-C30 were considered as secondary.

The primary PRO analysis was to assess the difference in distribution of the time to definitive 10% deterioration in the FACT-M subscale among the treatment arms in the full analysis set (FAS). Only assessments collected while the patient was on treatment and at the EOT visit were included.

## Results

## Participant flow

## Patient Flow Chart for Part 1 of Study CMEK162B2301

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Recruitment

Patients were randomised at 162 sites in 28 countries; 20 sites in North America, 124 sites in Europe and 18 sites in selected countries from the rest of the world. A small number were enrolled per site so data from all sites were pooled.

## Conduct of the study

The proportion of patients with at least one protocol deviation was similar among the 3 treatment arms (62.0% Combo 450, 66.0% encorafenib, 64.4% vemurafenib arm). Most protocol deviations were due to key procedures not performed as per protocol (48.4% Combo 450, 52.6% encorafenib, 54.5% vemurafenib arm). Deviations due to eligibility criteria not met were reported in each treatment arm (8.9% Combo 450 arm, 10.8% encorafenib arm, 4.7% vemurafenib arm).

There were 4 amendments to the original study protocol (dated 13 May 2013).

Version 1, Amendment 1 (3 October 2013) was issued before any patients were randomised and included clarification that patients known to be NRAS mutation positive should not be selected for prescreening.

Version 2, Amendment 2 (20 December 2013) after 2 patients had been randomised allowed inclusion of patients progressing on or after first line immunotherapy.

Version 3, Amendment 3 (4 November 2014) was issued when 364 patients had been randomised. Part 2 was added. Consequently, allocation to Part 1 was reduced, the primary objective of analysis of PFS of encorafenib monotherapy vs. vemurafenib was changed to a secondary endpoint and the key secondary endpoint of overall survival for Combo 450 vs. vemurafenib was changed to a secondary endpoint to be tested hierarchically after the Part 2 key secondary endpoint.

Version 4, Amendment 4 (13 Jul 2015), documented a change in study sponsorship.

At the time of the primary PFS analysis (data cut-off 19 May 2016), the required number of survival events had not occurred for analysis of overall survival (OS). On 14 October 2016, the DMC reviewed un-blinded data from Part 1 (data cut-off 19 May 2016) and un-blinded survival data, to which the Sponsor (Array) and Pierre Fabre remained blinded. The DMC recommended the following:

- Terminate the planned analyses and inform all patients (in Parts 1 and 2) of the Part 1 results.
- Inform patients in the vemurafenib arm that a combination of commercially available BRAF and MEK inhibitors may be a better alternative regimen.

There were no specific recommendations regarding the encorafenib monotherapy arm. The decision to continue encorafenib monotherapy or change to a BRAF/MEK inhibitor combination was to be based on a discussion between the patient and physician.

To minimise the delay in the timing of the OS interim analysis, the applicant proposed that the protocol be amended to de-couple the Part 1 OS analysis from the primary Part 2 PFS analysis. The timing of the Part 1 OS analysis became event driven; the interim OS data was submitted with the response to the D120 list of questions.

Per Protocol Amendment 5.0, two OS analyses of Combo 450 vs. vemurafenib were planned based on the number of OS events in the Combo 450 and vemurafenib arms combined:

<div style=\"page-break-after: always\"></div>

Part 1 OS Interim Analysis: The primary OS analysis was to be performed when approximately 232 OS events were observed

Final OS Update: to be performed when approximately 309 OS events were observed

The data cut-off date for this Part 1 OS interim analysis was 7 November 2017, by which time a total of 232 OS events were observed in the Combo 450 and vemurafenib arms combined in Part 1 of the study.

Table 35: Reasons Leading to Exclusion of Patients from Per-protocol Set (Full Analysis Set, Part 1)

| Reason                                                                                                                                        | Combo 450 N=192 n (%)   | Encorafenib N=194 n (%)   | Vemurafenib N=191 n (%)   |
|-----------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|---------------------------|---------------------------|
| Patients excluded from Per-protocol set                                                                                                       | 4 (2.1)                 | 10 (5.2)                  | 7 (3.7)                   |
| Patient did not receive at least one dose of study medication                                                                                 | 0                       | 2 (1.0)                   | 5 (2.6)                   |
| Nohistologically confirmed diagnosis of umresectableormetastaticcutaneous melanoma orunknownprimarymelanoma (stage IIIB, IIIC to IV per AJCC) | 1 (0.5)                 | 1 (0.5)                   | 0                         |
| Not positive for BRAF V600 mutation *                                                                                                         | 0                       | 2 (1.0)                   | 0                         |
| Prior treatment for umresectable or metastatic cutaneous melanoma other than immunotherapy                                                    | 1 (0.5)                 | 0                         | 0                         |
| Prior treatment with a RAF and/or MEK inhibitor a                                                                                             | 0                       | 1 (0.5)                   | 0                         |
| No measurable lesion as detected by local review ofradiological or photographic methods based on RECIST version 1.1 a                         | 1 (0.5)                 | 0                         | 1 (0.5)                   |
| New anti-neoplastic therapy administered after start of study treatment and prior to first tumor assessment                                   | 1 (0.5)                 | 4 (2.1)                   | 1 (0.5)                   |

## Baseline data

Table 36: Demographics (Full Analysis Set, Part 1)

| Demographic Variable   | Combo 450 N=192   | Encorafenib N=194   | Vemurafenib N=191   |
|------------------------|-------------------|---------------------|---------------------|

<div style=\"page-break-after: always\"></div>

| Age (years) Mean (SD) Median Min - Max Age category (years), n (%) < 65 ≥ 65 Sex, n (%) Female Male Race, n (%) Caucasian Asian Native American Other Unknown b Missing c ECOG performance status, n (%) 0 1   | 56.2 (13.62) 57.0 20 - 89 132 (68.8) 60 (31.3) 77 (40.1) 115 (59.9) 181 (94.3) 5 (2.6) 0 3 (1.6) 2 (1.0) 1 (0.5) 136 (70.8) 56 (29.2)   | 54.6 (12.63) 54.0 23 - 88 154 (79.4) 40 (20.6) 86 (44.3) 108 (55.7) 174 (89.7) 6 (3.1) 2 (1.0) 2 (1.0) 9 (4.6) 1 (0.5) 140 (72.2) 54 (27.8)   | 55.2 (14.18) 56.0 21 - 82 140 (73.3) 51 (26.7) 80 (41.9) 111 (58.1) 166 (86.9) 8 (4.2) 2 (1.0) 2 (1.0) 12 (6.3) 1 (0.5) 140 (73.3) 51 (26.7)   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------|

a Last non-missing ECOG performance status prior to/at the start of study treatment for patients who took at least one study treatment or prior to/ on Cycle 1 Day 1 for patients who didn't take any study treatment.

b  Unknown denotes 'unknown' was selected on the eCRF.

c Missing denotes the race field on the eCRF was not completed.

<div style=\"page-break-after: always\"></div>

Table 37: Patient and Disease Characteristics (Full Analysis Set, Part 1)

| Disease history                                                     | Combo 450 N=192   | Encorafenib N=194   | Vemurafenib N=191   |
|---------------------------------------------------------------------|-------------------|---------------------|---------------------|
| Primary site of cancer, n (%)                                       |                   |                     |                     |
| Skin Melanoma                                                       | 191 (99.5)        | 192 (99.0)          | 190 (99.5)          |
| Unknown                                                             | 1 (0.5)           | 2 (1.0)             | 1 (0.5)             |
| Stage at time of study entry, n (%)                                 |                   |                     |                     |
| Stage IIIB                                                          | 0                 | 2 (1.0)             | 1 (0.5)             |
| Stage IIIC                                                          | 9 (4.7)           | 4 (2.1)             | 10 (5.2)            |
| Stage IV M1A                                                        | 26 (13.5)         | 29 (14.9)           | 24 (12.6)           |
| Stage IV M1B                                                        | 34 (17.7)         | 39 (20.1)           | 31 (16.2)           |
| Stage IV M1C with elevated LDH                                      | 50 (26.0)         | 50 (25.8)           | 36 (18.8)           |
| Stage IV M1C with normal LDH                                        | 73 (38.0)         | 70 (36.1)           | 89 (46.6)           |
| Time from initial diagnosis to onset of metastatic disease (months) |                   |                     |                     |
| n1                                                                  | 187               | 191                 | 187                 |
| Mean (SD)                                                           | 37.02 (61.090)    | 36.45 (62.708)      | 38.14 (52.994)      |
| Median                                                              | 15.05             | 13.04               | 14.92               |
| Min - Max                                                           | 0.0- 448.5        | 0.0 - 388.8         | 0.0 - 280.5         |
| Number of organs involved at Baseline a, n (%)                      |                   |                     |                     |
| 1                                                                   | 47 (24.5)         | 56 (28.9)           | 45 (23.6)           |
| 2                                                                   | 58 (30.2)         | 52 (26.8)           | 59 (30.9)           |
| 3                                                                   | 45 (23.4)         | 42 (21.6)           | 42 (22.0)           |
| >3                                                                  | 42 (21.9)         | 44 (22.7)           | 45 (23.6)           |
| LDH at Baseline (U/L)                                               |                   |                     |                     |
| n                                                                   | 192               | 194                 | 191                 |
| Mean (SD)                                                           | 298.7 (368.93)    | 265.2 (251.21)      | 239.8 (189.27)      |
| Median                                                              | 173.0             | 188.5               | 174.0               |
| Min - Max                                                           | 76 -3590          | 75 - 1886           | 57-1285             |
| LDH at Baseline b, n (%)                                            |                   |                     |                     |
| Low                                                                 | 0                 | 0                   | 0                   |
| Normal                                                              | 137 (71.4)        | 147 (75.8)          | 139 (72.8)          |
| High                                                                | 55 (28.6)         | 47 (24.2)           | 52 (27.2)           |
| Missing                                                             | 0                 | 0                   | 0                   |

Note: The time from initial diagnosis to onset of metastatic disease are calculated only for patients with metastatic disease. A patient may have multiple metastatic sites. Metastatic sites and organs involved were derived from Diagnosis and Extent of Cancer eCRF page.

a For patients with stage IIIB and IIIC at study entry, the number of organs involved at baseline is equal to one and presented as skin.

b Low and high categories defined by normal ranges.

<div style=\"page-break-after: always\"></div>

Table 38: Prior Antineoplastic Therapy - Overall (Full Analysis Set, Part 1)

|                                            | Combo 450 N=192 n (%)   | Encorafenib N=194 n (%)   | Vemurafenib N=191 n (%)   |
|--------------------------------------------|-------------------------|---------------------------|---------------------------|
| Any therapy                                | 158 (82.3)              | 161 (83.0)                | 165 (86.4)                |
| Medication                                 | 62 (32.3)               | 63 (32.5)                 | 59 (30.9)                 |
| Surgery                                    | 146 (76.0)              | 149 (76.8)                | 157 (82.2)                |
| Radiotherapy                               | 30 (15.6)               | 42 (21.6)                 | 25 (13.1)                 |
| Medication: setting at last treatment      |                         |                           |                           |
| Adjuvant                                   | 52 (27.1)               | 46 (23.7)                 | 46 (24.1)                 |
| Neoadjuvant                                | 0                       | 1 (0.5)                   | 1 (0.5)                   |
| Therapeutic - Metastatic                   | 10 (5.2)                | 16 (8.2)                  | 12 (6.3)                  |
| Radiotherapy: setting at last radiotherapy |                         |                           |                           |
| Adjuvant                                   | 17 (8.9)                | 20 (10.3)                 | 11 (5.8)                  |
| Neoadjuvant                                | 0                       | 1 (0.5)                   | 0                         |
| Therapeutic - metastatic                   | 6 (3.1)                 | 11 (5.7)                  | 6 (3.1)                   |
| Therapeutic                                | 3 (1.6)                 | 6 (3.1)                   | 4 (2.1)                   |
| Palliative                                 | 2 (1.0)                 | 4 (2.1)                   | 2 (1.0)                   |
| Other                                      | 2 (1.0)                 | 0                         | 0                         |
| Missing                                    | 0                       | 0                         | 2 (1.0)                   |

Table 39: Prior Antineoplastic Therapies - Ipilimumab, anti-PD1/PDL1 or Interferons/Interleukins (Full Analysis Set, Part 1)

|                                     | Combo 450 N=192 n (%)   | Encorafenib N=194 n (%)   | Vemurafenib N=191 n (%)   |
|-------------------------------------|-------------------------|---------------------------|---------------------------|
| Any immunotherapy                   | 57 (29.7)               | 58 (29.9)                 | 57 (29.8)                 |
| Ipilimumab                          | 7 (3.6)                 | 10 (5.2)                  | 7 (3.7)                   |
| Anti-PD1/PDL1                       | 1 (0.5)                 | 2 (1.0)                   | 0                         |
| Interferons/Interleukins            | 51 (26.6)               | 51 (26.3)                 | 52 (27.2)                 |
| Ipilimumab -- Setting ab            | n=7                     | n=10                      | n=7                       |
| Adjuvant                            | 2 (28.6)                | 1 (10.0)                  | 2 (28.6)                  |
| Therapeutic-metastatic              | 5 (71.4)                | 9 (90.0)                  | 5 (71.4)                  |
| Anti-PD1/PDL1 - Setting ab          | n=1                     | n=2                       | n=0                       |
| Therapeutic-metastatic              | 1 (100)                 | 2 (100)                   | 0                         |
| Interferons/Interleukins -- Setting | n=51                    | n=51                      | n=52                      |
| Adjuvant                            | 47 (92.2)               | 46 (90.2)                 | 46 (88.5)                 |
| Neoadjuvant                         | 0                       | 1 (2.0)                   | 1 (1.9)                   |
| Therapeutic-metastatic              | 4 (7.8)                 | 4 (7.8)                   | 5 (9.6)                   |

PD1 = programmed death 1 (receptor); PDL1 = programmed death (receptor) ligand 1

a A patient may have multiple settings.

b A patient may have received ipilimumab or anti-PD1/PDL1 in combination.

A similar percentage of patients (29.7% Combo 450, 29.9% Enco 300, 29.8% vemurafenib arm) received prior immunotherapy (metastatic and adjuvant). This was mainly cytokines (interferon/ interleukin); the proportion who received prior ipilimumab was &lt;5% and anti PD1/ anti PDL1 &lt;1%.

The median age of patients was 56 years (range 20¬-89), 58% were male, 90% were Caucasian, and 72% of patients had baseline ECOG performance status of 0. Most patients had metastatic disease (95%) and were Stage IVM1c (64%); 27% of patients had elevated baseline serum lactate dehydrogenase (LDH), and 45% of patients had at least 3 organs with tumour involvement at baseline

<div style=\"page-break-after: always\"></div>

and 3.5% had brain metastases. 27 patients (5%) had received prior checkpoint inhibitors (antiPD1/PDL1 or ipilimumab) (8 patients in Combo 450 arm (4%); 7 patients in vemurafenib arm (4%); 12 patients in Enco 300 arm (6%) including 22 patients in the metastatic setting (6 patients in Combo 450 arm; 5 patients in vemurafenib arm; 11 patients in Enco 300 arm) and 5 patients in the adjuvant setting (2 patients in Combo 450 arm; 2 patients in vemurafenib arm; 1 patient in Enco 300 arm).

Table 40: Anti-neoplastic Therapy Since Study Drug Discontinuation

| Discontinued treatment/ not treated           | Combo 450 N=124   | Encorafenib N=148   | Vemurafenib N=164   |
|-----------------------------------------------|-------------------|---------------------|---------------------|
| Subsequent antineoplastic therapy, n (n%)     | 65 (52.4%)        | 90 (60.8%)          | 106 (64.6%)         |
| Subsequent monoclonal antibodies, n (n%)      | 48 (38.7%)        | 53 (35.8%)          | 63 (38.4%)          |
| Subsequent BRAF/ BRAF + MEK inhibitor, n (n%) | 17 (13.7%)        | 35 (23.6%)          | 55 (33.5%)          |
| Subsequent encorafenib + binimetinib, n (%)   | 0                 | 4 (2.7%)            | 5 (3.0%)            |

A similar proportion of patients in each treatment arm received subsequent treatment with checkpoint inhibitors, mainly pembrolizumab, nivolumab and ipilimumab (34.4% Combo 450 arm, 36.1% encorafenib arm, 39.8% vemurafenib arm).

## Numbers analysed

Table 41: Analysis Sets (Part 1)

| Analysis Set                   | Combo 450 N=192 n (%)   | Encorafenib N=194 n (%)   | Vemurafenib N=191 n (%)   | Total N=577 n (%)   |
|--------------------------------|-------------------------|---------------------------|---------------------------|---------------------|
| Full Analysis Set a            | 192 (100)               | 194 (100)                 | 191 (100)                 | 577 (100)           |
| Safety Set b                   | 192 (100)               | 192 (99.0)                | 186 (97.4)                | 570 (98.8)          |
| Per-protocol Set c             | 188 (97.9)              | 184 (94.8)                | 184 (96.3)                | 556 (96.4)          |
| Pharmacokinetic Analysis Set d | 192 (100)               | 191 (98.5)f               | 0                         | 383 (66.4)          |

Twenty-one patients (3.6%) were excluded from the PPS (4 patients [2.1%] Combo 450, 10 patients [5.2%] encorafenib, 7 patients [3.7%] vemurafenib). The most common reasons were that patients did not receive at least one dose of study medication or new anti-neoplastic therapy was administered after the start of study treatment and prior to first tumour assessment.

<div style=\"page-break-after: always\"></div>

## Outcomes and estimation

## Primary Endpoint: PFS based on BIRC review in the FAS

PFS for the Combo 450 vs. vemurafenib alone was 14.9 vs. 7.3 months, respectively, with a HR of 0.54 (95% CI 0.41, 0.71, 1 sided stratified log rank p&lt;0.001). No imputations were used for the start or end dates for the primary PFS analysis.

Table 42: Kaplan-Meier Summary of PFS by BIRC - Combo 450 vs. Vemurafenib (FAS, Part 1)

|                                                        | Combo 450 N=192   | Vemurafenib N=191   |
|--------------------------------------------------------|-------------------|---------------------|
| Patients with events/Patients included in analysis (%) | 98/192 (51.0)     | 106/191 (55.5)      |
| Percentiles (95% CI) *                                 |                   |                     |
| 25th                                                   | 7.3 (5.5, 7.5)    | 3.7 (3.6, 4.0)      |
| 50th                                                   | 14.9 (11.0, 18.5) | 7.3 (5.6, 8.2)      |
| 75th                                                   | 25.0 (22.0, NE)   | 18.5 (12.8, NE)     |
| Event-free probability estimates (95% C1) b            |                   |                     |
| 4 months                                               | 86.9 (80.9, 91.1) | 68.9 (61.1, 75.5)   |
| 8 months                                               | 65.6 (57.9, 72.2) | 42.7 (34.6, 50.6)   |
| 12 months                                              | 56.7 (48.8, 63.9) | 33.4 (25.6, 41.4)   |
| 16 months                                              | 48.7 (40.6, 56.2) | 28.3 (20.7,36.4)    |
| 20 months                                              | 38.6 (30.0, 47.1) | 23.9 (16.2, 32.3)   |
| 24 months                                              | 32.3 (22.7,42.2)  | 23.9 (16.2,32.3)    |

Figure 8: Kaplan-Meier Estimate of PFS Based on BIRC - Combo 450 vs. Vemurafenib (FAS, Part1)

<!-- image -->

<div style=\"page-break-after: always\"></div>

The median PFS values based on Kaplan-Meier estimates were 14.8 months (95% CI 10.4, 18.4) and 7.3 months (95% CI 5.7, 8.5) for the Combo 450 and vemurafenib arms, respectively (HR of 0.49, 95% CI 0.37, 0.64; nominal p &lt; 0.001).

Median follow-up time for PFS per BIRC was 16.7 months for the Combo 450 arm and 14.4 months for the vemurafenib arm. Just under half of the patients were censored for the primary PFS analyis, most prior to the median PFS in each arm. The most common reason for censoring in the Combo 450 and encorafenib arms was because patients remained on treatment (29.7% and 24.2%, respectively), whilst in the vemurafenib arm it was because patients had started a new cancer therapy (19.9%).

Table 43: Reasons for Censoring Patients in the PFS by BIRC - Combo 450 Arm, Encorafenib Arm, Vemurafenib Arm (FAS, Part 1) i.e. Primary &amp; Secondary PFS Analyses

|                                          | Combo 450 N=192 n (%)   | Encorafenib N=194 n (%)   | Vemurafenib N=191 n (%)   | Total N=577 n (%)   |
|------------------------------------------|-------------------------|---------------------------|---------------------------|---------------------|
| Number of patients censored              | 94 (49.0)               | 98 (50.5)                 | 85 (44.5)                 | 277 (48.0)          |
| Reason for censoring                     |                         |                           |                           |                     |
| Ongoinga                                 | 57 (29.7)               | 47 (24.2)                 | 25 (13.1)                 | 129 (22.4)          |
| Lost to follow-up                        | 1 (0.5)                 | 1 (0.5)                   | 0                         | 2 (0.3)             |
| Adequate assessment no longer availablec | 7 (3.6)                 | 2 (1.0)                   | 6 (3.1)                   | 15 (2.6)            |
| Event after 2 or more missed assessments | 4 (2.1)                 | 7 (3.6)                   | 1 (0.5)                   | 12 (2.1)            |
| New anti-neoplastic therapy given        | 18 (9.4)                | 27 (13.9)                 | 38 (19.9)                 | 83 (14.4)           |
| No baseline assessment                   | 2 (1.0)                 | 2 (1.0)                   | 0                         | 4 (0.7)             |
| No post-baseline assessment              | 4 (2.1)                 | 11 (5.7)                  | 11 (5.8)                  | 26 (4.5)            |
| Withdrew consent                         | 1 (0.5)                 | 1 (0.5)                   | 4 (2.1)                   | 6 (1.0)             |

## Sensitivity analyses

The median PFS by investigator assessment was similar to the BIRC result: 14.8 months (95% CI 10.4, 18.4) vs. 7.3 months (95% CI 5.7, 8.5) for the Combo 450 and vemurafenib arms, respectively, with a HR of 0.49 (95% CI 0.37, 0.64; nominal p &lt; 0.001). In general, there was agreement regarding the type of event (PD/ death) between the Investigator and BIRC. There was discordance regarding the timing of the PD event in about 30% of cases, with no evidence of bias between the arms.

The results in the per protocol set (PPS) by BIRC were reflective of the primary analysis. The median PFS was 15.5 months (95% CI, 11.0, 18.7) in the Combo 450 arm and 7.3 months (95% CI, 5.6, 8.3) in the vemurafenib arm (HR =0.53; 95% CI, 0.40, 0.70; nominal p &lt; 0.001).

Results of additional sensitivity analyses of PFS by BIRC were consistent with the primary PFS analysis, yielding similar HRs (0.53 - 0.56), median PFS values and p values.

These included:

<div style=\"page-break-after: always\"></div>

- using unstratified log-rank and Cox regression tests in the FAS
- using stratification factors per the eCRF (per the SAP due to &gt; 5% discordance between randomization strata and eCRF strata)
- 'Actual event' including those after ≥2 missing tumour assessments
- 'Backdating' events after missing tumour assessments to 8 weeks after the last adequate tumour assessment
- Tumour assessments after initiation of subsequent anticancer therapy

Table 44: Analysis of PFS by BIRC, Sensitivity Analyses (Full Analysis Set, Part 1)

|                                                 | Median (95% C1) a   | HR (95% CI)       | P value   |
|-------------------------------------------------|---------------------|-------------------|-----------|
| Primary PFS analysis (FAS)                      |                     |                   |           |
| Combo 450                                       | 14.9 (11.0, 18.5)   |                   |           |
| Vemurafenib                                     | 7.3 (5.6, 8.2)      | 0.54 (0.41, 0.71) | <0.001    |
| PFS by eCRF stratification factors              |                     |                   |           |
| Combo 450                                       | 14.9 (11.0, 18.5)   |                   |           |
| Vemurafenib                                     | 7.3 (5.6, 8.2)      | 0.54 (0.41, 0.72) | <0.001    |
| PFS by \"Actual Event\" analysis                  |                     |                   |           |
| Combo 450                                       | 14.5 (10.7, 18.0)   |                   |           |
| Vemurafenib                                     | 7.3 (5.6, 8.2)      | 0.54 (0.41, 0.72) | <0.001    |
| PFS by “Backdating\" analysis                    |                     |                   |           |
| Combo 450                                       | 14.1 (9.4, 18.0)    |                   |           |
| Vemurafenib                                     | 7.3 (5.6, 7.9)      | 0.55 (0.42, 0.72) | <0.001    |
| PFS by “Further Anticancer Treatment\"' analysis |                     |                   |           |
| Combo 450                                       | 14.9 (11.0, 18.0)   |                   |           |
| Vemurafenib                                     | 7.3 (5.6, 7.9)      | 0.53 (0.40, 0.70) | <0.001    |

The effect of potential prognostic factors was investigated using a multivariate Cox regression model stratified AJCC stage and ECOG PS.

Table 45: Stratified Multivariate Cox Regression Model of PFS per Central Review with treatment and Other Prognostic Variables as Covariates Encorafenib 450mg + Binimetinib versus Vemurafenib (FAS, Part 1)

| Encorafenib 450mg + Binimetinib versus Vemurafenib (FAS, Part                       | Encorafenib 450mg + Binimetinib versus Vemurafenib (FAS, Part   | Encorafenib 450mg + Binimetinib versus Vemurafenib (FAS, Part   | Encorafenib 450mg + Binimetinib versus Vemurafenib (FAS, Part   |
|-------------------------------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|
| Prognostic Variables                                                                | Hazard ratio                                                    | 95% CI                                                          | P-value                                                         |
| Full Cox regression model [1] Treatment Combo 450 vs. Vemurafenib [2] V600 mutation | 0.47                                                            | (0.35, 0.62)                                                    | <0.001                                                          |
| V600E vs. V600k                                                                     | 0.83                                                            | (0.52, 1.32)                                                    | 0.430                                                           |

<div style=\"page-break-after: always\"></div>

| LDH (increase of 125 IU/L)   | 1.18   | (1.13, 1.24)   | <0.001   |
|------------------------------|--------|----------------|----------|
| Gender                       |        |                |          |
| Male vs. Female              | 1.02   | (0.76, 1.37)   | 0.871    |
| Baseline brain metastases    |        |                |          |
| Yes vs. No                   | 1.11   | (0.48, 2.54)   | 0.807    |
| Region                       |        |                | 0.242    |
| North America vs. Europe     | 1.67   | (1.01, 2.75)   | 0.047    |
| Australia vs. Europe 0.902   | 1.07   | (0.39, 2.89)   | 0.902    |
| Other vs. Europe             | 1.20   | (0.70, 2.05)   | 0.502    |
| Age (increase of 10 years)   | 1.01   | (0.91, 1.13)   | 0.851    |

[1] Cox model stratified by IVRS AJCC stage and ECOG performance status.

[2] Hazard Ratio Encorafenib 450mg + Binimetinib versus Vemurafenib. Vemurafenib is the reference group.

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 9: Forest Plot of PFS by BIRC - Combo 450 vs. Vemurafenib (Full Analysis Set, Part 1)

<!-- image -->

Key Secondary Efficacy Endpoint

## PFS Combo 450 vs. Encorafenib

In Part 1, the median PFS was 14.9 months (11.0, 18.5) and 9.6 months (7.5, 14.8) for Combo 450 and encorafenib respectively (HR 0.75, 95% CI 0.56, 1.00). The PFS difference was not statistically significant  (p  =  0.0256)  by  the  one-sided  stratified  log-rank  test  according  to  the  threshold  of  p  &lt; 0.025. Approximately half the patients in each arm had a PFS event (98 patients [51.0%] Combo 450; 96 patients [49.5%] encorafenib). The median follow-up time for PFS per BIRC was 16.7 months for the Combo 450 and 16.6 months for the encorafenib arm.

An updated PFS analysis performed on 07 November 2017 gave a similar result (median PFS: Combo 450  vs  encorafenib  14.9  vs  9.6  months,  HR:  0.77  (95%  CI  [0.59-1]),  one  sided  nominal  p value=0.0249).

<div style=\"page-break-after: always\"></div>

Figure 10: Kaplan-Meier Estimate of PFS Based on BIRC - Combo 450 vs. Encorafenib (FAS, Part 1)

<!-- image -->

Per Investigator assessment of response, the median PFS estimates were 14.8 months (95% CI 10.4, 18.4) and 9.2 months (95% CI 7.4, 12.9) in the Combo 450 and encorafenib arms, respectively (HR 0.68; 95% CI 0.52, 0.90; nominal p = 0.003). Approximately half the patients in each arm had a PFS event (102 [53.1%] Combo 450; 108 [55.7%] encorafenib).

Sensitivity analyses of PFS by BIRC using data from the FAS were conducted as per the primary efficacy endpoint.

The HR for PFS of Combo 450 vs. encorafenib using unstratified log-rank and Cox regression tests was 0.81 (95% CI 0.61, 1.07; nominal p = 0.0714).

The remaining sensitivity analyses yielded nominal p values &lt;0.025 (see Table below).

Table 46: Analysis of PFS by BIRC, Sensitivity Analyses of Secondary Endpoint (FAS, Part 1)

|                                                | Median (95% C1) a   | HR (95% C1) b     | P value   |
|------------------------------------------------|---------------------|-------------------|-----------|
| Secondary PFS analysis (FAS)                   |                     |                   |           |
| Combo 450                                      | 14.9 (11.0, 18.5)   |                   |           |
| Encorafenib                                    | 9.6 (7.5, 14.8)     | 0.75 (0.56, 1.00) | 0.0256    |
| PFS by eCRF stratification factors             |                     |                   |           |
| Combo 450                                      | 14.9 (11.0, 18.5)   |                   |           |
| Encorafenib                                    | 9.6 (7.5, 14.8)     | 0.73 (0.55, 0.98) | 0.0173    |
| PFS by \"Actual Event\" analysis                 |                     |                   |           |
| Combo 450                                      | 14.5 (10.7, 18.0)   |                   |           |
| Encorafenib                                    | 9.6 (7.5, 13.8)     | 0.74 (0.56, 0.98) | 0.0190    |
| PFS by \"Backdating\" analysis                   |                     |                   |           |
| Combo 450                                      | 14.1 (9.4, 18.0)    |                   |           |
| Encorafenib                                    | 9.3 (7.4, 12.9)     | 0.74 (0.56, 0.98) | 0.0166    |
| PFS by \"Further Anticancer Treatment\" analysis |                     |                   |           |
| Combo 450                                      | 14.9 (11.0, 18.0)   |                   |           |
| Encorafenib                                    | 9.5 (7.5, 13.0)     | 0.72 (0.55, 0.96) | 0.0114    |

<div style=\"page-break-after: always\"></div>

Table 47: Unstratified Cox Regression Model for PFS per Central Review by Subgroup (FAS, Part 1)

|                                | Event /N (%)   | Median Time           | Cox Model [1]   | Cox Model [1]   |
|--------------------------------|----------------|-----------------------|-----------------|-----------------|
|                                |                | (95% CI) (months) [2] | Hazard Ratio    | 95% CI          |
| All Subjects                   |                |                       |                 |                 |
| Combo 450                      | 98/192 (51.0)  | 14.9 (11.0, 18.5)     |                 |                 |
| Encorafenib [3]                | 96/194 (49.5)  | 9.6 (7.5, 14.8)       | 0.81            | (0.61, 1.07)    |
| Vemurafenib [4]                | 106/191 (55.5) | 7.3 (5.6, 8.2)        | 0.58            | (0.44, 0.77)    |
| AJCC stage                     |                |                       |                 |                 |
| IIIB, C, IVM1a, b Combo 450    | 37/ 84 (44.0)  | 17.8 (11.4, NE)       |                 |                 |
| Encorafenib                    | 36/ 84 (42.9)  | 16.6 (9.2, NE)        | 0.97            | (0.61, 1.53)    |
| [3] Vemurafenib [4]            | 42/ 84 (50.0)  | 11.0 (7.3, 14.7)      | 0.67            | (0.43, 1.04)    |
| IVM1c                          |                |                       |                 |                 |
| Combo 450                      | 61/108 (56.5)  | 13.0 (7.5, 18.0)      |                 |                 |
| Encorafenib [3]                | 60/110 (54.5)  | 7.4 (5.5, 12.8)       | 0.68            | (0.47, 0.98)    |
| Vemurafenib [4]                | 64/107 (59.8)  | 5.6 (3.8, 7.3)        | 0.48            | (0.34, 0.69)    |
| ECOG PS                        |                |                       |                 |                 |
| ECOG PS =0 Combo 450           | 63/139 (45.3)  | 17.7 (12.3, 25.9)     |                 |                 |
| Encorafenib [3]                | 65/143 (45.5)  | 13.0 (9.2, 17.3)      | 0.83            | (0.58, 1.17)    |
| Vemurafenib [4]                | 73/140 (52.1)  | 7.3 (5.6, 10.1)       | 0.54            | (0.38, 0.76)    |
| ECOG PS =1                     |                |                       |                 |                 |
| Combo 450                      | 35/ 53 (66.0)  | 11.0 (5.6, 16.6)      |                 |                 |
| Encorafenib [3]                | 31/ 51 (60.8)  | 5.5 (3.7, 9.1)        | 0.70            | (0.43, 1.15)    |
| Vemurafenib [4]                | 33/ 51 (64.7)  | 7.3 (3.6, 8.6)        | 0.62            | (0.38, 1.01)    |
| Prior first-line immunotherapy |                |                       |                 |                 |
| Yes Combo                      | 5/ 8 (62.5)    | 11.4 (3.7, NE)        |                 |                 |
| 450 Encorafenib [3]            | 5/ 11 (45.5)   | 5.6 (1.4, NE)         | 0.81            |                 |
| Vemurafenib [4]                | 4/ 7 (57.1)    | 5.6 (3.8, 8.3)        | 0.40            | (0.10, 1.64)    |
| No                             |                |                       |                 |                 |
| Combo 450                      | 93/184 (50.5)  | 14.9 (11.0, 18.7)     |                 |                 |
| Encorafenib [3]                | 91/183 (49.7)  | 11.0 (8.0, 14.8)      | 0.81            | (0.60, 1.08)    |
| Vemurafenib [4]                | 102/184 (55.4) | 7.3 (5.6, 8.6)        | 0.59            | (0.44, 0.78)    |
| Prior adjuvant immunotherapy   |                |                       |                 |                 |
| Yes Combo                      | 27/ 49 (55.1)  | 15.5 (9.1, 25.0)      |                 |                 |
| 450 Encorafenib [3]            | 23/ 47 (48.9)  | 12.8 (5.6, NE)        | 0.80            | (0.45, 1.40)    |
| Vemurafenib [4]                | 25/ 48 (52.1)  | 11.1 (5.5, NE)        | 0.78            | (0.45, 1.35)    |
| No                             |                |                       |                 |                 |
| Combo 450                      | 71/143 (49.7)  | 14.9 (10.4, 18.7)     |                 |                 |
| Encorafenib [3]                | 73/147 (49.7)  | 9.6 (7.4, 15.7)       | 0.82            | (0.59, 1.13)    |
| Vemurafenib [4]                | 81/143 (56.6)  | 7.3 (5.6, 7.7)        | 0.51            | (0.37, 0.71)    |
| BRAF Mutation Status           |                |                       |                 |                 |
| V600E Combo 450                | 90/170 (52.9)  | 14.9 (10.4, 18.5)     |                 |                 |
| Encorafenib [3]                | 87/173 (50.3)  | 11.0 (8.0, 14.8)      | 0.86            | (0.64, 1.15)    |
| Vemurafenib [4]                | 91/168 (54.2)  | 7.4 (5.6, 9.2)        | 0.64            | (0.48, 0.85)    |
| Combo 450                      | 8/ 22 (36.4)   | NE (7.5, NE)          |                 |                 |
|                                | 8/ 19 (42.1)   |                       | 0.53            | (0.20,          |
| Encorafenib [3]                |                |                       |                 |                 |
| V600K                          |                |                       |                 |                 |
|                                |                | 9.2 (3.7, NE)         |                 | 1.44)           |
| Vemurafenib [4]                | 15/ 23 (65.2)  | 5.5 (3.7, 12.8)       | 0.27            | (0.11, 0.68)    |

<div style=\"page-break-after: always\"></div>

- [1] Cox PH model are unstratified.
- [2] Median (time to event) and its 95% CI are generated by KM estimation.
- [3] Analyses comparing Combo 450 versus Encorafenib (Part 1) only consider data from patients randomized to those treatment groups. Hazard ratio Combo versus Encorafenib. Encorafenib is the reference group.

[4] Analyses comparing Combo 450 versus Vemurafenib only consider data from patients randomized to those treatment groups. Hazard ratio Combo 450 versus Vemurafenib. Vemurafenib is the reference group.

Overall 103 out of the 577 (17.9%) patients randomised in the CMEK162B2301 study changed therapy before progression. Of these 103, 44 (42.7%) were followed until progression or death (death as first event, all due to study indication): 9 (37.5%), 14 (42.4%) and 21 (45.7%) in the Combo 450, Enco 300 and vemurafenib arms respectively.

Table 48: Outcomes of patients who received a new anticancer treatment before progression, death [CMEK162B2301, FAS (Part 1)]

| Outcomes after change of therapy a      | Encorafenib 450mg + Binimetinib N=24 n (%)   | Encorafenib N=33 n (%)   | Vemurafenib N=46 n (%)   |
|-----------------------------------------|----------------------------------------------|--------------------------|--------------------------|
| Progression                             | 1 (4.2)                                      | 9 (27.3)                 | 4 (8.7)                  |
| Death                                   | 8 (33.3)                                     | 5 (15.2)                 | 17 (37.0)                |
| Censored                                | 15 (62.5)                                    | 19 (57.6)                | 25 (54.3)                |
| No baseline assessment                  | 2 (8.3)                                      | 0                        | 0                        |
| No post-baseline assessment             | 1 (4.2)                                      | 4 (12.1)                 | 4 (8.7)                  |
| Adequate assessment no longer available | 10 (41.7)                                    | 12 (36.4)                | 16 (34.8)                |
| Withdrew Consent                        | 0                                            | 1 (3.0)                  | 3 (6.5)                  |
| Lost to Follow-up                       | 0                                            | 1 (3.0)                  | 0                        |
| Ongoing                                 | 2 (8.3)                                      | 1 (3.0)                  | 2 (4.3)                  |

To fufil the EMA guidelines definition, three additional sensitivity analyses were performed as requested during the procedure. These supported the results of the initial analysis with regards to Combo 450 vs vemurafenib (primary objective) and Combo 450 vs encorafenib 300mg QD (key secondary objective).

<div style=\"page-break-after: always\"></div>

Table 49: Stratified Cox Regression Model of Progression Free Survival per Central Review - Sensitivity analysis [CMEK162B2301, FAS]

Median

|                                                                             | Event N(%)     | (95% CI) (month)   | Survival (%) at 24 months   | P value   | HR (95% CI)       |
|-----------------------------------------------------------------------------|----------------|--------------------|-----------------------------|-----------|-------------------|
| Primary analysis[1]                                                         |                |                    |                             |           |                   |
| Encorafenib 450mg +Binimetinib                                              | 98/192 (51.0)  | 14.9 (11.0, 18.5)  | 32.3 (22.7, 42.2)           |           |                   |
| Encorafeniba                                                                | 96/194 (49.5)  | 9.6 (7.5, 14.8)    | 35.5 (27.5, 43.7)           | 0.0513    | 0.75 (0.56 -1.00) |
| Vemurafenibb                                                                | 106/191 (55.5) | 7.3 (5.6, 8.2)     | 23.9 (16.2, 32.3)           | <.0001    | 0.54 (0.41 -0.71) |
| 'Objective event (EMA recommendation) sensitivity analysis[2]               |                |                    |                             |           |                   |
| Encorafenib 450mg+Binimetinib                                               | 112/192 (58.3) | 14.1 (10.7, 16.6)  | 27.5 (18.9, 36.9)           |           |                   |
| Encorafeniba                                                                | 118/194 (60.8) | 9.3 (7.4, 12.3)    | 29.5 (22.4, 36.9)           | 0.0181    | 0.73 (0.56 -0.95) |
| Vemurafenibb                                                                | 129/191 (67.5) | 7.3 (5.6, 8.6)     | 17.6 (11.4, 24.9)           | <.0001    | 0.56 (0.43 -0.72) |
| Change of therapy andwithdrawal included as events' sensitivity analysis[3] |                |                    |                             |           |                   |
| Encorafenib 450mg+Binimetinib                                               | 128/192 (66.7) | 10.7 (9.1, 13.0)   | 24.8 (17.0, 33.4)           |           |                   |
| Encorafeniba                                                                | 144/194 (74.2) | 7.2 (5.6, 9.1)     | 22.2 (15.9, 29.2)           | 0.0018    | 0.68 (0.53 -0.87) |
| Vemurafenibb                                                                | 161/191 (84.3) | 5.6 (4.4, 6.1)     | 12.7 (8.1, 18.2)            | <.0001    | 0.48 (0.38 -0.61) |
| Push back censoring' sensitivity analysis[4]                                |                |                    |                             |           |                   |
| Encorafenib 450mg+Binimetinib                                               | 112/192 (58.3) | 16.4 (12.3, 19.2)  | 36.6 (28.4, 44.7)           |           |                   |
| Encorafeniba                                                                | 118/194 (60.8) | 11.8 (9.1, 14.8)   | 37.9 (30.9, 44.9)           | 0.1317    | 0.82 (0.63 -1.06) |
| Vemurafenibb                                                                | 129/191 (67.5) | 8.2 (7.2, 11.0)    | 31.0 (24.3, 37.9)           | 0.0017    | 0.67 (0.52 -0.86) |

[1] Primary analysis uses censoring of events occurring after 2 or more missing tumour assessments or change of therapy

[2] 'Objective event' analysis includes the event (progressive disease or death) whenever it occurs even after 2 or more missing tumour assessments, withdrawal or new anticancer therapy.

[3] 'Change of therapy and withdrawal included as events' analysis considers as events progression and death as well as change of therapy or withdrawal whichever occurs the first

[4] 'Push back censoring' analysis includes the event (progressive disease or death) whenever it occurs and censored patients at the clinical cut-off date.

## Other Secondary Efficacy Endpoints

## PFS, Encorafenib vs. Vemurafenib

Analysis of the PFS by BIRC of encorafenib vs. vemurafenib treatment showed a difference of approximately 2.3 months (9.6 months vs. 7.3 months; nominal one-sided log-rank p = 0.004; HR = 0.68, 95% CI 0.52, 0.90). Investigator assessment of response gave similar PFS durations (encorafenib 9.2 months, vemurafenib 7.3 months; nominal one-sided log-rank p = 0.004; HR = 0.68, 95% CI 0.52, 0.90). Median PFS values by BIRC were the same in the PPS as in the FAS.

<div style=\"page-break-after: always\"></div>

Figure 11: Kaplan-Meier Estimate of PFS Based on BIRC Assessment -Encorafenib vs. Vemurafenib (FAS, Part 1)

<!-- image -->

## Objective Response Rate and Disease Control Rate

Table 50: Best Overall Response by BIRC (FAS, Part 1)

|                                                     | Combo 450 N=192 n (%)   | Encorafenib N=194 n (%)   | Vemurafenib N=191 n (%)   |
|-----------------------------------------------------|-------------------------|---------------------------|---------------------------|
| Patients with measurable disease at baseline?       | 175 (91.1)              | 180 (92.8)                | 183 (95.8)                |
| Patientswithnon-measurabledisease only at baselinea | 15 (7.8)                | 12 (6.2)                  | 8(4.2)                    |
| Confirmed ORR:CR +PR                                | 121 (63.0)              | 98 (50.5)                 | 77 (40.3)                 |
| 95% CI                                              | (55.8, 69.9)            | (43.3, 57.8)              | (33.3, 47.6)              |
| Confirmed BORbc                                     |                         |                           |                           |
| CR                                                  | 15 (7.8)                | 10 (5.2)                  | 11 (5.8)                  |
| PR                                                  | 106 (55.2)              | 88 (45.4)                 | 66 (34.6)                 |
| Stable disease                                      | 46 (24.0)               | 53 (27.3)                 | 73 (38.2)                 |
| Non-CR/Non-PDd                                      | 10 (5.2)                | 12 2(6.2)                 | 6(3.1)                    |
| PD                                                  | 2 (1.0)                 | 6 (3.1)                   | 13 (6.8)                  |
| DCR:CR+PR+stable disease+ Non-PD/Non-CR             | 177 (92.2)              | 163 (84.0)                | 156 (81.7)                |
| 95% CIe                                             | (87.4 , 95.6)           | (78.1 , 88.9)             | (75.4 , 86.9)             |
| Unknownf                                            | 11 (5.7)                | 25 (12.9)                 | 22 (11.5)                 |
| Not Assesseds                                       | 2 (1.0)                 | 0                         | 0                         |

<div style=\"page-break-after: always\"></div>

f Unknown response: Not included in BOR assessment but included in denominator for ORR and DCR. Progression has not been documented and one or more lesions have not been assessed or have been assessed using a different method than baseline. See Table 14.2-3.2a for reasons for unknown status. g Not included in BOR assessment but included in denominator for ORR and DCR. No assessment has occurred by BIRC; not included in patients with measurable or non-measurable disease at baseline.

Median  time  to  objective  response  (TTR) per  BIRC,  calculated  for  responding  patients  only (confirmation not required), was 1.9 months in the Combo 450 arm (95% CI 1.9, 1.9), 2.0 months in the encorafenib arm (95% CI 1.9, 3.6) and 2.1 months in the vemurafenib arm (95% CI 1.9, 3.7). Median TTR per Investigator assessment was also approximately 2 months for each arm. This timing corresponded with the first post-baseline response assessment at Cycle 3 Day 1.

Kaplan-Meier estimates of median duration of response (DOR) per BIRC, calculated for confirmed responses, were 16.6 months in the Combo 450 arm (95% CI 12.2, 20.4; range 1.64 - 22.11), 14.9 months in the encorafenib arm (95% CI 11.1, NE; range 0.62 - 15.47) and 12.3 months in the vemurafenib arm (95% CI 6.9, 16.9; range 0.92 - 16.89).

Investigator review revealed a similar pattern but a higher ORR in each arm (75.0 % [95% CI 68.3, 81.0]; 57.7% [95% CI 50.4, 64.8]; 49.2 % [95% CI 41.9, 56.5], respectively).

The confirmed CR by Investigator review was higher than by BIRC (16.1%, 8.8% and 7.3% of patients in the Combo 450, encorafenib and vemurafenib arms, respectively) and their median time to CR was 5.5 months, 5.5 months and 3.9 months, respectively.

The DCR per Investigator review was similar to per BIRC.

Median TTR per Investigator assessment was also approximately 2 months for each arm. This timing corresponded with the first post-baseline response assessment at Cycle 3 Day 1.

Kaplan-Meier estimates of median DOR per Investigator, calculated for confirmed responses, were similar to those by BIRC: 16.2 months, 14.8 months and 8.4 months in the Combo 450, encorafenib and vemurafenib arms.

## Overall Survival, Combo 450 vs. Vemurafenib

As of the data cut-off (7 November 2017), 80 patients (13.9%) were ongoing in the treatment period of the study (22.4% Combo 450 arm, 12.4% encorafenib arm, 6.8% vemurafenib arm). The median duration of exposure to study treatment in the Combo 450 arm (11.8 months) was longer than in the encorafenib (7.2 months) and vemurafenib (6.1 months) arms. Within the Combo 450 arm, median durations of exposure to encorafenib and binimetinib were identical (11.8 months).

The most common reason for discontinuation from study treatment, in all arms, was progressive disease and the rate was higher in the vemurafenib arm (57.1%) as compared with the Combo 450 (51.6%) and encorafenib (51.5%) arms. The rates of withdrawal by physician and by patients were higher for vemurafenib (8.9% each) and encorafenib (12.4% and 8.8%) vs Combo 450 (4.7% and 5.7%). The proportion of patients censored for this OS analysis in the Combo 450 arm (45.3%) was higher than that observed in the vemurafenib arm (33.5%). Most censored patients in both groups who were alive and ongoing had a last contact within the 12 weeks prior to data cut-off.

For all randomized patients, the median time between randomisation and OS cut-off dates was 37.45 months [30.98-46.29 months]. When measured as the time from randomisation until event/censoring, the median potential follow-up duration using reverse Kaplan Meier for OS was 37.2 months in the Combo 450 arm, 36.3 months in the encorafenib arm and 35.9 months in the vemurafenib arm.

<div style=\"page-break-after: always\"></div>

A lower proportion of patients in the Combo 450 arm (41.7%) received antineoplastic therapy after discontinuation of study treatment compared with the encorafenib (55.7%) and vemurafenib (62.3%) arms, partly due to a higher proportion of patients in the Combo 450 arm who continued to receive study treatment as of the data cut-off. A similar proportion of patients in each arm received subsequent treatment with a monoclonal antibody, mainly checkpoint inhibitors (34.4% Combo 450, 36.1% encorafenib, 39.8% vemurafenib arm). A lower proportion of patients in the Combo 450 arm (10.9%) received subsequent treatment with BRAF inhibitors and/or combinations of BRAF and MEK inhibitors after discontinuation of study treatment as compared with either the encorafenib (21.6 %) or the vemurafenib (32.9%) arms.

<!-- image -->

Abbreviations:CI=confidenceinterval

Figure 12: Kaplan-Meier Plot of Overall Survival, Combo 450 vs. Vemurafenib (Full Analysis Set, Part 1)

An estimated 39% reduction in the risk of death was observed for patients treated with Combo 450 compared to those treated with vemurafenib (HR 0.61, 95% CI 0.47, 0.79), with median OS values of 33.6 months (95% CI 24.4, 39.2) and 16.9 months (95% CI 14.0, 24.5), respectively.

Estimates of OS at 12 months and 24 months were 75.5% (95% CI 68.8, 81.0) and 57.6% (95% CI 50.3, 64.3) for Combo 450 compared to 63.1% (95% CI 55.7, 69.6) and 43.2% (95% CI 35.9, 50.2) for vemurafenib.

The results of sensitivity analyses are consistent with those of the interim OS analysis and lead to similar conclusions about treatment effect.

A multivariate Cox regression model stratified by the study stratification factors was used to explore the  robustness  of  the  statistical  significance  of  treatment  effect  on  OS  when  adjusting  for  main prognostic factors. The only other prespecified covariate that reached statistical significance was LDH, which  was  associated  with  an  increase  in  the  relative  risk  of  death  which  was  associated  with  an

<div style=\"page-break-after: always\"></div>

increase in the relative risk of death (HR 1.21; 95% CI 1.16, 1.27; p &lt; 0.001, 2-sided) for each 125 IU/L increase in LDH.

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 13: Forest Plot of Hazard Ratio with 95% Confidence Interval for Overall Survival from Subgroup Analysis Encorafenib 450mg+Binimetinib versus Vemurafenib (Full Analysis Set, Part 1)

<!-- image -->

<!-- image -->

## Overall Survival, Combo 450 vs. Encorafenib

Median OS values for Combo 450 and encorafenib were 33.6 months (24.4, 39.2) and 23.5 months (19.6, 33.6) respectively (HR 0.81, 95% CI 0.61, 1.06, nominal p value =0.0613, 2-sided).

<div style=\"page-break-after: always\"></div>

<!-- image -->

Abbreviations:CI=confidenceinterval

Figure 14: Kaplan-Meier Plot of Overall Survival, Combo 450 vs. Encorafenib (Full Analysis Set, Part 1)

Estimates of OS at 12 months and 24 months were 75.5% (68.8, 81.0) and 57.6% (50.3, 64.3) for Combo 450 compared to 74.6% (67.6, 80.3) and 49.1% (41.5, 56.2) for encorafenib.

A multivariate Cox regression model stratified by the study stratification factors was used to explore the  robustness  of  the  statistical  significance  of  treatment  effect  on  OS  when  adjusting  for  main prognostic factors. The only other prespecified covariate that reached statistical significance was LDH, which was associated with an increase in the relative risk of death (HR 1.21; 95% CI 1.16, 1.27; p &lt; 0.001, 2-sided) for each 125 IU/L increase in LDH. All unstratified subgroup analyses demonstrated median OS point estimates in favour of the Combo 450 arm except for Japanese patients (6 patients in total)  and  Region  Other  (27  patients  in  total)  and  &gt;  3  organs  involved  at  baseline  (66  patients  in total).

## Overall Survival, Encorafenib vs. Vemurafenib

The  median  OS  was  23.5  months  (95%  CI  19.6,  33.6)  and  16.9  months  (95%  CI  14.0,  24.5), respectively, for patients treated with encorafenib compared with vemurafenib with a HR 0.76 (95% CI 0.58, 0.98). Estimates of OS at 12 months and 24 months were 74.6% (67.6, 80.3) and 49.1% (41.5, 56.2) for encorafenib compared to 63.1% (55.7, 69.6) and 43.2% (35.9, 50.2) for vemurafenib.

<div style=\"page-break-after: always\"></div>

Figure 15: Kaplan-Meier Plot of Overall Survival, Encorafenib vs. Vemurafenib (Full Analysis Set, Part 1)

<!-- image -->

The data cut-off date for the OS analysis reviewed by the DMC was 19 May 2016, by which time a total of 157 OS events were observed in the Combo 450 and vemurafenib arms combined in Part 1 of the study.

For patients treated with Combo 450, median OS value was 26.0 months compared to 16.9 months for those treated with vemurafenib (HR 0.58, 95% CI 0.42, 0.80. Confidence intervals were not provided.

For patients treated with Combo 450 compared to those treated with encorafenib (HR 0.77, 95% CI 0.55, 1.08), median OS values were 26.0 months and 23.5 months, respectively.

Table 51: Study CMEK162B2301, Part 1: Overall survival interim results (cut-off date: 7 November 2017)

|                                                         | Encorafenib + binimetinib N=192 (Combo 450)   | Encorafenib N=194 (Enco 300)   | Vemurafenib N=191 (Vem)   |
|---------------------------------------------------------|-----------------------------------------------|--------------------------------|---------------------------|
| OS                                                      |                                               |                                |                           |
| Number of events (%)                                    | 105 (54.7)                                    | 106 (54.6)                     | 127 (66.5)                |
| Median, months (95% CI)                                 | 33.6 (24.4, 39.2)                             | 23.5 (19.6, 33.6)              | 16.9 (14.0, 24.5)         |
| Survival at 12 months (95% CI)                          | 75.5% (68.8, 81.0)                            | 74.6% (67.6, 80.3)             | 63.1% (55.7, 69.6)        |
| Survival at 24 months (95% CI)                          | 57.6% (50.3, 64.3)                            | 49.1% (41.5, 56.2)             | 43.2% (35.9, 50.2)        |
| HR (95% CI) (vs Vem) p-value (stratified log-rank)      | 0.61 (0.47, 0.79) <0.0001                     |                                |                           |
| HR (95% CI) (vs Enco 300) p-value (stratified log-rank) | 0.81 (0.61,1.06) 0.061                        |                                |                           |

<div style=\"page-break-after: always\"></div>

## Health related Quality of Life (HRQoL) Analyses

Patient compliance with the 3 QoL instruments (FACT-M, EORTC-QLQ-C30, EQ-5D-5L) was calculated for  patients  still  'at-risk'  i.e.  receiving  treatment  or  in  post-treatment  follow-up  on  the  protocolscheduled PRO assessment date. Compliance with the 3 questionnaires was equivalent among the 3 treatment arms, with approximately 80%-95% of patients still at risk completing the assessment from baseline to Cycle 25.

At baseline, the mean [SD] FACT-M score was similar in the 3 treatment arms: Combo 450 (52.39 [9.05]), Enco 300 (52.84 [8.23]) and vemurafenib arm (52.01 [8.65]). The median time to definitive 10% deterioration in the FACT-M global health status score was not reached in the Combo 450 arm (95% CI 22.1, NE) and was 22.1 months (95% CI 15.2, NE) in the vemurafenib arm with a HR for the difference of 0.46 (95% CI 0.29, 0.72) using a stratified Cox regression model. The median time to definitive 10% deterioration in the FACT-M was 20.3 months (95% CI 15.0, NE) in the encorafenib arm with a HR for the difference between Combo 450 and encorafenib of 0.48 (95% CI 0.31, 0.75) using a stratified Cox regression model.

Figure 16: Kaplan-Meier Plot of Time to Definitive 10% Deterioration in FACT-M Global Health Status - Combo 450 vs. Vemurafenib (FAS, Part 1)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 17: Kaplan-Meier Plot of Time to Definitive 10% Deterioration in FACT-M Global Health Status - Combo 450 vs. Enco 300 (FAS, Part1)

<!-- image -->

At  baseline,  the  mean  [SD] EORTC  QLQ-C30  global  health  status score  was  similar  in  the  3 treatment  arms:  Combo  450  (66.72  [21.59]),  Enco  300  (66.10  [21.16])  and  the  vemurafenib  arm (64.74 [23.61]). The median time to definitive 10% deterioration in the EORTC QLQ-C30 global health status score was delayed by more than 7 months in the Combo 450 arm compared to the vemurafenib arm: 23.9 months (95% CI 20.4, NE) vs. 16.6 months (95% CI 11.9, NE) with a HR for the difference of 0.55 (95% CI 0.37, 0.80) using a stratified Cox regression model. The median time to definitive 10%  deterioration  in  the  QLQ-C30  global  health  status  scores  was  longer  in  the  Combo  450  arm compared with the Enco 300 arm (14.7 months [95% CI 9.2, 18.4]), with a HR for the difference of 0.45 (95% CI 0.31, 0.65) using a stratified Cox regression model .

At  baseline,  the  mean EQ-5D-5L index  score  was  similar  for  each  arm  (Combo  450  =  0.74, encorafenib = 0.76, vemurafenib = 0.73) and the median was 0.77 for each of the 3 treatment arms. The Combo 450 arm showed a slight improvement at Cycle 3 Day 1 from baseline and the vemurafenib showed no change. In subsequent visits, the scores decreased over time for both arms. Comparison of the Combo 450 arm vs. the encorafenib arm showed similar results to the comparison of the Combo 450 arm and vemurafenib arm.

## Study CMEK162B2301 PART 2

The main objective of Part 2 (a key secondary objective) was to further quantify the contribution of binimetinib to the combination of encorafenib and binimetinib, by comparing PFS of Combo 300 (encorafenib 300 mg QD and binimetinib 45 mg BID) vs. encorafenib single-agent (encorafenib 300 mg QD).

Approximately 320 patients were planned to be randomised in a 3:1 ratio to Combo 300: Enco 300. The inclusion - exclusion criteria were identical to Part 1.

Statistical Methods for Efficacy Analyses in the Part 2 CSR (Combo 300 vs. Enco 300)

<div style=\"page-break-after: always\"></div>

An unplanned initial analysis of Part 2 based on 293 events (vs 340 events planned) was performed using a data cut-off date of 09 November 2016 in agreement with the FDA. Analysis of the Part 1 key secondary endpoint (PFS, Combo 450 vs. encorafenib) was not statistically significant; therefore, per protocol-specified testing hierarchy, the data in this PFS part 2 analysis are summarized descriptively without formal testing.

As pre-specified, (SAP version IV), the Part 2 initial CSR reports data from the combined Part 1 and Part 2 encorafenib monotherapy patients (N=280) and Part 2 encorafenib monotherapy patients only (N=86) through to the cut-off date for the Part 2 report.

All efficacy analyses were performed using the full analysis set (FAS).

## Results

Part 2 patients were randomised between 19 March 2015 and 12 November 2015. A total of 344 patients were randomised during Part 2, 258 patients in the Combo 300 arm and 86 in the encorafenib arm.

Part 2

<!-- image -->

## Figure 18: Patient flow chart for Part 2 of study CMEK162B2301

The two treatment groups (Combo 300 and Enco 300 [Parts 1 + 2]) were reasonably well balanced in terms of baseline and disease characteristics. As would be expected because these were directly randomised groups, the Combo 300 and Enco 300 Part 2 populations were similar at baseline.

However, there were some differences between the two encorafenib monotherapy arms (Part 1 and Part 2). Patients in the encorafenib Part 2 arm were older (median age 57 years, 30.2% were ≥ 65 years old) than those in the encorafenib Part 1 arm (median age 54 years, 20.6% were ≥ 65 years

<div style=\"page-break-after: always\"></div>

old). The proportion of patients with Stage IV M1C with elevated LDH was higher in the Enco 300 Part 2 arm compared with Enco 300 Part 1 (37.2% vs. 25.8%). More Enco 300 Part 1 patients had Stage IV M1B (20.1% vs 11.6%), and Stage IV M1C with normal LDH (36.1% vs 30.2% respectively). A difference was seen in the overall duration of disease with a median time from initial diagnosis to randomisation that was nearly 5 months longer in the Enco 300 Part 2 population (28.4 vs 23.6 months). Distribution of disease location was similar between combinations for skin and/or lymph nodes; however more Enco 300 Part 1 patients had lung metastases (19.6% vs 8.1% respectively), while more patients in Enco 300 Part 2 had other organs involved. Baseline LDH levels were higher in Enco 300 Part 2 patients, with a mean of 338 U/L vs 265 UI/L and a median of 217 U/L vs 189 U/L vs respectively.

<div style=\"page-break-after: always\"></div>

Table 52: Patient and Disease Characteristics (Full Analysis Set, Part 2 Initial)

| Disease history                                                     | Combo 300 N=258                                                     | Encorafenib (Part l +Part 2) N=280                                  | Encorafenib (Part 1) N=194                                          | Encorafenib (Part 2) N=86                                           |
|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|
| Primary site of cancer, n (%)                                       |                                                                     |                                                                     |                                                                     |                                                                     |
| Skin Melanoma                                                       | 239 (92.6)                                                          | 271 (96.8)                                                          | 192 (99.0)                                                          | 79 (91.9)                                                           |
| Unknown                                                             | 19 (7.4)                                                            | 9 (3.2)                                                             | 2 (1.0)                                                             | 7 (8.1)                                                             |
| Stage at time of study entry, n (%)                                 |                                                                     |                                                                     |                                                                     |                                                                     |
| Stage IIIB                                                          | 0                                                                   | 2 (0.7)                                                             | 2 (1.0)                                                             | 0                                                                   |
| Stage IIIC                                                          | 8 (3.1)                                                             | 9 (3.2)                                                             | 4 (2.1)                                                             | 5 (5.8)                                                             |
| Stage IV M1A                                                        | 31 (12.0)                                                           | 42 (15.0)                                                           | 29 (14.9)                                                           | 13 (15.1)                                                           |
| Stage IV M1B                                                        | 47 (18.2)                                                           | 49 (17.5)                                                           | 39 (20.1)                                                           | 10 (11.6)                                                           |
| Stage IV M1C                                                        | 172 (66.7)                                                          | 178 (63.6)                                                          | 120 (61.9)                                                          | 58 (67.4)                                                           |
| Stage IV M1C with elevated LDH \"                                    | 73 (28.3)                                                           | 82 (29.3)                                                           | 50 (25.8)                                                           | 32 (37.2)                                                           |
| Stage IV M1C with normal LDH                                        | 99 (38.4)                                                           | 96 (34.3)                                                           | 70 (36.1)                                                           | 26 (30.2)                                                           |
| Time from initial diagnosis to onset of metastatic disease (months) | Time from initial diagnosis to onset of metastatic disease (months) | Time from initial diagnosis to onset of metastatic disease (months) | Time from initial diagnosis to onset of metastatic disease (months) | Time from initial diagnosis to onset of metastatic disease (months) |
| n                                                                   | 249                                                                 | 276                                                                 | 191                                                                 | 85                                                                  |
| Mean (SD)                                                           | 28.13 (45.617)                                                      | 36.53 (58.902)                                                      | 36.45 (62.708)                                                      | 36.72 (49.639)                                                      |
| Median                                                              | 10.41                                                               | 14.31                                                               | 13.04                                                               | 15.84                                                               |
| Min - Max                                                           | 0-306.7                                                             | 0-388.8                                                             | 0-388.8                                                             | 0-262.4                                                             |
| Number of organs involved at Baseline *, n (%)                      | Number of organs involved at Baseline *, n (%)                      | Number of organs involved at Baseline *, n (%)                      | Number of organs involved at Baseline *, n (%)                      | Number of organs involved at Baseline *, n (%)                      |
| 1                                                                   | 78 (30.2)                                                           | 79 (28.2)                                                           | 56 (28.9)                                                           | 23 (26.7)                                                           |
| 2                                                                   | 66 (25.6)                                                           | 74 (26.4)                                                           | 52 (26.8)                                                           | 22 (25.6)                                                           |
| 3                                                                   | 59 (22.9)                                                           | 61 (21.8)                                                           | 42 (21.6)                                                           | 19 (22.1)                                                           |
| >3                                                                  | 55 (21.3)                                                           | 66 (23.6)                                                           | 44 (22.7)                                                           | 22 (25.6)                                                           |
| LDH at Baseline (U/L)                                               | LDH at Baseline (U/L)                                               | LDH at Baseline (U/L)                                               | LDH at Baseline (U/L)                                               | LDH at Baseline (U/L)                                               |
|                                                                     | 258                                                                 | 280                                                                 | 194                                                                 | 86                                                                  |
| Mean (SD)                                                           | 300.8 (319.24)                                                      | 287.7 (293.43)                                                      | 265.2 (251.21)                                                      | 338.4 (368.19)                                                      |
| Median                                                              | 201.5                                                               | 197.0                                                               | 188.5                                                               | 217.0                                                               |
| Min - Max                                                           | 103-3095                                                            | 75-2101                                                             | 75 -1886                                                            | 115-2101                                                            |
| LDH at Baseline b, n (%)                                            | LDH at Baseline b, n (%)                                            | LDH at Baseline b, n (%)                                            | LDH at Baseline b, n (%)                                            | LDH at Baseline b, n (%)                                            |
| Low                                                                 | 0                                                                   | 0                                                                   | 0                                                                   | 0                                                                   |
| Normal                                                              | 178 (69.0)                                                          | 201 (71.8)                                                          | 147 (75.8)                                                          | 54 (62.8)                                                           |
| High c                                                              | 80 (31.0)                                                           | 79 (28.2)                                                           | 47 (24.2)                                                           | 32 (37.2)                                                           |

Abbreviations: eCRF = electronic case report fom; L = liter(s); LDH = lactate dehydrogenase; Max = maximum; Min =minimum; SD=standard deviation;U=units

Note: The time from initial diagnosis to onset of metastatic disease are calculated only for patients with metastatic disease. A patient may have multiple metastatic sites.

* For patients with stage IIB and IIC at study entry, the number of organs involved at baseline is equal to one and presented as skin.

Note: Metastatic sites and organs involved were derived from Diagnosis and Extent of Cancer eCRF page.

Low and high categories defined by normal ranges.

Some discrepancies were noted between the numbers of patients with Stage IV M1c LDH elevated and LDH high at baseline. The LDH level assessed for staging (M1lc LDH elevated) was determined at screening whereas baseline values were used to report LDH at baseline. Also patients with Stage III disease could have elevated LDH.

Source:Table 14.1-3.2.1b;Table 14.1-3.3.1b

## Combo 300 vs Enco 300 (Parts 1 and 2)

The median follow-up for PFS per BIRC (Kaplan-Meier) was 13.9 months for the Combo 300 arm and 18.5 months for the encorafenib (Parts 1 + 2) group.

For the primary analysis of Part 2 the PFS in the Combo 300 arm was 3.7 months longer than that of the encorafenib (Parts 1 + 2) group, with median PFS estimates of 12.9 months (95% CI 10.1, 14.0) and 9.2 months (95% CI 7.4, 11.0), respectively (HR=0.77, 95% CI 0.61, 0.97; nominal one-sided p=0.015).

<div style=\"page-break-after: always\"></div>

[Parts 1 + 2] (FAS, Part 2 Initial)

<!-- image -->

Figure 19: Kaplan-Meier Estimate of PFS Based on BIRC - Combo 300 vs. Enco 300 (Part 1 and 2)

The analysis was supported by the sensitivity analysis of the Investigator assessment (HR=0.72, 95% CI: 0.57, 0.91; nominal p=0.003), which had the same median PFS values as those by BIRC at 12.9 months (95% CI: 10.9, 14.8) and 9.2 months (95% CI: 7.4, 11.1) for the Combo 300 arm and the encorafenib (Parts 1 + 2) group.

Sensitivity analyses of PFS by BIRC were conducted: per protocol, unstratified, actual event, backdating and further anticancer therapy yielded similar HRs (0.75 - 0.78).

Most subgroup analyses of PFS per BIRC demonstrated point estimates in favour of the Combo 300 arm. In the 3 subgroups for which point estimates were in favour of the encorafenib (Parts 1 +2) group ( BRAF V600K mutation status, AJCC stage IIIb-IVM1B and one organ involved at baseline), all had large 95% CIs which overlapped with the other subgroup of the respective category.

The confirmed ORR per BIRC in the Combo 300 arm was 65.9% (95% CI: 59.8, 71.7) compared with 50.4% (95% CI 44.3, 56.4) in the Enco 300 (Parts 1 + 2) group. Responses were of similar duration with a median DOR for confirmed responses per BIRC of one year in each treatment group (Combo 300 arm=12.7 months [95% CI: 9.3, 15.1]; encorafenib (Parts 1 + 2) group=12.9 months [95% CI 8.9, 15.5].

The ORR per Investigator review was higher in both the Combo 300 arm and the encorafenib (Parts 1 + 2) group than by BIRC, with the difference in favour of Combo 300 maintained (72.5% Combo 300 arm, 56.4% Enco 300 [Parts 1 + 2] group). Median DORs per Investigator were approximately 13 months in each treatment group.

## Combo 300 vs. Enco 300 Part 2

PFS including only the encorafenib monotherapy patients who were concurrently randomised in Part 2 was conducted as a sensitivity analysis as per protocol. The median follow-up for PFS per BIRC

<div style=\"page-break-after: always\"></div>

(Kaplan-Meier) was 13.9 months for the Combo 300 arm and 14.8 months for the encorafenib Part 2 arm.

In patients randomised concurrently in Part 2 of the study, there was an estimated 43% risk reduction in BIRC-assessed PFS in the Combo 300 arm (N=258) compared to the encorafenib monotherapy arm (N=86); HR=0.57, 95% CI: 0.41, 0.78; nominal stratified one-sided log-rank p&lt;0.001. Median PFS was 12.9 months (95% CI: 10.1, 14.0) and 7.4 months (95% CI: 5.6, 9.2), respectively.

Figure 20: Kaplan-Meier Estimate of PFS Based on BIRC - Combo 300 vs. Enco 300 [Part 2] (FAS, Part 2 Initial)

<!-- image -->

The effect of treatment on PFS was estimated using a non-adjusted regression analysis, stratified by the study randomisation stratification factors (ECOG and disease stage). The crude HR was 0.57 (95% CI: 0.42, 0.79).

The four Propensity Score approaches including stratification (3 and 5 strata), matching, and IPW showed a benefit of Combo 300 over Enco 300 Part 2. HRs ranged from 0.52 to 0.70 (upper 95% cI 0.80 to 1.00).

## PFS by BIRC - Encorafenib 300 Part 1  vs. Encorafenib 300  Part 2

Results of the prespecified sensitivity analysis of PFS by BIRC for the encorafenib arm (Part 1) vs. encorafenib arm (Part 2) showed an estimated 32% risk reduction in the encorafenib (Part 1) arm (HR 0.68; 95% CI: 0.49, 0.95; nominal one-sided p=0.013). The median PFS times of the encorafenib Part 1 arm vs. Part 2 arm were 9.6 months (95% CI: 7.4, 14.8) and 7.4 months (95% CI: 5.6, 9.2), respectively.

<div style=\"page-break-after: always\"></div>

Figure 21: Kaplan-Meier plot of PFS by BIRC - Encorafenib Part 1 vs Encorafenib Part 2 (Full Analysis Set, Part 2 Initial)

<!-- image -->

PFS analyses of Enco 300 Part 1 vs Part 2, adjusted for confounding factors in the context of two independent cohorts, were conducted using the propensity score (PS) test. However, the PS is normally used for the description of populations accrued at a similar time point, whereas Enco 300 populations were recruited sequentially in Parts 1 and 2. The model cannot account for the potential bias introduced by this temporal difference.

Table 53: Comparison of Baseline Covariates for Enco Part 1 vs. Enco Part 2

|                                                                                                                                                                                                                                                               | P-value                                                                                                       |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|
| Sex Age Baseline Body Mass Index (kg/m) Race Region ECOG at baseline first dose Time from initial diagnosis to first Primary site of cancer at study entry Stage BRAF status Number of organs involved at Baseline brain metastases Baseline liver metastases | 0.4849 1 0.2453 0.0110 0.7956 1 0.0034 0.9901 1 0.4192 0.0043 0.3792 1 0.4316 0.8712 0.7287 2 0.0892 0.1372 1 |
|                                                                                                                                                                                                                                                               | 1                                                                                                             |
| metastasis                                                                                                                                                                                                                                                    |                                                                                                               |
|                                                                                                                                                                                                                                                               | 2                                                                                                             |
|                                                                                                                                                                                                                                                               | 1                                                                                                             |
| baseline                                                                                                                                                                                                                                                      | 1                                                                                                             |
|                                                                                                                                                                                                                                                               | 1                                                                                                             |
| Prior adjuvant immunotherapy                                                                                                                                                                                                                                  |                                                                                                               |
| LDH at baseline (U/L)                                                                                                                                                                                                                                         | 0.0177                                                                                                        |

Tests: Wilcoxon for continuous variables, Chi-square (1) or Fisher (2) for categorical variables.

The effect of treatment on PFS was estimated using a non-adjusted regression analysis, stratified by the stratification factors (ECOG performance status and stage). The crude HR was 0.69 (95% CI: 0.49, 0.96).

Four PS approaches including stratification (3 and 5 strata), matching, and IPW were then used to estimate the treatment effect on PFS and were adjusted for confounding. The different PS methods

<div style=\"page-break-after: always\"></div>

(adjusted and non-adjusted) gave HRs ranging from 0.57 to 0.68 and all showed a significant increase in the risk of disease progression or death for Enco 300 in Part 2 over Enco 300 in Part 1.

## Contribution of binimetinib 45 mg BID to the efficacy of Combo 450: Combo 450 vs. Combo 300

A post hoc comparison of data from the Combo 450 arm [Part 1 of CMEK162B2301 (N=192) at the cut-off date for the primary analysis of 19 May 2016] and the Combo 300 arm [Part 2 (N=258) unplanned initial analysis at the cut-off date of 09 November 2016] was conducted. The two data cutoffs were chosen to allow similar duration of follow up, as the populations were not recruited concomitantly. Median potential follow-up for PFS was comparable for the two populations (16.7 months vs 13.9 months) and the median follow-up time was 9.3 months for both combinations. A supportive analysis was performed using the 09 November 2016 for the two arms.

The Combo 450 and Combo 300 populations were similar in terms of age, sex, race and ECOG performance status. A slightly higher proportion of patients was enrolled in Europe, North America and Australia in Combo 450 compared to Combo 300 (9.5% difference). Median time from initial diagnosis to onset of metastatic disease was longer in the Combo 450 than the Combo 300 population (15.0 vs 10.4 months). Distribution of disease location and disease burden were similar between combinations, although a higher proportion of patients had only one disease site in Combo 300 (30.2% vs 24.5% with Combo 450). Median LDH levels at baseline were slightly higher in Combo 300 (202 vs. 173 U/L).

Median PFS (per BIRC) was 2 months longer for Combo 450 (14.9 months) than for Combo 300 (12.9 months), but the difference was not statistically significant (log rank p value 0.0845).

<!-- image -->

*The median confidence interval was calculated using the Brookmeyer and Crowley method in PROC LIFETEST

Figure 22: Kaplan-Meier PFS Comparison for Combo 450 (cut-off date: 19 May 2016) vs Combo 300 (Cut-off date: 09 November 2016) - FAS Population

<div style=\"page-break-after: always\"></div>

Table 54: Direct Comparison of Combo 450 (cut-off date: 19 May 2016) vs Combo 300 (Cut-off date: 09 November 2016) - FAS Population Stratified Analyses

|                                         | Combo 450 Part 1 (N=192)   | Combo 300 Part2 (N=258)   |
|-----------------------------------------|----------------------------|---------------------------|
| PFS by BIRC                             |                            |                           |
| # events n/N (%)                        | 98/192 (51.0%)             | 133/258 (51.6%)           |
| Median (95% CI) in months               | 14.9 (11.0, 18.5)          | 12.9 (10.1, 14.0)         |
| Log-rank p-value (*)                    | 0.0845                     |                           |
| Generalized Wilcoxon p-value (*)        | 0.3647                     |                           |
| HR (95% CI) (*)                         | 0.79 (0.60, 1.03)          |                           |
| PFS by Investigator                     |                            |                           |
| # events n/N (%)                        | 102/192 (53.1%)            | 136/258 (52.7%)           |
| Median (95% CI) in months               | 14.8 (10.4, 18.4)          | 12.9 (10.9, 14.8)         |
| Log-rank p-value (*)                    | 0.1918                     |                           |
| Generalized Wilcoxon p-value (*)        | 0.4569                     |                           |
| HR (95% CI) (*)                         | 0.84 (0.64, 1.09)          |                           |
| Confirmed Response per BIRC             |                            |                           |
| # responders (%)                        | 121 (63.0%)                | 170 (65.9%)               |
| 95% CI                                  | (55.8, 69.9)               | (59.8, 71.7)              |
| Confirmed DCR per BIRC                  |                            |                           |
| # responders (%)                        | 177 (92.2%)                | 234 (90.7%)               |
| 95% CI                                  | (87.4, 95.6)               | (86.5, 93.9)              |
| Duration of Confirmed Response per BIRC |                            |                           |
| # responders n/N (%)                    | 54/121 (44.6%)             | 81/170 (47.6%)            |
| Median (95% CI)                         | 16.6 (12.2, 20.4)          | 12.7 (9.3, 15.1)          |

Other efficacy parameters by BIRC showed similar results for the two combinations (ORR = 63.0% vs 65.9% and DCR = 92.2% vs 90.7%, respectively).  However, the duration of confirmed responses was longer for Combo 450 vs Combo 300 (16.6 months vs 12.7 months) which is aligned with the difference in PFS.

Similar results were seen when comparing median PFS per Investigator (14.8 vs 12.9 months, respectively). ORRs per Investigator review were also similar, although higher (75.0% vs 72.5%).

The analysis performed using the 09 November 2016 cut-off date for the two arms was supportive.

<div style=\"page-break-after: always\"></div>

Table 55: Direct Comparisons Combo 450 vs Combo 300 (Cut-off date for both: 09 Nov 2016) - FAS Population - Stratified Analyses

|                                     | Combo 450 P1 (N=192) 09Nov2016   | Combo 300 P2 (N=258) 09Nov2016   |
|-------------------------------------|----------------------------------|----------------------------------|
| PFS by BIRC                         |                                  |                                  |
| # events n/N (%)                    | 104/192 (54.2%)                  | 133/258 (51.6%)                  |
| Median (95% C1) in months           | 15.5 (11.0, 20.2)                | 12.9 (10.1, 14.0)                |
| Event-free at 12 months, % (95% CI) | 56.7 (48.8, 63.9)                | 51.9 (45.1, 58.2)                |
| Log-rank p-value (*)                | 0.0573                           |                                  |
| Generalized Wilcoxon p-value (*)    | 0.3205                           |                                  |
| HR (95% CI) (*)                     | 0.77 (0.58, 1.01)                |                                  |
| PFS by Investigator                 |                                  |                                  |
| # events n/N (%)                    | 109/192 (56.8%)                  | 136/258 (52.7%)                  |
| Median (95% C1) in months           | 14.8 (10.4, 18.4)                | 12.9 (10.9, 14.8)                |
| Event-free at 12 months, % (95% CI) | 53.8 (46.0, 60.9)                | 50.5 (43.9, 56.8)                |
| Log-rank p-value (*)                | 0.1664                           |                                  |
| Generalized Wilcoxon p-value (*)    | 0.4314                           |                                  |
| HR (95% CI) (*)                     | 0.83 (0.63, 1.08)                |                                  |

(*) two-sided p-values. Log-rank test, Wilcoxon's test and Cox PH model are stratified by IVRS AJCC and ECOG performance status

The multivariate Cox regression model stratified by the study stratification factors the applicant concluded a benefit of Combo 450 over Combo 300 for PFS when adjusting for the main prognostic factors [HR 0.74 (95% CI 0.56-0.98), nominal p value =0.0387] at the cut-off dates for initial analysis (19 May 2016 and 9 November 2016, respectively).

The propensity score was estimated using a logistic regression model that incorporates 14 variables potentially related to the outcome and/ or treatment decision.

Table 56: Comparison of Baseline Covariates for Combo 450 and Combo 300

|                                                                                                                                                                                                                                                                           | P-value                                                                                                               |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|
| Sex Age Baseline BMI (kg/m) Race Region ECOG at baseline a Time from initial diagnosis to first metastasis Stage BRAF status Number of organs involved at baseline Baseline brain metastases Baseline liver metastases Prior adjuvant immunotherapy LDH at baseline (U/L) | 0.7702 1 0.5053 0.2979 0.2601 1 0.0067 1 0.5704 1 0.0453 0.5653 1 0.5846 1 0.3332 1 0.2633 1 0.8398 1 0.0970 1 0.0128 |

Tests: Wilcoxon for continuous variables, Chi-square (1) or Fisher (2) for categorical variables.

The effect of treatment on PFS was estimated using a non-adjusted regression analysis, stratified by the study stratification factors (ECOG and Stage). Then four PS approaches, including stratification (3

<div style=\"page-break-after: always\"></div>

and 5 strata), matching, and inverse probability weighting (IPW), were used to estimate the treatment effect on PFS and adjust for confounding factors. The different PS methods (adjusted and nonadjusted) gave similar results when comparing Combo 450 and Combo 300 for PFS, reaching an HR of 0.75 to 0.79, with an upper 95% CI above 1 (1.01 to 1.09).

## Ancillary analyses

None.

## Summary of main study(ies)

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table EF-03: Summary of efficacy for trial CMEK162B2301 (COLUMBUS, Part 1 only)

Title:  A  2-part  phase  III  randomized,  open  label,  multicentre  study  of  LGX818  plus MEK162 versus vemurafenib and LGX818 monotherapy in patients  with unresectable or metastatic BRAF V600 mutant melanoma

| Study identifier          | B2301                                                                          | B2301                                                                          | B2301                                                                                                    |
|---------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| Design                    | 2-part, multicentre, randomised, 3-arm, open-label                             | 2-part, multicentre, randomised, 3-arm, open-label                             | 2-part, multicentre, randomised, 3-arm, open-label                                                       |
| Design                    | Duration of main phase: Duration of Run-in phase: Duration of Extension phase: | Duration of main phase: Duration of Run-in phase: Duration of Extension phase: | Until PD/ unacceptable toxicity/ death Screening up to 21 days Follow-up post study drug discontinuation |
| Hypothesis                | Superiority                                                                    | Superiority                                                                    | Superiority                                                                                              |
| Treatments groups         | Combo 450                                                                      | Combo 450                                                                      | Encorafenib 450mg QD + binimetinib 45mg BID, N= 192                                                      |
| Treatments groups         | Enco 300                                                                       | Enco 300                                                                       | Encorafenib 300mg QD, N= 194                                                                             |
| Treatments groups         | Vemurafenib                                                                    | Vemurafenib                                                                    | Vemurafenib 960mg BID, N=191                                                                             |
| Endpoints and definitions | Primary endpoint                                                               | PFS by BIRC                                                                    | Combo 450 vs. vemurafenib                                                                                |
| Endpoints and definitions | Key secondary endpoint                                                         | PFS by BIRC                                                                    | Combo 450 vs. encorafenib                                                                                |
| Endpoints and definitions | Other secondary endpoints                                                      | ORR                                                                            | Assess ORR by treatment arms                                                                             |
| Database lock             | 19 May 2016                                                                    | 19 May 2016                                                                    | 19 May 2016                                                                                              |

## Results and Analysis

| Analysis description                           | Primary Analysis                                             | Primary Analysis                                             | Primary Analysis                                             | Primary Analysis                                             |
|------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|
| Analysis population and time point description | Intent to treat (Full analysis set) read centrally by a BIRC | Intent to treat (Full analysis set) read centrally by a BIRC | Intent to treat (Full analysis set) read centrally by a BIRC | Intent to treat (Full analysis set) read centrally by a BIRC |
| Descriptive statistics and estimate            | Treatment group                                              | Combo 450                                                    | Enco 300                                                     | Vemurafenib                                                  |

<div style=\"page-break-after: always\"></div>

| variability                    | Number of subjects           | 192                                 | 194                                 | 194                           | 191                           |
|--------------------------------|------------------------------|-------------------------------------|-------------------------------------|-------------------------------|-------------------------------|
| variability                    | Median PFS per BIRC (months) | 14.9                                | 9.6                                 | 9.6                           | 7.3                           |
| variability                    | 95% CI                       | 11.0, 18.5                          | 7.5, 14.8                           | 7.5, 14.8                     | 5.6, 8.2                      |
| variability                    | ORR per BIRC (%)             | 63.0                                | 50.5                                | 50.5                          | 40.3                          |
| variability                    | 95% CI                       | 55.8, 69.9                          | 43.3, 57.8                          | 43.3, 57.8                    | 33.3, 47.6                    |
| Effect estimate per comparison | Primary endpoint             | Comparison groups                   | Comparison groups                   | PFS Combo 450 vs. Vemurafenib | PFS Combo 450 vs. Vemurafenib |
| Effect estimate per comparison | Primary endpoint             | HR                                  | HR                                  | 0.54                          | 0.54                          |
| Effect estimate per comparison | Primary endpoint             | 95% CI                              | 95% CI                              | 0.41, 0.71                    | 0.41, 0.71                    |
| Effect estimate per comparison | Primary endpoint             | 1 sided stratified log rank P-value | 1 sided stratified log rank P-value | <0.001                        | <0.001                        |
| Effect estimate per comparison | Key secondary endpoint       | Comparison groups                   | Comparison groups                   | PFS Combo 450 vs Enco 300     | PFS Combo 450 vs Enco 300     |
| Effect estimate per comparison | Key secondary endpoint       | HR                                  | HR                                  | 0.75                          | 0.75                          |
| Effect estimate per comparison | Key secondary endpoint       | 95% CI                              | 95% CI                              | 0.56, 1.00                    | 0.56, 1.00                    |
| Effect estimate per comparison | Key secondary endpoint       | 1 sided P-value                     | 1 sided P-value                     | 0.026                         | 0.026                         |

## Analysis performed across trials (pooled analyses and meta-analysis)

The applicant did not submit analyses across trials.

## Clinical studies in special populations

In study B2301 the following proportions of patients aged ≥65 years were recruited to each treatment arm.

Table 57: Proportions of patients aged ≥ 65 years were recruited to each treatment arm

|                     | Encorafenib 450mg + Binimetinib N=192   | Encorafenib N=194   | Vemurafenib N=191   | Total N=577   |
|---------------------|-----------------------------------------|---------------------|---------------------|---------------|
| Age ≥65 years, n(%) | 60 (31.3)                               | 40 (20.6)           | 51 (26.7)           | 151 (26.2)    |

Table 58: Unstratified Cox Regression Model for PFS per Central Review by Subgroup -age ≥ 65 years (FAS, Part 1)

|                          | Event N (%)   | Median Time [2]   | Cox model [1]   | Cox model [1]   |
|--------------------------|---------------|-------------------|-----------------|-----------------|
|                          |               | months (95% CI)   | Hazard ratio    | 95% CI          |
| Age ≥ 65 years Combo 450 | 29/ 60 (48.3) | 11.0 (7.6, NE)    |                 |                 |
| Encorafenib [3]          | 21/ 40 (52.5) | 8.0 (5.4, 15.9)   | 0.71            | (0.40, 1.25)    |
| Vemurafenib [4]          | 26/51 (51.0)  | 7.3 (4,1. 11.0)   | 0.66            | (0.39, 1.12)    |

<div style=\"page-break-after: always\"></div>

[3] Analyses comparing Encorafenib 450 + Binimetinib versus Encorafenib (Part 1) only consider data from patients randomized to those treatment groups. Hazard ratio Encorafenib 450mg + Binimetinib versus Encorafenib. Encorafenib is the reference group.

[4] Analyses comparing Encorafenib 450 + Binimetinib versus Vemurafenib only consider data from patients randomized to those treatment groups. Hazard ratio Encorafenib 450mg + Binimetinib versus Vemurafenib. Vemurafenib is the reference group.

## Supportive study(ies)

## Supportive study: CLGX818X2109- LOGIC 2

Study CLGX818X2109 (LOGIC  2)  is  an  ongoing  multicentre,  open-label,  2-part  Phase  2  study  of sequential LGX818/MEK162 (encorafenib/binimetinib) combination followed by a rational combination with targeted agents after progression, with the aim of overcoming resistance in adult patients with locally advanced or metastatic BRAF V600 melanoma. There was no control group.

BRAF mutation was assessed from blood samples locally and from tumour samples (archival or fresh), both locally and centrally. Eligibility was based on local tumour BRAF mutation results and included all V600 mutations (e.g. V600E, K, D, L or R).

Patients were to be ≥ 18 years of age with AJCC stage IIIC or IV melanoma, measurable disease as determined  by  RECIST v1.1 and an ECOG PS of ≤2. Patients were to have no symptomatic brain metastases or symptomatic/ untreated leptomeningeal disease. No prior treatment was allowed with radiation therapy (&gt; 30% of the bone marrow reserve), chemotherapy, biological therapy within ≤ 4 weeks  or  small  molecule  therapeutics  or  investigational  agents  within  5-half-lives  prior  to  starting study drug. Patients had to have recovered from the side effects of prior therapy.

In Part 1, patients were treated with the recommended Phase 2 dose (RP2D) of encorafenib 450mg QD in combination with binimetinib 45 mg BID [Combo 450]) until PD (as defined per RECIST v1.1) or no clinical benefit. Three different patient populations were included:

• Group A: Patients naïve to treatment with BRAF inhibitors

·  Group  B:  Patients  who  progressed  after  single-agent  BRAF  or  MEK  inhibitor  or  after  combination BRAF and MEK  inhibitors other than binimetinib/encorafenib or receiving binimetinib and/or encorafenib, who had not progressed yet or, in consultation with the Sponsor, who received any BRAF and/or MEK inhibitor other than binimetinib and/or encorafenib and had not progressed yet.

• Group C: Patients who progressed after binimetinib/encorafenib combination therapy

In  Part  2,  patients  previously  treated  with  binimetinib/encorafenib  combination  therapy  and  who relapsed on this therapy received tailored combination treatment with binimetinib/encorafenib and a third agent in one of four arms based on genetic assessment of a tumour biopsy obtained at disease progression. The four agents were BKM120 (PI3K inhibitor), BGJ398 (FGFR inhibitor), INC280 (cMET inhibitor) and LEE011 (CDK 4/6 inhibitor).

No primary efficacy endpoint was defined for Part 1 as it was designed as a run-in stage for Part 2 to allow  patients  initially  naïve  to  treatment  with  BRAF/MEK  inhibitors  (Group  A)  to  meet  the  Part  2 eligibility criterion of being resistant to the MEK/BRAF inhibitor combination.

The  primary  efficacy  endpoint  for  Part  2  of  the  study  was  the  ORR,  defined  as  the  proportion  of patients  with  a  best  overall  response  [BOR]  of  CR  or  PR  as  determined  by  the  Investigator  using RECIST v1.1. The key secondary endpoint was PFS with other secondary endpoints of DOR, TTR (time to response), DCR (disease control rate) and OS. Evaluations of ORR, PFS, DOR, TTR and DCR were

<div style=\"page-break-after: always\"></div>

also performed and analysed for Part 1. The CSR for Part 1 presents data for Groups A, B and C but the focus here is on data from Group A i.e. BRAF and MEK inhibitor-naïve patients. The FAS included all patients who received at least one dose of encorafenib or binimetinib and was used for the analysis of all endpoints unless noted otherwise.

A total of 75 treatment-naïve patients were enrolled into Part 1 (Group A) of the study between 31 July 2014  and  15  January  2016.  As  of  the  data  cut-off  (18  February  2016),  44  patients  (58.7%)  were ongoing with Combo 450 treatment. The most common reason for discontinuation from Combo 450 study treatment was PD (25.3%). As of the data cut-off, 13 patients (17.3%) had continued to Part 2 of the study.

Table 59: Study CLGX818X2109: Patient Disposition (Treatment-Naïve Patients, Part 1)

| Disposition Reason                                                                                                                                                                                                                                                                                                                                                                                       | Combo 450 (Treatment-Naïve) N =75 n (%)                                                     |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|
| Patients treated in Part 1 Treatment ongoing a End of treatment Primary reason for end of Part 1 treatment Adverse event(s) Completed Death Physician decision Progressive disease Withdrawal by parent/guardian Study follow-up after end of Part 1 treatment b Patients entering Part 2 Patients continuing to be followed for study evaluation Patients no longer being followed for study evaluation | 44 (58.7) 31 (41.3) 3 (4.0) 0 5 (6.7) 1 (1.3) 19 (25.3) 3 (4.0) 13 (17.3) 2 (2.7) 16 (23.1) |

Most patients were Caucasian (n=74, 98.7%), and there were more males enrolled (n= 47, 62.7%) than females. The median age was 56 years and nearly a quarter were aged ≥65 years (n=18, 24%). Most patients had an ECOG PS of 0 (n=55, 73.3%) and had AJCC stage IV disease (93.3%) at study entry. Baseline LDH was high in 18.7% (n=14) of patients; however, 40 patients (53.3%) did not have a baseline LDH value reported as this was not required until Protocol Amendment 2 (November 2014).

The  proportion  of  patients  with  skin  melanoma  as  the  primary  site  of  cancer  was  lower  than  in Columbus (82.7% vs &gt;99%) but, conversely, the proportion of patients with an unknown primary site was higher (6.7%).  The most common sites of metastases were lymph nodes (70.7%), lung (57.3%), liver  (40.0%)  and  bone  (26.7%).  Brain  metastases  at  baseline  were  reported  in  5.3%  of  patients. Forty-percent  of  patients  had  received  prior-antineoplastic  medication.  More  patients  had  received prior  immunotherapy  with  ipilimumab  (21%)  than  in  study  B2301  (≤5%).  Patients  could  have  had prior systemic chemotherapy and 2.7% of treatment-naïve patients in Study CLGX818X2109 had prior treatment with alkylating agents (dacarbazine, dacarbazine citrate).

Table 60: Study CLGX818X2109: Prior Cancer Therapy (Treatment-Naïve Patients, Part 1)

| Disease history   | Combo 450 (Treatment-Naïve) N =75 n (%)   |
|-------------------|-------------------------------------------|
| Any therapy       |                                           |

<div style=\"page-break-after: always\"></div>

| Medication                                 | 30 (40.0)   |
|--------------------------------------------|-------------|
| Surgery                                    | 74 (98.7)   |
| Radiotherapy                               | 18 (24.0)   |
| Antineoplastic medication                  |             |
| Protein kinase inhibitors                  | 0           |
| Monoclonal antibodies                      | 21 (28.0)   |
| Ipilimumab                                 | 16 (21.3)   |
| Pembrolizumab                              | 3 (4.0)     |
| Nivolumab                                  | 5 (6.7)     |
| Other                                      | 1 (1.3)     |
| Interferons                                | 12 (16.0)   |
| Radiotherapy: setting at last radiotherapy |             |
| Adjuvant                                   | 12 (16.0)   |
| Therapeutic                                | 1 (1.3)     |
| Palliative                                 | 5 (6.7)     |

Protocol deviations in BRAF/MEK-treatment naïve patients were reported for 28.0% of patients, 4.0% were due to eligibility violations and 21.3% were assessment deviations.

At data cut-off (18 February 2016), the median duration of exposure to study treatment for treatment naïve  patients  was  31.14  weeks  (range,  3.86  to  80.57).  The  confirmed  ORR  per  investigator  was 69.3% (95% CI 57.9, 79.5). Most patients experienced disease improvement or control, as the DCR was 90.7% (95% CI 81.7, 96.2).

Updated  results  from  the  data  cut-off  point  of  30  December  2016  have  been  provided  and  are summarised in the table below.

Table 61: Study CLGX818X2109: Best Overall Response per Investigator Assessment (FAS, Part 1)

|                          | Combo 450 (Treatment-Naive) N=75 n (%)   |
|--------------------------|------------------------------------------|
| Confirmed BORa, b        |                                          |
| CR                       | 6 (8.0)                                  |
| PR                       | 49 (65.3)                                |
| SD                       | 15 (20.0)                                |
| PD                       | 3 (4.0)                                  |
| Unknown                  | 2 (2.7)                                  |
| Confirmed ORR: CR + PR   | 55 (73.3)                                |
| pID %S6                  | (61.9, 82.9)                             |
| Confirmed DCR: CR+PR+ SD | 70 (93.3)                                |
| 95%CId                   | (85.1, 97.8)                             |

BID: twice daily;BOR: best overall response; Combo 450: binimetinib 45 mg BID in combination with encorafenib 450 mg QD; CR: complete response; DCR: disease control rate; ORR: objective response rate; PD: progressive disease; PR: partial response; QD: once daily; SD: stable disease

Source: Efficacy Appendix Table Q40BT 3.1

* Best overall response is based on local assessment using RECIST v1.1.

* Unknown = Progression has not been documented and one or more lesions have not been assessed or have been assessed using a differentmethodthanbaseline.

b CR and PR are confirmed by repeat assessments peformed not less than 4 weeks after the criteria for response is first met.

d The 95% CI for the frequency distribution of each variable were computed using Clopper-Pearson's method.

<div style=\"page-break-after: always\"></div>

Table 62: Study CLGX818X2109: Kaplan-Meier Summary of PFS by Investigator Assessment (FAS, Part 1)

|                                  | Combo 450 (Treatment-Naive) N =75 n (%)   |
|----------------------------------|-------------------------------------------|
| Number of PFS events             | 44/75 (58.7)                              |
| Progression                      | 38 (50.7)                                 |
| Death without progression        | 6 (8.0)                                   |
| Number censored                  | 31 (41.3)                                 |
| Percentiles (95% CI)a (months)   |                                           |
| 25th                             | 6.3 (4.6, 7.1)                            |
| 50th                             | 10.8 (8.1, 15.2)                          |
| 75th                             | 22.8 (15.4, NE)                           |
| Kaplan-Meier estimates (95% C1)b |                                           |
| 6 months                         | 76.2 (64.5, 84.4)                         |
| 12 months                        | 42.1 (30.3, 53.5)                         |
| 18 months                        | 35.2 (23.4, 47.2)                         |
| 24 months                        | 17.6 (1.9, 46.6)                          |

Source: Efficacy Appendix Table Q40BT1.1 and Q40B T1.2

Table 63: Study CLGX818X2109: Kaplan-Meier Plot of PFS by Investigator Assessment (FAS, Part 1)

<!-- image -->

<div style=\"page-break-after: always\"></div>

## 2.5.1. Discussion on clinical efficacy

## Design and conduct of clinical studies

The  pivotal  study CMEK162B2301  (COLUMBUS) was  a  Phase  3,  randomised,  open  label  study comprising  2  parts.  The  primary  endpoint  was  PFS  with  Combo  450  vs.  vemurafenib.  The  key secondary endpoint was PFS with Combo 450 vs. Enco 300 from Part 1 (plus PFS Combo 300 vs. Enco 300 from Part 2). With the hierarchical testing procedure, the secondary endpoint of OS Combo 450 vs.  vemurafenib  was  to  be  tested  only  if  these  comparisons  were  statistically  significant.  The  PFS analyses were conducted after more than the planned number of events had occurred [204 PFS events (planned 145) for Combo 450 vs. vemurafenib and 223 PFS events (planned 191) for Combo 450 vs. Enco 300].

The DMC reviewed the results (and unblinded survival data) to which the applicant remained blinded and recommended that the planned analyses be terminated and all patients be informed of the Part 1 results.  Patients in  the  vemurafenib arm were to be advised that a BRAF-MEK inhibitor combination might  be  a  better  alternative.    There  were  no  specific  recommendations  regarding  the  encorafenib monotherapy  arm.  The  OS  analysis  will  likely  be  confounded  by  patients  in  the  monotherapy  arms seeking alternative treatments. This early termination is probably inevitable as Combo 450 was being compared to single agent BRAF inhibitor which would not now be considered standard of care in this setting.  Patients  with  V600  mutant  tumours  would  routinely  be  treated  with  a  BRAF-MEK  inhibitor combination. Still, it is accepted that at the time the trial was designed, the combination of BRAF/MEK inhibitor was not the SoC..

The study was open label, given the likelihood of functional unblinding from the predicted treatment toxicities.  Efficacy  assessment  by  blinded  independent review was appropriate to prevent evaluation bias. Progression free survival as the primary endpoint is accepted as a meaningful reduction in the risk  of  progression  or  death  represents  a  clinical  benefit  in  patients  with BRAF mutation-positive melanoma. It also allowed for more rapid assessment, mitigating the potentially confounding effects of post-study treatments on OS. Overall, the design of the study is acceptable and the study was well conducted.

Supportive data is provided from Study CLGX818X2109 (LOGIC 2) , an open-label, single arm, Phase 2 trial. Data has been provided from a subsection of patients (n=75) in Part 1 - Group A - no prior treatment with a BRAF inhibitor.  There was no pre-defined efficacy endpoint but ORR, PFS, DOR, TTR and DCR were evaluated and provided supportive evidence of efficacy.

## Efficacy data and additional analyses

The  primary  endpoint  of  the  pivotal  study,  CMEK162B2301,  was  met  as  Combo  450  significantly improved median PFS versus vemurafenib alone (14.9 vs. 7.3 months) based on BIRC review in the full analysis set (FAS) with a HR of 0.54 (95% CI, 0.41, 0.71) (one-sided stratified log rank p&lt;0.001) which was statistically significant. PFS curves separate early (after approximately 1-2 months) and do not intersect until near the end of follow-up where the number of patients in each arm is ≤ 4. Median follow-up time for PFS per BIRC was 16.7 months for the Combo 450 arm and 14.4 months for the vemurafenib arm. About 50% of patients were censored at the time of the analysis,  approximately 30% in  the  Combo  450  arm  due  to  remaining  on  treatment  and  20%  in  the  vemurafenib  arm  for starting a new anti-cancer therapy. As the DMC recommended termination of further analyses and all patients  in  the  vemurafenib  arm  receive  BRAF-MEK  inhibitor  combination  therapy  there  will  be  no further information on this direct comparison.

<div style=\"page-break-after: always\"></div>

The  sensitivity  PFS  analyses  yielded  similar  HRs  (95%  CI)  and  median  PFS  values  to  the  primary analysis, reflecting the robustness of the PFS benefit. These included the investigator assessment in the  FAS,  the  per  protocol  set  (PPS)  and  tumour  assessments  after  initiation  of  further  anti-cancer therapy. The efficacy results based on investigator assessment were consistent with the independent central assessment.

Other than treatment, the only prognostic factor that significantly influenced PFS was LDH increase of 125 IU/L. The PFS benefit was consistent across the subgroups analysed, apart from the presence of brain  metastases.  Only  12  patients  (9  Combo  450  and  3  vemurafenib)  had  brain  metastases  at baseline so there were insufficient patients to evaluate efficacy in this subgroup. All patients had BRAF mutant V600 E or K melanoma, which comprise most BRAF mutant patients Across the 3 treatment arms only 24 patients (3.7% of the Combo 450 arm) had received prior ipilimumab in the adjuvant or metastatic  setting  and  3  patients  (0.5%  of  the  Combo  arm)  had  received  a  prior  anti  PD1/PDL1 inhibitor in the metastatic setting. The HR favoured Combo 450 in the small group of patients that had received  prior  immunotherapy  (n=15;  8  Combo  450  vs  7  vemurafenib)  although  the  confidence intervals were large. The use of Combo 450 in patients previously treated with a BRAF or MEK inhibitor is not supported. The median PFS in non-naïve patients in LOGIC 2 was 3.5 months.

Results for overall survival have been presented from the OS interim analysis with cut-off date 7 th November 2017, by which time a total of 232 OS events were observed in the Combo 450 and vemurafenib arms combined in Part 1 of the study. The median OS was 33.6 months (24.4, 39.2) and 16.9 months (14.0, 24.5), respectively, for patients treated with Combo 450 compared to those treated with vemurafenib with a HR 0.61 (95% CI 0.47, 0.79, nominal p value &lt;0.0001). The median OS was 33.6 months (24.4, 39.2) and 23.5 months (19.6, 33.6), respectively, for patients treated with Combo 450 compared to those treated with encorafenib with a HR 0.81 (95% CI 0.61, 1.06, nominal p value=0.0613). The observed HR and numerical increase in median OS supports the relevant contribution of binimetinib and demonstrates a statistically significant and clinically meaningful improvement in overall survival with the combination treatment of binimetinib and encorafenib compared with vemurafenib.

For  Combo  450  vs  vemurafenib  and  Combo450  vs  encorafenib,  results  of  the  planned  sensitivity analyses were consistent with those from the interim OS analysis and lead to similar conclusions about treatment effect. Most unstratified subgroup analyses also demonstrated median OS point estimates in favour of the Combo 450.

For the key secondary efficacy endpoint, the median PFS estimates by BIRC in the FAS were 14.9 and 9.6 months for Combo 450 and encorafenib, respectively, with a HR of 0.75 (95% CI 0.56, 1.00). The PFS  difference  of  5.3  months  just  missed  statistical  significance  (p  =  0.0256)  by  the  one-sided stratified log-rank test with a threshold of p &lt; 0.025. Therefore, by the hierarchical testing procedure none  of  the  further  endpoints  can  be  considered  statistically  significant  and  nominal  p  values  are presented for descriptive purposed only. Per Investigator assessment of response, the PFS difference between the Combo 450 and the encorafenib arm was consistent with that reported by the BIRC (14.8 months Combo 450 vs. 9.2 months Enco 300) and this difference reached nominal significance at the one-sided  0.025  level  (HR  0.68;  95%  CI  0.52,  0.90;  nominal  1-sided  p=0.003).  The  subgroup analyses,  including  the  unstratified  HRs,  were  generally  consistent  with  the  analysis  in  the  full population,  allowing  for  wide  confidence  intervals  in  the  subgroups  with  small  numbers  of  patients. There were some groups with small patient numbers where the HR was greater than 1 (e.g. number of organs involved at baseline 1 or &gt;3) but this is likely due to chance. Unstratified subgroup analyses demonstrated point estimates in favour of Combo 450, including LDH at baseline, ECOG performance status and AJCC stage. This supports benefit for the combination over single agent encorafenib, likely

<div style=\"page-break-after: always\"></div>

due  to  the  increased  tolerability  of  encorafenib  with  a  MEK  inhibitor  allowing  a  higher  dose  of encorafenib  to  be  administered  (450mg  vs  300mg)  as  well  as  the  anti-tumour  contribution  of binimetinib itself.

Part 2 of Study CMEK162B2301 was designed to assess the contribution of binimetinib to the encorafenib and binimetinib combination. Preliminary Part 2 data, at a cut-off date of 9 November 2016, demonstrated the contribution of binimetinib with an improved median PFS estimate of 12.9 months (95% CI: 10.1, 14.0) for Combo 300 compared to 9.2 months (95% CI: 7.4, 11.0) for Enco 300 (Parts 1 and 2) per independent central review (BIRC). The confirmed ORR per BIRC was 65.9% (95% CI: 59.8, 71.7) for Combo 300 and 50.4% (95% CI: 44.3, 56.4) for Enco 300 (Parts 1 and 2). Median DOR for confirmed responses per BIRC was 12.7 months [95% CI: 9.3, 15.1] for Combo 300 and 12.9 months [95% CI: 8.9, 15.5] for Enco 300. The median duration of treatment was longer for Combo 300 vs Enco 300, 52.1 weeks vs 31.5 weeks. The addition of binimetinib 45mg BID to encorafenib 300mg QD increased the median PFS by 3.7 months (stratified HR 0.77, 95% CI 0.61, 0.97; nominal 1-sided p=0.015) and the ORR by 15.5%. The investigator assessment and sensitivity analyses of PFS were similar. When only the patients randomised to Part 2 were assessed the results again supported a binimetinib contribution to efficacy; median PFS values (95% CI) were 12.9 months (10.1, 14.0) and 7.4 months (5.6, 9.2), respectively (HR 0.57, 95% CI: 0.41, 0.78; nominal one-sided p&lt;0.001 per stratified log-rank test). However, it is worth noting that the results for encorafenib monotherapy are better in part 1 than part 2 with a difference of over 2 months in median PFS. It is possible that differences in baseline characteristics (in particular age, stage of disease and elevated LDH) may be responsible for this difference in outcome. Some baseline imbalances can also be seen between Combo300 and Enco300 part 2. In particular, a greater proportion of the Enco 300 patients (Part 2) have Stage IV disease with elevated LDH compared with the Combo 300 patients.

Therefore, for patients that must reduce the dose to 300 mg due to ADRs, the data seems to indicate that patients will continue to have a similar magnitude of treatment effect.  The proposed dose regimen in the applied indication is Combo 450 (binimetinib 45mg BID and encorafenib 450mg QD). Combo 450 (part 1, n=192) and Combo 300 (part 2, n=258) were compared post-hoc. Median PFS by BIRC was not statistically significantly longer with Combo 450 vs Combo 300 (14.9 months [95% CI 11.0, 18.5] vs 12.9 months [95% CI 10.1, 14.0]; HR 0.79 [95% CI 0.60, 1.03]; one-sided log-rank p=0.0845) at the cut-off dates for initial analysis (19 May 2016 and 9 November 2016, respectively). Combo 450 did not increase the proportion of confirmed responses (63.0% vs. 65.9%), although the median duration of confirmed response was longer (16.6 vs. 12.7 months, with overlapping confidence intervals).  When Combo 450 and Combo 300 were compared at the same cut-off (9 November 2016) there had been an additional 5 PFS events in the Combo 450 arm; median PFS by BIRC was 15.5 vs. 12.9 months (stratified HR 0.77, 95% CI 0.58, 1.01; 2-sided log rank p value 0.0573). However as noted above, patients enrolled to part 2 of the trial seem to have a worse prognosis than those in part 1.

The confirmed response rate (CR + PR) was higher in the Combo 450 group (63.0%) compared with encorafenib (50.5%) and vemurafenib (40.3%). Confirmed ORR in the small subgroup of patients with prior first-line immunotherapy was lower but showed the same pattern as in the overall population; Combo  450  (N=8)  50.0%;  encorafenib  (N=11)  45.5%;  vemurafenib  (N=7)  28.6%.  These  were  all partial  responses,  with  no  complete  responses  in  this  subgroup.  The  median  time  to  response  for responders in all treatment arms was short (1.9 - 2.1 months), which corresponds with the first postbaseline response assessment at Cycle 3 Day 1. The median duration of response (DOR) per BIRC, calculated for confirmed responses, was longer in the Combo 450 arm (16.6 months) in the Combo 450 arm than the encorafenib (14.9 months) or vemurafenib arms (12.3 months).

<div style=\"page-break-after: always\"></div>

The PRO findings appeared supportive. The Functional Assessment of Cancer Therapy-Melanoma (FACT M), the European  Organisation for Research  and  Treatment  of Cancer's core quality of life questionnaire (EORTC QLQ C30) and the EuroQoL 5 Dimension 5 Level examination (EQ 5D 5L) were used  to explore patient-reported  outcomes  (PRO)  measures  of  health-related  Quality  of  Life, functioning, melanoma  symptoms,  and  treatment-related  adverse  reactions. A definitive  10% deterioration  in  FACT  M  and  in  EORTC  QLQ-C30  was  significantly  delayed  in  patients  treated  with Combo 450 relative to other treatments. The median time to definitive 10% deterioration in the FACTM score was not reached in the Combo 450 arm and was 22.1 months (95% CI: 15.2, NE) in the vemurafenib arm with a HR for the difference of 0.46 (95% CI: 0.29, 0.72). An analysis of time to definitive 10% deterioration in EORTC QLQ C30 score provided with similar results.

Patients receiving Combo 450 reported no change or a slight improvement in the mean change from baseline  EQ  5D  5L  index  score  at  all  visits,  whilst  patients  receiving  vemurafenib  or  encorafenib reported decreases at all visits (with statistical significant differences). An evaluation of change over time in score yielded the same trend for EORTC QLQ C30 and at all visit for FACT M).

The results from the Phase 2 study CLGX818X2109 provided preliminary support regarding the efficacy of Combo 450 in the treatment of BRAF V600 mutant melanoma. The overall response rate (confirmed ORR) of 69.3% was similar but the median PFS was shorter (14.9 months in Study CMEK162B2301 vs. 9.5 months in Study CLGX818X2109). This may be because the PFS data was not fully mature at the time of data cut off; median follow up time was 6.4 months compared to 16.7 months for the Combo 450 arm in the COLUMBUS trial. Tumour assessments were performed every 8 weeks in COLUMBUS compared to every 4 weeks in LOGIC 2.

Binimetinib is to be given in combination with encorafenib. For additional information on warnings and precautions associated with encorafenib treatment, see section 4.4 of encorafenib SmPC.

## BRAF mutation testing

Before taking binimetinib in combination with encorafenib, patients must have BRAF V600 mutation confirmed by validated test. The efficacy and safety of binimetinib in combination with encorafenib have been established only in patients with tumours expressing BRAF V600E and V600K mutations. Binimetinib in combination with encorafenib should not be used in patients with wild type BRAF malignant melanoma.

## Binimetinib in combination with encorafenib in patients who have progressed on a BRAF inhibitor

There are limited data for use of the combination of binimetinib with encorafenib in patients who have progressed on a prior BRAF inhibitor given for the treatment of unresectable or metastatic melanoma with BRAF V600 mutation. These data show that the efficacy of the combination would be lower in these patients.

## Binimetinib in combination with encorafenib in patients with brain metastases

There are limited efficacy data with the combination of binimetinib and encorafenib in patients with a BRAF V600 mutant melanoma which have metastasised to the brain (see section 5.1).

The safety and efficacy of binimetinib in children and adolescents have not yet been established. No data are available. The European Medicines Agency has deferred the obligation to submit the results of studies with binimetinib in one or more subsets of the paediatric population in melanoma (see section 4.2 for information on paediatric use).

<div style=\"page-break-after: always\"></div>

## 2.5.2. Conclusions on the clinical efficacy

Overall,  Combo  450  demonstrates  both  a  statistically  significant  and  clinically  meaningful  benefit  in PFS  over  the  comparator  vemurafenib  as  well  as  a  clinically  relevant  benefit  over  encorafenib monotherapy at its maximally tolerated monotherapy dose of 300 mg QD. The OS results of Part I of the COLUMBUS study demonstrate a statistically significant benefit favouring the Combo 450 treatment over vemurafenib.

The  combination  therapy  of  binimetinib  and  encorafenib  showed  an  improved  efficacy  compared  to BRAF inhibitors given as monotherapies (vemurafenib and encorafenib) which is consistent with clinical data from other combination therapies of BRAF/MEK inhibition of patients with advanced or metastatic melanoma harbouring BRAF V600 mutations.

The CHMP requests the following measures to address issues related to efficacy:

- -OS results for Combo 300 and updated Combo 300 PFS analysis, including more mature data for the Enco300 Part 2 arm.

## 2.6. Clinical safety

The  safety  data  from  a  total  of  864  patients  were  presented;  427  patients  received  binimetinib monotherapy and 437 patients received binimetinib in combination with encorafenib.

As of 20 January 2016, a total of 2555 healthy subjects and patients have received at least 1 dose of binimetinib.  The  specific  combination  of  binimetinib  plus  encorafenib  has  been  evaluated  in  274 patients with metastatic melanoma at the recommended doses of 450 mg once daily [QD] encorafenib and  45  mg  twice  daily  [BID]  binimetinib  (Combo  450),  with  121  (44.2%)  patients  exposed  to  this combination for ≥48 weeks.

Data  from  5  supportive  clinical  trials  in  patients  with  unresectable  or  metastatic  melanoma  were included for the safety evaluation of the combination of binimetinib and encorafenib for the treatment of patients with unresectable or metastatic BRAF V600-mutant melanoma (Figure 23):

- 3 clinical studies are pooled to summarise the safety of the combination
- 2 clinical studies are pooled to summarise the safety of binimetinib monotherapy.

<div style=\"page-break-after: always\"></div>

## Supportive Clinical studiesforBinimetinibincombinationwithEncorafenibMAA

<!-- image -->

## InformativeClinicalstudyforBinimetinibincombinationwithEncorafenibMAA

Array11ThMStdy（MEKhibioriw-graeerousvarianCancer）:MultinationanmizenLabehasStudfbinimtinibshysicianChiceChmtherapinPatietswitheurrenr PersistentLow-gradeSerousCarcinomasoftheOvary,FallopianTubeorPrimaryPeritoneum

## Figure 23: Supportive Clinical Trials for the Binimetinib and Encorafenib Combination

The safety data presented includes:

- The binimetinib monotherapy safety pool , which includes data from 427 patients with metastatic melanoma, who were previously naïve to MEK inhibitors and were enrolled at or randomised to a dose of  45  mg  BID  binimetinib  (269  patients  from  Study  CMEK162A2301  and  158  patients  from  Study CMEK162X2201).
-  The broad  combination  safety  pool ,  which  includes  pooled  data  from  437  patients  with BRAF V600-mutant metastatic melanoma enrolled at or randomized to a dose of 45 mg BID binimetinib plus various  doses  of  encorafenib,  ranging  from  400  mg  QD  to  600  mg  QD  (192  patients  from  Study CMEK162B2301  [Part  1],  158  patients  from  Study  CLGX818X2109  and  87  patients  from  Study CMEK162X2110).
- The restricted combination safety pool , which includes data from 274 patients with BRAF V600mutant metastatic melanoma enrolled at or randomized to a dose of 45 mg BID binimetinib plus 450 mg  QD  encorafenib  (192  patients  from  Study  CMEK162B2301  [Part  1],  75  patients  from  Study CLGX818X2109 [Group A] and 7 patients from Study CMEK162X2110) who were previously naïve to BRAF inhibitors (either as monotherapy or in combination with a MEK inhibitor).

Two displays are utilised:

<div style=\"page-break-after: always\"></div>

·  The Broad Safety Set ,  which  includes  columns  for  the  binimetinib  monotherapy  safety  pool,  the broad  combination  safety  pool,  the  restricted  combination  safety  pool,  and  CMEK162B2301  Part  1 treatment arms (binimetinib in combination with encorafenib [Combo 450], encorafenib monotherapy [Enco 300] arm and vemurafenib arm).

·  The Restricted Safety Set ,  which  includes  columns for the binimetinib monotherapy safety pool, the  restricted  combination  safety  pool  and  CMEK162B2301  Part  1  treatment  arms  (binimetinib  in combination with Enco 300 arm, encorafenib monotherapy arm and vemurafenib arm).

## In the pooled safety analyses

· 'Combo 450' refers  to  the  combination of binimetinib 45 mg BID and encorafenib 450 mg QD in Study CMEK162B2301 [Part 1]

· 'Combo  RP' refers  to  the  restricted  combination  safety  pool  (patients  who  received  doses  of binimetinib at 45 mg BID in combination with encorafenib at 450 mg QD,

· ' Combo BP' refers to the broad combination safety pool (who received doses of binimetinib at 45 mg BID in combination with encorafenib ranging from 400 mg to 600 mg QD).

· 'Bini P' refers to the pooled binimetinib monotherapy population.

At the cut-off date for the studies with encorafenib+ binimetinib combination [CMEK162B2301 (09 Nov 2016), CLGX818X2109 ( 20 Dec 2016), CMEK162X2110 (31 Dec 2016)] and for binimetinib monotherapy [CMEK162B2301 Part 1 (09 Nov 2016), CLGX818X2101 Part 1 (18 Aug 2014), CLGX818X2102 (05 May 2015)], 83 of 274 (30.3%) patients and 37 of 217 patients (17.1%) remained on treatment in the Combo 450°RP and in the Enco 300°P, respectively.

## Patient exposure

As of 20 January 2016, a total of 2555 subjects which comprises 220 healthy subjects, 164 patients with  rheumatoid  arthritis,  12  patients  with  hepatic  dysfunction  and  2159  patients  with  advanced cancer,  have  received  at  least  1  dose.  The  specific  combination  of  binimetinib  plus  encorafenib  has been evaluated in 274 patients with metastatic melanoma at the recommended doses of 45 mg BID binimetinib and 450 mg QD encorafenib (Combo 450).

The median duration of exposure was 11.7 months in patients treated with Combo 450, 7.1 months in patients treated with encorafenib 300 mg and 6.2 months in patients treated with vemurafenib.

In the Combo 450 RP population, the median relative dose intensity of encorafenib and binimetinib was 99.66% and 99.50%. The relative dose intensity in the Combo 450 RP population for encorafenib was 100% for 123 patients (44.9%) and 100% for binimetinib in 109 patients (39.8%).

The median relative dose intensity for encorafenib remained higher in the Combo 450 RP population compared to the Enco 300 P population (99.66% vs 84.98%) and a higher proportion of patients in the Combo  450  RP  population  had  a  relative  dose  intensity  of  100%  (44.9%  vs  28.6%).  The  median relative dose intensity (RDI) for Combo 450 was 99.6 % for binimetinib and 100 % for encorafenib the median RDI was 86.2 % for Enco 300 and 94.5 % for vemurafenib.

<div style=\"page-break-after: always\"></div>

## Table 64: Duration of Exposure to Study Drug

|                                  | Melanoma             | Melanoma             | Melanoma                 | Melanoma              | Stuidy CMEK162B2301   | Stuidy CMEK162B2301           | Stuidy CMEK162B2301   |
|----------------------------------|----------------------|----------------------|--------------------------|-----------------------|-----------------------|-------------------------------|-----------------------|
|                                  | Bini 45 mg BID N=427 | Enco 300 mg QD N=217 | Combo pooled doses N=433 | Combo 450 mg QD N=274 | mg QD N=192           | Combo 450Enco 300 mg QD N=192 | Vemurafenib N=186     |
| Duration of exposure (weeks) [1] |                      |                      |                          |                       |                       |                               |                       |
| n                                | 427                  | 217                  | 433                      | 274                   | 192                   | 192                           | 186                   |
| Mean                             | 18.91                | 40.44                | 41.96                    | 48.90                 | 54.32                 | 42.42                         | 35.94                 |
| SD                               | 19.470               | 30.342               | 30.607                   | 29.485                | 30.881                | 31.181                        | 29.474                |
| Median                           | 13.00                | 29.71                | 34.00                    | 41.93                 | 51.21                 | 31.36                         | 27.14                 |
| Minimum                          | 0.3                  | 0.1                  | 0.1                      | 0.4                   | 0.4                   | 0.1                           | 0.9                   |
| Maximum                          | 183.33               | 113.3                | 132.9                    | 128.7                 | 116.0                 | 113.3                         | 121.6                 |
| Patient-months                   | 1856.95              | 2018.30              | 4178.79                  | 3081.43               | 2398.69               | 1872.89                       | 1537.31               |
| Exposure ≥48 weeks, n(%)         | 30 (7.00)            | 77 (35.5)            | 157 (36.3)               | 121 (44.2)            | 101 (52.6)            | 75 (39.1)                     | 47 (25.3)             |

Source: ISS Table 1.5.1.1

[1] Duration of exposure is defined as: date of last exposure to study treatment - date of first administration of study treatment +1.

## Adverse events

Table 65 presents an overall summary of AEs and deaths for the Broad Safety Set.

<div style=\"page-break-after: always\"></div>

Table 65: Death and Overall Summary of Adverse Events by Treatment (Broad Safety Set)

|                              | Melanoma                  | Melanoma                  | Melanoma                       | Melanoma                   | StudyCMEK162B2301          | StudyCMEK162B2301         | StudyCMEK162B2301       |
|------------------------------|---------------------------|---------------------------|--------------------------------|----------------------------|----------------------------|---------------------------|-------------------------|
|                              | Bini 45mg BID N=427 n (%) | Enco 300mg QD N=217 n (%) | Combo pooled doses N=433 n (%) | Combo 450mg QD N=274 n (%) | Combo 450mg QD N=192 n (%) | Enco 300mg QD N=192 n (%) | Vemurafenib N=186 n (%) |
| On-treatment deaths [1]      | 46 (10.8)                 | 15 (6.5)                  | 44 (10.2)                      | 23 (8.4)                   | 17 (8.9)                   | 14 (7.3)                  | 19 (10.2)               |
| Adverse events (AEs)         |                           |                           |                                |                            |                            |                           |                         |
| All grades                   | 427 (100)                 | 216 (99.5)                | 426 (98.4)                     | 271 (98.9)                 | 189 (98.4)                 | 191 (99.5)                | 185 (99.5)              |
| Grades 3/4                   | 285 (66.7)                | 146 (67.3)                | 254 (58.7)                     | 159 (58.0)                 | 111 (57.8)                 | 127 (66.1)                | 118 (63.4)              |
| Suspected to be drug-related |                           |                           |                                |                            |                            |                           |                         |
| All grades                   | 414 (97)                  | 216 (99.5)                | 386 (89.1)                     | 246 (89.8)                 | 169 (89.8)                 | 191 (99.5)                | 180 (96.8)              |
| Grades 3/4                   | 209 (48.9)                | 109 (50.2)                | 142 (32.8)                     | 91 (33.2)                  | 69 (35.9)                  | 95 (49.5)                 | 85 (45.7)               |
| Serious adverse events       |                           |                           |                                |                            |                            |                           |                         |
| All grades                   | 141 (33)                  | 69 (31.8)                 | 158 (36.5)                     | 98 (35.8)                  | 66 (34.4)                  | 65 (33.9)                 | 69 (37.1)               |
| Grades 3/4                   | 116 (27.2)                | 58 (26.7)                 | 142 (32.8)                     | 87 (31.8)                  | 57 (29.7)                  | 54 (28.1)                 | 60 (32.3)               |
| Suspected to be dnug-related |                           |                           |                                |                            |                            |                           |                         |
| All grades                   | 52 (12.2)                 | 34 (15.7)                 | 45 (10.4)                      | 28 (10.2)                  | 21 (10.9)                  | 33 (17.2)                 | 25 (13.4)               |
| Grades 3/4                   | 44 (10.3)                 | 25 (11.5)                 | 34 (7.9)                       | 21 (7.7)                   | 15 (7.8)                   | 24 (12.5)                 | 22 (11.8)               |
| AEsleading to treatment      |                           |                           |                                |                            |                            |                           |                         |
| discontinuation              |                           |                           |                                |                            |                            |                           |                         |
| All grades                   | 103 (24.1)                | 38 (17.5)                 | 45 (10.4)                      | 28 (10.2)                  | 24 (12.5)                  | 27 (14.1)                 | 31 (16.7)               |
| Grades 3/4                   | 70 (16.4)                 | 29 (13.4)                 | 33 (7.6)                       | 24 (8.8)                   | 22 (11.5)                  | 21 (10.9)                 | 18 (9.7)                |
| Suspected to be drug-related |                           |                           |                                |                            |                            |                           |                         |
| All grades                   | 82 (19.2)                 | 28 (12.9)                 | 26 (6.0)                       | 13 (4.7)                   | 12 (6.3)                   | 19 (9.9)                  | 26 (14.0)               |
| Grades 3/4                   | 54 (12.6)                 | 22 (10.1)                 | 15 (3.5)                       | 10 (3.6)                   | 10 (5.2)                   | 16 (8.3)                  | 13 (7.0)                |
| AEs requiring dose           |                           |                           |                                |                            |                            |                           |                         |
| interruptionand/orchange     |                           |                           |                                |                            |                            |                           |                         |
| All grades                   | 285 (66.7)                | 152 (70.0)                | 212 (49.0)                     | 129 (47.1)                 | 92 (47.9)                  | 135 (70.3)                | 114 (61.3)              |
| Grades 3/4                   | 176 (41.2)                | 93 (42.9)                 | 139 (32.1)                     | 88 (32.1)                  | 63 (32.8)                  | 85 (44.3)                 | 71 (38.2)               |
| Suspected to be              |                           |                           |                                |                            |                            |                           |                         |
| drug-related                 |                           |                           |                                |                            |                            |                           |                         |
| All grades                   | 253 (59.3)                | 136 (62.7)                | 169 (39.0)                     | 109 (39.8)                 | 81 (42.2)                  | 121 (63.0)                | 106 (57.0)              |
| Grades 3/4                   | 145 (34)                  | 83 (38.2)                 | 103 (23.8)                     | 65 (23.7)                  | 52 (27.1)                  | 75 (39.1)                 | 57 (30.6)               |
| AEs requiring additional     |                           |                           |                                |                            |                            |                           |                         |
| therapy [2]                  |                           |                           |                                |                            |                            |                           |                         |
| All grades                   | 394 (92.3)                | 205 (94.5)                | 364 (84.1)                     | 236 (86.1)                 | 165 (85.9)                 | 181 (94.3)                | 171 (91.9)              |
| Grades 3/4                   | 163 (38.2)                | 120 (55.3)                | 160 (37.0)                     | 101 (36.9)                 | 67 (34.9)                  | 106 (55.2)                | 91 (48.9)               |
| Suspected to be              |                           |                           |                                |                            |                            |                           |                         |
| drug-related                 |                           |                           |                                |                            |                            |                           |                         |
| All grades                   | 364 (85.2)                | 198 (91.2)                | 268 (61.9)                     | 171 (62.4)                 | 117 (60.9)                 | 174 (90.6)                | 159 (85.5)              |
| Grades 3/4                   | 99 (23.2)                 | 89 (41)                   | 54 (12.5)                      | 37 (13.5)                  | 25 (13.0)                  | 79 (41.1)                 | 56 (30.1)               |

Source:ISSTable2.2.1

[1] Deaths occurring &gt;30 days after end of treatment are not included.

[2] Additional therapy includes all non-drug therapy and concomitant medications.

A patient is counted once within each category.

MedDRA Version 19.0 has been used for the reporting of adverse events.

## Adverse Events by System Organ Class (SOC)

Table 66 presents a summary of AEs, regardless of relationship to study drug, by SOC, and reported in ≥20% of patients in any study population under each SOC (overall and maximum Grade 3/4) for the Broad Safety Set.

<div style=\"page-break-after: always\"></div>

Table 66: Adverse Events, Regardless of Study Drug Relationship, by Primary System Organ Class by Treatment - Overall and Maximum Grade 3 or 4 (≥20% in any population) (Broad Safety Set) Study CMEK162B2301

Source:ISS Table 2.2.2.1

| PrimarySystem Organ Class           | Bini 45mg BID   | Enco 300mg QD N=217   | Combo pooled doses   | Combo 450mg QD N=274   | Combo 450mg QD   | Enco 300mg QD   | Vemurafenib N=186   |
|-------------------------------------|-----------------|-----------------------|----------------------|------------------------|------------------|-----------------|---------------------|
| Preferred Term                      | N=427           |                       | N=433                |                        | N=192            | N=192           |                     |
| Grades                              | n (%)           | n (%)                 | n (%)                | n (%)                  | n (%)            | n (%)           | n (%)               |
| Anyprimary system organ class       |                 |                       |                      |                        |                  |                 |                     |
| All grades                          | 427 (100)       | 216 (99.5)            | 426 (98.4)           | 271 (98.9)             | 189 (98.4)       | 191 (99.5)      | 185 (99.5)          |
| Grades 3/4                          | 283 (66.3)      | 146 (67.3)            | 254 (58.7)           | 159 (58.0)             | 111 (57.8)       | 127 (66.1)      | 118 (63.4)          |
| Blood and lymphatic system          |                 |                       |                      |                        |                  |                 |                     |
| disorders                           |                 |                       |                      |                        |                  |                 |                     |
| All grades                          | 62 (14.5)       | 26 (12.0)             | 96 (22.2)            | 63 (23.0)              | 40 (20.8)        | 20 (10.4)       | 30 (16.1)           |
| Grades 3/4                          | 20 (4.7)        | 11 (5.1)              | 30 (6.9)             | 17 (6.2)               | 11 (5.7)         | 9 (4.7)         | 9 (4.8)             |
| Eye disorders                       |                 |                       |                      |                        |                  |                 |                     |
| All grades                          | 237 (55.5)      | 58 (26.7)             | 252 (57.7)           | 158 (57.7)             | 104 (54.2)       | 53 (27.6)       | 62 (33.3)           |
| Grades 3/4                          | 16 (3.7)        | 1 (0.5)               | 12 (2.8)             | 6 (2.2)                | 5 (2.6)          | 1 (0.5)         | 1 (0.5)             |
| Gastrointestinal disorders          |                 |                       |                      |                        |                  |                 |                     |
| All grades                          | 305 (71.4)      | 151 (69.6)            | 320 (73.9)           | 201 (73.4)             | 138 (71.9)       | 130 (67.7)      | 127 (68.3)          |
| Grades 3/4                          | 39 (9.1)        | 26 (12.0)             | 58 (13.4)            | 35 (12.8)              | 22 (11.5)        | 25 (13.0)       | 19 (10.2)           |
| General disorders and               |                 |                       |                      |                        |                  |                 |                     |
| administrationsiteconditions        |                 |                       |                      |                        |                  |                 |                     |
| All grades                          | 320 (74.9)      | 138 (63.6)            | 266 (61.3)           | 168 (61.3)             | 122 (63.5)       | 123 (64.1)      | 130 (69.9)          |
| Grades 3/4                          | 45 (10.5)       | 25 (11.5)             | 44 (10.2)            | 28 (10.2)              | 24 (12.5)        | 21 (10.9)       | 24 (12.9)           |
| Infections and infestations         |                 |                       |                      |                        |                  |                 |                     |
| All grades                          | 175 (41.0)      | 92 (42.4)             | 192 (44.3)           | 137 (50)               | 97 (50.5)        | 82 (42.7)       | 92 (49.5)           |
| Grades 3/4                          | 32 (7.5)        | 7 (3.2)               | 33 (7.6)             | 25 (9.1)               | 19 (9.9)         | 6 (3.1)         | 9 (4.8)             |
| Investigations                      |                 |                       |                      |                        |                  |                 |                     |
| All grades                          | 268 (62.8)      | 82 (37.8)             | 244 (56.4)           | 156 (56.9)             | 103 (53.6)       | 71 (37.0)       | 77 (41.4)           |
| Grades 3/4                          | 130 (30.4)      | 20 (9.2)              | 96 (22.2)            | 61 (22.3)              | 47 (24.5)        | 17 (8.9)        | 14 (7.5)            |
| Metabolismandnutritiondisorders     |                 |                       |                      |                        |                  |                 |                     |
| All grades                          | 87 (20.4)       | 75 (34.6)             | 124 (28.6)           | 62 (22.6)              | 44 (22.9)        | 61 (31.8)       | 49 (26.3)           |
| Grades 3/4                          | 20 (4.7)        | 18 (8.3)              | 33 (7.6)             | 14 (5.1)               | 10 (5.2)         | 14 (7.3)        | 10 (5.4)            |
| Musculoskeletal and connective      |                 |                       |                      |                        |                  |                 |                     |
| tissue disorders                    |                 |                       |                      |                        |                  |                 |                     |
| All grades                          | 157 (36.8)      | 172 (79.3)            | 237 (54.5)           | 150 (54.7)             | 102 (53.1)       | 149 (77.6)      | 125 (67.2)          |
| Grades 3/4                          | 20 (4.7)        | 46 (21.2)             | 17 (3.9)             | 12 (4.4)               | 5 (2.6)          | 43 (22.4)       | 19 (10.2)           |
| Neoplasms benign, malignant and     |                 |                       |                      |                        |                  |                 |                     |
| unspecified (incl cysts and polyps) |                 |                       |                      |                        |                  |                 |                     |
| All grades                          | 22 (5.2)        | 83 (38.2)             | 88 (20.6)            | 60 (21.9)              | 44 (22.9)        | 72 (37.5)       | 82 (44.1)           |
| Grades 3/4                          | 5 (1.2)         | 13 (6.0)              | 13 (3.0)             | 6 (2.2)                | 5 (2.6)          | 11 (5.7)        | 22 (11.8)           |
| Nervous system disorders            |                 |                       |                      |                        |                  |                 |                     |
| All grades                          | 133 (31.1)      | 126 (58.1)            | 190 (43.9)           | 129 (47.1)             | 95 (49.5)        | 107 (55.7)      | 77 (41.4)           |
| Grades3/4                           | 17 (4.0)        | 20 (9.2)              | 34 (7.9)             | 26 (9.5)               | 18 (9.4)         | 18 (9.4)        | 14 (7.5)            |
| Psychiatric disorders               |                 |                       |                      |                        |                  |                 |                     |
| All grades                          | 45 (10.3)       | 78 (35.9)             | 76 (17.6)            | 53 (19.3)              | 42 (21.9)        | 64 (33.3)       | 31 (16.7)           |
| Grades 3/4                          | 3 (0.7)         | 8 (3.7)               | 7 (1.6)              | 5 (1.8)                | 3 (1.6)          | 6 (3.1)         | 0                   |
| Respiratory,thoracic and            |                 |                       |                      |                        |                  |                 |                     |
| mediastinaldisorders                |                 |                       |                      |                        |                  |                 |                     |
| All grades                          | 119 (27.9)      | 57 (26.3)             | 134 (30.9)           | 76 (27.7)              | 57 (29.7)        | 52 (27.1)       | 50 (26.9)           |
| Grades 3/4                          | 20 (4.7)        | 10 (4.6)              | 16 (3.7)             | 9 (3.3)                | 8 (4.2)          | 10 (5.2)        | 8 (4.3)             |
| Skin and subcutaneous tissue        |                 |                       |                      |                        |                  |                 |                     |
| disorders                           |                 |                       |                      |                        |                  |                 |                     |
| All grades                          | 375 (87.8)      | 207 (95.4)            | 255 (58.9)           | 174 (63.5)             | 125 (65.1)       | 184 (95.8)      | 170 (91.4)          |
| Grades 3/4                          | 37 (8.7)        | 49 (22.6)             | 10 (2.3)             | 7 (2.6)                | 6 (3.1)          | 43 (22.4)       | 38 (20.4)           |
| Vascular disorders                  |                 |                       |                      |                        |                  |                 |                     |
| All grades                          | 98 (23.0)       | 43 (19.8)             | 87 (20.1)            | 52 (19.0)              | 36 (18.8)        | 36 (18.8)       | 36 (19.4)           |
| Grades 3/4                          | 44 (10.3)       | 7 (3.2)               | 22 (5.1)             | 17 (6.2)               | 12 (6.3)         | 7 (3.6)         | 6 (3.2)             |

Apatient is counted oncewithineach preferred term and systemorgan class.

## Bini P vs Combo 450 RP (pooled sets)

The overall incidence of AEs and SAEs was similar between the Combo 450 RP population and Bini P population but a lower proportion of patients in the Combo 450 RP population reported Grade 3/4 AEs (58%  vs  66.3%).  In  addition,  in  the  Combo  450  RP  population,  a  lower  proportion  of  patients compared to the Bini  P  population  reported  AEs  leading  to  treatment  discontinuation,  AEs  requiring dose  interruption  or  additional  therapy  (discontinuation:  10.2%  vs  22.5%;  interruption:  47.1%  vs 66.3%,  additional  therapy  86.1%vs  92.3%).  On-treatment  deaths  were  reported  in  a  similar proportion of patients in both arms.

In the Bini P population, the maximum reported severity of AEs was Grade 1, 2, 3 and 4 for 6.1%, 27.2%, 53.6% and 13.1% of patients, respectively. In the Combo 450 RP population, the maximum

<div style=\"page-break-after: always\"></div>

reported severity of AEs was Grade 1, 2, 3 and 4 for 10.2%, 30.7%, 48.2% and 9.9% of patients, respectively, indicating less Grade 3 AEs (5.4% difference) than in the Bini P population.

The median time to onset of first Grade ¾ AEs was longer in the combo 450 RP population than in the Bini P population (2.6 months (95% CI: 1.8, 3.2) vs 1.0 month (95% CI: 0.9, 1.3)) (Figure OS 1):

Figure 24: Kaplan-Meier-Plot of time to first adverse event grade ¾ (pooled studies)

<!-- image -->

AEs reported in ≥50% of patients in the Combo 450 RP population and at a higher incidence (≥10% difference) as compared to the Bini P population were reported under the SOC of musculoskeletal and connective tissue disorders (54.7% vs 36.8%). No Grade 3/4 AEs reported in ≥10% of patients in the Combo 450 RP population were reported under any SOC at a higher incidence as compared to the Bini P population (≥5% difference).

AEs reported in ≥50% of patients in the Bini P population and at a higher incidence as compared to the Combo 450 RP population (≥10% difference) were reported under the SOCs of skin and subcutaneous tissue conditions (74.9% vs 61.3%) and general and administrative site conditions (74.7% vs 60.9%). Grade 3/4 AEs reported in ≥10% of patients in the Bini P population and at a higher incidence as compared  to  the  Combo  450  RP  population  (≥5%  difference)  were  reported  under  the  SOC  of investigations (30.4% vs 22.3%).

## Adverse Events by Preferred Term

Table 67 presents a summary of AEs, regardless of relationship to study drug that were reported for ≥10% of patients  in  any  study  population  by  PT  (overall  and  maximum  Grade  3/4)  for  the  Broad Safety Set.

<div style=\"page-break-after: always\"></div>

Table 67: Adverse Events, Regardless of Study Drug Relationship, by Preferred Term and Treatment - Overall and Maximum Grade 3 or 4 (≥10% in any population) (Broad Safety Set)

| Melanoma   | Melanoma   | Melanoma   | Melanoma   |
|------------|------------|------------|------------|

<div style=\"page-break-after: always\"></div>

| Melanoma   | Study CMEK162B2301   | Melanoma   |
|------------|----------------------|------------|

Source: ISS Table 2.2.3

A patient is counted once within each prefered tem.

MedDRA Version 19.0 has been used fo the reporting o adverse events.

Prefered termns are soted in descending frequeny in the Combo 450omg-melanoma column

Abdpain =AmulodCKres=Bldcre pshkaseasd; GGTeas=Gam-glutaltaferaseasd; ALTre=Alaemtafeas AST increased = Aspatate aminotansferase increased EF = Ejection faction; PP keratodema =Palmoplantar keratodema; PPE syndrome = Palmar-plantarerythrodysaesthesia syndrome

## Relationship of Adverse Events to Study Treatment

The relationship  of  study  treatment  to  each  AE  (suspected or  not  suspected)  was  evaluated  by  the investigator  and  treatment-related  AEs  that  were  reported  for  ≥20%  of  patients  in  any  study population by PT (overall and maximum Grade 3/4) for the Broad Safety Set are summarised below.

## Bini P vs Combo 450 RP (pooled sets)

The overall  incidence  of  treatment-related  AEs  and  Grade  3/4  AEs  was  lower  in  the  Combo  450  RP population than the Bini P population (AEs: 89.8% vs 97%; Grade 3/4 AEs: 33.2% vs 48.9%).

In the Bini P population, treatment-related AEs reported in ≥20% of patients were blood CK increased (42.2%), diarrhoea (33.5%), rash (32.8%) and nausea (21.3%). The only treatment related Grade 3/4 adverse event reported in ≥5% of patients was blood CK increased (20.4%).

In  the  Combo 450 RP population, treatment-related AEs reported in ≥20% of patients were nausea (29.6%),  diarrhoea  (27%),  fatigue  (25.5%)  and  blood  CK  increased  (22.6%).  The  only  treatment related Grade 3/4 AE reported in ≥5% of patients was GGT increased (6.2%).

<div style=\"page-break-after: always\"></div>

Treatment-related AEs reported at a higher incidence in the Combo 450 RP population than the Bini P population (≥10% difference) were arthralgia (16.1% vs 3.5%). GGT increased, the only treatmentrelated Grade 3/4 AE reported in ≥5% of patients in the Combo 450 RP population was reported at a higher incidence compared to the Bini P population (6.2% vs 0.2%).

Treatment-related AEs reported at a higher incidence in the Bini P population than the Combo 450 RP population (≥10% difference) were blood CK increased (42.2% vs 22.6%), diarrhoea (33.5% vs 27%) and rash (32.8% vs 10.2%). The only treatment-related Grade 3/4 AE reported in ≥5% of patients were blood CK increased, which was also reported at a higher incidence compared to the Combo 450 RP population (20.4% vs 4%).

## 4-month update

As of the 4-month safety update, the incidence of AEs assessed by the Investigator as related to study treatment  was  generally  consistent  with  the  trends  observed  in  summaries  of  all-cause  AEs  by treatment group and to that previously reported for the same population in the initial.

The  overall  incidence  of  treatment-related  AEs  and  Grade  3/4  AEs  at  the  4-month  safety  update remained lower in the Combo 450 RP population compared to the Enco 300 P population (AEs: 98.9% vs 99.5%; Grade 3/4 AE: 61.3% vs 67.7%). The only relevant changes for incidences of individual AEs since the initial MAA were in the Combo 450 RP population: Arthralgia (27% vs 24.8%), Blood creatine phosphokinase (CK) increased (27.0% vs 24.8%) and back pain (10.9% vs 8.8%).

Table 68: Adverse Reactions Occurring in Metastatic Melanoma Patients Receiving

| System Organ Class                              | Adverse reaction                                  | Frequency (All grades)   | Grade3/4 (%)   |
|-------------------------------------------------|---------------------------------------------------|--------------------------|----------------|
| Infections and i nfestations                    | Skin infection                                    | Very common              | 4              |
| Nervous system                                  | Dropped head syndrome b                           | Uncommon                 | 0              |
| Eye disorder                                    | RPED                                              | Very common              | 1              |
| Eye disorder                                    | Visual impairment                                 | Very common              | Below 1        |
| Eye disorder                                    | Increased intraocular pressure including glaucoma | Common                   | 0              |
| Eye disorder                                    | Retinal vein occlusion                            | Common                   | 1              |
| Cardiac disorders                               | Left ventricular dysfunction                      | Very common              | 4              |
| Cardiac disorders                               | Bradycardia                                       | Common                   | 0              |
| Vascular disorders                              | Hypertension                                      | Very common              | 8              |
| Vascular disorders                              | Venous thromboembolism                            | Common                   | 2              |
| Vascular disorders                              | Haemorrhage f                                     | Common                   | 2              |
| Respiratory, thoracic and mediastinal disorders | Dyspnoea                                          | Very common              | 2              |
| Respiratory, thoracic and mediastinal disorders | Pneumonitis                                       | Common                   | Below 1        |
| Gastrointestial disorders                       | Diarrhoea                                         | Very common              | 2              |
| Gastrointestial disorders                       | Vomiting                                          | Very common              | 2              |
| Gastrointestial disorders                       | Nausea                                            | Very common              | 1              |
| Gastrointestial disorders                       | Dry mouth                                         | Common                   | 0              |
| Gastrointestial disorders                       | Stomatitis g                                      | Common                   | 2              |
| Skin and subcutaneous tissue disorders          | Rash h                                            | Very common              | 4              |
| Skin and subcutaneous tissue disorders          | Acneiform dermatitis                              | Very common              | 3              |
| Skin and subcutaneous tissue disorders          | Pruritus                                          | Very common              | 1              |

<div style=\"page-break-after: always\"></div>

|                                           | Dry skin                                      |             | 0       |
|-------------------------------------------|-----------------------------------------------|-------------|---------|
|                                           | Alopecia                                      | Common      | 0       |
|                                           | Skin fissures                                 |             | 0       |
| Musculoskeletal                           | Myopathy i                                    | Very common | 2       |
| and connective                            | Rhabdomyolysis                                | Uncommon    | Below 1 |
| Renal and urinary                         | Renal failure                                 | Common      | Below 1 |
| General disorders and administration site | Peripheral oedema j                           | Very common | Below 1 |
| General disorders and administration site | Periorbital oedema, eye oedema, eyelid oedema | Very common | Below 1 |
| conditions                                | Face oedema                                   | Common      | Below 1 |
| Investigations                            | Blood creatine phosphokinase increased        | Very common | 21      |
| Investigations                            | Aspartate aminotransferase increased          | Very common | 2       |
| Investigations                            | Alanine aminotransferase increased            | Common      | 2       |
| Investigations                            | Hypokalaemia                                  | Common      | 2       |
| Investigations                            | Hypoalbuminaemia                              | Common      | Below 1 |
| Investigations                            | Blood creatinine increased                    | Common      | 0       |

Table 69: Adverse reactions occurring in patients receiving binimetinib in combination with encorafenib at the recommended dose (n = 274)

| System Organ Class                          | Adverse reaction                    | Frequency (All grades) n (%)   | Frequency (Grade 3-4) n (%)   |
|---------------------------------------------|-------------------------------------|--------------------------------|-------------------------------|
| Neoplasms benign, malignant and unspecified | Cutaneous squamous cell carcinoma a | 9 (3.3)                        | 1 (0.4)                       |
| Neoplasms benign, malignant and unspecified | Basal cell carcinoma *              | 3 (1.1)                        | 0                             |
| Neoplasms benign, malignant and unspecified | Skin papilloma *                    | 22 (8.0)                       | 0                             |
| Blood and lymphatic system disorders        | Anaemia                             | 54 (19.7)                      | 13 (4.7)                      |
| Immune system disorders                     | Hypersensitivity b                  | 9 (3.3)                        | 0                             |
| Nervous system disorders                    | Neuropathy peripheral *             | 36 (13.1)                      | 3 (1.1)                       |
| Nervous system disorders                    | Dizziness *                         | 42 (15.3)                      | 7 (2.6)                       |
| Nervous system disorders                    | Headache *                          | 59 (21.5)                      | 4 (1.5)                       |
| Nervous system disorders                    | Dysgeusia                           | 18 (6.6)                       | 0                             |
| Nervous system disorders                    | Facial paresis c                    | 2 (0.7)                        | 1 (0.4)                       |
| Eye disorders                               | Visual impairment *                 | 59 (21.5)                      | 1 (0.4)                       |
| Eye disorders                               | RPED *                              | 81 (29.6)                      | 5 (1.8)                       |
| Eye disorders                               | Uveitis *                           | 12 (4.4)                       | 1 (0.4)                       |
| Cardiac disorders                           | Left ventricular dysfunction d      | 23 (8.4)                       | 3 (1.1)                       |
| Vascular disorders                          | Haemorrhage e                       | 49 (17.9)                      | 9 (3.3)                       |
| Vascular disorders                          | Hypertension *                      | 32 (11.7)                      | 15 (5.5)                      |
| Vascular disorders                          | Venous thromboembolism f            | 13 (4.7)                       | 3 (1.1)                       |

<div style=\"page-break-after: always\"></div>

| Gastrointestinal disorders                           | Abdominal pain *                                   | 75 (27.4)   | 7 (2.6)   |
|------------------------------------------------------|----------------------------------------------------|-------------|-----------|
| Gastrointestinal disorders                           | Diarrhoea *                                        | 104 (38.0)  | 9 (3.3)   |
| Gastrointestinal disorders                           | Vomiting *                                         | 77 (28.1)   | 6 (2.2)   |
| Gastrointestinal disorders                           | Nausea                                             | 114 (41.6)  | 7 (2.6)   |
| Gastrointestinal disorders                           | Constipation                                       | 66 (24.1)   | 0         |
| Gastrointestinal disorders                           | Colitis g                                          | 6 (2.2)     | 2 (0.7)   |
| Gastrointestinal disorders                           | Pancreatitis *                                     | 2 (0.7)     | 2 (0.7)   |
| Skin and subcutaneous tissue disorders               | Hyperkeratosis *                                   | 57 (20.8)   | 1 (0.4)   |
| Skin and subcutaneous tissue disorders               | Rash *                                             | 54 (19.7)   | 2 (0.7)   |
| Skin and subcutaneous tissue disorders               | Dry skin *                                         | 40 (14.6)   | 0         |
| Skin and subcutaneous tissue disorders               | Pruritus *                                         | 32 (11.7)   | 1 (0.4)   |
| Skin and subcutaneous tissue disorders               | Alopecia *                                         | 40 (14.6)   | 0         |
| Skin and subcutaneous tissue disorders               | Photosensitivity *                                 | 11 (4.0)    | 1 (0.4)   |
| Skin and subcutaneous tissue disorders               | Dermatitis acneiform *                             | 12 (4.4)    | 0         |
| Skin and subcutaneous tissue disorders               | Palmar-plantar erythrodysaesthesia syndrome (PPES) | 17 (6.2)    | 0         |
| Skin and subcutaneous tissue disorders               | Erythema *                                         | 22 (8.0)    | 0         |
| Skin and subcutaneous tissue disorders               | Panniculitis *                                     | 4 (1.5)     | 0         |
| Musculoskeletal and connective tissue disorders      | Arthralgia *                                       | 74 (27.0)   | 2 (0.7)   |
| Musculoskeletal and connective tissue disorders      | Muscular disorders/Myalgia h                       | 71 (25.9)   | 2 (0.7)   |
| Musculoskeletal and connective tissue disorders      | Back pain                                          | 30 (10.9)   | 2 (0.7)   |
| Musculoskeletal and connective tissue disorders      | Pain in extremity                                  | 29 (10.6)   | 4 (1.5)   |
| Musculoskeletal and connective tissue disorders      | Rhabdomyolysis                                     | 1 (0.4)     | 1 (0.4)   |
| Renal and urinary disorders                          | Renal failure *                                    | 9 (3.3)     | 6 (2.2)   |
| General disorders and administration site conditions | Pyrexia *                                          | 47 (17.2)   | 8 (2.9)   |
| General disorders and administration site conditions | Peripheral oedema i                                | 42 (15.3)   | 3 (1.1)   |
| General disorders and administration site conditions | Fatigue *                                          | 120 (43.8)  | 8 (2.9)   |
| Investigations                                       | Blood creatine phosphokinase increased             | 74 (27.0)   | 16 (5.8)  |
| Investigations                                       | Transaminase increased *                           | 43 (15.7)   | 15 (5.5)  |
| Investigations                                       | Gamma-glutamyl transferase increased *             | 40 (14.6)   | 23 (8.4)  |
| Investigations                                       | Blood creatinine increased *                       | 17 (6.2)    | 2 (0.7)   |
| Investigations                                       | Blood alkaline phosphatase increased               | 20 (7.3)    | 2 (0.7)   |
| Investigations                                       | Amylase increased                                  | 9 (3.3)     | 4 (1.5)   |
| Investigations                                       | Lipase increased                                   | 14 (5.1)    | 7 (2.6)   |

*composite terms which included more than one preferred term

a includes keratoacanthoma, squamous cell carcinoma, lip squamous cell carcinoma and squamous cell carcinoma of skin

b

includes angioedema, drug hypersensitivity, hypersensitivity, hypersensitivity vasculitis and urticaria c includes facial nerve disorder, facial paralysis, facial paresis

d includes left ventricular dysfunction, ejection fraction decreased, cardiac failure and ejection fraction abnormal

<div style=\"page-break-after: always\"></div>

e includes haemorrhage at various sites including cerebral haemorrhage f includes pulmonary embolism, deep vein thrombosis, embolism, thrombophlebitis, thrombophlebitis superficial and thrombosis

g includes colitis, colitis ulcerative, enterocolitis and proctitis h includes myalgia, muscular weakness, muscle spasm, muscle injury, myopathy, myositis

i includes fluid retention, peripheral oedema, localised oedema

## Severity of Adverse Events

## Bini P vs Combo 450 RP (pooled sets)

In the Bini P population, the maximum reported severity of AEs was Grade 1, 2, 3 and 4 for 6.1%, 27.2%, 53.6% and 13.1% of patients, respectively.

In the Combo 450 RP population, the maximum reported severity of AEs was Grade 1, 2, 3 and 4 for 10.2%,  30.7%,  48.2%  and  9.9%  of  patients,  respectively,  indicating  less  Grade  3  AEs  (5.4% difference) than in the Bini P population.

When encorafenib was used at a dose of 300 mg once daily in combination with binimetinib 45 mg twice daily (Combo 300) in study CMEK162B2301-Part 2, the frequency category was lower compared to the pooled Combo 450 population for the following adverse reactions: anemia, peripheral neuropathy, haemorrhage, hypertension, pruritus (common) and colitis, increased amylase and increased lipase (uncommon).

## Adverse Events by Time of Onset

## Bini P vs Combo 450 RP (pooled sets) .

The median time to onset of first Grade 3/4 AEs was longer in the Combo 450 RP population than the Bini P population: 2.6 months (95% CI: 1.8, 3.2) vs 1.0 month (95% CI: 0.9, 1.3).

Of note, a shorter time to onset was reported for the Combo BP population (1.8 months; 95% CI: 1.4, 2.4) than the Combo 450 RP population.

## Adverse events of special interest (AESI)

These  were  identified  based  on  the  known  class  effects  of  MEK-  and  BRAF-  inhibitors  as  well  as emerging safety signals from the clinical program and health authority interactions. Table 70 and Table 71 present an overview of AESIs by category (AESIs related to both drugs, specifically to encorafenib and  specifically  to  binimetinib)  and  grouping  (overall  and  Grade  3/4)  for  patients  in  the  three treatment arms of Study CMEK162B2301 and also includes separate columns for patients from the Bini 45mg BID, Enco 300mg QD and the Combo 450 RP pooled doses population.

<div style=\"page-break-after: always\"></div>

Table 70: Adverse of special interest -  regardless of relationship to study drug overall and maximum Grades 3 and 4 - AESIs relating to both drugs

|                                                 | Melanoma Binimetinib 5 N=427                    | Encorafenib BID300mg N=217 D(96)                | Combo QDpooled N=433 (96)                       | Combo N=274  (46)                               | Study CMEK162B2301                              | Study CMEK162B2301                              |                                                 |
|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| Grouping                                        | 0(46)                                           |                                                 |                                                 |                                                 | Combo N=192 ()                                  | Encorafenib doses450mgQD450mgQD300mg N=192 (46) | QDVemurafenib N=186 m(%6)                       |
| AESIsRelating toBothBininetinib and Encorafenib | AESIsRelating toBothBininetinib and Encorafenib | AESIsRelating toBothBininetinib and Encorafenib | AESIsRelating toBothBininetinib and Encorafenib | AESIsRelating toBothBininetinib and Encorafenib | AESIsRelating toBothBininetinib and Encorafenib | AESIsRelating toBothBininetinib and Encorafenib | AESIsRelating toBothBininetinib and Encorafenib |
| Retinopathy ewcluding RVO                       | 189 (44.3)                                      | 27 (12.4)                                       | 232 (53.6)                                      | 144 (52.6)                                      | (+8+) E6                                        | 26 (13.5)                                       | 23 (12.4)                                       |
| Grade 3/4                                       | 9 (2.1)                                         | 0                                               | 11 (2.5)                                        | 6(2.2)                                          | 5 (2.0)                                         |                                                 | 0                                               |
| Rash                                            | 353 (82.7)                                      | 111 (51.2)                                      | 104 (24.0)                                      | 65 (23.7)                                       | 50 (26.0)                                       | 95 (49.5)                                       | 111 (59.7)                                      |
| Grade 3/4                                       | 29 (6.8)                                        | 12 (5.5)                                        | 3 (0.7)                                         | 2(0.7)                                          | 2(1.0)                                          | 10 (5.2)                                        | 25 (13.4)                                       |
| Liver function test abnormalities               | 74 (17.3)                                       | 30 (13.8)                                       | 107 (24.7)                                      | 69 (25.2)                                       | 48 (25.0)                                       | 28 (14.6)                                       | 39 (21.0)                                       |
| Grade 3/4                                       | 18 (4.2)                                        | 12 (5.5)                                        | 50 (11.5)                                       | 34 (12.4)                                       | 28 (14.6)                                       | 11 (5.7)                                        | 7(3.8)                                          |
| Muscle enzymeprotein changes                    | 191 (44.7)                                      | 3 (1.4)                                         | 94 (21.7)                                       | 68 (24.8)                                       | 44 (22.9)                                       | 3 (1.0)                                         | 4 (2.2)                                         |
| Grade 3/4                                       | 89 (20.8)                                       | 0                                               | 22 (5.1)                                        | 15 (5.5)                                        | 13 (6.8)                                        | 0                                               | 0                                               |
| Myopathy                                        | 66 (15.5)                                       | 73 (33.6)                                       | 69 (15.9)                                       | 44 (16.1)                                       | 32 (16.7)                                       | 60 (31.3)                                       | 37 (19.9)                                       |
| Grade 3/4                                       | 10 (23)                                         | 20 (9.2)                                        | 2 (0.5)                                         | 2 (0.7)                                         | 0                                               | 19 (9.9)                                        | 1 (0.5)                                         |
| Skin infections                                 | 74 (17.3)                                       | 24 (11.1)                                       | 41 (9.5)                                        | 31 (11.3)                                       | 22 (11.5)                                       | 23 (12.0)                                       | 26 (14.0)                                       |
| Grade 3/4                                       | 20 (4.7)                                        | 1 (0.5)                                         | 7 (1.6)                                         | 4(1.5)                                          | 4 (2.1)                                         | 1(0.5)                                          | 0                                               |
| PPE syndrome                                    | 5 (1.2)                                         | 112 (51.6)                                      | 19 (4.4)                                        | 16 (5.8)                                        | 13 (6.8)                                        | 98 (51.0)                                       | 26 (14.0)                                       |
| Grade 3/4                                       | 1 (0.2)                                         | 27 (12.4)                                       | 0                                               | 0                                               | 0                                               | 26 (13.5)                                       | 2(1.1)                                          |
| Photosensitivity                                | 7 (1.0)                                         | 9 (4.1)                                         | 15 (3.5)                                        | 10 (3.6)                                        | 9 (4.7)                                         | 9 (4.7)                                         | 70 (37.0)                                       |
| Grade 3/4                                       | 0                                               | 0                                               | 1 (0.2)                                         | 1 (0.4)                                         | 1 (0.5)                                         | 0                                               | 3(1.6)                                          |
| Uveitis type events                             | 1 (0.2)                                         | 1 (0.5)                                         | 16 (3.7)                                        | 8 (2.9)                                         | 7(3.6)                                          | 1 (0.5)                                         | 7 (3.8)                                         |
| Grade 3/4                                       | 0                                               | 0                                               | 2 (0.5)                                         | 1(0.4)                                          | 1 (0.5)                                         | 0                                               | 0                                               |
| Nail disorders                                  | 19 (4.4)                                        | 6 (2.8)                                         | 6 (1.4)                                         | 5(1.8)                                          | 3 (1.0)                                         | 6 (3.1)                                         | 0                                               |
| Grade 3/4                                       | 1(0.2)                                          | 0                                               | 0                                               | 0                                               | 0                                               | 0                                               | 0                                               |
| Severe cutaneous adverse reactions              | 5 (1.2)                                         | 3 (1.4)                                         | 2 (0.5)                                         | 2 (0.7)                                         | 1(0.5)                                          | 2 (1.0)                                         | 8 (4.3)                                         |
| Grade 3/4                                       | 0                                               | 1 (0.5)                                         | 0                                               | 0                                               | 0                                               | 1(0.5)                                          | 5(2.7)                                          |
| Hepatic filure                                  | 1 (0.2)                                         | 0                                               | 1 (0.2)                                         | 1 (0.4)                                         | 1(0.5)                                          | 0                                               | 0                                               |
| Grade 3/4                                       | 1 (0.2)                                         | 0                                               | 1(0.2)                                          | 1 (0.4)                                         | 1(0.5)                                          | 0                                               | 0                                               |
| Rhabdomyolysis                                  | 2(0.5)                                          | 0                                               | 1 (0.2)                                         | 1 (0.4)                                         | 1 (0.5)                                         | 0                                               | 0                                               |
| Grade 3/4                                       | 2(0.5)                                          | 0                                               | 1(0.2)                                          | 1(0.4)                                          | 1 (0.5)                                         | 0                                               | 0                                               |
| Retinal vein occlusion                          | 9 (2.1)                                         | 0                                               | 0                                               | 0                                               | 0                                               | 0                                               | 0                                               |
| Grade 3/4                                       | 5 (1.2)                                         | 0                                               | 0                                               | 0                                               | 0                                               | 0                                               | 0                                               |

<div style=\"page-break-after: always\"></div>

Table 71: Adverse of special interest -  regardless of relationship to study drug overall and maximum Grades 3 and 4 - AESIs relating to Binimetinib/Encorafenib alone

|                                       | Mehnoma                |                                |                            |                              | Shudy CMEK162B2301        | Shudy CMEK162B2301              |                        |
|---------------------------------------|------------------------|--------------------------------|----------------------------|------------------------------|---------------------------|---------------------------------|------------------------|
| Grouping                              | Binimetinib N=421 0(6) | Encorafenib BID300mg N=211 D() | Combo QDpooled N=433 0(%6) | Combo doses450mg N=274 0(46) | Combo QD450 mg（ N=192 n() | Encorafenib QD300mg N=192 0(46) | QDVemurafenib N=186 () |
| AESIs Relating to Bininethinib Alone  |                        |                                |                            |                              |                           |                                 |                        |
| Hhemonhage                            | 49 (11.5)              | 28(12.9)                       | 69(15.9)                   | 43 (15.7)                    | 35 (18.2)                 | 24(12.5)                        | 15 (8.1)               |
| Grade 3/4                             | 10(23)                 | 4(1.8)                         | 15(3.5)                    | 7(2.0)                       | 6(3.1)                    | 4(.1)                           | 3(1.6)                 |
| Peripheral oedema                     | 202 (47.3)             | 24 (11.1)                      | 65 (15.0)                  | 40 (14.6)                    | 24 (12.5)                 | 19(9.9)                         | 22(11.8)               |
| Grade 3/4                             | 4(0.9)                 | 0                              | 2(0.5)                     | 2(0.7)                       | 2(1.0)                    | 0                               | 2(1.1)                 |
| Hypertension                          | 68 (15.9)              | 12(5.5)                        | 45(10.4)                   | 33(12.0)                     | 22(11.5)                  | 12(6.3)                         | 21(11.3)               |
| Grade 3/4                             | 37(8.7)                | 6(2.8)                         | 19(4.4)                    | 17(6.2)                      | 11(5.7)                   | 6(3.1)                          | 6(3.2)                 |
| Left ventricular dysfimction          | 48 (11.2)              | 4(1.8)                         | 31(7.2)                    | 23(8.4)                      | 15(7.8)                   | 4(2.1)                          | 2(11)                  |
| Gnade 3/4                             | 18 (42)                | 2(0.9)                         | 4(0.9)                     | 3(1.1)                       | 3(1.0)                    | 2(1.0)                          | 0                      |
| Venous thromboembolism                | 17(4.0)                | 6(2.8)                         | 14(3.2)                    | 11(4.0)                      | 10(5.2)                   | 6 (3.1)                         | 3(1.6)                 |
| Gnade 3/4                             | 6(1.4)                 | 2(0.9)                         | 5(1.2)                     | 2(0.7)                       | 2(1.0)                    | 2(1.0)                          | 1(0.5)                 |
| Bradycardia                           | 13 (3.0)               | 1(0.5)                         | 5(1.2)                     | 4(1.5)                       | 2(1.0)                    | 1(0.5)                          | 2(11)                  |
| Grade 3/4                             | 0                      | 0                              | 0                          | 0                            | 0                         | 0                               | 1(0.5)                 |
| Pneumonitis                           | 6(1.4)                 | 2(0.9)                         | 1(0.2)                     | 1(0.4)                       | 1(0.5)                    | 2(1.0)                          | 1(0.5)                 |
| Grde 3/4                              | 2(0.5)                 | 0                              | 0                          | 0                            | 0                         | 0                               | 1(0.5)                 |
| AESIs Relating to Encorafenib Alone   |                        |                                |                            |                              |                           |                                 |                        |
| Acute renal filre                     | (610)8                 | 6 (2.8)                        | 15(3.5)                    | 8(2.9)                       | 7(0.0)                    | 5(2.0)                          | 9(4.8)                 |
| Grade 3/4                             | 2(0.5)                 | 3(1.4)                         | 9 (2.1)                    | 5(1.8)                       | 5(2.6)                    | 3(1.6)                          | 3(1.6)                 |
| Cutaneous squnmous cellcarcinoma      | 1(0.2)                 | 15(6.9)                        | 8(1.8)                     | 7(2.6)                       | 5(2.6)                    | 15(7.8)                         | 31(16.7)               |
| Gnade 3/4                             | 1(0.2)                 | 0                              | 0                          | 0                            | 0                         | 0                               | 12(6.5)                |
| Cutaneous non-squamous cell carcinoma | 3(0.7)                 | 2 (0.9)                        | 10(2.3)                    | 5(1.8)                       | 4(2.1)                    | 2(1.0)                          | 5(2.7)                 |
| Gnade 3/4                             | 0                      | 1(0.5)                         |                            | 0                            | 0                         | 1(0.5)                          | 1(0.5)                 |
| Tachyeardia                           | 17 (4.0)               | 13 (6.0)                       | 7(1.6)                     | 5 (1.8)                      | 3(1.6)                    | 12(63)                          | 10(5.4)                |
| Grade 3/4                             | 5(.2)                  | 3(1.4)                         | 2(0.5)                     | 1(0.4)                       | 1(0.5)                    | 2(1.0)                          | 1(0.5)                 |
| Facialparesis                         | 0                      | 16(7.4)                        | 3 (0.7)                    | 2(0.7)                       | 2(1.0)                    | 14(7.3)                         | 1(0.5)                 |
| Grade 3/4                             | 0                      | 3(1.4)                         | 1(0.2)                     | 1(0.4)                       | 1(0.5)                    | 3(1.6)                          | 0                      |
| Melanomns                             | 0                      | 10(4.0)                        | 0                          | 0                            | 0                         | 10(5.2)                         | 8(4.3)                 |
| Grade 3/4                             | 0                      | 3(1.4)                         | 0                          | 0                            | 0                         | 3(1.0)                          | 6(3.2)                 |

## Retinal events

Retinal events were reported in a higher incidence in the Combo 450 RP population compared to the Bini  P  population  but  this  tendency  was  reversed  when  considering  adjustment  for  study  drug exposure. However, regarding the PTs, retinal detachment was reported at a higher incidence for the binimetinib  monotherapy  (10.3%  Bini  P  vs  6.6%  Combo  450),  vision  blurred  for  the  combination therapy (15.3% Combo 450 vs 6.6% Bini P). In summary, an additive adverse effect of binimetinib and encorafenib regarding Retinopathy can be suggested. Grade 3 events occurred not very frequent and most of the events were transient, self-limiting and reversible and the proposed recommendations regarding management and dose modification seem to be acceptable. However, it should be kept in mind  that  events  under  the  PT  of  blindness  (in  the  grouping  of  retinopathy  excluding  RVO)  were reported  in  3  patients  in  Study  CMEK162B2301  Part  1  (2  patients  in  the  Combo  450  arm

<div style=\"page-break-after: always\"></div>

[CMEK162B2301  Patient  4015-  015  and  CMEK162B2301  Patient  6085-003]  and  1  patient  in  the encorafenib  300mg  monotherapy  Part  1  arm  [CMEK162B2301  Patient  6085-005]).  In  the  Bini  P population, no cases of blindness were reported.

Vascular  eye  events  (RVO)  as  potentially  sight-threatening  events  were  seen  only  in  the  Bini  P population  (2.1%).  In  contrast  uveitis-Type  AESIs  were  mainly  reported  for  the  Combo  450  RP population but only in a quite low incidence and in a mild severity 2.9%).

## Ocular events

In the pooled Combo 450 population, RPED was reported in 29.6 % (81/274) of patients. RPED was Grade 1 (asymptomatic) in 21.2 % (58/274) of patients, Grade 2 in 6.6 % (18/274) of patients and Grade 3 in 1.8 % (5/274) of patients. Most events were reported as retinopathy, retinal detachment, subretinal  fluid,  macular  oedema,  and  chorioretinopathy  and  led  to  dose  interruptions  or  dose modifications in 4.7 % (13/274) of patients. The median time to onset of the first event of RPED (all grades) was 1.5 month (range 0.03 to 17.5 months).

Visual impairment, including vision blurred and reduced visual acuity, occurred in 21.5 % (59/274) of patients. Visual impairment was generally reversible.

Uveitis was also reported when binimetinib was used in combination with encorafenib (see section 4.8 of encorafenib SmPC).

In Study CMEK162B2301-Part 2, in the Combo 300 arm, RPED was observed in 12.5% (32/257) of patients with 0.4% (1/257) Grade 4 event.

## Dermatologic reactions

Dermatologic reactions may occur when binimetinib is used in combination with encorafenib.

Rash is among the most frequently observed AEs reported for both monotherapy populations (Bini P 82.7%,  Enco  P  51.2%)  and  is  reported  at  a  remarkably  lower  frequency  when  binimetinib  and encorafenib are combined  (Combo  450  RP  23.7%).  Compared  to  other MEK/BRAF  inhibitor combinations the incidence of rash seems to be lower for the combination therapy with binimetinib and encorafenib. In addition, it should be kept in mind that, with regard to the preliminary data of part 2 of the pivotal study, the incidence of rash seems to be lower in the Combo 300 mg population (7.0% vs 14.1%). In the pooled Combo 450 population, rash occurred in 19.7 % (54/274) of patients. Most events  were  mild,  with  Grade 3 or 4  events  reported  in  0.7 %  (2/274)  of  patients.  Rash  led  to treatment discontinuation in 0.4 % (1/274) of patients and to dose interruption or dose modification in 1.1 % (3/274) of patients.

In patients treated with Combo 450, dermatitis acneiform occurred in 4.4 % (12/274) of patients, was Grade 1 and 2 and no event led to treatment discontinuation. Dose modification was reported in 0.7 % (2/274) of patients.

In contrast, palmar-plantar Erythrodysaesthesia (PPES) is reported in a remarkably higher incidence for  the  encorafenib  monotherapy  (Enco  P  51.6%)  compared  to  the  Bini  P  (1.2%)  and  Combo  450 RP (5.8%) populations. However, according to the presented data of part 2 of the pivotal study, the incidence  of  PPE  is  higher  with  the  lower  dose  of  encorafenib  (Combo  300).  PPES  can  occur  when binimetinib is used in combination with encorafenib. Please refer to the encorafenib SmPC.

Photosensitivity reaction occurred in 4.7% of the patients in the Combo 450 arm in the pivotal study and was identified also as a relevant toxicity of binimetinib (and encorafenib) in the non-clinical trials. In  the  pooled Combo 450 population,  photosensitivity  was  observed  in  4.0 %  (11/274)  of  patients. Most events were Grade 1-2, with Grade 3 reported in 0.4 % (1/274) of patients and no event led to discontinuation. Dose interruption or dose modification was reported in 0.4 % (1/274) of patients.

<div style=\"page-break-after: always\"></div>

The incidence of skin infections was remarkably lower in the Combo 450 RP population than in the Binimetinib  monotherapy  set  (11.3%-1.10  cases  per  100  patient-months  vs  17.3%-4.60  cases  per 100 patient-months).

Liver function test abnormalities AESIs were reported at a remarkably higher incidence in the Combo 450  RP  population  than  in  the  Bini  P  population,  overall  (25.2%  vs  17.3%),  for  Grade  3/4  AESIs (12.4% vs 4.2%) and for AESIs requiring dose adjustment/study drug interruption (8.4% vs 3%). Regarding the PTs, GGT increased was reported at a higher incidence for the encorafenib monotherapy and  the  combination  therapy  population  than  for  the  binimetinib  monotherapy  population  (Enco  P 10.6%,  Combo  450 RP  13.9  %  vs  Bini  P  3.5%).  In  contrast  ALT/AST  increased  was  reported  in  a higher incidence for the binimetinib monotherapy and the combination therapy population than for the encorafenib monotherapy population.

## Liver laboratory abnormalities

The incidences of liver laboratory abnormalities reported in the pooled Combo 450 population are listed below:

- Increased transaminases: 15.7% (43/274) overall - Grade 3-4: 5.5% (15/274)
- Increased GGT: 14.6% (40/274) overall - Grade 3-4: 8.4% (23/274)

In Study CMEK162B2301-Part 2, in the Combo 300 arm, the incidences of liver laboratory abnormalities are listed below:

- Increased transaminases: 13.2% (34/257) overall - Grade 3-4: 5.4% (14/257)
- Increased GGT: 14.0% (36/257) overall - Grade 3-4: 4.7% (12/257)

## Elevation of blood CK

Elevation of blood CK is a frequently observed laboratory finding associated with the administration of Binimetinib  45  mg  monotherapy  and  is  clinically  associated  sometimes  with  concomitant  muscular symptoms.  However,  the  addition  of  encorafenib  to  binimetinib  appears  to  mitigate  this  effect  as demonstrated  by  fewer  patients  in  the  Combo  450  RP  population  experiencing  CK  elevations  as compared  with  the  Bini  P  population  (24.8%-2.66  cases  per  100  patient-months  vs  44.7%-18.86 cases per 100 patient-months), as well as a lower incidence of Grade 3/4 events, SAEs, AEs leading to discontinuation, AEs requiring dose interruption and/or change and AEs requiring additional therapy.

In the pooled Combo 450 population, mostly mild asymptomatic blood CK elevation was reported in 27.0 % (74/274) of patients. The incidence of Grade 3 or 4 adverse reactions was 5.8 % (16/274). The median time to onset of the first event was 2.7 months (range: 0.5 to 17.5 months).

Rhabdomyolysis was reported in 0.4 % (1/274) of patients treated with encorafenib in combination with binimetinib. In this patient, rhabdomyolysis was observed with concomitant symptomatic Grade 4 CK elevation.

In contrast, muscle-related AEs, including myalgia, is a frequently observed with the administration of Encorafenib 300 mg monotherapy. However, the combination of binimetinib and encorafenib appears to mitigate this effect as demonstrated by fewer patients in the Combo 450 arm experiencing musclerelated AEs as compared with the encorafenib 300 mg monotherapy arm Part 1 (16.7% vs 31.3%), as well  as  a  distinctly  lower  incidence  of  Grade  3/4  events,  SAEs,  AEs  leading  to  discontinuation,  AEs requiring dose interruption and/or change and AEs requiring additional therapy.

The incidence of cardiac events (a significant safety concern of Binimetinib monotherapy) was similar respectively lower after adjustment for treatment exposure in the Combo 450 RP population compared

<div style=\"page-break-after: always\"></div>

to  the  Bini  P  population  (8.4%-0.79  case  per  100  patient-months  vs  11.2%-2.77  cases  per  100 patient-months). Grade 3/4 events were reported at a remarkably lower incidence in the Combo 450 RP population than in the Bini P population (1.1% vs 4.2%). In addition, there were no events leading to study drug discontinuation in the Combo 450 RP population whilst 4.2% were reported in the Bini P population.  Few  events  were  serious  or  required  additional  therapy.  The  most  frequent  PT  in  both populations was ejection fraction decreased (Combo 450 RP 6.6% vs Bini P 10.3%).

Overall, regarding the presented data of part 2 of the pivotal study CMEK162B2301 the frequency of patients with events in the left ventricular dysfunction grouping in the Combo 450 arm (7.8% [1.6% Grade 3/4]) seems to be similar to that in the Combo 300 arm (5.8% [1.2% Grade 3/4], showing equivalent tolerability between these 2 Combo dose arms and with no increased burden to patients with the higher encorafenib dose in the Combo 450 arm.

## Cardiac electrophysiology

In the safety analysis of pooled studies of encorafenib 450 mg once daily in combination with 45 mg binimetinib twice daily (Combo 450), the incidence of new QTc prolongation &gt; 500 ms was 0.7 % (2/268) in the encorafenib 450 mg plus binimetinib group, and 2.5 % (5/203) in the encorafenib single agent group. QTc prolongation of &gt; 60 ms compared to pre-treatment values was observed in 4.9 % (13/268) patients in the encorafenib plus binimetinib group, and in 3.4 % (7/204) in the encorafenib single agent group (see section 5.1 of encorafenib SmPC).

## Left ventricular dysfunction

In the pooled Combo 450 population, LVD was reported in 8.4 % (23/274) of patients. Grade 3 events occurred in 1.1 % (3/274) of patients. LVD led to treatment discontinuation in 0.4% (1/274) of patients and led to dose interruptions or dose reductions in 6.6 % (18/274) of patients.

The median time to first occurrence of LVD (any grade) was 4.4 months (range 0.03 to 21.3 months) in patients who developed an LVEF below 50 %. The mean LVEF value dropped by 5.9 % in the pooled Combo 450 population, from a mean of 63.9 % at baseline to 58.1 %. LVD was generally reversible following dose reduction or dose interruption.

## Venous thromboembolism

In  patients  treated  with  Combo 450,  VTE  occurred  in  4.7 %  (13/274)  of  patients,  including  2.2 % (6/274) of  patients  who  developed  pulmonary  embolism.  In  the  pooled Combo 450 population,  VTE was  reported  as  Grade 1 or 2  in  3.6 %  (10/274)  of  patients  and  Grade 3 or 4  in  1.1 %  (3/274)  of patients.  VTE  led  to  dose  interruptions  or  dose  modifications  in  1.1 %  (3/274)  patients  and  to additional therapy in 4.7 % (13/274) of patients.

## Hypertension

Hypertension AESIs were reported at a similar incidence in the Bini P and Combo 450 RP populations overall, although the incidence was higher in the Bini P when adjusted for drug exposure (15.9%-4.49 cases per 100 patient-months vs 12%-1.19 cases per 100 patient-months) and for Grade 3/4 events (8.7% vs 6.2%).

In Study CMEK162B2301 the incidence of a 2-grade shift in LVEF was higher in in the hypertension risk factor group (=history of hypertension, SBP ≥140 at screening, or DBP ≥ 90 at screening) as well. Thus, severe hypertension should be controlled before initiating treatment with binimetinib.

The  incidence  of  hypertension  AESIs  was  similar  in  the  Combo  450  and  vemurafenib  arms  of  the pivotal  study,  overall  (11.5%-1.01  cases  per  100  patient-months  vs  11.3%-1.49  cases  per  100 patient-months) and for Grade 3/4 events (5.7% vs 3.2%).

<div style=\"page-break-after: always\"></div>

New onset elevated blood pressure or worsening of pre-existing hypertension were reported in 11.7 % (32/274) of patients treated with the Combo 450. Hypertension events were reported as Grade 3 in 5.5 % (15/274) of patients, including hypertensive crisis (0.4 % (1/274)). Hypertension led to dose interruption or adjustment in 2.9 % of patients. Hypertensive adverse reactions required additional therapy in 8.0 % (22/274) of patients.

## Haemorrhage

Haemorrhage AESIs were reported at a similar overall incidence in the Bini P, Enco P and Combo 450 RP populations (11.5%-2.98 cases per 100 patient-months vs 12.9%-1.52 cases per 100 patientmonth vs 15.7%-1.55 cases per 100 patient months). Additionally, with regard to the preliminary data of part 2 of the pivotal study the incidence of haemorrhage events seems to be lower in the Combo 300mg population compared to the Combo 450 mg arm (7.0% vs 18.2%).

Haemorrhagic  events  were  observed  in  17.9 %  (49/274)  of  patients  in  the  pooled Combo  450 population. Most of these cases were Grade 1 or 2 (14.6 %) and 3.3 % were Grade 3 or 4 events. Few patients requiring dose interruptions or dose reductions (0.7 % or 2/274). Haemorrhagic events led to discontinuation  of  treatment  in  1.1 %  (3/274)  of  patients.  The  most  frequent  haemorrhagic  events were haematuria in 3.3 % (9/274) of patients, rectal haemorrhage  in 2.9 % (8/274) and haematochezia  in  2.9 %  (8/274)  of  patients.  Fatal  gastric  ulcer  haemorrhage  with  multiple  organ failure  as  a  concurrent  cause  of  death,  occurred  in  one  patient.  Cerebral  haemorrhage  occurred  in 1.5 % (4/274) of patients with fatal outcome in 3 patients. All events occurred in the setting of new or progressive brain metastases.

In Study CMEK162B2301-Part 2, in the Combo 300 arm, haemorrhagic events were observed in 6.6% (17/257) of patients and were Grade 3-4 in 1.6% (4/257) of patients.

## Anaemia

In  the  pooled Combo 450 population, anaemia was  reported in 19.7 % (54/274) of patients; 4.7 % (13/274) of patients had Grade 3 or 4. No patients discontinued treatment due to anaemia, 1.5 % (4/274) required dose interruption or dose modification.

In Study CMEK162B2301-Part 2, in the Combo 300 arm, anaemia was observed in 9.7% (25/257) of patients with Grade 3-4 reported in 2.7% (7/257) patients.

## Bradycardia and peripheral oedema

Bradycardia  and  peripheral  oedema  have  been  identified  as  AESIs  for  binimetinib.  However,  the incidences  of  these  AESIs  are  remarkably  reduced  when  binimetinib  is  given  in  combination  with encorafenib.

## Pneumonitis

AESIs were reported at a similar (low) overall incidence in the Bini P and Combo 450 RP populations.

## Facial paresis

Facial paresis was reported when binimetinib was used in combination with encorafenib (see section 4.8 of encorafenib SmPC).

Increased heart rate and facial paresis have been identified as an AESI for encorafenib. However, the incidence  of  these  AESIs  is  remarkably  reduced  when  encorafenib  is  given  in  combination  with binimetinib.

## Renal dysfunction

<div style=\"page-break-after: always\"></div>

Blood creatinine elevation and renal failure occurred when binimetinib was used in combination with encorafenib (see section 4.8 of encorafenib SmPC).

The incidence of renal failures seems to be similar in the presented safety populations. However, the severity  seems  to  be  slightly  higher  in  the  combo  450  RP  population  than  in  the  binimetinib  and encorafenib mono populations (incidence of Grade ¾ events: Bini P 0.5%, Enco P 1.4%, Combo 450 1.8%). However, laboratory serum creatinine elevations were reported in most of the patients in the Combo 450 arm of the pivotal study (overall 92. 7%). Although most of the creatinine elevations seem to be asymptomatic, the grade ¾ elevations seem to result in renal failures.

## Cutaneous malignancies

Secondary  skin  neoplasms  have  been  identified  as  an  AESI  for  encorafenib.  Regarding  the  data presented  (CMEK162B2301)  the  addition  of  binimetinib  to  encorafenib  appears  to  attenuate  the development of cutaneous squamous cell carcinoma (cuSCC) as compared to encorafenib treatment alone (Combo 450 arm2.6% vs enco 300 arm 7.8%).

Compared to vemurafenib cuSCC AESIs were reported at a distinctly lower incidence in the Combo 450 arm (2.6%) than the vemurafenib arm (16.7%), overall, for Grade 3/4 events (none vs 6.5%) and for events requiring additional  therapy  (1%  vs  12.4%).  However,  compared  to  the  combination vemurafenib / cobimetinib the incidences seem to be similar.

Cutaneous non-squamous cell carcinoma (cuSCC) events were reported in a low percentage of patients overall (2.1% Combo 450 arm, 1.0% encorafenib 300 arm, 2.7% vemurafenib arm). No melanoma events were reported for any patient in the Combo 450 arm while in the encorafenib 300 arm and vemurafenib arm, melanoma events occurred in a similar percentage of patients (5.2% encorafenib Part 1 arm, 4.3% vemurafenib arm). CuSCC was reported when binimetinib was used in combination with encorafenib (see section 4.8 of encorafenib SmPC).

Compared to the combination dabrafenib/trametinib the incidence of pyrexia in the Combo 450 mg RP seem  to  be  distinctly  lower  (53%  vs  15.7%)  and  other  secondary  causes  were  generally  evident. However, it should be kept in mind that the most commonly reported SAE by PT in the Combo 450 arm of  Study  CMEK162B2301  Part  1  was  pyrexia  in  6  (3.1%)  patients.  None  of  the  6  patients  had concurrent events of hypotension, chills/rigors, dehydration, renal failure or syncope and most of the patients had concurrent factors including disease progression or underlying infection which may have contributed to the pyrexia.

## Pancreatitis

The pancreatic enzyme elevations in the combo 450 RP population (Lipase 4.7%, Amylase 2.9%) were mostly asymptomatic. Pancreatitis is an uncommon ADR (incidence &lt;1%) when encorafenib is used in combination with binimetinib. Pancreatitis was reported when binimetinib was used in combination with encorafenib (see section 4.8 of encorafenib SmPC).

## Gastrointestinal disorders

In the pooled Combo 450 population, diarrhoea was observed in 38 % (104/274) of patients and was Grade 3 or 4 in 3.3 % (9/274) of patients. Diarrhoea led to dose discontinuation in 0.4 % of patients and to dose interruption or dose modification in 4.4 % of patients. Constipation occurred in 24.1 % (66/274) of patients and was Grade 1 or 2. Abdominal pain was reported in 27.4 % (75/274) of patients and was Grade 3 in 2.6 % (7/274) patients. Nausea occurred in 41.6 % (114/274) with Grade 3 or 4 observed in 2.6 % (7/274) of patients. Vomiting occurred in 28.1 % (77/274) of patients with Grade 3 or 4 reported in 2.2 % (6/274) of patients.

<div style=\"page-break-after: always\"></div>

In Study CMEK162B2301-Part 2, in the Combo 300 arm, nausea was observed in 27.2% (70/257) of patients and was Grade 3 in 1.6% (4/257) of patients. Vomiting occurred in 15.2% (39/257) of patients with Grade 3 reported in 0.4% (1/257) of patients. Diarrhoea occurred in 28.4% (73/257) of patients with Grade 3 reported in 1.6% (4/257) of patients.

Gastrointestinal disorders were typically managed with standard therapy.

## Headache

In the pooled Combo 450 population, headache occurred in 21.5% (59/274) of patients including Grade 3 in 1.5% (4/274) of patients.

In Study CMEK162B2301-Part 2, in the Combo 300 arm, headache was reported in 12.1% (31/257) of patients and was Grade 3 in 0.4% (1/257) of patients.

## Fatigue

In the pooled Combo 450 population, fatigue occurred in 43.8% (120/274) of patients including Grade 3 in 2.9% (8/274) of patients.

In Study CMEK162B2301-Part 2, in the Combo 300 arm, fatigue was observed in 33.5% (86/257) of patients with 1.6% (4/257) Grade 3-4 events.

## Combo BP versus Combo 450 RP:

The overall safety profile (as of 09 November 2016 data cutoff) of overall AEs, SAEs and AEs leading to treatment discontinuation is similar between Combo BP and Combo 450 RP populations. Discrete AE PTs reported in the Combo BP but not in Combo 450 RP occurred at an incidence of &lt;1%, were nonspecific, and no new safety concerns were identified from the Combo BP.

## Serious adverse event/deaths/other significant events

## Deaths

On-treatment deaths for all studies included in the Broad Safety Set were collected while patients were on treatment or within 30 days of the last dose of study drug.

Table 65 presents a summary of on-treatment deaths (occurring during treatment or within 30 days of the last dose) by PT for the Broad Safety Set.

## Bini P vs Combo 450 RP (pooled sets)

The overall  incidence  of  on-treatment  deaths  (with  or  without  adjustment  for  study  drug  exposure) was lower in the Combo 450 RP population compared to the Bini P population (8.4% vs 10.8%), with EAIR of deaths per 100 patient-months of 0.74 vs 2.45 and with most deaths in both populations due to progression of malignant melanoma (5.8% Combo 450 vs 9.4% Bini P).

The higher incidence of deaths not related to progression in the Combo 450 RP population is due to the higher exposure duration to Combo 450 than to binimetinib alone.

Overall two deaths due to AE (sepsis and multiorgan failure) and 10 deaths due to disease progression occurred within 30 days of the first dose of study drug in the Bini P population and a single death (due to AE: completed suicide) occurred within 30 days of the first dose of study drug in the Combo 450 RP population (Combo 450 arm of study CMEK162B2301).

## Combo 450 vs vemurafenib (Study CMEK162B2301)

The overall  incidence  of  on-treatment  deaths  (with  or  without  adjustment  for  study  drug  exposure) was slightly lower in the Combo 450 arm (8.9%, with an EAIR of deaths per 100 patient-months of

<div style=\"page-break-after: always\"></div>

0.71) than the vemurafenib arm (10.2%, with an EAIR of deaths per 100 patient-months of 1.23), with most deaths in both arms due to progression of malignant melanoma (5.2% vs 9.1%).

In  the  Combo 450 arm, one death (completed suicide) occurred within 30 days of the first dose of study drug vs no deaths in the vemurafenib arm.

Table 72: On-treatment Deaths by Primary System Organ Class, Preferred Term and Treatment (Broad Safety Set)

| Principal cause of death             | Bini 45mg BID N=427 n (%)   | Enco 300mg QD N=217 n (%)   | Combo pooled doses N=433 n (%)   | QD N=274 n (%)   | Combo 450mg Combo 450mg Enco 300mg QD N=192 n (%)   | QD N=192 n (%)   | Vemurafenib N=186 n (%)   |
|--------------------------------------|-----------------------------|-----------------------------|----------------------------------|------------------|-----------------------------------------------------|------------------|---------------------------|
| Any primary system organ class       | 46 (10.8)                   | 15 (6.9)                    | 44 (10.2)                        | 23 (8.4)         | 17 (8.9)                                            | 14 (7.3)         | 19 (10.2)                 |
| Malignant melanoma                   | 40 (9.4)                    | 12 (5.5)                    | 28 (6.5)                         | 16 (5.8)         | 10 (5.2)                                            | 12 (6.3)         | 17 (9.1)                  |
| Death                                | 0                           | 1 (0.5)                     | 3 (0.7)                          | 2 (0.7)          | 2 (1.0)                                             | 1 (0.5)          | 0                         |
| Cerebral haemorhage                  | 0                           | 0                           | 1 (0.2)                          | 1 (0.4)          | 1 (0.5)                                             | 0                | 0                         |
| Completed suicide                    | 0                           | 0                           | 1 (0.2)                          | 1 (0.4)          | 1 (0.5)                                             | 0                | 0                         |
| Euthanasia                           | 1 (0.2)                     | 0                           | 1 (0.2)                          | 1 (0.4)          | 1 (0.5)                                             | 0                | 0                         |
| Metastases to central nervous system | 0                           | 0                           | 1 (0.2)                          | 1 (0.4)          | 1 (0.5)                                             | 0                | 0                         |
| Multiple organ dysfunction syndrome  | 0                           | 0                           | 1 (0.2)                          | 1 (0.4)          | 1 (0.5)                                             | 0                | 0                         |
| Acute myocardial infarction          | 0                           | 1 (0.5)                     | 0                                | 0                | 0                                                   | 1 (0.5)          | 0                         |
| Disease progression                  | 0                           | 0                           | 1 (0.2)                          | 0                | 0                                                   | 0                | 0                         |
| Dyspnoea                             | 1 (0.2)                     | 0                           | 0                                | 0                | 0                                                   | 0                | 0                         |
| Embolism                             | 1 (0.2)                     | 0                           | 0                                | 0                | 0                                                   | 0                | 0                         |
| Intestinal sepsis                    | 0                           | 0                           | 0                                | 0                | 0                                                   | 0                | 1 (0.5)                   |
| Lung infection                       | 0                           | 0                           | 0                                | 0                | 0                                                   | 0                | 1 (0.5)                   |
| Malignant melanoma stageIV           | 0                           | 0                           | 1 (0.2)                          | 0                | 0                                                   | 0                | 0                         |
| Metastatic malignant melanoma        | 0                           | 0                           | 4 (0.9)                          | 0                | 0                                                   | 0                | 0                         |
| Multi-organ failure                  | 1 (0.2)                     | 0                           | 0                                | 0                | 0                                                   | 0                | 0                         |
| Myocardial infarction                | 0                           | 0                           | 1 (0.2)                          | 0                | 0                                                   | 0                | 0                         |
| Neoplasm progression                 | 0                           | 0                           | 1 (0.2)                          | 0                | 0                                                   | 0                | 0                         |
| Sepsis                               | 2 (0.5)                     | 0                           | 0                                | 0                | 0                                                   | 0                | 0                         |

Source: ISS Table 2.7.1

Preferred terms are sorted in descending frequency in the *Combo 450 mg QD-melanoma² column

MedDRAVersion19.0hasbeen used for thereportingof adverse events.

## Deaths related to adverse events in patients treated with binimetinib monotherapy

In  the  2  studies  that  provide  safety  results  for  patients  receiving  binimetinib  45  mg  monotherapy (Studies  CMEK162A2301  and  CMEK162X2201,  a  total  of  6  patients  died  due  to  events  other  than disease progression (Table 73).

Table 73: On-Treatment Deaths Considered Due to an Adverse Event (Binimetinib 45 mg)

| Patient ID         | Age                | Gender             | Cause of death by PT   | Study day of last dose   | Study day of death   |
|--------------------|--------------------|--------------------|------------------------|--------------------------|----------------------|
| Study CMEK162A2301 | Study CMEK162A2301 | Study CMEK162A2301 | Study CMEK162A2301     | Study CMEK162A2301       | Study CMEK162A2301   |
| 3015-016           | 65                 | M                  | sepsis                 | 80                       | 88                   |
| 4011-006           | 64                 | M                  | sepsis                 | 15                       | 16                   |
| 3012-005           | 78                 | M                  | multiple organ failure | 22                       | 23                   |
| 6051-004           | 52                 | F                  | embolism               | 153                      | 171                  |
| StudyCMEK162X2201  | StudyCMEK162X2201  | StudyCMEK162X2201  | StudyCMEK162X2201      | StudyCMEK162X2201        | StudyCMEK162X2201    |
| 1201-00101         | 47                 | F                  | euthanasia             | 116                      | 132                  |
| 1101-00101         | 58                 | F                  | dyspnoea               | 96                       | 96                   |

Source:CMEK162A2301andCMEK162X2201CSRs.

Abbreviations: F = female; ID = identification number; M = male; PT = preferred term.

<div style=\"page-break-after: always\"></div>

## Deaths related to adverse events in patients treated with Combo (450-600 mg)

In the Broad Safety Set, a total of 7 patients receiving Combo 450 mg or 600 mg died due to events other  than  disease  progression  (malignant  melanoma/metastases),  including  6  patients  in  Study CMEK162B2301 and 1 patient in Study CMEK162X2110. A summary of on-treatment deaths considered due to an AE is provided in Table 74.

Table 74: On-Treatment Deaths Considered Due to an Adverse Event (Combo 450 mg or 600 mg)

| Patient ID         | Age                | Gender             | Causeof deathbyPT                   | Study day of last dose   | Study day of death   |
|--------------------|--------------------|--------------------|-------------------------------------|--------------------------|----------------------|
| Study CMEK162B2301 | Study CMEK162B2301 | Study CMEK162B2301 | Study CMEK162B2301                  | Study CMEK162B2301       | Study CMEK162B2301   |
| 2056-004           | 51                 | F                  | death                               | 148                      | 148                  |
| 4075-011           | 35                 | M                  | death                               | 77                       | 77                   |
| 3010-010           | 67                 | M                  | multiple organ dysfunction syndrome | 15                       | 37                   |
| 4023-002           | 54                 | M                  | cerebral haemorrhage                | 230                      | 246                  |
| 8010-001           | 73                 | F                  | completed suicide                   | 9                        | 24                   |
| 8045-011           | 43                 | M                  | euthanasia                          | 256                      | 268                  |
| Study CMEK162X2110 | Study CMEK162X2110 | Study CMEK162X2110 | Study CMEK162X2110                  | Study CMEK162X2110       | Study CMEK162X2110   |
| 2000-210b          | 65                 | M                  | myocardial infarction               | 160                      | 160                  |

Source:CMEK162B2301,CLGX818X2109andCMEK162X2110CSRs.

F: female, ID: identification number, M: male, PT: preferred term

*All deaths in this study were more than 30 days after the last dose of Combo 450 mg.

bPatient received encorafenib at a dose of 600 mg QD in combination with binimetinib 45 mg BID.

## Deaths in the Other On-going Studies

Of  the  30  patients  treated  in  Compassionate  Use  Protocols  and  Investigator-sponsored  trials  with single-agent binimetinib, single-agent encorafenib or the combination of encorafenib plus binimetinib in the  relevant NRAS / BRAF -mutant  metastatic  melanoma  population,  11  patients  (all  treated  with binimetinib) had SAEs with a fatal outcome. Of these 11 patients, 6 fatal outcomes were due to PD, 1 was due to an SAE of pneumonia (only PT reported as related to the study drug by the Investigator) and sepsis, 1 was due to an SAE of ileus and multi-organ failure and 3 others provided no further information other than patient death. The SAE of pneumonia was the only reported as related with the study drug.

## Serious Adverse Events in Completed Studies

## SAEs in the Broad Safety Set

A summary of SAEs, regardless of relationship to study drug, that were reported for ≥2% of patients in any  population  by  PT  (overall  and  Grade  3/4  maximum)  for  the  Broad  Safety  Set  are  presented  in Table 75.

<div style=\"page-break-after: always\"></div>

Table 75: Serious Adverse Events, Regardless of Study Drug Relationship, by Preferred Term and Treatment - Overall and Maximum Grade 3 or 4 (≥2% in any population) (Broad Safety Set)

|                         | Melanoma                  | Melanoma                  | Melanoma                        | Melanoma                   | Study CMEK162B2301         | Study CMEK162B2301        | Study CMEK162B2301      |
|-------------------------|---------------------------|---------------------------|---------------------------------|----------------------------|----------------------------|---------------------------|-------------------------|
| Preferred Term Grades   | Bini 45mg BID N=427 n (%) | Enco 300mg QD N=217 n (%) | Combo pooled doses  N=433 n (%) | Combo 450mg QD N=274 n (%) | Combo 450mg QD N=192 n (%) | Enco 300mg QD N=192 n (%) | Vemurafenib N=186 n (%) |
| Any preferred term      |                           |                           |                                 |                            |                            |                           |                         |
| All grades              | 141 (33.0)                | 69 (31.8)                 | 158 (36.5)                      | 98 (35.8)                  | 66 (34.4)                  | 65 (33.9)                 | 69 (37.1)               |
| Grades 3/4              | 116 (27.2)                | 58 (26.7)                 | 142 (32.8)                      | 87 (31.8)                  | 57 (29.7)                  | 54 (28.1)                 | 60 (32.3)               |
| Pyrexia                 |                           |                           |                                 |                            |                            |                           |                         |
| All grades              | 0                         | 3 (1.4)                   | 15 (3.5)                        | 6 (2.2)                    | 6 (3.1)                    | 3 (1.6)                   | 2 (1.1)                 |
| Grades 3/4              | 0                         | 2 (0.9)                   | 9 (2.1)                         | 5 (1.8)                    | 5 (2.6)                    | 2 (1.0)                   | 0                       |
| Pneumonia               |                           |                           |                                 |                            |                            |                           |                         |
| All grades              | 2 (0.5)                   | 1 (0.5)                   | 7 (1.6)                         | 6 (2.2)                    | 3 (1.6)                    | 0                         | 0                       |
| Grades 3/4              | 2 (0.5)                   | 1 (0.5)                   | 4 (0.9)                         | 4 (1.5)                    | 3 (1.6)                    | 0                         | 0                       |
| Nausea                  |                           |                           |                                 |                            |                            |                           |                         |
| All grades              | 3 (0.7)                   | 6 (2.8)                   | 15 (3.5)                        | 6 (2.2)                    | 2 (1.0)                    | 6 (3.1)                   | 0                       |
| Grades 3/4              | 2 (0.5)                   | 4 (1.8)                   | 11 (2.5)                        | 5 (1.8)                    | 1 (0.5)                    | 4 (2.1)                   | 0                       |
| Anaemia                 |                           |                           |                                 |                            |                            |                           |                         |
| All grades              | 3 (0.7)                   | 1 (0.5)                   | 8 (1.8)                         | 5 (1.8)                    | 4 (2.1)                    | 1 (0.5)                   | 2 (1.1)                 |
| Grades 3/4              | 3 (0.7)                   | 1 (0.5)                   | 8 (1.8)                         | 5 (1.8)                    | 4 (2.1)                    | 1 (0.5)                   | 1 (0.5)                 |
| Vomiting                |                           |                           |                                 |                            |                            |                           |                         |
| All grades              | 5 (1.2)                   | 6 (2.8)                   | 17 (3.9)                        | 5 (1.8)                    | 3 (1.6)                    | 6 (3.1)                   | 2 (1.1)                 |
| Grades 3/4              | 4 (0.9)                   | 6 (2.8)                   | 11 (2.5)                        | 4 (1.5)                    | 2 (1.0)                    | 6 (3.1)                   | 1 (0.5)                 |
| Abdominal pain          |                           |                           |                                 |                            |                            |                           |                         |
| All grades              | 2 (0.5)                   | 2 (0.9)                   | 8 (1.8)                         | 4 (1.5)                    | 4 (2.1)                    | 2 (1.0)                   | 1 (0.5)                 |
| Grades 3/4              | 1 (0.2)                   | 2 (0.9)                   | 6 (1.4)                         | 3 (1.1)                    | 3 (1.6)                    | 2 (1.0)                   | 1 (0.5)                 |
| General physical health |                           |                           |                                 |                            |                            |                           |                         |
| deterioration           |                           |                           |                                 |                            |                            |                           |                         |
| All grades              | 16 (3.7)                  | 2 (0.9)                   | 8 (1.8)                         | 4 (1.5)                    | 3 (1.6)                    | 2 (1.0)                   | 6 (3.2)                 |
| Grades 3/4              | 15 (3.5)                  | 2 (0.9)                   | 7 (1.6)                         | 3 (1.1)                    | 2 (1.0)                    | 2 (1.0)                   | 6 (3.2)                 |
| Pain                    |                           |                           |                                 |                            |                            |                           |                         |
| All grades              | 0                         | 4 (1.8)                   | 2 (0.5)                         | 2 (0.7)                    | 1 (0.5)                    | 4 (2.1)                   | 0                       |
| Grades 3/4              | 0                         | 4 (1.8)                   | 2 (0.5)                         | 2 (0.7)                    | 1 (0.5)                    | 4 (2.1)                   | 0                       |
| Back pain               |                           |                           |                                 |                            |                            |                           |                         |
| All grades              | 1 (0.2)                   | 4 (1.8)                   | 0                               | 0                          | 0                          | 4 (2.1)                   | 2 (1.1)                 |
| Grades 3/4              | 1 (0.2)                   | 3 (1.4)                   | 0                               | 0                          | 0                          | 3 (1.6)                   | 2 (1.1)                 |

Source:ISS Table 2.3.2

Categories are not mutually exclusive. Patients with events in more than 1 category are counted once in each of those categories. Preferred terms are sorted in descending frequency in the'Combo 450mgQD-melanoma' column. MedDRA Version 19.0 has been used for the reporting of adverse events.

## Comparison of the Safety Profile of Combo 300 and Combo 450

The safety profile comparison is based on the 192 patients randomised to the Combo 450 arm as of the 19 May 2016 cut-off date (Part 1) and the 258 patients randomised to the Combo 300 arm (one of whom was not treated) as of the 09 November 2016 cut-off date (Part 2).

The median durations of potential follow-up for PFS of 16.7 months for Combo 450 part 1 and 13.9 months for Combo 300 part 2 were broadly comparable. The median duration of exposure in the Combo 450 arm and Combo 300 arms were similar with 52.6% and 54.9% of patients having received ≥ 48 weeks of study treatment, respectively.

In the Combo300, the median relative dose intensity (RDI) of encorafenib and binimetinib was 100% and 99.76% respectively, similar to the median RDI of encorafenib and binimetinib in the Combo450.

The overall safety profiles for the Combo 450 and Combo 300 arms are similar in terms of incidence (difference &lt;5%) of deaths, AEs, treatment discontinuation due to AEs and AEs leading to dose modifications/ interruptions or additional therapy. The overall incidence of Grade 3-4 AEs, as well as the overall incidences of SAEs, was lower in the Combo 300 as compared to Combo 450.

<div style=\"page-break-after: always\"></div>

Table 76: Overall Safety summary [Restricted Safety Set]

| Category                                          |                      | Study - CMEK162B2301                                         | Study - CMEK162B2301                                         |
|---------------------------------------------------|----------------------|--------------------------------------------------------------|--------------------------------------------------------------|
| Median duration of exposure:                      | Grade                | Combo 450mg QD Cutoff Date 19MAY2016 N=192 n (%) 51.21 weeks | Combo 300mg QD Cutoff Date 09NOV2016 N=257 n (%) 52.14 weeks |
| On-treatment deaths a                             | All Grades           | 17 (8.9)                                                     | 25 (9.7)                                                     |
| AEs                                               | All Grades           | 189 (98.4)                                                   | 252 (98.1)                                                   |
| Serious AEs                                       | All Grades Grade 3/4 | 66 (34.4) 57 (29.7)                                          | 75 (29.2) 65 (25.3)                                          |
| AEs leading to discontinuation                    | All Grades           | 24 (12.5)                                                    | 32 (12.5) 23 (8.9)                                           |
|                                                   | Grade 3/4            | 22 (11.5)                                                    |                                                              |
| AEs requiring dose interruption and/or adjustment | All Grades           | 92 (47.9)                                                    | 115 (44.7)                                                   |
|                                                   | Grade 3/4            | 63 (32.8)                                                    | 59 (23.0)                                                    |
| AEs requiring additional therapy                  | All Grade 3/4        | 165 67 (34.9)                                                | 211 (82.1) 77 (30.0)                                         |
| b                                                 | Grades               | (85.9)                                                       |                                                              |

Melanoma: Naive to BRAF inhibitors and MEK inhibitors. Combo = Binimetinib + Encorafenib (doses 300 mg QD or 450 mg QD).

Combo 450 mg under Melanoma column = Restricted safety pool. All Binimetinib doses were 45 mg BID.

Abbreviations: AE=adverse event; EOT=end of treatment; PT=preferred term.

Categories are not mutually exclusive. Patients with multiple events in the same category were counted only once in that category.

Patients with events in more than 1 category were counted once in each of those categories.

a Deaths occurring &gt;30 days after EOT were not included.

b Additional therapy includes all non-drug therapy and concomitant medications.

* A patient may have had both a dose interruption and a dose adjustment for a single AE PT.

# A patient with only a dose adjustment with no dose interruption for a single AE PT.

MedDRA Version 19.0 has been used for the reporting of adverse events.

AEs more frequent in the Combo 450 arm are shown in Table A and those more frequent in the Combo 300 arm are shown in Table B. The EAIR values were consistent with the imbalances in AE incidences between the Combo 450 vs the Combo 300 arm.

Table 77: Overall incidence of AEs (increased by ≥5%) or grade 3-4 (increased by ≥2%) in the Combo 450 arm as compared to Combo 300 arm [Restricted Safety Set]

|                       | Combo 450mg QD Cutoff Date 19MAY2016 N=192 N%(grade 3- 4%)   | EAIR*   | Combo 300mg QD Cutoff Date 09NOV2016 N=257 N%(grade 3- 4%)   | EAIR*   |
|-----------------------|--------------------------------------------------------------|---------|--------------------------------------------------------------|---------|
| Any preferred term AE | 98.4(57.8)                                                   |         | 98.1 (46.7)                                                  |         |
| Nausea                | 41.1(1.6)                                                    | 5.03    | 27.2(1.6)                                                    | 3.12    |
| Diarrhoea             | 36.5(2.6)                                                    | 4.43    | 28.4 (1.6)                                                   | 3.43    |
| Vomiting              | 29.7 (1.6)                                                   | 3.05    | 15.2(0.4)                                                    | 1.55    |
| Fatigue               | 28.6 (2.1)                                                   | 3.02    | 22.2 (0.8)                                                   | 2.47    |
| Constipation          | 21.9 (-)                                                     | 3.05    | 16.7 (-)                                                     | 1.75    |
| Headache              | 21.9 (1.6)                                                   | 2.04    | 11.7 (0.4)                                                   | 1.15    |
| Pyrexia               | 18.2(3.6)                                                    | 1.69    | 16.7(0)                                                      | 1.69    |

<div style=\"page-break-after: always\"></div>

| Abdominal pain   | 16.7(2.6)   |   1.57 | 10.5(1.2)   |   1.03 |
|------------------|-------------|--------|-------------|--------|
| Vision blurred   | 15.6(0)     |   1.5  | 10.1(0.4)   |   1.02 |
| Anaemia          | 15.1(4.2)   |   1.5  | 9.3 (2.7)   |   0.89 |
| GGT increased    | 15.1 (9.4)  |   1.35 | 14 (4.7)    |   1.4  |
| Dry skin         | 14.1 (-)    |   1.29 | 8.2 (-)     |   0.8  |
| Rash             | 14.1 (1.0)  |   1.19 | 7.0 (0.8)   |   0.68 |
| Hypertension     | 10.9 (5.7)  |   0.96 | 8.2 (3.5)   |   0.79 |

* EAIR (Exposure adjusted incidence rate per 100 patient-months) = (n*100)/ (total exposure time (in months) of Broad Safety Set).

Table 78: Overall incidence of AEs (increased≥5%) or grade 3-4 (increased ≥2%) increased in the Combo 300 arm as compared to Combo 450 arm [Restricted Safety Set]

|               | Combo 450mg QD N=192 50.64 weeks %(%grade 3-4) EAIR*   | Combo 300mg QD N=257 52.14 weeks %(%grade 3-4)   |   EAIR* |
|---------------|--------------------------------------------------------|--------------------------------------------------|---------|
| Back pain     | 9.4 (0.5) 0.8                                          | 14 (0.8)                                         |    1.39 |
| AST increased | 8.3 (2.1) 0.71                                         | 8.2 (4.3)                                        |    0.78 |

The increase in GI events in the Combo 450 arm did not have a big impact on the renal function; PTs of renal failure, blood creatinine increased and clinically notable shifts from baseline of creatinine lab parameter were similar in both arms. Worsening creatinine from baseline by at least 2 grades or to ≥ Grade 3 occurred for 17.7 % of patients in the Combo 300 vs 17.1% in the Combo 450. Worst postbaseline Grade 3 increased creatinine values occurred in 1.6% in the Combo 300 arm vs 3.6% in the Combo 450.

The overall incidence of SAEs was lower (difference &lt;5%) in the Combo 300 arm as compared to Combo 450 arm (29.7% vs 34.4%). The most frequently reported SAEs that were ≥ 2.0% of patients in either treatment group occurred under the SOCs of gastrointestinal disorders (3.1% Combo 300 arm, 9.4% Combo 450), infections and infestations (6.2% Combo 300 arm, 8.9% Combo 450), general disorders and administration site conditions (3.5% Combo 300 arm, 8.3% Combo 450) and nervous system disorders (Combo 450 arm 8.2% Combo 300 arm, 7.3%).

The incidence of on-treatment deaths was similar between the treatment groups (9.7% Combo 300 arm, 9.9% Combo 450). Most on-treatment deaths were considered due to disease progression. In the Combo 300 arm and the Combo 450 group, 3 (1.2%) and 2 (1.0%) on-treatment deaths, respectively, were considered due to AEs other than disease progression (malignant melanoma/metastases).

The percentage of patients with AESIs (any grade) considered common to both drugs was higher in the Combo 450 arm compared with the Combo 300 arm (66.1% vs 51.4%). The mitigating effect of adding binimetinib to encorafenib remined evident for PTs of retinal or pigment epithelium detachment,

<div style=\"page-break-after: always\"></div>

RVO, myopathy, muscle enzyme elevations, rash, nail disorders, and facial paresis. However, retinopathy (excluding retinal vein occlusion), rash, LFT abnormalities, haemorrhage and hypertension were more common for Combo 450 vs Combo 300.

Table 79: AESIs, Regardless of Relationship to Study Drug, by Grouping and Contribution of Each Component of the Combination- Overall, Maximum Grades 3 and 4 [Restricted Safety Set]

|                                                              | Combo 450 arm QD N=192 n (%)   | Combo 300mg QD N=257 n (%)   |
|--------------------------------------------------------------|--------------------------------|------------------------------|
| AESIs common to both drugs                                   |                                |                              |
| Any AESI N%(%Grade3-4)                                       | 66.1 (22.9)                    | 51.4 (14.8)                  |
| Serious AESI N%(%Grade3-4)                                   | 10.4 (8.3)                     | 6.2(4.7)                     |
| AESI leading to discontinuation N%(%Grade3-4)                | 5.2(3.6)                       | 4.3(3.1)                     |
| AESI requiring dose interruption and/or change N%(%Grade3-4) | 15.6(10.9)                     | 12.5(7.8)                    |
| AESI requiring additional therapy N%(%Grade3-4)              | 33.3(8.3)                      | 27.6(6.6)                    |
| Liver function test abnormalities                            | 48 (25.0)                      | 51 (19.8)                    |
| Grade 3/4                                                    | 28 (14.6)                      | 24(9.3)                      |
| EAIR                                                         | 2.1                            | 2.06                         |
| Rash                                                         | 50(26.0)                       | 44 (17.1)                    |
| Grade 3/4                                                    | 2(1.0)                         | 7 (2.7)                      |
| EAIR                                                         | 2.61                           | 0.68                         |
| Myopathy                                                     | 32(16.7)                       | 39 (15.2)                    |
| Grade 3/4                                                    | 0                              | 2 (0.8)                      |
| Haemorrhage                                                  | 32(16.7)                       | 18 (7.0)                     |
| Grade 3/4                                                    | 0                              | 3 (1.2)                      |
| EAIR                                                         | 1.61                           | 0.67                         |
| Skin infections                                              | 22(11.5)                       | 30 (11.7)                    |
| Grade 3/4                                                    | 4(2.1)                         | 7 (2.7)                      |
| EAIR                                                         | 0.88                           | 1.15                         |
| Photosensitivity                                             | 9(4.7)                         | 6 (2.3)                      |
| Grade 3/4 EAIR                                               | 1(0.5) 0.39                    | 0 0.22                       |
| Acute renal failure                                          | 7 (3.6)                        | 6 (2.3)                      |
| Grade 3/4                                                    | 5(2.6)                         |                              |
|                                                              |                                | 1 (0.4)                      |
| Tachycardia                                                  | 3 (1.6)                        | 8 (3.1)                      |
| Grade 3/4                                                    | 1(0.5)                         | 1 (0.4)                      |
| Severe cutaneous adverse reactions Grade 3/4                 | 1 (0.5) 0                      | 2 (0.8) 0                    |
| Nail disorders                                               | 3 (1.6)                        | 4 (1.6)                      |
| Grade 3/4                                                    | 0                              |                              |
| Hepatic failure                                              | 1(0.5)                         | 0                            |
| Grade 3/4                                                    | 1(0.5)                         | 0 0                          |
|                                                              | Combo                          | Combo 300mg                  |
|                                                              |                                | QD                           |
|                                                              | 450 arm QD                     | N=257                        |
|                                                              | N=192                          | n (%)                        |
|                                                              | n (%)                          |                              |
| AESIs Specific to Binimetinib                                |                                |                              |
| Any AESI N%(%Grade3-4)                                       | 69.3(18.2)                     | 56.8(12.8)                   |
| Serious AESI N%(%Grade3-4)                                   | 4.7(2.6)                       | 2.7 (1.6)                    |
| AESI leading to discontinuation N%(%Grade3-4)                | 1.0(0.5)                       | 2.3 (0.8)                    |
| AESI requiring dose interruption or change N%(%Grade3-4)     | 19.8(8.3)                      | 16.7(5.1)                    |
| AESI requiring additional therapy N%(%Grade3-4)              | 19.3(8.3)                      | 12.8(3.5)                    |
| Retinopathy excluding RVO                                    | 93 (48.4)                      | 79 (30.7)                    |
| Grade 3/4                                                    | 5(2.6)                         | 4 (1.6)                      |
| EAIR                                                         | 7.06                           |                              |
| Muscle enzyme/protein changes                                | 44 (22.9)                      | 51 (19.8)                    |
| Grade ¾                                                      | 13 (6.8)                       | 14 (5.4)                     |

<div style=\"page-break-after: always\"></div>

| EAIR                                                     | 2.20       | 2.13      |
|----------------------------------------------------------|------------|-----------|
| Peripheral oedema                                        | 24(12.5)   | 30 (11.7) |
| Grade ¾                                                  | 2(1.0)     | 9 (3.5)   |
| EAIR                                                     | 1.01       | 1.13      |
| Hypertension                                             | 22(11.5)   | 23 (8.9)  |
| Grade 3/4                                                | 11(5.7)    | 9(3.5)    |
| EAIR                                                     | 0.89       | 0.87      |
| Left ventricular dysfunction                             | 15(7.8)    | 15 (5.8)  |
| Grade 3/4                                                | 3(1.6)     | 3 (1.2)   |
| Venous thromboembolism                                   | 10(5.2)    | 5 (1.9)   |
| Grade 3/4                                                | 2(1.0)     | 3 (1.2)   |
| EAIR                                                     | 0.42       | 0.18      |
| Bradycardia                                              | 2(1.0)     | 2(0.8)    |
| Grade 3/4                                                | 0          | 0         |
| EAIR                                                     | 0.08       |           |
| Pneumonitis                                              | 1(0.5)     | 1(0.4)    |
| Grade 3/4                                                | 0          | 0         |
| EAIR                                                     | 0.04       | 0.04      |
| Rhabdomyolysis                                           | 1(0.5)     | 0         |
| Grade ¾                                                  | 1(0.5)     | 0         |
| Retinal vein occlusion                                   | 0          | 1 (0.4)   |
| Grade 3/4                                                | 0          | 0         |
| AESIs Specific to Encorafenib                            |            |           |
| Any AESI N%(%Grade3-4)                                   | 14.6 (1.0) | 14.4(3.1) |
| Serious AESI N%(%Grade3-4)                               | 0          | 1.6 (1.2) |
| AESI leading to discontinuation N%(%Grade3-4)            | 0          | 1.6(1.2)  |
| AESI requiring dose interruption or change N%(%Grade3-4) | 4.2(1.0)   | 3.9(1.2)  |
| AESI requiring additional therapy N%(%Grade3-4)          | 9.4(1.0)   | 8.9(1.9)  |
| PPE syndrome                                             | 13 (6.8)   | 10 (3.9)  |
| Grade 3/4                                                | 0          | 4 (1.6)   |
| EAIR                                                     | 0.57       | 0.36      |
| Uveitis                                                  | 7(3.6)     | 10 (3.9)  |
| Grade 3/4                                                | 1(0.5)     |           |
| Cutaneous squamous cell carcinoma                        | 5(2.6)     | 8 (3.1)   |
| Grade 3/4                                                | 0          | 0         |
| EAIR                                                     | 0.23       | 0.31      |
| Cutaneous non-squamous cell carcinoma                    | 4 (2.1)    | 8 (3.1)   |
| Grade 3/4                                                | 0          | 2 (0.8)   |
| Melanomas                                                | 2 (1.0)    | 3 (1.2)   |
| Grade 3/4                                                | -          | 1 (0.4)   |
| Facial paresis                                           | 2(1.0)     | 1 (0.4)   |
| Grade 3/4                                                | 1(0.5)     | 0         |
| EAIR                                                     | 0.08       | 0.04      |

Source Safety appendix Table Q96E\\_T\\_6\\_1

## Laboratory findings

## Haematology

In both the Bini P and Combo 450 RP populations, decreased haemoglobin was the most common new or worsened haematology abnormality and decreases were mostly Grade 1, with no Grade 4 decreases reported (Grade 1: 47.1% vs 32.1% of patients, respectively; Grade 2: 14.2% vs 10.5%; Grade 3: 2.9% vs 4.5%). In both populations, decreases in leukocyte count and lymphocyte count were also reported in ≥10% of patients (for any CTCAE grade) but were mostly Grade 1/2. All other abnormal decreases or increases in the Combo 450 RP populations were reported in &lt;10% of patients for any CTCAE  grade,  whilst  decreases  in  neutrophil  and  platelet  counts  and  increases  in  activated  partial thromboplastin time (mostly Grade 1) were also reported in ≥10% of patients in the Bini P population.

<div style=\"page-break-after: always\"></div>

No new or worsened haematology abnormality was reported at a higher incidence in the Combo 450 RP than in the Bini P population whilst, additionally to Grade 1 decreased haemoglobin (see above), Grade  1  activated  partial  thromboplastin  time  was  reported  at  a  higher  incidence  in  the  Bini  P population than in the Combo 450 RP population.

Similarly, in both Combo 450 and vemurafenib arms of Study CMEK162B2301, decreased haemoglobin was the most common new or worsened haematology abnormality and decreases were mostly Grade 1, with no Grade 4 reported (Grade 1: 30.7% vs 36.2% of patients, respectively; Grade 2: 10.9% vs 7.3%;  Grade  3:  3.7%  vs  2.2%).  Grade  1-3  decreased  lymphocyte  count  was  reported  at  a  lower incidence in the Combo 450 arm than in the vemurafenib arm.

Grade 1 decreased platelet count was the only haematology abnormality reported at a higher incidence in the Combo 450 arm than in the vemurafenib arm (8.6% vs 2.8%).

## Biochemistry

In both the Bini P and Combo 450 RP populations, increased creatinine was the most common new or worsened biochemistry abnormality and increases were mostly Grade 1 (Grade 1: 79.5% vs 79.2% of patients, respectively; Grade 2: 5.3% vs 15.2%; Grade 3: 0.5% vs 3%; Grade 4: 0.7% vs none).

Grade 2 increased creatinine was the only biochemistry abnormality reported at a higher incidence in the Combo 450 RP population than in the Bini P population.

Grade 1 increased ALT and AST were reported at a higher incidence in the Bini P population than in the Combo 450 RP population (40.8% vs 23.6% and 69.4% vs 25.1%) as well as Grade 3 and 4 increased CK (14.5% vs 3.4% and 8.7% vs 0.8%, respectively).

## Safety in special populations

## Age, gender and race

Overall, there were no clinically important effects of age on the safety of binimetinib, or on the safety of binimetinib in combination with encorafenib. Subgroups defined for the reporting of AEs were age (&lt;65 vs ≥65 years, &lt;75 vs &gt;75 years), gender and race (Caucasian vs Asian vs Other) and baseline brain  metastases.  No  clinically  relevant  differences  were  observed.  No  safety  trends  or  differences were observed in this subgroup as compared to the overall patient population in Study CMEK162B2301.

Table 80: Overview of Safety according to age in Combo 450 RP

|                                  |            | <65 years N=194 N (%)   | 65-74 years N=65 N (%)   | 75-84 years N=14 N (%)   | ≥85 years N=1 N (%)   |
|----------------------------------|------------|-------------------------|--------------------------|--------------------------|-----------------------|
| At least one TEAEs               | All grades | 192 (99.0)              | 64 (98.5)                | 14 (100.0)               | 1 (100.0)             |
| At least one TEAEs               | Grade 3-4  | 116 (59.8)              | 41 (63.1)                | 10 (71.4)                | 1 (100.0)             |
| At least one SAEs                | All grades | 76 (39.2)               | 27 (41.5)                | 7 (50.0)                 | 0 (0.0)               |
| At least one SAEs                | Grade 3-4  | 64 (33.0)               | 23 (35.4)                | 7 (50.0)                 | 0 (0.0)               |
| Fatal                            | All grades | 13(6.7)                 | 2(3.1)                   | 2(14.3)                  | 0 (0.0)               |
| Hospitalization/prolong existing | All grades | 58(29.9)                | 24(36.9)                 | 7(50.0)                  | 0 (0.0)               |
| hospitalization                  |            |                         |                          |                          |                       |
| Life-threatening                 | All grades | 4(2.1)                  | 2(3.1)                   | 2(14.3)                  | 0 (0.0)               |
| Disability/incapacity            | All grades | 1(0.5)                  | 0 (0.0)                  | 0 (0.0)                  | 0 (0.0)               |

<div style=\"page-break-after: always\"></div>

| Other (medically significant)                                                                | All grades            | 5(2.6)                | 2(3.1)                  | 0 (0.0)                  | 0 (0.0)                 |
|----------------------------------------------------------------------------------------------|-----------------------|-----------------------|-------------------------|--------------------------|-------------------------|
| AEs leading to discontinuation                                                               | All grades Grade 3-4  | 20 (10.3) 16 (8.2)    | 6 (9.2) 4 (6.2)         | 5 (35.7) 5 (35.7)        | 1 (100.0) 1 (100.0)     |
| SOC Psychiatric disorders                                                                    | All grades Grade 3-4  | 39 (20.1) 2 (1.0)     | 14 (21.5) 2 (3.1)       | 3 (21.4) 1 (7.1)         | 0 (0.0) 0 (0.0)         |
| SOC Nervous system                                                                           | All grades Grade 3-4  | 92 (47.4) 22 (11.3)   | 33 (50.8) 7 (10.8)      | 9 (64.3) 2 (14.3)        | 1 (100.0) 0 (0.0)       |
| Accidents and injuries SMQ                                                                   | All grades Grade 3-4  | 48 (24.7) 0 (0.0)     | 19 (29.2) 3 (4.6)       | 2 (14.3) 0 (0.0)         | 0 (0.0) 0 (0.0)         |
| SOC Cardiac disorders                                                                        | All grades Grade 3-4  | 27 (13.9) 1 (0.5)     | 12 (18.5) 1 (1.5)       | 3 (21.4) 2 (14.3)        | 0 (0.0) 0 (0.0)         |
| SOC Vascular disorders                                                                       | All grades Grade 3-4  | 38 (19.6) 10 (5.2)    | 13 (20.0) 6 (9.2)       | 1 (7.1) 0 (0.0)          | 1 (100.0) 0 (0.0)       |
| SMQ Cerebrovascular disorders a                                                              | All grades Grade 3-4  | 13 (6.7) 8 (4.1)      | 3 (4.6) 2 (3.1)         | 2 (14.3) 1 (7.1)         | 0 (0.0) 0 (0.0)         |
| SOC Infections and infestations                                                              | All grades Grade 3-4  | 97 (50.0) 18 (9.3)    | 36 (55.4) 8 (12.3)      | 9 (64.3) 0 (0.0)         | 0 (0.0) 0 (0.0)         |
| Sum of following PT                                                                          | All grades Grade 3-4  | 32 (16.5) 3 (1.5)     | 15 (23.1) 6 (9.2)       | 4 (28.6) 1 (7.1)         | 0 (0.0) 0 (0.0)         |
| Postural Hypotensionb Fall Loss of consciousness                                             | All grades All grades | 1 (0.5) 4 (2.1)       | 0 (0.0) 5 (7.7) 0 (0.0) | 0 (0.0) 2 (14.3) 0 (0.0) | 0 (0.0) 0 (0.0) 0 (0.0) |
| Syncope                                                                                      | All grades All grades | 0 (0.0) 1 (0.5)       | 1 (1.5)                 | 0 (0.0)                  | 0 (0.0)                 |
| Dizziness                                                                                    | All grades            | 23 (11.9)             | 8 (12.3)                | 3 (21.4)                 | 0 (0.0)                 |
| Ataxia                                                                                       | All grades            | 1 (0.5)               | 1 (1.5)                 | 0 (0.0)                  | 0 (0.0)                 |
| Fracturec PT Anticholinergic syndrome                                                        | All grades All grades | 5 (2.6) 0 (0.0)       | 4 (6.2) 0 (0.0)         | 0 (0.0) 0 (0.0)          | 0 (0.0) 0 (0.0)         |
| PT Quality of life decreased                                                                 | Grade 3-4 All         | 0 (0.0) 0 (0.0) (0.0) | 0 (0.0) 0 (0.0)         | 0 (0.0) 0 (0.0)          | 0 (0.0) 0               |
|                                                                                              | grades Grade 3-4      | 0                     | 0 (0.0)                 | 0 (0.0)                  | (0.0) 0 (0.0)           |
| Other AEs appearing more frequently in older patients d Blood alkaline phosphatase increased | All grades Grade 3-4  | 8 (4.1) 1 (0.5)       | 8 (12.3) 1 (1.5)        | 3 (21.4) 0 (0.0)         | 1 (100.0) 0 (0.0)       |
| Diarrhoea                                                                                    | All grades Grade 3-4  | 66 (34.0) 5 (2.6) 22  | 28 (43.1) 2 (3.1) 13    | 9 (64.3) 2 (14.3)        | 1 (100.0) 0 (0.0)       |
| increased                                                                                    | All                   |                       |                         | 4 (28.6)                 | 1                       |
| Gamma-glutamyltransferase                                                                    | grades                | (11.3)                | (20.0)                  |                          | (100.0)                 |
|                                                                                              | Grade 3-4             | 11 (5.7)              | 8 (12.3)                | 3 (21.4)                 |                         |
| Pruritus                                                                                     | All grades            | 12 (6.2)              | 13 (20.0)               | 1 (7.1)                  | 1 (100.0)               |
|                                                                                              |                       |                       |                         |                          | 1 (100.0)               |
|                                                                                              | Grade 3-4             | 1 (0.5)               | 0 (0.0)                 | 0 (0.0)                  | 0 (0.0)                 |

## Hepatic impairment

<div style=\"page-break-after: always\"></div>

Study CMEK162A2104 was a dedicated study investigating the PK of binimetinib in hepatic impairment subjects, as defined by the NCI Organ Dysfunction Working Group, versus healthy subjects. Results indicate that, compared to healthy subjects, the exposure of binimetinib is not significantly altered in subjects with mild hepatic impairment but is increased 2-fold in subjects with moderate and severe hepatic impairment. Due to the increase in exposure observed in the moderate impairment cohort, the dose was reduced to 15 mg in the severe impairment cohort. All AEs reported in Study CMEK162A2104 were mild or moderate, except for 1 Grade 3 AE of motor vehicle accident deemed not related, and were generally consistent with previous AEs observed following binimetinib administration (headache, constipation, abdominal pain, vision blurred). Based on the results of the clinical study, the dose in moderate and severe hepatic impairment is proposed to be 30 mg BID.  This dose results in a dose corresponding  to  60mg  BID  in  normal  patients.  The  60mg  BID  dose,  however,  was  not  developed further  during  the  clinical  programme  as  AEs  were  observed.  No  significant  differences  have  been noted  between  healthy  subjects  and  those  with  mild  hepatic  impairment,  therefore,  no  dose adjustment  is  required.  A  hepatic  impairment  study  has  been  performed.    Based  on  these  study results,  popPK  modelling  was  performed  to  simulate  different  dosing  regimens  for  patients  with moderate  and  severe  HI.  Considering  total  binimetinib,  as  15mg  TID  dosing  could  be  appropriate. However, considering the unbound drug concentrations which were impaired to a higher degree with increasing  hepatic  impairment,  then  a  dose  adjustment  to  15mg  BID  was  more  reasonable,  and  it therefore proposed.  Recommendations are required for dose reductions in case of adverse reactions in patients with HI.

In  the  Combo 450 RP population, there was no increase in notable hepatic laboratory values in the patients with liver metastases as compared with patients without liver metastases.

## Renal impairment

The effect of renal impairment on binimetinib exposure was assessed in a dedicated clinical study with an abbreviated design (Study ARRAY-162-106). Results from the severe impairment cohort (eGFR ≤29 mL/min/1.73 m2), indicate an approximate 29% increase in exposure (AUCinf) and 21% increase in Cmax compared to matching healthy subjects. Based on the results in the severely-impaired cohort compared to matching healthy subjects in Study ARRAY-162-106, no dose adjustment is required in subjects with renal impairment.

The following subgroup analyses were also performed:

·  Hepatic  lab  test  abnormalities-  in  the  Combo  450  RP  population  there  was  no  increase  in  notable hepatic laboratory values in the patients with liver metastases as compared with patients without liver metastasis.  In  the  Bini  P  population,  more  patients  with  liver  metastases  had  notable  hepatic laboratory values (ALT, AST, ALP) as compared with the overall population and patients with no liver metastases;  however,  there  were  still  limited  numbers  of  patients  overall  with  notable  hepatic laboratory values.

· LVEF - in the Combo 450 RP population, there was no difference in the incidence of 'worst change from baseline' in LVEF between those with or without baseline risk factors (cardiac risk, hypertension, LVD risk)  and  a  small  difference  in  the  incidence  of  'shift'  in  LVEF,  with  more  Combo  450-treated patients without baseline risk factors having Grade 2/3 shifts than patients with baseline risk factors.

·  Cardiac  enzymes  -  more  Combo  450-treated  patients  who  did  not  receive  concomitant  statin treatment had a 2-Grade worst shift in CK than patients who did receive concomitant statin treatment.

<div style=\"page-break-after: always\"></div>

## Safety related to drug-drug interactions and other interactions

The applicant did not submit data on the safety related to drug-drug interaction (see clinical safety discussion).

See section on Pharmacokinetic interaction studies and Pharmacokinetic using biomaterials.

## Discontinuation due to adverse events

## AEs leading to study drug discontinuation

## Adverse Events Leading to Study Drug Discontinuation in the Broad Safety Set

Table 81 presents a summary of AEs leading to study drug discontinuation, regardless of relationship to study drug, that were reported for ≥1% of patients in any population by PT (overall and maximum Grade 3/4) for the Broad Safety Set.

<div style=\"page-break-after: always\"></div>

Table 81: Adverse Events Leading to Study Drug Discontinuation, Regardless of Study Drug Relationship, by Preferred Term and Treatment - Overall and Maximum Grade 3 or 4 (any grade and Grade 3/4 AE ≥1% in any population) (Broad Safety Set)

|                                       | Melanoma              | Melanoma                                     | Melanoma                       | Melanoma                    | StudyCMEK162B2301           | StudyCMEK162B2301                          | StudyCMEK162B2301   |
|---------------------------------------|-----------------------|----------------------------------------------|--------------------------------|-----------------------------|-----------------------------|--------------------------------------------|---------------------|
| Preferred Term                        | 45 mg BID N=427 n (%) | BinimetinibEncorafenib 300 mg QD N=217 n (%) | Combo pooled doses N=433 n (%) | Combo 450 mg QD N=274 n (%) | Combo 450 mg QD N=192 n (%) | Encorafenib 300mgQDVemurafenib N=192 n (%) | N=186 n (%)         |
| All grades                            | 103 (24.1)            | 38 (17.5)                                    | 45 (10.4)                      | 28 (10.2)                   | 24 (12.5)                   | 27 (14.1)                                  | 31 (16.7)           |
| Grades 3/4                            | 70 (16.4)             | 29 (13.4)                                    | 33 (7.6)                       | 24 (8.8)                    | 22 (11.5)                   | 21 (10.9)                                  | 18 (9.7)            |
| ALT increased                         | 4 (0.9)               | 0                                            | 8 (1.8)                        | 5 (1.8)                     | 5 (2.6)                     | 0                                          | 2 (1.1)             |
| Grades 3/4                            | 3 (0.7)               | 0                                            | 5 (1.2)                        | 4 (1.5)                     | 4 (2.1)                     | 0                                          | 2 (1.1)             |
| AST increased                         | 4 (0.9)               | 0                                            | 8 (1.8)                        | 5 (1.8)                     | 5 (2.6)                     | 0                                          | 2 (1.1)             |
| Grades 3/4                            | 4 (0.9)               | 0                                            | 3 (0.7)                        | 2 (0.7)                     | 2 (1.0)                     | 0                                          | 2 (1.1)             |
| Blood creatinine increased            | 0                     | 0                                            | 5 (1.2)                        | 3 (1.1)                     | 2 (1.0)                     | 0                                          | 0                   |
| GGT increased                         | 0                     | 1 (0.5)                                      | (0.5)                          | 2 (0.7)                     | 2 (1.0)                     | 1 (0.5)                                    | 3 (1.6)             |
| Grades 3/4                            | 0                     | 1 (0.5)                                      | 1 (0.2)                        | 1 (0.4)                     | 1 (0.5)                     | 1 (0.5)                                    | 3 (1.6)             |
| Headache                              | 0                     | 2 (0.9)                                      | (0.5)                          | 2 (0.7)                     | 2 (1.0)                     | 2 (1.0)                                    | 1 (0.5)             |
| Grades 3/4                            | 0                     | 2 (0.9)                                      | 1 (0.2)                        | 1 (0.4)                     | 1 (0.5)                     | 2 (1.0)                                    | 0                   |
| Blood CK increased                    | 8 (1.9)               | 0                                            | 2 (0.5)                        | (0.4)                       | 1 (0.5)                     | 0                                          | 0                   |
| Grades 3/4                            | 8 (1.9)               | 0                                            | 0                              | 0                           | 0                           | 0                                          | 0                   |
| Diamhoea                              | 2 (0.5)               | 2 (0.9)                                      | 2 (0.5)                        | (0.4)                       | (0.5)                       | 2 (1.0)                                    | 0                   |
| Grades 3/4                            | 1 (0.2)               | 2 (0.9)                                      | 2 (0.5)                        | (0.4)                       | (0.5)                       | 2 (1.0)                                    | 0                   |
| Metastases to CNS                     | 0                     | 2 (0.9)                                      | 1 (0.2)                        | (0.4)                       | (0.5)                       | 2 (1.0)                                    | 0                   |
| Rash                                  | 4 (0.9)               | (0.5)                                        | (0.2)                          | (0.4)                       | (0.5)                       | 1 (0.5)                                    | 2 (1.1)             |
| Arthralgia                            | 0                     | 1 (0.5)                                      | 0                              | 0                           | 0                           | 1 (0.5)                                    | 3 (1.6)             |
| Dermatitis acneifom                   | 5 (1.2)               | 0                                            | 0                              | 0                           | 0                           | 0                                          | 0                   |
| Ejectionfractiondecreased             | 16 (3.7)              | 2 (0.9)                                      | (0.2)                          | 0                           | 0                           | 2 (1.0)                                    | 0                   |
| Grades 3/4                            | 8 (1.9)               | 2 (0.9)                                      | 0                              | 0                           | 0                           | 2 (1.0)                                    | 0                   |
| Facial paralysis                      | 0                     | 2 (0.9)                                      | 0                              | 0                           | 0                           | 2 (1.0)                                    | 0                   |
| General physical health deterioration | 5 (1.2)               | 0                                            | (0.2)                          | 0                           | 0                           | 0                                          | (0.5)               |
| Grades 3/4                            | 5 (1.2)               | 0                                            | (0.2)                          | 0                           | 0                           | 0                                          | 1 (0.5)             |
| Hepatotoxicity                        | 0                     | 0                                            | 0                              | 0                           | 0                           | 0                                          | 2 (1.1)             |
| Grades 3/4                            | 0                     | 0                                            | 0                              | 0                           | 0                           | 0                                          | 2 (1.1)             |
| Hypersensitivity                      | 0                     | 2 2 (0.9)                                    | 0                              | 0                           | 0                           | 2 (1.0)                                    | 1 (0.5)             |
| Nausea                                | 2 (0.5)               | 0                                            | 0                              | 0                           | 0                           | 0                                          | 2 (1.1)             |
| Oedema peripheral                     | 5 (1.2)               | 0                                            | 0                              | 0                           | 0                           | 0                                          | 0                   |
| PPE syndrome                          | 1 (0.2)               | 8 (3.7)                                      | 0                              | 0                           | 0                           | 5 (2.6)                                    | 0                   |
| Grades 3/4                            | 0                     | 4 (1.8)                                      | 0                              | 0                           | 0                           | 3 (1.6)                                    | 0                   |
| Photosensitivity reaction             | 0                     | 0                                            | 0                              | 0                           | 0                           | 0                                          | 3 (1.6)             |
| Retinal vein occlusion                | 7 (1.6)               | 0                                            | 0                              | 0                           | 0                           | 0                                          | 0                   |
|                                       | 5 (1.2)               | 0                                            | 0                              |                             |                             | 0                                          | 0                   |
| Grades 3/4                            |                       |                                              |                                | 0                           | 0                           |                                            |                     |
| Vomiting Grades 3/4                   | 2 (0.5) (0.2)         | 3 3 (1.4) 2 (0.9)                            | 2 (0.5) 2 (0.5)                | 0 0                         | 0 0                         | 3 (1.6) 2 (1.0)                            | 1 (0.5) 0           |

Source:ISS Table 2.4.2

Categories are not mutually exclusive. Patients with events in more than 1 category are counted once in each of those categories. Preferred terms are sorted in descending frequency in the ^Combo 450mg QD-melanoma' column.

AST: aspartate aminotransferase, ALT: alanine aminotransferase, GGT: gamma glutamy1 transferase, CK: creatine kinase, CNS: central nervous system

## Bini P vs Combo 450 RP (pooled sets)

The incidences of overall and Grade 3/4 AEs leading to study drug discontinuation were lower in the Combo 450 RP population compared to the Bini P population (AEs: 10.2% vs 24.1%; Grade 3/4 AEs: 8.8% vs 16.4%).

There were no AEs leading to study drug discontinuation reported in ≥2% of patients in the Combo 450 RP population and the only Grade 3/4 AE leading to study drug discontinuation reported in ≥1% of patients was ALT increased (1.5%).

## Adverse Events Leading to Dose Interruption or Adjustment

Table 82 presents a summary of AEs requiring dose adjustment or study-drug interruption, regardless of relationship to study drug, that were reported in ≥5% of patients for AEs of any grade and in ≥2% of patients for AEs of Grade 3/4 in any population by PT for the Broad Safety Set.

<div style=\"page-break-after: always\"></div>

Table 82: Adverse Events Requiring Dose Adjustment or Study-drug Interruption, Regardless of Study Drug Relationship, by Preferred Term and Treatment - Overall and Maximum Grade 3 or 4 (any grade ≥5% or Grade 3/4 AE≥2% in any population) (Broad Safety Set)

|                             | Melanoma                  | Melanoma                   | Melanoma                       | Melanoma                   | Study CMEK162B2301         | Study CMEK162B2301         | Study CMEK162B2301     |
|-----------------------------|---------------------------|----------------------------|--------------------------------|----------------------------|----------------------------|----------------------------|------------------------|
| Preferred Temm Grades       | Bini45mg BID N=427 n (96) | Enco 300mg QD N=217 n (96) | Combo pooled doses N=433 n(96) | Combo 450mg QD tL7=N n(96) | Combo 450mg QD N=192 n(96) | Enco 300mg QD N=192 n (96) | Vemwafemib N=186  (96) |
| Any preferred temm          |                           |                            |                                |                            |                            |                            |                        |
| All grades                  | 285 (66.7)                | 152 (70.0)                 | 212 (49.0)                     | 130 (47.4)                 | 92 (47.9)                  | 135 (70.3)                 | 114 (61.3)             |
| Grades 3/4                  | 176 (41.2)                | 93 (42.9)                  | 142 (32.8)                     | 88 (32.1)                  | 63 (32.8)                  | 85 (44.3)                  | 71 (38.2)              |
| Nausea                      |                           |                            |                                |                            |                            |                            |                        |
| All grades                  | 18 (4.2)                  | 17 (7.8)                   | 26 (6.0)                       | 18 (6.6)                   | 16 (8.3)                   | 17 (8.9)                   | 14 (7.5)               |
| Grades 3/4                  | 3 (0.7)                   | 5 (2.3)                    | 6 (1.4)                        | 4 (1.5)                    | 3 (1.6)                    | 5 (2.6)                    | 2 (1.1)                |
| Vomiting                    |                           |                            |                                |                            |                            |                            |                        |
| All grades                  | 19 (4.4)                  | 10 (4.6)                   | 23 (5.3)                       | 16 (5.8)                   | 13 (6.8)                   | 10 (5.2)                   | 4 (2.2)                |
| Grades 3/4                  | 5 (1.2)                   | 4 (1.8)                    | 3 (0.7)                        | 2 (0.7)                    | 1 (0.5)                    | 4 (2.1)                    | 1 (0.5)                |
| Ejection fraction decreased |                           |                            |                                |                            |                            |                            |                        |
| All grades                  | 26 (6.1)                  | 0                          | 18 (4.2)                       | 14 (5.1)                   | 10 (5.2)                   | 0                          | 0                      |
| Grades 3/4                  | 5 (1.2)                   | 0                          | 3 (0.7)                        | 2 (0.7)                    | 2 (1.0)                    | 0                          | 0                      |
| GGT increased               |                           |                            |                                |                            |                            |                            |                        |
| All grades                  | 1 (0.2)                   | 5 (2.3)                    | 11 (2.5)                       | 10 (3.6)                   | 9 (4.7)                    | 4 (2.1)                    | 2 (1.1)                |
| Grades 3/4                  | 1 (0.2)                   | 3 (1.4)                    | 10 (2.3)                       | 9 (3.3)                    | 9 (4.7)                    | 3 (1.6)                    | 0                      |
| Pyrexia                     |                           |                            |                                |                            |                            |                            |                        |
| All grades                  | 10 (2.3)                  | 5 (2.3)                    | 19 (4.4)                       | 10 (3.6)                   | 8 (4.2)                    | 5 (2.0)                    | 14 (7.5)               |
| Grades 3/4                  | 0                         | 2 (0.9)                    | 5 (1.2)                        | 4 (1.5)                    | 4 (2.1)                    | 2 (1.0)                    | 0                      |
| ALT increased               |                           |                            |                                |                            |                            |                            |                        |
| All grades                  | 7 (1.0)                   | 4 (1.8)                    | 30 (6.9)                       | 15 (5.5)                   | 7 (3.6)                    | 4 (2.1)                    | 4 (2.2)                |
| Grades 3/4                  | 4 (0.9)                   | 2 (0.9)                    | 17 (3.9)                       | 8 (2.9)                    | 6 (3.1)                    | 2 (1.0)                    | 1 (0.5)                |
| AST increased               |                           |                            |                                |                            |                            |                            |                        |
| All grades                  | 10 (2.3)                  | 2 (0.9)                    | 24 (5.5)                       | 10 (3.6)                   | 6 (3.1)                    | 2 (1.0)                    | 3 (1.6)                |
| Grades 3/4                  | 2 (0.5)                   | 0                          | 9 (2.1)                        | 2 (0.7)                    | 1 (0.5)                    | 0                          | 1 (0.5)                |
| Blood CK                    |                           |                            |                                |                            |                            |                            |                        |
| increased                   |                           |                            |                                |                            |                            |                            |                        |
| All grades                  | 80 (18.7)                 | 0                          | 11 (2.5)                       | 8 (2.9)                    | 6 (3.1)                    | 0                          | 1 (0.5)                |
| Grades 3/4                  | 65 (15.2)                 | 0                          | 6 (1.4)                        | 4 (1.5)                    | 3 (1.6)                    | 0                          | 0                      |
| Dianhoea                    |                           |                            |                                |                            |                            |                            |                        |
| All grades                  | 24 (5.6)                  | 4 (1.8)                    | 18 (4.2)                       | 11 (4.0)                   | 7 (3.6)                    | 4 (2.1)                    | 9(4.8)                 |
| Grades 3/4                  | 4 (0.9)                   | 0                          | 5 (1.2)                        | 3 (1.1)                    | 1 (0.5)                    | 0                          | 3 (1.0)                |
| Abdominal pain              |                           |                            |                                |                            |                            |                            |                        |
| All grades                  | 3 (0.7)                   | 3 (1.4)                    | 10 (2.3)                       | 7 (2.6)                    | 5 (2.6)                    | 3 (1.0)                    | 2 (1.1)                |
| Grades 3/4                  | 0                         | 1 (0.5)                    | 4 (0.9)                        | 3 (1.1)                    | 3 (1.6)                    | 1 (0.5)                    | 0                      |
| Anaemia                     |                           |                            |                                |                            |                            |                            |                        |
| All grades                  | 2 (0.5)                   | 2 (0.9)                    | 8 (1.8)                        | 4 (1.5)                    | 4 (2.1)                    | 2 (1.0)                    | 2 (1.1)                |
| Grades 3/4                  | 2 (0.5)                   | 2 (0.9)                    | 5 (1.2)                        | 2 (0.7)                    | 2 (1.0)                    | 2 (1.0)                    | 1 (0.5)                |
| Bloodalkalinephosphatase    |                           |                            |                                |                            |                            |                            |                        |
| All grades                  | 1 (0.2)                   | 1 (0.5)                    | 8 (1.8)                        | 7 (2.6)                    | 4 (2.1)                    | 1 (0.5)                    | 1 (0.5)                |
| Grades 3/4                  | 0                         | 0                          | 3 (0.7)                        | 2 (0.7)                    | 1 (0.5)                    | 0                          | 0                      |
| Blood creatinine increased  |                           |                            |                                |                            |                            |                            |                        |
| All grades                  | 0                         | 0                          | 11 (2.5)                       | 6 (2.2)                    | 4 (2.1)                    | 0                          | 4 (2.2)                |
| Grades 3/4                  | 0                         | 0                          | 0                              | 0                          | 0                          | 0                          | 1 (0.5)                |
| Hyperkeratosis              |                           |                            |                                |                            |                            |                            |                        |

<div style=\"page-break-after: always\"></div>

|                                                                                   | Melanoma                                          | Melanoma                                 | Melanoma                                      |                                            | StudyCMEK162B2301                        | StudyCMEK162B2301                                           | StudyCMEK162B2301                      |
|-----------------------------------------------------------------------------------|---------------------------------------------------|------------------------------------------|-----------------------------------------------|--------------------------------------------|------------------------------------------|-------------------------------------------------------------|----------------------------------------|
| Preferred Tenm Grades                                                             | Bini 45mg BID N=427 n(96)                         | Enco 300mg QD N=217  (96)                | Combo pooled doses N=433 (96)                 | Combo 450mg QD N=274 n (96)                | Combo 450mg QD N=192 n (96)              | Enco300mg QD N=192 n(96)                                    | Vemwrafenib N=186 n (96)               |
| All grades Grades 3/4                                                             | 0 0                                               | 16 (7.4) 9 (4.1)                         | 4(0.9) 1 (0.2)                                | 4 (1.5) 1 (0.4)                            | 4 (2.1) 1 (0.5)                          | 10 (5.2) 6 (3.1)                                            | 2 (1.1) 0                              |
| Arthralgia All grades Grades 3/4                                                  | (0.2)                                             | 26 (12.0) 16 (7.4)                       | 10(2.3) 4 (0.9)                               | 6 (2.2)                                    | 4 (2.1)                                  | 24 (12.5)                                                   | 16 (8.6)                               |
| Fatigue All grades                                                                | (0.2)                                             | 6(2.8)                                   | 12 (2.8)                                      | 1 (0.4)                                    | 0                                        | 14 (7.3)                                                    | 8 (4.3)                                |
| Grades 3/4 Hypertension                                                           | 10 (2.3) 7 (1.6)                                  | 2 (0.9)                                  | 4 (0.9)                                       | 6 (2.2) 4 (1.5)                            | 4 (2.1) 2 (1.0)                          | 4 (2.1) (0.5)                                               | 7 (3.8) 2 (1.1)                        |
| All grades Grades 3/4 Lipase increased                                            | 15 (3.5) 12 (2.8) 2 (0.5) 2 (0.5)                 | 1(0.5) 1 (0.5) 1(0.5) 1                  | 7(1.6) 7 (1.6) 14 (3.2)                       | 6(2.2) 6(2.2) 6(2.2)                       | 4 (2.1) 4 (2.1) 3(1.6)                   | 1 (0.5) (0.5) (0.5) 1 (0.5)                                 | 2 (1.1) 1 (0.5) 0 0                    |
| All grades Grades 3/4 Retinal detachment                                          |                                                   | (0.5)                                    | 14 (3.2)                                      | 6 (2.2)                                    | 3 (1.6)                                  |                                                             | 1 (0.5)                                |
| All grades Grades 3/4 Amylase increased                                           | 18 (4.2) 0                                        | 1(0.5) 0                                 | 6(1.4) 2 (0.5)                                | 5 (1.8) 1 (0.4)                            | 4 (2.1) 1(0.5)                           | (0.5) 0                                                     | 0 0                                    |
| All grades Grades 3/4 Rash All grades                                             | 2 2(0.5) 2 (0.5) 31 (7.3)                         | 0 0 7(3.2)                               | 9(2.1) 5 (1.2)                                | 4 (1.5) 3 (1.1) 3 (1.1)                    | 2(1.0) 2 (1.0) 3(1.6)                    | 0 0                                                         | 0                                      |
| Grades 3/4 Headache                                                               | 11 (2.6) 0                                        | 3 (1.4) 12 (5.5)                         | 3(0.7) 1 (0.2) 3(0.7)                         | 1 (0.4) 3 (1.1) 2 (0.7)                    | (0.5) 2(1.0)                             | 7(3.6) 3 (1.6) 12(6.3)                                      | 14 (7.5) 6 (3.2) 2 (1.1)               |
| All grades Grades 3/4 Palmar-plantar                                              | 0                                                 | 1 (0.5)                                  | 2 (0.5)                                       | 3 (1.1)                                    | (0.5)                                    | 1 (0.5)                                                     | 0 3 (1.6)                              |
| erythrodysaesthesia symdrome All grades Grades 3/4 Abdominal pain upper           | (0.2) (0.2) (0.2) 0                               | 49 (22.6) 22 (10.1) 5 (2.3)              | 4 (0.9) 0 3(0.7)                              | 0 2 (0.7)                                  | 1 (0.5) 0                                | 48 (25.0) 22 (11.5) 5 (2.6)                                 | 2 (1.1) 2 (1.1)                        |
| All grades Grades 3/4 Asthenia                                                    | 12 (2.8) 2                                        | 1 (0.5) 9 (4.1)                          | 1 (0.4) 2 (0.5)                               | 1 (0.4)                                    | 2 (1.6) 1 (0.5)                          | 1 (0.5) 7 (3.6) 3 (1.6)                                     | 0 7 (3.8)                              |
| All grades Grades 3/4 Decreased appetite                                          | (0.5)                                             | 4 (1.8)                                  | 0                                             | 2 (0.7) 0                                  | 2 (1.0) 0                                |                                                             | 5 (2.7)                                |
| All grades Grades 3/4                                                             | (0.2) 0                                           | 3 (1.4) 0                                | 4 (0.9) 1 (0.2)                               | 2 (0.7) 0                                  | 2 (1.0) 0                                | 3 (1.6) 0                                                   | 7 (3.8) 1 (0.5)                        |
| Pain in extremity All grades Grades 3/4                                           | 0 0                                               | 7(3.2) 1 (0.5)                           | 2 (0.5) 1(0.2)                                | 2 (0.7) 1(0.4)                             | 1(0.5) 0                                 | 7 (3.6) 1 (0.5)                                             | 4 (2.2) 0                              |
| Denmatitis acneiform All grades Grades 3/4 Dyspnoea                               | 28 (6.6) 7 (1.6)                                  | 2 (0.9) 0                                | 1 (0.2) 0 2 (0.5)                             | 1 (0.4) 0                                  | (0.5) 0                                  | 2 (1.0) 0 0                                                 | (0.5) 0 2 (1.1)                        |
| All grades Grades 3/4                                                             | 11 (2.6) 2 (0.5)                                  | 0 0                                      | 1 (0.2)                                       | 1 (0.4) 0                                  | (0.5) 0                                  | 0                                                           | 0                                      |
| Facial paralysis All grades                                                       | 0 0                                               | 5 (2.3)                                  | 1 (0.2)                                       | 1 (0.4)                                    | (0.5) 1(0.5)                             | 4 (2.1)                                                     | 0                                      |
| Grades 3/4                                                                        |                                                   | 1 (0.5)                                  | 1 (0.2)                                       | 1 (0.4)                                    |                                          | 1 (0.5)                                                     | 0                                      |
| Preferred Tenm Grades General physical health deterioration All grades Grades 3/4 | Melamoma Bini 45mg BD N=427 n (96) 5(1.2) 2 (0.5) | Enco 300mg QD N=217 n(96) 2(0.9) 2 (0.9) | Combo pooled doses N=433 m(96) 1(0.2) 1 (0.2) | Combo 450mg QD N=274 \"(96) 1 (0.4) 1 (0.4) | Combo 450mg QD N=192 (98) 1(0.5) 1 (0.5) | StudyCMEK162B2301 Enco 300mg QD N=192 m(96) 2 (1.0) 2 (1.0) | Vemwrafenib N=186 \"(96) 5(2.7) 4 (2.2) |
| Myalgia All grades Grades 3/4                                                     | 10 (2.3) 2 (0.5)                                  | 25 (11.5) 18 (8.3)                       | 1 (0.2) 0                                     | 1 (0.4) 0                                  | 1 (0.5) 0                                | 24 (12.5) 17( (8.9)                                         | 3(1.6) 0                               |
| Oedema peripheral All grades Grades 3/4 Rash generalised                          | 19 (4.4) 0                                        | 3 (1.4) 0                                | 2 (0.5) (0.2)                                 | 1 (0.4) (0.4)                              | 1 (0.5) (0.5)                            | 2 (1.0) 0                                                   | 1 (0.5) 0                              |
| Allgrades Grades 3/4 Rash maculo-papular                                          | 0 0                                               | 3 (1.4) 1(0.5)                           | (0.2) 1 (0.2)                                 | 0 0                                        | 0 0                                      | 3(1.6) 1 (0.5)                                              | 10 (5.4) 7(3.8)                        |
| All grades                                                                        | 4 (0.9) 3                                         | 4 (1.8)                                  | 0 0                                           | 0 0                                        | 0 0                                      | 4 (2.1) (0.5)                                               | 10 (5.4)                               |
| Grades 3/4                                                                        | (0.7)                                             | (0.5)                                    |                                               |                                            |                                          |                                                             | 7(3.8)                                 |

Sowuce:ISS Table 2.4.4

Categories are not mumually exclusive. Patients with events in more than 1 category are coumted once in each of those categories. Preferred temms are sorted in descending frequency in the'Combo 45Omg QD-melanoma' columm. MedDRA Version lg.o has been lsed for the reporting of adwerse events.

<div style=\"page-break-after: always\"></div>

## Post marketing experience

The applicant did not submit post-marketing data as the product has not been marketed.

## 2.6.1. Discussion on clinical safety

Currently, safety data for binimetinib is assessable from a total of 2555 healthy subjects and patients. They have received at least 1 dose of binimetinib including 220 healthy subjects, 164 patients with rheumatoid  arthritis,  12  patients  with  hepatic  dysfunction  and  2159  patients  with  advanced  cancer have received at least one dose.

Safety  data  from  a  total  of  860  patients  with  unresectable  or  metastatic  melanoma  are  presented. Binimetinib 45 mg BID as monotherapy was evaluated in 427 patients with metastatic melanoma with 7%  of  patients  receiving  ≥48  weeks  of  study  treatment.  The  recommended  combination  dose  of binimetinib 45mg BID and encorafenib 450 mg QD (Combo 450) was evaluated in 274 patients treated for metastatic melanoma with 44.2% of patients receiving ≥48 weeks of study treatment. The overall size  of  the  safety  data  set  and  the  extent  of  exposure  are  sufficient  to  characterise  the  safety  of binimetinib at the dose of 45 mg BID as monotherapy and in combination with encorafenib 450 mg QD.  Combo  450  is  intended  for  treatment  of  advanced  or  metastatic BRAF -mutated  melanoma,  a serious and life-threatening condition.

Furthermore, a 'broad combination safety pool' (Combo BP) was defined which includes pooled data from 437 patients with BRAF V600-mutant metastatic melanoma enrolled at or randomized to a dose of 45 mg BID binimetinib plus various doses of encorafenib, ranging from 400 mg QD to 600 mg QD (192 patients from Study CMEK162B2301 [Part 1], 158 patients from Study CLGX818X2109 and 87 patients from Study CMEK162X2110).

For  this  submission,  the  restricted  combination  safety  pool  (Combo  450  RP)  and  the  binimetinib monotherapy safety pool (Bini P) provide the most clinical relevant safety data.

The  median  duration  of  exposure  to  study  treatment  was  respectively  13.0  weeks  in  the  bini  P population (mostly NRAS mutant melanoma) and 41.9 weeks in the Combo 450 RP BRAF melanoma population. The median duration of exposure to study treatment was longer in the Combo 450 arm than in the encorafenib and vemurafenib arms of Study CMEK162B2301, (51.2 weeks vs 31.4 weeks vs 27.1 weeks).

Despite the higher dose intensity and more than 3 times longer duration of exposure in Combo 450 patients compared with Bini P population, a better tolerability of Combo 450 vs binimetinib alone was observed. A lower percentage of patients experienced at least one, grade3/4 AE (58.0% vs 66.7%), AE leading to treatment discontinuation (10.2% vs 24.1%), AE requiring dose interruption/change (47.4% vs  66.7%) and AE requiring additional therapy (86.1% vs 92.3%). The percentage of patients who experienced  at  least  one  SAE  was  similar  in  the  two  populations,  (35.8%  vs  33.0%),  regardless  of causal relationship to study drugs.

In Study CMEK162B2301, despite a 50% longer median duration of treatment in the Combo 450 arm than in the vemurafenib arm, a better tolerability of Combo 450 vs vemurafenib alone was observed. A lower percentage of patients experienced at least one, grade 3/4 AE (57.8% vs. 63.4%), AE leading to treatment  discontinuation  (12.5%  vs  16.7%),  AE  requiring  dose  interruption/reduction  (47.9%  vs 61.3%) and AE requiring additional therapy (85.9% vs 91.9%). In addition, a similar percentage of patients experienced SAEs (34.4% vs 37.1%).

<div style=\"page-break-after: always\"></div>

Similarly, in Study CMEK162B2301, despite a 60% longer median duration of treatment in the Combo 450 arm compared to the Enco 300 arm a better tolerability of Combo 450 vs Enco 300 alone was observed. A lower percentage of patients experienced at least, one grade 3/4 AE (57.8% vs 66.1%), AE  leading  to  treatment  discontinuation  (12.5%  vs  14.1%),  AE  requiring  dose  interruption/change (47.9% vs 70.3%) and AE requiring additional therapy (85.9% vs 94.3%). The percentage of patients who experienced at least one SAE was similar (34.4% vs 33.9%) in the two populations, regardless of causal relationship to study drugs.

There is no study with a direct comparison of Combo 450 and binimetinib 45 mg BID, however indirect comparison  showed  a  more  favourable  tolerability  profile  for  Combo  450  than  that  reported  for binimetinib 45 mg BID monotherapy. The overall incidence of AEs and SAEs was similar between the Combo 450 RP population and Bini P population but a lower proportion of patients in the Combo 450 RP population reported Grade 3/4 AEs (58% vs 66.3%). In addition, in the Combo 450 RP population, a lower proportion of patients compared to the Bini P population reported AEs leading to treatment discontinuation,  AEs  requiring  dose  interruption  or  additional  therapy  (discontinuation:  10.2%  vs 22.5%; interruption: 47.1% vs 66.3%, additional therapy 86.1%vs 92.3%). On-treatment deaths were reported in a similar proportion of patients in both arms. The median time to onset of first AEs resp. SAEs was longer in the combination population than in the binimetinib monotherapy population.

The  safety  and  tolerability  of  binimetinib  in  combination  with  encorafenib  appear  favourable  and acceptable as compared to vemurafenib regarding the observed benefit. The majority of the reported ADRs  reflects  the  common  AEs  observed  in  the  clinical  programme  of  binimetinib  45  mg  BID monotherapy  and  binimetinib  45  mg  BID  given  in  combination  with  encorafenib  450  mg  QD.  The addition of binimetinib 45 mg BID in the combination allows for the administration of encorafenib at the  dose  of  450  mg  QD.  The  observed  toxicities  of  the  combination  are  generally  manageable  and acceptable in the population of adult patient with metastatic or unresectable melanoma harbouring a BRAF mutation, and no prior therapy.

A comparison of the safety results of Combo 450 in Study CMEK162B2301 with those of the recently approved  BRAF/MEK  inhibitor  combinations  vemurafenib/cobimetinib  and  dabrafenib/trametinib  in pivotal Phase 3 studies is presented in the table below. The studies were broadly comparable in terms of  the  demographic and disease characteristics of patient populations and in terms of study design. Vemurafenib, the comparator used in Study CMEK162B2301 had a safety profile similar to that of other trials  using  vemurafenib as a comparator 15 , 17 , 23 ).  For  the  combination,  similar  rates of  AEs  overall, grade ≥3  AEs treatment-related AEs, serious AEs, and AEs leading to death, or to dose interruptions/modifications or to treatment discontinuation compared to COMBI-v and similar or higher incidences of these events in Study CMEK162B2301 compared to coBRIM.

A  4-month  update  of  the  safety  profile  was  provided  with  the  responses. The  updated  safety  data provided with additional follow-up shows a similar safety profile for the Combo 450 as demonstrated in the  initial  submission.  New  ADRs  of  blood  creatinine  increased,  renal  failure  and  GGT  increased  for encorafenib  in  combination  with  binimetinib,  and  blood  creatinine  increased  for  encorafenib  single agent, have been added to the proposed SmPC since the initial submission.

## Combo 450 vs Combo 300

The median duration of exposure in the Combo 450 and Combo 300 arms were similar with, respectively, 52.6% and 54.9% of patients having received ≥ 48 weeks of study treatment.

23 Daud A, Gill J, Kamra S, Chen L, Ahuja A. Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients. J Hematol Oncol. 2017 Jan 4;10(1):3

<div style=\"page-break-after: always\"></div>

The overall tolerability profiles of these two combinations were broadly similar (for AEs requiring discontinuation, dose modifications or additional therapy) but Combo 450 led to an increased incidence of SAEs and Grade 3-4 AEs. Combo 450 generated an increased incidence of the most common side effects compared to Combo 300, particularly nausea (41.1 vs. 27.2%), vomiting (29.7 vs. 15.2) and headache (21.9 vs. 11.7%).

The median time to onset of key tolerability parameters was longer in the Combo 300 arm compared with the Combo 450 arm for:

- First SAE (3.5 vs 4.7 months respectively)
- First AE resulting in study drug discontinuation (3.8 vs 4.7 months respectively)

The percentage of patients with one or more encorafenib AESI (any grade) was similar in the two populations (14.6% vs 14.4%). Surprisingly, the percentage of patients with one or more binimetinib specific AESIs (any grade) was higher too in the Combo 450 arm compared with the Combo 300 arm (69.3% vs 56.8% respectively). However, the incidence of binimetinib specific AESIS leading to drug discontinuation or drug modification were similar between Combo 450 and Combo 300. This may be due to a rather arbitrary allocation of AESI between encorafenib and binimetinib in the original assessment, which has since been changed/ rectified. Retinopathy (excluding retinal vein occlusion), rash, liver function tests (LFT) abnormalities, haemorrhage and hypertension were more common for Combo 450 vs Combo 300.

This is comparison of Combo 450 vs. Combo 300 is a post-hoc analysis and patients were recruited at different times (30 Dec 2013 to 10 Apr 2015 for Combo 450 and 19 March 2015 to 12 Nov 2015 for Combo 300). It is possible that investigators had more experience in treating/ preventing AEs by the time of recruitment to Combo 300; given that different centres participated in Part 1 and Part 2 of the study it is more likely that the difference is simply due to the encorafenib dose.

As for other MEK and BRAF inhibitors 24 , several main toxicities are presumed to be class effects and are defined as AESIs for the clinical development of binimetinib and encorafenib.

The AESI groupings common to both binimetinib and encorafenib reported and analysed include the following:

Ocular AESI groupings: retinopathy (mainly due to binimetinib) excluding RVO, RVO and uveitis-type events (mainly due to encorafenib)

- Dermatologic-related  AESI  groupings:  rash  (photosensitivity,  nail  disorders,  skin  infections, severe cutaneous adverse reactions) and PPE syndrome (mainly due to encorafenib)
- Liver-related AESI groupings: liver function test abnormalities and hepatic failure
- Myopathy/rhabdomyolysis-related  AESI  groupings:  muscle  enzyme/protein  changes  (mainly due to binimetinib), myopathy and rhabdomyolysis (mainly due to encorafenib)

The AESI groupings relating to binimetinib alone reported and analysed in this Application include the following:

- Cardiac-related AESI groupings: (bradycardia) and left ventricular dysfunction;
- Hypertension
- Haemorrhage

24 Daud A, Tsai K. Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma. Oncologist. 2017 Jul;22(7):823-833

<div style=\"page-break-after: always\"></div>

- (Peripheral oedema)
- Pneumonitis
- (Venous thromboembolism)

The AESI groupings relating to encorafenib alone reported and analysed in this Application include the following:

- (Tachycardia)
- Acute renal failure
- (Facial paresis)
- Cutaneous malignancies AESI groupings: cutaneous squamous cell carcinoma, cutaneous nonsquamous cell carcinoma and melanomas

Regarding the incidences and severities of the known BRAF and MEK inhibitor AESIs, the tolerability of the MEK inhibitor binimetinib seems to be remarkably better when given in combination with the BRAF inhibitor encorafenib.

However,  the  incidence  of  retinopathies,  liver  function  test  abnormalities  and  haemorrhage  events seems to be higher. This point should be kept in mind as these AESIs (at least retinopathies and liver function  test  abnormalities)  resulted  in  the  reduction  of  the  RP2D  to  45  mg  BID  in  the  binimetinib monotherapy.  Preliminary data of part 2 of the pivotal study indicate a better tolerability in the Combo 300mg population regarding retinopathies, liver function test abnormalities and haemorrhage events.

Specifically, for binimetinib, the most important risks associated with binimetinib treatment defined by ADRs in the proposed patient population are described below. This includes data from monotherapy trials conducted for binimetinib. Descriptions of the events during use in combination with encorafenib are also included below.

## RPED and RVO:

The  ocular  toxicities  of  binimetinib  can  in  rare  instances  be  sight  threatening  although  no  cases  of permanent  blindness  have  been  reported.  Visual  impairment,  including  vision  blurred  and  reduced visual  acuity,  occurred  in  13%  (56/427)  of  patients  and  was  generally  reversible.  RPED  is  a characteristic  adverse  effect  of  MEK  inhibition  and  was  closely  monitored  in  the  binimetinib  clinical program. While evidence of retinopathy was detected frequently, in 31.6% of patients treated at the recommended dose, i.e., all melanoma binimetinib 45 mg group, it was often asymptomatic (grade 1 in 18% of patients) or mildly symptomatic (grade 2 in 12% of patients) and could be managed without need  for  dose  modification.  RVO  was  seen  infrequently  (1.6%  [9/566  patients  in  the  all  cancers (binimetinib  any  dose)  population]),  but  is  a  potentially  sight-threatening  event.  Patients  with  RVO were discontinued from treatment with binimetinib and the majority with available follow-up showed evidence of recovery. The safety of binimetinib has not been established in patients with a history of or current evidence of RVO or current risk factors for RVO including uncontrolled glaucoma, or a history of hyperviscosity or hypercoagulability syndromes. Binimetinib must be discontinued with the occurrence of RVO. Binimetinib is not recommended in patients with a history of RVO.

In comparison with Binimetinib monotherapy (Bini P) there was a higher incidence of retinal events in the combination arm (Combo 450 RP) but this tendency was reversed when considering adjustment for study  drug  exposure.  However,  regarding  the  PTs,  retinal  detachment  was  reported  at  a  higher incidence  for  the  binimetinib  monotherapy  (10.3%  Bini  vs  6.6%  Combo),  vision  blurred  for  the combination therapy (15.3% Combo vs 6.6% Bini). However, in summary, an additive adverse effect

<div style=\"page-break-after: always\"></div>

of binimetinib and encorafenib regarding Retinopathy can be suggested. In addition, in 3 patients (in the  pivotal  study  CMEK162B2301  Part  1)  events  under  the  PT  of  blindness  (in  the  grouping  of retinopathy  excluding  RVO)  were  reported  (2  patients  in  the  Combo  450  arm  and  1  patient  in  the encorafenib  Part  1  arm).  In  the  binimetinib  monotherapy  population  no  cases  of  blindness  were reported.

In the Vemurafenib-Arm ocular events were only reported with a low incidence. However, it should be kept  in  mind  that  for  the  combination  of  vemurafenib  and  cobimetinib  a  similar  incidence  of  ocular events was reported as for Combo 450 RP.

Vascular eye events (RVO) as potentially sight-threatening events were seen only in the Binimetinib arm. In contrast uveitis-Type AESIs were mainly reported for the combination but only in a quite low incidence and in a mild severity.

See section 4.4 for further information on special warnings and precautions of use concerning ocular toxicities.

## Skin-related 'rash' events

These  were  observed  very  common  and  reported  in  81.4  %  of  patients  treated  with  binimetinib monotherapy.  Most  cases  were  grade  1  or  2  severity  but  68%  were  requiring  additional  therapy. Considering that these events often results in an impairment of infection protection and the binimetinib is also a TNF inhibitor, the increase rates of infections and cases of sepsis observed may be also seen as  drug  related  complications.  As  the  median  time  of  onset  was  0.4  month  for  these  events,  more clarification of potential dangerous consequences of these very frequent events and early occurring AE is needed.

Rash has been identified as an AESI for encorafenib and binimetinib and is a known class effect of both, BRAF and MEK inhibitors. Rash is among the most frequently observed AEs reported with these two classes of agents when used as single agents (Bini P 82.7%, Enco P 51.2%) and is reported at a lower frequency when these 2 classes of agents are combined (Combo 450 RP 23.7%). Compared to other MEK/BRAF inhibitors the incidence of rash seems to be lower for the combination therapy with binimetinib/  encorafenib.  In  addition,  the  presented  data  of  part  2  of  the  pivotal  study  indicates  a better tolerability in the Combo 300 mg population.

Palmar-plantar  erythrodysaesthesia  syndrome  (PPES)  has  been  identified  as  an  AESI  for  both encorafenib  and  binimetinib  as  these  types  of  dermatologic  complications  are  known  class  effects reported with the use of BRAF inhibitors. In addition, these reactions have also been reported with MEK inhibitors but less frequently. The incidence of PPES was obviously lower in the combination therapy than in the encorafenib monotherapy.

## Dermatologic 'non-rash' events :

These occurred in 42.4% of patients with binimetinib monotherapy. The median time of onset of this toxicity  was  1.4-month,  additional  therapy  was  required  in  24%.  In  addition,  approx.  25%  of  the patients  showed  -  often  secondary  to  other  dermatologic  events-  a  skin  infection;  3.3%  of  these events were resulting in hospitalization.

## New primary malignancies

New primary malignancies, cutaneous and non-cutaneous, have been observed in patients treated with BRAF inhibitors and can occur when binimetinib is administered in combination with encorafenib (see section 4.8).

<div style=\"page-break-after: always\"></div>

## Cutaneous malignancies

The combination of binimetinib to encorafenib appeared to attenuate the development of cutaneous squamous  cell  carcinoma  (cuSCC)  as  compared  to  encorafenib  treatment  alone.  Cutaneous  nonsquamous cell carcinoma (cnSCC) events were reported in a low percentage of patients overall (2.1% Combo 450 arm, 1.0% encorafenib Part 1 arm). No Melanoma events were reported in the Combo 450 populations and in the Bini P population while in the encorafenib Part 1 and vemurafenib monotherapy arms, melanoma events occurred in a similar percentage of patients (5.2% encorafenib Part 1 arm, 4.3% vemurafenib arm).

Cutaneous malignancies such as cutaneous squamous cell carcinoma (cuSCC) including kerathoacanthoma has been observed in patients treated with binimetinib when used in combination with encorafenib.

Dermatologic evaluations should be performed prior to initiation of therapy with binimetinib in combination with encorafenib, every 2 months while on therapy and for up to 6 months following discontinuation of the combination. Suspicious skin lesions should be managed with dermatological excision and dermatopathologic evaluation. Patients should be instructed to immediately inform their physicians if new skin lesions develop. Binimetinib and encorafenib should be continued without any dose modifications.

In summary, the addition of Binimetinib (MEK inhibitor) to encorafenib seems to mitigate the risks of secondary skin neoplasms, in the Combo 450 population (compared to the Combo 300 population).

## Liver related events:

## Liver laboratory abnormalities

Liver enzyme abnormalities are also common (ALT in 9.6%; AST in 13.6% of patients treated at the recommended dose) with binimetinib treatment. Although liver enzyme monitoring was enhanced as a result of a case of hepatic failure in a single patient treated at the 60 mg BID dose of binimetinib, the applicant states that no Hy's law cases or other clear cases of drug-induced liver injury have been observed at the recommended 45 mg BID dose. Liver laboratory abnormalities including AST and ALT elevations can occur with binimetinib (see section 4.8). Liver laboratory values should be monitored before initiation of binimetinib and encorafenib and at least monthly during the 6 first months of treatment, and then as clinically indicated. Liver laboratory abnormalities should be managed with dose interruption, reduction or treatment discontinuation (see Table 1 in section 4.2).

With respect to overall tolerability hepatotoxicity observed indicate a critical safety issue which needed to be balanced by a clear benefit.

As already mentioned above liver function test abnormalities AESIs were reported at a higher incidence in the Combo 450 RP population than the Bini P population, overall (25.2% vs 17.3%), for Grade 3/4 AESIs (12.4% vs 4.2%) and for AESIs requiring dose adjustment/study drug interruption (8.4% vs 3%). Few events were serious (none vs 0.5%) or led to study drug discontinuation (1.8% vs 0.9%). In summary regarding liver function test abnormalities an additive effect of encorafenib und binimetinib can be suggested.

The  data  presented  shows  a  high  incidence  of  increases  of  GGT  (overall  and  grade  ¾)  for  the combination therapy. The mechanisms behind the GGT abnormalities are not understood. However, it seems to be a kind of class effect, for the MEK/BRAF inhibitor combinations.

## Hepatic impairment

<div style=\"page-break-after: always\"></div>

Liver  metabolism  mainly  via  glucuronidation  is  the  primary  route  of  elimination  of  binimetinib  (see section 5.2). As encorafenib is not recommended in patients with moderate (Child Pugh B) and severe hepatic impairment (Child Pugh C), administration of binimetinib is not recommended in these patients (see sections 4.2 and 5.2).

## Muscular toxicity:

Blood CK increase was a very commonly reported AE with binimetinib treatment (in 43.3% of patients treated  at  the  recommended dose). This was rarely associated with symptoms, although symptoms were more common with higher reported grades of CK elevation. It was the most frequent cause of dose adjustment or treatment interruption. Frank rhabdomyolysis, defined by published criteria of high CK,  evidence  of  end  organ  damage  and  muscle  symptoms  was  infrequent,  with  only  a  single documented case meeting case defining criteria based on published literature and regulatory guidance. CK  and  creatinine  levels  should  be  monitored  prior  to  initiating  binimetinib,  periodically  during treatment, and as clinically indicated, and ensure that the patient is adequately hydrated. In case of rhabdomyolysis  treatment  should  be  discontinued.  Depending  on  CK  elevation,  dose  interruption  or discontinuation  of  binimetinib  may  be  required.  Renal  complications  and  clinical  symptoms  of myopathy are often clinically not very impressive, but their impact on overall morbidity and mortality should not be underestimated.

The  addition  of  binimetinib  to  encorafenib  appeared  to  mitigate  the  effects  observed  in  the  Bini  P population.

Muscle-related AEs, including myalgia, have been observed with the administration of BRAF inhibitors including  Encorafenib.  The  addition  of  binimetinib  to  encorafenib  appeared  to  mitigate  the  effects observed in the Enco 300 mg population.

In summary, the combination therapy seems to mitigate both the incidence of elevations of the blood CK as well as the incidence of symptomatic myopathy, which makes the effect (as a MEKi class effect) per se more plausible.

The overall incidence of Muscle enzyme/protein changes AESIs was higher in the Combo 450 arm than in  the  vemurafenib  arm  overall.  However,  for  the  combination  vemurafenib/cobimetinib  a  distinctly higher  incidence  of  elevations  of  blood  CK  was  seen  (32.4%  vemurafenib/cobimetinib  vs  22.9% encorafenib/binimetinib).

See  section  4.4  for  further  information  on  special  warnings  and  precautions  of  use  concerning  CK elevation and rhabdomyolysis.

## Left ventricular dysfunction:

This is a class effect of MEK. Left ventricular dysfunction occurred in 10% (44/427) of patients treated at the recommended dose, with a maximum severity of grade 3 (in 4.4% of patients). It frequently led to  dose  modification  or  treatment  discontinuation.  LVEF  was  routinely  monitored  with  MUGA  or echocardiography across the clinical program. The safety of binimetinib has not been established in patients with a baseline LVEF that is either below 50% or below the institutional lower limits of normal. It  is  recommended  that  there  be  assessment  of  LVEF  by  ECHO  or  MUGA  scan  before  initiation  of binimetinib,  1  month  after  initiation,  and  then  at  2  to  3-month  intervals  while  on  treatment. Binimetinib should be interrupted for up to 3 weeks if absolute LVEF value decreases by 10% from pretreatment  values  and  is  less  than  the  lower  limit  of  normal.  Binimetinib  should  be  permanently discontinued for symptomatic left ventricular dysfunction or persistent, asymptomatic left ventricular dysfunction that does not resolve within 3 weeks.

<div style=\"page-break-after: always\"></div>

According the non-clinical data binimetinib has no electrophysiological effects in the heart and lack of effects  on  cardiac  waveform  and  intervals  (including  QTc)  at  doses  as  high  as  10  mg/kg  (mean Maximum Concentration [Cmax] 2.7 μM, range 1.04 to 7.05 μM) in monkeys. QT prolongation was routinely monitored and classified as an AESI. This is confirmed by the clinical data in the different safety sets (restricted and broad). In the pivotal trial QTc prolongation events occurred with similar frequency  in  patients  in  both  arms  (binimetinib:  3.3%  versus  DTIC:  3.5%).  All  events  were asymptomatic and none of the patients had presyncope, syncope or loss of consciousness associated with the QT prolongation, potentially indicating dangerous arrhythmias (e.g. 'torsade de pointes').

In the Combo 450 mg population the incidence of cardiac events overall and grade 3/4 were reported at a lower incidence in the Combo 450 RP population than in the Bini P population. In addition, there were no events leading to study drug discontinuation in the Combo 450 RP population whilst 4.2% were reported in the Bini P population. Few events were serious or required additional therapy. The most frequent PT in both populations was ejection fraction decreased (6.6% vs 10.3%). Compared to other  MEK/BRAF  inhibitor  combinations  events  in  the  LVEF  grouping  were  reported  with  a  lower incidence in the encorafenib/binimetinib combination.

The recommendations in the SmPC (Section 4.2) regarding dose modifications (provided for cardiac adverse reactions, including asymptomatic, absolute decreases in LVEF from baseline of ≥ 10% and ejection  fraction  below  the  institutional  LLN)  currently  is  acceptable.    See  section  4.4  for  further information on special warnings and precautions of use concerning left ventricular dysfunction.

## Hypertension:

New-onset  hypertension  or  worsening  of  hypertension  was  seen  with  binimetinib  treatment  in  16% (68/427)  of  patients  at  the  recommended  dose,  with  grade  3  in  8%  of  patients.  It  was  generally manageable with antihypertensive medications and rarely required treatment discontinuation. Patients should  be  monitored  for  hypertension  and  temporary  suspension  of  binimetinib  is  recommended  in case  of  severe  hypertension,  until  hypertension  is  controlled.  The  significantly  high  frequency  for increases of creatinine (82.0%) indicating a decrease in renal function may explain at least partially this finding . It seems very likely that the increase in cardiac events was also triggered by hypertension results.

Hypertension  is  a  class  effect  of  MEK  inhibitors,  either  when  treated  with  these  agents  alone  or  in combination with a BRAF inhibitor (see also Mekinist® [trametinib] prescribing information; Cotellic® [cobimetinib] prescribing information). Hypertension AESIs were reported at a similar incidence in the Bini P and Combo 450 RP populations, overall (although the incidence was higher in the Bini P when adjusted for drug exposure) and for Grade 3/4 events (8.7% vs 6.2%).

In  Study  CMEK162B2301  Part  1,  Kaplan-Meier  plots  of  time  to  LVEF  below  50%  and/or  absolute decrease of 10% or more in LVEF from baseline by baseline hypertension risk factor for patients in the Combo 450 arm with at least one event, showed a shorter median time for patients with as compared to  patients  without  baseline  hypertension  risk  factor.  The  incidence  of  a  2-grade  shift  in  LVEF  was higher in in the hypertension risk factor group (=history of hypertension, SBP ≥ 140 at screening, or DBP ≥ 90 at screening) as well.

The given recommendations regarding management and dose modifications in the SmPC section 4.2 as  well  as  the  warning  in  4.4  are  acceptable.  See  section  4.4  for  further  information  on  special warnings and precautions of use concerning hypertension.

## Haemorrhage:

<div style=\"page-break-after: always\"></div>

Although haemorrhage is classified as an AESI an occurred in 11.2 of patients in the binimetinib arm of the pivotal trial it seems that clinical relevant haemorrhage event beside epistaxis were not observed. The  INR  increases  reported  were  also  classified  in  this  category,  but  no  obvious  reason  for  these elevations were found beside concomitant treatment with anticoagulants from the analyses. The PTs reported  failed  to  indicate  a  clear  signal  for  systemic  impairment  of  haemostasis  system  or thrombocytes, although at the time being it cannot be completely excluded. The retinal haemorrhage (2.2% in the binimetinib arm) seems to reflect more a symptom of the retinal toxicity than really a bleeding  disorder.  Additionally,  haematuria  (0.4%  in  the  binimetinib  arm)  in  the  absence  of  a haemostatic impairment is often symptom of a urogenital infection like acute cystitis. In summary, the data  presented  seemed  not  to  indicate  a  significantly  increase  bleeding  risk  during  binimetinib treatment.

Hemorrhages have been noted to occur with MEK-inhibitor treatment (see also Mekinist® [trametinib] prescribing information; Cotellic® [cobimetinib] prescribing information). Although the overall frequency of hemorrhage events was higher in the Combo 450 RP population as compared to the Bini P population, adjusting for exposure, the rate of hemorrhage events in the Combo 450 RP seems to be lower than the rate for the Bini P population. In comparison with the other known BRAF/MEK inhibitor combination  therapies  the  overall  incidence  of  a  hemorrhage  seems  to  be  similar.  However,  the incidence of Grade ¾ events is higher under the combination therapy with encorafenib and binimetinib compared to the other combinations. Preliminary data of part 2 of the pivotal study indicates a slightly reduced incidence in the Combo 300 mg population.

See  section  4.4  for  further  information  on  special  warnings  and  precautions  of  use  concerning haemorrhage.

## Pneumonitis:

This was seen following binimetinib treatment in 1.4% of patients in the all cancers [binimetinib any dose] population) and is a well-recognized ADR associated with a number of kinase inhibitors, including MEK  inhibitors.  The  underlying  mechanism  behind  pulmonary  toxicities,  considered  as  being  MEK inhibitor  class  effects,  is  not  yet  known.  It  has  been  hypothesized  that  the  blockage  of  epidermal growth  factor  receptor  (EGFR)-dependent  epithelial  proliferation  by  EGFR  tyrosine  kinase  inhibitors augments pulmonary fibrosis (Min et al, 2011, Suzuki et al, 2003). However, it is notable that MEK inhibition may not have the same effect. For example, an in vivo study in mice demonstrated that the MEK  inhibitor,  selumetinib  (ARRY-142886),  prevented  the  progression  of  established  pulmonary fibrosis associated with EGFR activation (Madala et al 2012).

Pneumonitis/interstitial  lung  disease  (ILD)  has  been  noted  to  occur  with  MEK-inhibitor  treatment (Mekinist®  [trametinib]  prescribing  information;  Cotellic®  [cobimetinib]  prescribing  information), including binimetinib.  Pneumonitis AESIs were reported at a similar (low) overall incidence in the Bini P and Combo 450 RP populations.

See  section  4.4  for  further  information  on  special  warnings  and  precautions  of  use  concerning pneumonitis/ILD.

## Renal Failure:

The incidence of renal failures seems to be similar in the presented safety populations. However, the severity  seems  to  be  higher  in  the  combo  450  populations  than  in  the  binimetinib  and  encorafenib mono populations (higher incidence of grade ¾ events and SAEs).

## Gastro-intestinal disorders

<div style=\"page-break-after: always\"></div>

Including  diarrhoea  and  vomiting:  in  the  9-month  repeat-dosing  study  in  the  monkey,  the  primary findings were gastrointestinal intolerance and inflammation. All large intestinal findings resolved after a treatment-free period. In the gastric irritation study in rats, there were no significant effects at the 10 and  30  mg/kg  doses.  At  100  mg/kg  binimetinib,  there  was  an  increased  incidence  of  superficial mucosal lesions and of haemorrhagic ulcers. ADRs  reported most  commonly  by  PT  at the recommended dose were diarrhoea (43% of patients), nausea (30% of patients) and vomiting (20% of patients).  Gastrointestinal  events  required  dose  adjustment  or  study  drug  interruption  in  11%  of patients and led to discontinuation of binimetinib in 1.2% of patients.

Regarding preliminary data of part 2 of the pivotal incidences seem to be remarkably higher in the Combo 450mg than in the Combo 300mg population. In addition, the incidence of abdominal pain was remarkably higher compared to other MEK/BRAF inhibitors.

Pancreatitis is a known effect of BRAF inhibitors (Muluneh et al. 2013). Although in most cases the increase of lipase and amylase in the Combo 450mg RP was asymptomatic and the incidence of acute pancreatitis was low, it seems to be an important safety issue. The incidence is comparable with that reported for marketed BRAF inhibitors, and the ADR attribution is also comparable.  Based on the available data, this identified risk is not considered a safety concern in the updated encorafenib RMP in the context of the severity of metastatic disease. Lipase increased and amylase increased are both reported as common ADRs (&lt;10%).

The common ADRs in the category of gastrointestinal disorders include nausea, diarrhoea, vomiting, abdominal pain and constipation. In the Combo 450 arm of the pivotal study AEs in this category were reported overall in 71.9% including Grade 3/4 events in 11.9% and SAEs in 9.4%. 42.2% % of the patients  needed  additional  therapy.  Incidences  seem  to  be  remarkably  higher  in  the  Combo  450mg than  in  the  Combo  300mg  population  (71.9%  vs  63.8%,  preliminary  data  of  part  2  of  the  pivotal study).    In  addition,  the  incidence  of  abdominal  pain  was  remarkably  higher  compared  to  other MEK/BRAF inhibitor combinations. The given information in the SmPC for binimetinob is acceptable.

## Anaemia :

Occurred in 18.2% of patients in the Combo 450 RP population (vs 9.6% in the Bini P population), 4.4%  patients  had  grade  3/4  events  (vs  2.3%  in  the  Bini  P  population).  No  patients  discontinued Combo 450 RP due to anaemia, 1.5% required dose adjustment or study drug interruption and 9.5% patients required additional therapy. With regard to the preliminary data, incidences were remarkably higher in the Combo 450mg arm (Part 1) than in the Combo 300mg arm (Part 2) of the pivotal study (15.1% vs 9.3%). Compared to other MEK/BRAF inhibitors, a higher incidence of grade 3/4 anaemia was reported with the combination therapy binimetinib/encorafenib than with other combinations.

## Venous thromboembolism :

In  melanoma  patients  treated  at  the  recommended  dose  of  binimetinib,  VTE  occurred  in  4.2% (18/427)  of  patients  receiving  binimetinib,  including  1.4%  (6/427)  of  patients  with  pulmonary embolism. It is a common complication related to malignancy and there is generally a high degree of vigilance  for  signs  and  symptoms  of  VTE  in  cancer  patients,  and  use  of  thromboprophylaxis  in appropriate settings is recognized as a standard of care in oncology.

See section 4.4 for further information on special warnings and precautions of use concerning venous thromboembolism.

## Reproductive risk:

Based on findings from animal studies and its mechanism of action, binimetinib may cause foetal harm when administered to a pregnant woman. Binimetinib was embryotoxic and abortifacient in rabbits at

<div style=\"page-break-after: always\"></div>

doses  greater  than  or  equal  to  those  resulting  in  exposures  approximately  12  times  the  human exposure  at  the  recommended  clinical  dose.  The  main  risk  factor  is  the  women  of  child-bearing potential  (i.e.,  pre  or  peri-menopausal)  with  exposure  during  the  first  trimester  without  effective method  of  contraception.  The  risk  may  be  managed  by  highlighting  in  the  patient  information leaflet/summary  of  product  characteristics  that  female  patients  of  reproductive  potential  should  use effective contraception during treatment with binimetinib and for 2 weeks after treatment.

There are no data on the effect on fertility in humans for binimetinib.

The overall incidence of SAEs and of SAEs of Grade 3/4 was similar in the Bini P and Combo 450 RP populations. However the onset of SAEs was earlier for binimetinib monotherapy (1.6 month) than for the combination binimetinib/encorafenib (3.8 months in the Combo 450 RP population resp 3.5 months in the Combo 450 arm of the pivotal study). In addition, in contrast to binimetinib monotherapy, SAEs were reported (in low incidences) for several different PTs and not particular for the PT general physical health deterioration (possibly due to the multiplicity of toxicities).

In Study CMEK162B2301 Part 1, a similar percentage of patients died on treatment across the three treatment arms (8.9% Combo 450 arm, 7.3% encorafenib Part 1 arm, 10.2% vemurafenib arm). The adjusted death rate per 100 patient-months of exposure was 0.71 in the Combo 450 arm, 0.75 in the encorafenib Part 1 arm and 1.23 in the vemurafenib arm. In the Binimetinib monotherapy population the  incidence  seems  to  be  similar  as  well.  However,  the  adjusted  death  rate  was  higher  (2.45) indicating in a shorter survival of this monotherapy population.

Binimetinib is a substrate of UGT1A1.  It is suggested that a study with an inhibitor is not required but instead cautionary wording is proposed.  This is not agreed.   Data on the effect of polymorphisms is limited and there are few patients on UGT inhibitors in the POPPK analysis (n=20) and this is not as sensitive  to  determine  an  effect.    The  applicant  should  perform  a  study  to  determine  the  effect  of UGT1A1 inhibitors on binimetinib.

Binimetinib is also a substrate for Pgp and BCRP, however an effect on biliary secretion is proposed to be  unlikely  based  on  non-clinical  data  and  effects  on  absorption  unlikely,  due  to  high  intestinal permeability.    This  too  is  not  accepted  and  it  is  considered  a  clinical  study  should  be  performed  to determine the effect of Pgp and BCRP inhibition.

In cocktail uptake studies binimetinib did not appear to be a substrate of hepatic uptake transporters. The concentration studied however is high, 15.3 µM compared to Cmax,u of 0.06µM, further studies are required at more physiologically relevant concentrations.

Binimetinib  does  not  inhibit  CYPs  except  for  CYP  2B6  which  had  a  Ki  of  1.7  µM,  however  the mechanistic static model was used to rule out an interaction.

Binimetinib shows induction of CYP 3A4 in vitro and this was investigated in a clinical study. Induction of mRNA for CYP 1A2 and 2B6 is greater than 2-fold (16.5 and 2.6-fold respectively).  This should be discussed.

Binimetinib is not an inhibitor of Pgp, BCRP, OAT1, OCT1, OCT2, MATE-1, MATE-2k or BSEP.  It is a weak  inhibitor  of  OATP1B1  and  1B3,  but  it  can  be  agreed  this  does  not  appear  to  be  at  clinically relevant concentrations and therefore there are no safety concerns. Binimetinib does inhibit OAT3 and further clarification should be provided to discount an effect on this transporter.

## Non-cutaneous malignancies

Based on its mechanism of action, encorafenib may promote malignancies associated with activation of RAS through mutation or other mechanisms. Patients receiving binimetinib in combination with

<div style=\"page-break-after: always\"></div>

encorafenib should undergo a head and neck examination, chest/abdomen computerised tomography (CT) scan, anal and pelvic examinations (for women) and complete blood cell counts prior to initiation, during and at the end of treatment as clinically appropriate.

Permanent discontinuation of binimetinib and encorafenib should be considered in patients who develops RAS mutation-positive non-cutaneous malignancies. Benefits and risks should be carefully considered before administering binimetinib in combination with encorafenib to patients with a prior or concurrent cancer associated with RAS mutation.

## Lactose intolerance

Mektovi contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.

Contraindications: Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

## Overdose

The highest dose of binimetinib evaluated as single agent in clinical studies was 80 mg administered orally twice daily and was associated with ocular (chorioretinopathy) and skin toxicities (dermatitis acneiform).

There is no specific treatment of overdose. If overdose occurs, the patient should be treated supportively with appropriate monitoring as necessary.

Since binimetinib is highly bound to plasma proteins, haemodialysis is likely to be ineffective in the treatment of overdose with binimetinib.

## Elderly

In patients treated with Combo 450 (n = 274), 194 patients (70.8 %) were &lt; 65 years old, 65 patients (23.7 %) were 65 -74 years old and 15 patients (5.5 %) were aged &gt; 75. No overall differences in safety or efficacy were observed between elderly patients (≥ 65) and younger patients. The proportion of patients experiencing adverse events and serious adverse events were similar in patients aged &lt;65 years and those aged &gt; 65 years. The most common adverse events reported with a higher incidence in patients aged ≥ 65 years compared to patients aged &lt; 65 years included diarrhoea, pruritus, GGT and blood phosphatase alkaline elevation. In the small group of patients aged ≥ 75 years (n=15), patients  were  more  likely  to  experience  serious  adverse  events  and  adverse  events  leading  to discontinuation of treatment.

Binimetinib has minor influence on the ability to drive or use machines. Visual disturbances have been reported in patients treated with binimetinib during clinical trials. Patients should be advised not to drive or use machines if they experience visual disturbances or any other adverse reaction that may affect their ability to drive and use machines (see sections 4.4 and 4.8).

## Dose modification

The management of adverse reactions may require dose reduction, temporary interruption or treatment discontinuation (see section 4.2 and Table 1 and Table 2 of the SmPC).

For patients receiving 45 mg binimetinib twice daily, the recommended reduced dose of binimetinib is 30 mg twice daily. Dose reduction below 30 mg twice daily is not recommended. Therapy should be discontinued if the patient is not able to tolerate 30 mg orally twice daily.

<div style=\"page-break-after: always\"></div>

If the adverse reaction that resulted in a dose reduction is under effective management, dose re escalation to 45 mg twice daily may be considered. Dose re escalation to 45 mg twice daily is not recommended if the dose reduction is due to left ventricular dysfunction (LVD) or any Grade 4 toxicity.

If treatment related toxicities occur when binimetinib is used in combination with encorafenib, then both treatments should be simultaneously dose reduced, interrupted or discontinued. Exceptions where dose reductions are necessary for encorafenib only (adverse reactions primarily related to encorafenib) are: palmar-plantar erythrodysaesthesia syndrome (PPES), uveitis including iritis and iridocyclitis and QTc prolongation.

If binimetinib is temporarily interrupted, encorafenib should be reduced to 300 mg once daily during the time of binimetinib dose interruption (see Tables 1 and 2) as encorafenib is not well-tolerated at the dose of 450 mg as a single agent. If binimetinib is permanently discontinued, encorafenib should be discontinued.

If encorafenib is temporarily interrupted (see section 4.2 of encorafenib SmPC), binimetinib should be interrupted. If encorafenib is permanently discontinued, then binimetinib should be discontinued.

For information on the posology and recommended dose modifications of encorafenib, see section 4.2 of encorafenib SmPC.

Reporting  suspected  adverse  reactions  after  authorisation  of  the  medicinal  product  is  important.  It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

## 2.6.2. Conclusions on the clinical safety

The overall safety results for binimetinib show ADRs consistent with the known safety profile of other drugs  in  this  class  and  are  considered  acceptbale  and  manageable  with  routine  risk  minimisation activities.  However,  the  incidences  of  some  of  the  expected  adverse  events  are  more  frequent  that seen  with  other  approved  MEK  inhibitors.  Some  of  these  ADRs  are  serious  or  potentially  life threatening (thromboembolic events, hypertension, serious skin toxicities and infections, left ventricular  dysfunction,  pneumonitis,  liver  function  abnormalities  and  rhabdomyolysis),  or  are  sight threatening (RVO) and are reflected in the deaths, SAEs and AEs leading to discontinuation across the safety sets.

The  safety  and  tolerability  of  binimetinib  in  combination  with  encorafenib  appears  favourable  and acceptable  as  compared  to  vemurafenib  with  regard  to  the  observed  benefit.  The  majority  of  the reported  ADRs  reflects  the  common  AEs  observed  in  the  clinical  program  of  binimetinib  45  mg  QD single  agent  and  given  in  combination  to  binimetinib  45  mg  BID.  The  observed  toxicities  of  the combination  are  generally  manageable  and  acceptable  in  the  population  of  adult  patient  with metastatic  or  unresectable  melanoma  harbouring  a  BRAFV600  mutation,  and  no  prior  therapy.  The overall  safety  profile  of  the  combination  of  binimetinib  45  mg  BID  with  encorafenib  450  mg  QD  is consistent with the mechanisms of action and the known safety profiles of MEK and BRAF inhibitors as single agents or in combination.

A comparison of safety profile between Combo 450 and Combo 300 suggests a better safety profile with the Combo 300 with lower incidences of grade 3-4 events and serious adverse events. The overall safety  profiles  for  the  Combo  450  and  Combo  300  arms  are  similar  in  terms  of  incidence (difference&lt;5%)  of  deaths,  AEs,  treatment  discontinuation  due  to  AEs,  and  AEs  leading  to  dose

<div style=\"page-break-after: always\"></div>

modifications/ interruptions or additional therapy. The overall incidence of grade 3-4 AEs was lower in the Combo°300 (46.7% vs 57.8%) as compared to Combo 450.

A 4-month update of the safety profile was provided with the responses. The updated safety data provided with additional follow-up shows a similar safety profile for the Combo 450 as demonstrated in the initial submission. New ADRs of blood creatinine increased, renal failure and GGT increased for encorafenib in combination with binimetinib, and blood creatinine increased for encorafenib single agent, have been added to the proposed SmPC since the initial submission.

## 2.7. Risk Management Plan

## Safety concerns

## Safety concerns of binimetinib in combination with encorafenib

## Important identified risks

- -Left ventricular dysfunction
- -Hypertension
- -Rhabdomyolysis
- -Retinal pigment epithelial detachment
- -Venous thromboembolism
- -Haemorrhage

## Important potential risks

- -Hepatotoxicity
- -Pneumonitis/Interstitial lung disease
- -Retinal vein occlusion
- -Embryo-foetal toxicity
- -Over-exposure in patients with moderate to severe hepatic impairment

## Missing information

- -Use in patients with reduced cardiac function (LVEF &lt;50%) or symptomatic chronic heart failure

## Pharmacovigilance plan

There is no planned or ongoing additional study in the pharmacovigilance plan.

Routine pharmacovigilance activities are sufficient to address the safety concerns of this medicinal product.

## Risk minimisation measures

| Safety Concern                                                             | Risk minimisation measures                                                 | Pharmacovigilance activities                                               |
|----------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|
| Important identified risks for binimetinib in combination with encorafenib | Important identified risks for binimetinib in combination with encorafenib | Important identified risks for binimetinib in combination with encorafenib |
| Left ventricular dysfunction                                               | Routine: Dose modification recommendations in Section 4.2 of the           | Routine Additional: none.                                                  |

<div style=\"page-break-after: always\"></div>

| Safety Concern                               | Risk minimisation measures                                                                                                                                                                                                                                                                                                                                                                                   | Pharmacovigilance activities   |
|----------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------|
|                                              | SmPC. Warning in Section 4.4 of the SmPC and relevant PIL section. Listed in Section 4.8 of the SmPC and relevant PIL section. Prescription only medicine. Treatment with binimetinib should be initiated and supervised under the responsibility of a physician experienced in the use of anticancer medicinal products. Additional: none.                                                                  |                                |
| Hypertension                                 | Routine: Dose modification recommendations in Section 4.2 of the SmPC. Warning in Section 4.4 of the SmPC and relevant PIL section. Listed in Section 4.8 of the SmPC and relevant PIL section. Prescription only medicine. Treatment with binimetinib should be initiated and supervised under the responsibility of a physician experienced in the use of anticancer medicinal products.                   | Routine Additional: none.      |
| Rhabdomyolysis                               | Routine: Dose modification recommendations in Section 4.2 of the SmPC. Warning in Section 4.4 of the SmPC and relevant PIL section. Listed in Section 4.8 of the SmPC and relevant PIL section. Prescription only medicine. Treatment with binimetinib should be initiated and supervised under the responsibility of a physician experienced in the use of anticancer medicinal products. Additional: none. | Routine Additional: none       |
| Retinal pigment epithelial detachment (RPED) | Routine: Dose modification recommendations in Section 4.2 of the SmPC. Warning in Section 4.4 of the SmPC and relevant PIL section. Listed in Section 4.8 of the SmPC and relevant PIL section. Prescription only medicine. Treatment with binimetinib should be initiated and supervised under the responsibility of a physician experienced in the use of anticancer medicinal products. Additional: none. | Routine Additional: none.      |

<div style=\"page-break-after: always\"></div>

| Safety Concern                                                            | Risk minimisation measures                                                                                                                                                                                                                                                                                                                                                                                   | Pharmacovigilance activities                                              |
|---------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------|
| Venous thromboembolism (VTE)                                              | Routine: Dose modification recommendations in Section 4.2 of the SmPC. Warning in Section 4.4 of the SmPC and relevant PIL section. Listed in Section 4.8 of the SmPC and relevant PIL section. Prescription only medicine. Treatment with binimetinib should be initiated and supervised under the responsibility of a physician experienced in the use of anticancer medicinal products. Additional: none. | Routine Additional: none.                                                 |
| Haemorrhage                                                               | Routine: Dose modification recommendations in Section 4.2 of the SmPC. Warning in Section 4.4 of the SmPC and relevant PIL section. Listed in Section 4.8 of the SmPC and relevant PIL section. Prescription only medicine. Treatment with binimetinib should be initiated and supervised under the responsibility of a physician experienced in the use of anticancer medicinal products. Additional: none. | Routine Additional: none.                                                 |
| Important potential risks for binimetinib in combination with encorafenib | Important potential risks for binimetinib in combination with encorafenib                                                                                                                                                                                                                                                                                                                                    | Important potential risks for binimetinib in combination with encorafenib |
| Hepatotoxicity                                                            | Routine: Dose modification recommendations in Section 4.2 of the SmPC. Warning in Section 4.4 of the SmPC and relevant PIL section. Listed in Section 4.8 of the SmPC and relevant PIL section. Prescription only medicine. Treatment with binimetinib should be initiated and supervised under the responsibility of a physician experienced in the use of anticancer medicinal products. Additional: none. | Routine Additional: none                                                  |
| Pneumonitis/ Interstitial lung disease                                    | Routine: Dose modification recommendations in Section 4.2 of the SmPC. Warning in Section 4.4 of the SmPC and relevant PIL section. Listed in Section 4.8 of the SmPC and relevant PIL section. Prescription only medicine. Treatment with binimetinib should be initiated and supervised under the responsibility of a physician experienced in the use of anticancer medicinal products.                   | Routine Additional: none                                                  |
| Retinal vein                                                              | Routine:                                                                                                                                                                                                                                                                                                                                                                                                     | Routine                                                                   |

<div style=\"page-break-after: always\"></div>

| Safety Concern                                                                              | Risk minimisation measures                                                                                                                                                                                                                                                                                                                                                                                 | Pharmacovigilance activities                                        |
|---------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------|
| occlusion (RVO)                                                                             | Treatment discontinuation is recommended in Section 4.2 of the SmPC. Warning in Section 4.4 of the SmPC and relevant PIL section. Listed in Section 4.8 of the SmPC and relevant PIL section. Prescription only medicine. Treatment with binimetinib should be initiated and supervised under the responsibility of a physician experienced in the use of anticancer medicinal products. Additional: none. | Additional: none                                                    |
| Embryo-foetal toxicity                                                                      | Routine: Warning in Section 4.6 of the SmPC and relevant PIL section. Information provided in Section 5.3 of the SmPC. Prescription only medicine. Treatment with binimetinib should be initiated and supervised under the responsibility of a physician experienced in the use of anticancer medicinal products. Additional: none.                                                                        | Routine Additional: none.                                           |
| Over-exposure in patients with moderate to severe hepatic impairment                        | Routine: Reduced dose and dose modification recommendations in Section 4.2 of the SmPC. Warning in Section 4.4 of the SmPC and relevant PIL section. Information in Section 5.2 of the SmPC. Prescription only medicine. Treatment with binimetinib should be initiated and supervised under the responsibility of a physician experienced in the use of anticancer medicinal products. Additional: none   | Routine Additional: none.                                           |
| Missing information for binimetinib in combination with encorafenib                         | Missing information for binimetinib in combination with encorafenib                                                                                                                                                                                                                                                                                                                                        | Missing information for binimetinib in combination with encorafenib |
| Use in patients with reduced cardiac function (<50%) or symptomatic chronic cardiac failure | Routine: Warning in Section 4.4 of the SmPC and relevant PIL section. Prescription only medicine. Treatment with binimetinib should be initiated and supervised under the responsibility of a physician experienced in the use of anticancer medicinal products. Additional: none.                                                                                                                         | Routine: Additional: none.                                          |

Routine risk minimisation measures are considered sufficient to minimise the safety concerns of this medicinal product.

## Conclusion

The CHMP and PRAC considered that the risk management plan version 0.7 is acceptable.

<div style=\"page-break-after: always\"></div>

## 2.8. Pharmacovigilance

## Pharmacovigilance system

The CHMP considered that the pharmacovigilance system summary submitted by the applicant fulfils the requirements of Article 8(3) of Directive 2001/83/EC.

## Periodic Safety Update Reports submission requirements

The requirements for submission of periodic safety update reports for this medicinal product are set out in the Annex II, Section C of the CHMP Opinion. The applicant did request alignment of the PSUR cycle with the international birth date (IBD). The IBD is 27 June 2018. The new EURD list entry will therefore use the IBD to determine the forthcoming Data Lock Points.

## 2.9. New Active Substance

The applicant compared the structure of binimetinib with active substances contained in authorised medicinal products in the European Union and declared that it is not a salt, ester, ether, isomer, mixture of isomers, complex or derivative of any of them.

The CHMP, based on the available data, considers binimetinib to be a new active substance as it is not a constituent of a medicinal product previously authorised within the European Union.

## 2.10. Product information

## 2.10.1. User consultation

The results of the user consultation with target patient groups on the package leaflet submitted by the applicant show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use.

## 2.10.2. Additional monitoring

Pursuant to Article 23(1) of Regulation No (EU) 726/2004, Mektovi (binimetinib) is included in the additional monitoring list as it contains a new active substance which, on 1 January 2011, was not contained in any medicinal product authorised in the EU.

Therefore the summary of product characteristics and the package leaflet includes a statement that this medicinal product is subject to additional monitoring and that this will allow quick identification of new safety information. The statement is preceded by an inverted equilateral black triangle.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The applicant applied for a marketing authorisation application for an indication of binimetinib for use in combination with encorafenib for the treatment of adult patients with unresectable or metastatic melanoma, with BRAF V600 mutation.

<div style=\"page-break-after: always\"></div>

## 3.1.2. Available therapies and unmet medical need

BRAF- MEK inhibitor combination regimens are currently the main standard of care for treatment of advanced unresectable or metastatic melanoma that have tumours harbouring the BRAF V600 mutation.  Tumour responses have reported as high as up to 70% and rapid response induction has been associated with symptom control. Median PFS has been shown to be increased to approximately 12 months and this has translated into an improvement in median OS to 22-25 months.

Other treatment options include anti PD-1 antibodies, nivolumab and pembrolizumab, which showed a clinically and statistically significant PFS benefit over the anti-CTLA4 antibody ipilimumab. Emerging data suggest that BRAF inhibition is effective following immunotherapy, and checkpoint inhibitors are still effective in patients who have progressed on kinase-inhibitor therapy.

Although there are treatments for metastatic melanoma with BRAFV600 mutation that have shown clinical benefit, patients usually relapse or discontinue due to AE or tolerability issues. Therefore, there is still a need for treatment choices with improved efficacy or different safety profiles over existing medicinal products.

## 3.1.3. Main clinical studies

The Phase 3 clinical study (COLUMBUS) was a randomised, open label trial in patients with advanced unresectable or metastatic BRAF (either V600 E or K) mutation-positive melanoma comprised of 2 parts:

- -Part 1 randomised 577 patients in a 1:1:1 ratio to encorafenib 450mg QD and binimetinib 45mg BID (Combo 450, N=192), encorafenib 300mg QD (N=194) or vemurafenib 960mg BID (N=191). Randomisation was stratified by AJCC stage, ECOG performance status and prior first line immunotherapy.
- -Part 2 was planned to randomise 320 patients in a 3: 1 ratio to Combo 300 (encorafenib 300mg QD and binimetinib 45mg BID) or encorafenib 300mg QD. This part of the trial was to estimate the treatment effect of Combo 300 vs. LGX818 in terms of overall survival (OS), to estimate the treatment effect of Combo 300 vs. vemurafenib in terms of PFS and OS and to estimate the treatment effect of Combo 300 vs. Combo 450 in terms of PFS and OS.

## 3.2. Favourable effects

The DMC advised study termination on 14 October 2016 based on unblinded efficacy data, including OS results  to  which  the  Sponsor  remained  blinded.  The  Part  1  efficacy  data  were  presented  in  the initial dossier and the Part 2 results were provided during the procedure.

The trial met its primary endpoint, with an improved median PFS by 7.6 months in the Combo 450 arm compared to single agent vemurafenib with a median PFS of 14.9 months vs. 7.3 months, respectively, HR = 0.54 (95% CI 0.41, 0.71, 1 -sided stratified log-rank p&lt;0.001) is the FAS.

The HR was consistent by investigator review and in the sensitivity analyses, including an analysis counting new therapy as an event (HR=0.53).

The median PFS of single agent vemurafenib (7.3 months) was consistent with what has been seen in previous studies and, it was noted that the median PFS of the Combo 450 (14.9 months) was longer than that reported for  other BRAF- MEK inhibitor combination treatments (median PFS for trametinib and dabrafenib = 11.4 months; cobimetinib and vemurafenib = 12.3 months).

<div style=\"page-break-after: always\"></div>

Encorafenib monotherapy increased median PFS by 2.3 months compared to vemurafenib (9.6 months vs. 7.3 months; nominal one-sided log-rank p = 0.004; HR = 0.68, 95% CI 0.52, 0.90) by BIRC. This was a secondary efficacy endpoint, downgraded from a co-primary endpoint with Protocol Amendment 3 (post randomisation of 364 patients). Investigator assessment of response gave similar median PFS durations. Median PFS values by BIRC were the same in the PPS as in the FAS.

The confirmed overall response rate (ORR) per BIRC was higher with combination treatment: 63.0% (95% CI 55.8, 69.9) in the Combo 450 arm compared with 50.5% (95% CI 43.3, 57.8) in the encorafenib arm and 40.3% (95% CI 33.3, 47.6) in the vemurafenib arm.

The median time to definitive 10% deterioration in the FACT-M global health status score was not reached in the Combo 450 arm (95% CI 22.1, NE) and was 22.1 months (95% CI 15.2, NE) in the vemurafenib arm with a HR for the difference of 0.46 (95% CI 0.29, 0.72) using a stratified Cox regression model. The median time to definitive 10% deterioration in the FACT-M was 20.3 months (95% CI 15.0, NE) in the encorafenib arm with a HR for the difference between Combo 450 and encorafenib of 0.48 (95% CI 0.31, 0.75) using a stratified Cox regression model.

The median time to definitive 10% deterioration in the EORTC QLQ-C30 global health status score was delayed by 7.3 months in the Combo 450 arm compared to the vemurafenib arm: 23.9 months (95% CI 20.4, NE) vs. 16.6 months (95% CI 11.9, NE) with a HR for the difference of 0.55 (95% CI 0.37, 0.80) using a stratified Cox regression model. The median time to definitive 10% deterioration in the QLQ-C30 global health status scores was 9.2 months longer in the Combo 450 arm compared with the Enco 300 arm (14.7 months [95% CI 9.2, 18.4]), with a HR for the difference of 0.45 (95% CI 0.31, 0.65) using a stratified Cox regression model.

The median OS was 33.6 months (95% CI [24.4, 39.2]) and 16.9 months ((95% CI [14.0, 24.5]) for Combo  450  compared  to  vemurafenib  (HR  0.61,  95%  CI  0.47,  0.79,  nominal  p  value  &lt;0.0001). Estimates of OS at 12 months and 24 months were 75.5% (95% CI [68.8, 81.0]) and 57.6% ((95% CI [50.3, 64.3]) for Combo 450 compared to 63.1% ((95% CI [55.7, 69.6]) and 43.2% ((95% CI [35.9, 50.2]) for vemurafenib.

The median (95% CI) OS was 33.6 months (24.4, 39.2) and 23.5 months (19.6, 33.6) with Combo 450  compared  to  encorafenib,  respectively,  with  a  HR  0.81  (95%  CI  0.61,  1.0;  nominal  p  value =0.0613, 2-sided). Estimates of OS at 12 months and 24 months were 75.5% (68.8, 81.0) and 57.6% (50.3, 64.3) for Combo 450 compared to 74.6% (67.6, 80.3) and 49.1% (41.5, 56.2) for encorafenib.

## 3.3. Uncertainties and limitations about favourable effects

There were some uncertainties concerning the best dose for encorafenib (450mg vs 300 mg) that should be used in combination with binimetinib. Single agent binimetinib has limited activity in BRAFmutated melanoma patients. In the phase II study CMEK162X2201, the 4.9% response rate in 41 patients, based on locally assessed unconfirmed responses, is low for a monotherapy MEK inhibitor compared to results of trametinib reported in a pivotal phase III study. Binimetinib 45mg BID contributed to the efficacy of Combo 300 and allowed a higher dose of encorafenib to be administered in Combo 450.

It was unclear whether Combo 450 offered an additional PFS benefit over Combo 300. In the analysis with comparable median duration of potential follow-up for PFS (16.7 months and 13.9 months), Combo 450 showed a median 2-month improvement in PFS compared with Combo 300 (14.9 vs 12.9 months). This difference was not statistically significant (HR of 0.79 [95% CI 0.60, 1.03]) one-sided log-rank p=0.0845). The second analysis performed using the 09 November 2016 cut-off date for the two arms was statistically significant (HR 0.73 95%CI [0.55 0.97]; 2-sided p=0.0278). However, this

<div style=\"page-break-after: always\"></div>

result is due to a very uneven duration of follow-up for PFS per BIRC (Kaplan Meier) with 22.5 months for Part 1 Combo 450 arm compared with 13.9 months for Part 2 Combo 300 arm. Combo 450 did not improve the response rate compared with Combo 300 (63.0% vs 65.9%) but did lead to a numerically longer duration of confirmed responses (16.6 months vs 12.7 months).

Normally statistical significance would not be demanded between the two parts of the study and the 2.8-month improvement in median PFS with Combo 450 compared with Combo 300 could be considered clinically relevant. However, in this instance, the fact that encorafenib 300mg performed significantly better in Part 1 than in Part 2 with a 2.2-month difference in median PFS hinders the PFS comparison of the combination treatment (Combo 450 vs Combo 300) between the two parts of the study. Therefore, the OS results for Combo 300 and updated Combo 300 PFS analysis, including more mature data for the Enco300 Part 2 arm will be provide as a post-authorisation measure.

The Exposure-Response analyses suggest that increasing encorafenib AUCss in Combo 450 has a negative influence on ORR and PFS. Baseline LDH &gt;ULN was more common in patients with a higher AUCss; high LDH is known to be a negative prognostic marker predicting a shorter PFS. In Part 1, in the high LDH group only patients with high encorafenib exposure in Combo 450 did worse. There was no such finding with Combo 300 in Part 2. There remains the possibility that this association in the Combo 450 arm is a chance finding or artefact. It remains possible that the B/R ratio could be improved in patients with high baseline LDH by identification of other factors that potentially influence encorafenib exposure. Therefore, the applicant is requested to submit the overall survival results stratified by LDH level for Combo 300 and Enco 300 (Part 2) as a post-authorisation measure.

In order to characterise the patient population that responds to treatment, the applicant is requested to submit the results of the planned biomarker analyses for Study B2301 (from all 3 treatment arms) for evaluation as soon as available, to support the synergistic pharmacodynamic activity of encorafenib in combination with binimetinib. The results will be provided as a recommendation.

In addition, genomic analysis of baseline samples remaining after centralized BRAF testing would be informative to assess whether there is a relationship between baseline mutations and efficacy outcomes. As indicated in the protocol, genomic alterations in BRAF, HRAS, KRAS, NRAS, PTEN, cKIT, PIK3CA, MAP2K1, MAP2K2, ARAF, c-MET, CRAF, EGFR and CCND1 may be explored to find a potential association between baseline mutations and efficacy outcomes. The results will be provided as a recommendation.

## 3.4. Unfavourable effects

The safety of binimetinib (45 mg orally twice daily) in combination with encorafenib (450 mg orally once daily) (hereafter referred to as Combo 450) was evaluated in 274 patients with BRAF V600 mutant unresectable or metastatic melanoma, based on two Phase II studies (CMEK162X2110 and CLGX818X2109) and one Phase III study (CMEK162B2301, Part 1) (hereafter referred to as the pooled Combo 450 population). At the recommended dose (n = 274) in patients with unresectable or metastatic melanoma, the most common adverse reactions (&gt; 25 %) occurring in patients treated with binimetinib administered with encorafenib were fatigue, nausea, diarrhoea, vomiting, retinal detachment, abdominal pain, arthralgia, blood CK increased and myalgia.

The safety of encorafenib (300 mg orally once daily) in combination with binimetinib (45 mg orally twice daily) was evaluated in 257 patients with BRAF V600 mutant unresectable or metastatic melanoma (hereafter referred to as the Combo 300 population), based on the Phase III study (CMEK162B2301, Part 2). The most common adverse reactions (&gt;25%) occurring in patients treated with encorafenib 300 mg administered with binimetinib were fatigue, nausea and diarrhoea.

<div style=\"page-break-after: always\"></div>

The overall safety results for binimetinib show ADRs consistent with the known safety profile of other drugs in this class. However, the incidences of some of the expected adverse events are more frequent that seen with other approved MEK inhibitors. Some of these ADRs are serious or potentially life threatening (thromboembolic events, hypertension, serious skin toxicities and infections, left ventricular dysfunction, pneumonitis, liver function abnormalities and rhabdomyolysis), or are sight threatening (RVO) and are reflected in the deaths, SAEs and AEs leading to discontinuation across the safety sets.

The  safety  and  tolerability  of  binimetinib  in  combination  with  encorafenib  appears  favourable  and acceptable as compared to vemurafenib regarding the observed benefit. The majority of the reported ADRs reflects the common AEs observed in the clinical program of binimetinib 45 mg QD single agent and given in combination to binimetinib 45 mg BID. Regarding the presented safety data of part 2, Combo 300 seems to be better tolerable than Combo 450.

Pneumonitis is an important potential risk.  This was seen following binimetinib treatment in 1.4% of patients in the all cancers [binimetinib any dose] population) and is a well-recognized ADR associated with a number of kinase inhibitors, including MEK inhibitors. T

Specifically, for binimetinib, the most important risks associated with binimetinib treatment defined by ADRs in the proposed patient population are (see warning in SmPC 4.4):

- Left ventricular dysfunction: is a class effect of MEK. Left ventricular dysfunction occurred in 10%  (44/427)  of  patients  treated  at  the  recommended  dose,  with  a  maximum  severity  of grade 3 (in 4.4%  of patients). It frequently led to dose modification or treatment discontinuation.  LVEF  was  routinely  monitored  with  MUGA  or  echocardiography  across  the clinical program.
- Hypertension: New-onset hypertension or worsening of hypertension was seen with binimetinib treatment  in  16%  (68/427)  of  patients  at  the  recommended  dose,  with  grade  3  in  8%  of patients. It was generally manageable with antihypertensive medications and rarely required treatment discontinuation.
- RPED and RVO: the ocular toxicities of binimetinib can be sight threatening although no cases of  permanent blindness have been reported. Visual impairment, including vision blurred and reduced  visual  acuity,  occurred  in  13%  (56/427)  of  patients  and  was  generally  reversible. RPED  is  a  characteristic  adverse  effect  of  MEK.  RVO  was  seen  infrequently  (1.6%  [9/566 patients  in  the  all  cancers  (binimetinib  any  dose)  population]),  but  is  a  potentially  sightthreatening event.
- Muscular toxicity with a blood CK increase was a very commonly reported AE with binimetinib treatment  (in  43.3%  of  patients  treated  at  the  recommended  dose).  Frank  rhabdomyolysis, defined by published criteria of high CK, evidence of end organ damage and muscle symptoms was infrequent, with only a single documented case meeting case defining criteria based on published  literature  and  regulatory  guidance.  CK  and  creatinine  levels  should  be  monitored prior  to  initiating  binimetinib,  periodically  during  treatment,  and  as  clinically  indicated,  and ensure that the patient is adequately hydrated. The incidence of musculoskeletal toxicity was higher in the use in combination with encorafenib.
- Haemorrhagic events were observed in 17.9 % (49/274) of patients in the pooled Combo 450 population. Most of these cases were Grade 1 or 2 (14.6 %) and 3.3 % were Grade 3 or 4 events. Few patients requiring dose interruptions or dose reductions (0.7 % or 2/274).

<div style=\"page-break-after: always\"></div>

- VTE occurred in 4.7 % (13/274) in patients treated with Combo 450, including 2.2 % (6/274) of patients who developed pulmonary embolism.

The overall tolerability profiles of Combo 450 and Combo 300 were broadly similar in terms of AEs requiring discontinuation, dose modifications or additional therapy but Combo 450 led to increased incidence of SAEs and Grade 3-4 AEs. Combo 450 generated an increased incidence of the most common side effects compared to Combo 300, particularly nausea (41.1 vs. 27.2%), vomiting (29.7 vs. 15.2) and headache (21.9 vs. 11.7%). The time to first SAE and AE resulting in study drug discontinuation was shorter for Combo 450.

## 3.5. Uncertainties and limitations about unfavourable effects

There  is  the  potential  risk  of  embryo-foetal  toxicity  as  described  in  the  non-clinical  section.  This potential risk has been communicated in the SmPC in section 4.6. There is also a potential risk of overexposure of binimetinib in patients with moderate to severe hepatic impairment. The potential hs been described in the SmPC and recommendations for dose modification has been added to section 4.2 of the SmPC.

Missing  information  regarding  safety  includes  information  regarding  use  in  patients  with  reduced cardiac function (LVEF &lt;50%) or symptomatic chronic heart failure and safety in paediatric population (children less than 18 years) (see RMP).

There is a potential of over-exposure in patients with moderate to severe hepatic impairment. The CHMP considers that the applicant should collect PK samples from BRAF melanoma patients with moderate and severe hepatic impairment after repeated dosing of encorafenib in combination with binimetinib to determine the plasma concentrations in relation to administered dose and AEs observed to guide dosing recommendations in these patient populations.

## 3.6. Effects Table

Table 83 . Effects Table for Binimetinib in Combination with Encorafenib for the Treatment of Adult Patients with Unresectable or Metastatic Melanoma with BRAF V600 mutation (data cut-off: 19 May 2016).

| Effect              | Short Description   | Unit               | Treatment          | Control            | Uncertainties/ Strength of evidence                                                                     | Refere nces        |
|---------------------|---------------------|--------------------|--------------------|--------------------|---------------------------------------------------------------------------------------------------------|--------------------|
| Favourable Effects  | Favourable Effects  | Favourable Effects | Favourable Effects | Favourable Effects | Favourable Effects                                                                                      | Favourable Effects |
| Median PFS          | Combo 450 vs Vem    | months             | 14.9               | 7.3                | Strong; consistent across analyses + previous BRAF-MEKi combos; uncertainty re binimetinib contribution |                    |
| Median PFS          | Enco vs. Vem        | months             | 9.6                | 7.3                | Strong; little uncertainty                                                                              |                    |
| Median PFS          | Combo 450 vs Enco   | months             | 14.9               | 9.6                | HR: 0.77 (95% CI [0.59- 1]), one sided nominal p value=0.0249                                           |                    |
| Overall survival OS | Combo 450 vs Vem    | months             | 33.6               | 16.9               | Stratified Hazard Ratio: 0.6195% CI: (0.47, 0.79)Log-rank p-value: <0.0001TreatmentComb o               |                    |

<div style=\"page-break-after: always\"></div>

| Effect              | Short Description   | Unit   |   Treatment |   Control | Uncertainties/ Strength of evidence                          | Refere nces   |
|---------------------|---------------------|--------|-------------|-----------|--------------------------------------------------------------|---------------|
| Overall survival OS | Combo 450 vs Enco   | months |        33.6 |      23.5 | HR 0.81, 95% CI 0.61, 1.06, nominal p value =0.0613, 2-sided |               |

## Unfavourable Effects - initial MAA (except deaths updated 9 November 2016)

|                      |                         |   Combo 450 RP |   Enco 300 P | Vem    |
|----------------------|-------------------------|----------------|--------------|--------|
| EAIR All grade AEs   | Per 100 patient- months |         142.83 |       604.83 | 226.32 |
| G3/4 AEs             | Treatment emergent%     |          58    |        67.3  | 63.4   |
| SAEs                 | Treatment emergent%     |          35.8  |        31.8  | 37.1   |
| Dis- contin          | Treatment emergent%     |          10.2  |        17.5  | 16.7   |
| G3/4 PPE             | Treatment emergent%     |           0    |        12.4  | 1.1    |
| G3/4 vomiting        | Treatment emergent%     |           2.2  |         4.1  | 1.6    |
| G3/4 diarrhoea       | Treatment emergent%     |           3.3  |         1.4  | 2.2    |
| G3/4 inc. CK         | Treatment emergent%     |           5.5  |         0    | 0.0    |
| G3/4 inc GGT         | Treatment emergent%     |           8    |         4.6  | 3.2    |
| G3/4 inc transami n  | Treatment emergent%     |           5.8  |         1.4  | 1.6    |
| G3/4 haemorrh age    | Treatment emergent%     |           2.6  |         1.8  | 1.0    |
| SCC                  | Treatment emergent%     |           2.6  |         6.9  | 17.2   |
| On treatmen t deaths | %                       |          10.2  |         7.4  | 10.2   |
| EAIR deaths          | Per 100 patient- months |           0.73 |         0.71 |        |

Abbreviations: Combo 450: encorafenib 450mg QD + binimetinib 45mg BID; Enco: encorafenib 300mg QD; Vem: vemurafenib 960mg BID; mon: months; EAIR: exposure adjusted incidence rate; G: Grade; AE: adverse event; Dis-contin: discontinuation due to AE; transamin: transaminases; inc: increased; HTN: hypertension; SCC: squamous cell carcinoma; aPPE: -Palmar-plantar erythrodysaesthesia syndrome

<div style=\"page-break-after: always\"></div>

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

The PFS improvement for Combo 450 compared to vemurafenib is considered clinically meaningful. In addition, the significant prolongation in OS with a difference in median survival of 16.7 months in favour of Combo 450 is clinically important.

Combo 450 had better general tolerability than encorafenib monotherapy, as evidenced by the QoL analysis and the lower overall rate of AEs. Treatment continued at high relative dose intensity in the combination arm. Still, the proportion of SAEs was not reduced compared to encorafenib monotherapy, and the combination did introduce additional toxicities, specifically increased CK, hypertension, abnormal LFTs, LV dysfunction and eye disorders. These events may not have influenced tolerability, but decreased ejection fraction and increased ALT did result in dose adjustment or study drug interruption. These AEs have the potential to be serious but are manageable if the routine regular screening of patients whilst on treatment is adhered to and recommendations from the SmPC are followed.

## 3.7.2. Balance of benefits and risks

BRAF-MEK inhibitor combinations are known to be effective in BRAF V600 mutant malignant melanoma. Combo 450 led to an improved PFS compared to monotherapy vemurafenib and a median OS at the upper end of the range of survivals currently reported for metastatic malignant melanoma. While vemurafenib monotherapy is no longer the main standard of care for metastatic melanoma with BRAF V600 mutations and as a result, the comparison with a treatment arm which is currently regarded as suboptimal is not encouraged, it nevertheless remains evident that there is a clinically relevant benefit that has been demonstrated with the combination treatment of encorafenib with binimetinb in patients with metastatic melanoma harbouring BRAF V600 mutation.  The safety of the combination is considered acceptable and ADRs can be managed through routine risk minimisation activities with no further additional risk minimisation activities required.

## 3.7.3. Additional considerations on the benefit-risk balance

Approximately 37-50% of patients with metastatic melanoma have mutations in BRAF , and over 95% of these are in BRAF exon 15 at the V600 position. The most common V600 mutations are V600E and V600K accounting for 80-90% and 7-30% of all BRAF V600 mutations, respectively. Other more rare activating mutations include V600R and V600D. These mutations constitutively activate BRAF protein and  signal  downstream  to  activate  the  RAF/MEK/ERK  pathway,  which  signals  for  cancer  cell proliferation and survival. The patient population recruited in the pivotal clinical trial were tested for the presence of BRAF V600 E or K mutation, which was an inclusion criteria that a patient's tumour had to be confirmed by a validated test prior to treatment initiation. Based on the mechanism of action and the non-clinical data showing the inhibitory activity of binimetinb in tumour cells that harbour BRAF V600E/K/R, the indication has been expanded to include all BRAF V600 mutations as it is expected that binimetinib may target and inhibit MEK, which is downstream of the RAF/MEK ERK pathways and hence would be able to block MEK activation regardless of the type of BRAF V600 substitution.

The patient population included in the pivotal study were patients with histologically confirmed diagnosis of locally advanced, unresectable or metastatic cutaneous melanoma or unknown primary melanoma (AJCC Stage IIIB, IIIC or IV) and excluded patients with uveal and mucosal melanoma. The indication includes all types of melanoma as the prevalence of uveal melanoma and mucosal melanoma

<div style=\"page-break-after: always\"></div>

is low and few patients would have been recruited in the trial. In addition, there is no standard of care for these types of melanoma and it is expected that all melanoma patients with a BRAF V600 mutation would benefit from having treatment options that are targeted and have demonstrated efficacy. Patients also had not received prior treatment with a BRAF or MEK inhibitor. A warning has been included in section 4.4 of the SmPC to inform treating physicians that it appears that patients who have received prior BRAF treatment seem to have lower efficacy when treated with the combination. It is also noteworthy that the trial population included naive untreated patients or patients who have progressed on or after prior first-line immunotherapy for unresectable locally advanced or metastatic melanoma. Nevertheless, the indication does not specify the line of treatment as it is left to the treating physician and clinical practice to determine the best treatment algorithm for an individual patient. Section 5.1 of the SmPC describes the patient population that was included in trial.

## 3.8. Conclusions

The overall B/R of Mektovi is positive.

The CHMP requests the following measures to address the issues related to pharmacology:

- -OS results for Combo 300 and updated Combo 300 PFS analysis, including more mature data for the Enco300 Part 2 arm.
- -DDI cocktail study: OATP and BCRP will be explored in the ongoing DDI study with rosuvastatin (study ARRAY-818-103)
- -Overall survival results stratified by LDH level for Combo 300 and Enco 300 (Part 2).
- -To collect PK samples from BRAF melanoma patients with moderate and severe hepatic impairment after repeated dosing of encorafenib in combination with binimetinib to determine the plasma concentrations in relation to administered dose and AEs observed to guide dosing recommendations in these patient populations.

The CHMP recommends the applicant to submit the following measures to address the issues related to pharmacology:

- -The applicant should commit to submit the results of the planned biomarker analyses for Study B2301 (from all 3 treatment arms) for evaluation as soon as available, to support the synergistic pharmacodynamic activity of encorafenib in combination with binimetinib. Genomic analysis of baseline samples remaining after centralized BRAF testing. As indicated in the protocol, genomic alterations in BRAF, HRAS, KRAS, NRAS, PTEN, cKIT, PIK3CA, MAP2K1, MAP2K2, ARAF, c-MET, CRAF, EGFR and CCND1 may be explored to find a potential association between baseline mutations and efficacy outcomes.
- -The relationship between baseline mutations and efficacy outcomes should be performed, and a date provided to submit the results.

## 4. Recommendations

## Outcome

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by consensus that the benefit-risk balance of Mektovi is favourable in the following indication:

Binimetinib in combination with encorafenib is indicated for the treatment of adult patients with

<div style=\"page-break-after: always\"></div>

unresectable or metastatic melanoma with a BRAF V600 mutation (see sections 4.4 and 5.1).

The CHMP therefore recommends the granting of the marketing authorisation subject to the following conditions:

## Conditions or restrictions regarding supply and use

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

## Other conditions and requirements of the marketing authorisation

## Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

The marketing authorisation holder shall submit the first periodic safety update report for this product within 6 months following authorisation.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## Risk Management Plan (RMP)

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product to be implemented by the Member States

Not applicable.

## New Active Substance Status

Based on the CHMP review of the available data, the CHMP considers that binimetinib is a new active substance as it is not a constituent of a medicinal product previously authorised within the European Union.